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Metabolomics studies the collection of small molecules (metabolites) involved in
enzymatically catalyzed reactions, cell signaling and cellular structure. Perturbations in
metabolite concentrations have been used to reflect the activity of corresponding
enzymes or proteins. Nuclear magnetic resonance (NMR) spectroscopy is a well-known
approach for the structure determination of biological macromolecules. Alternatively,
NMR has recently been established as a valuable tool of metabolomics, in which NMR
spectral signals correlate small molecules with cellular activities. This has been
accomplished through the chemometric analysis of high-throughput one dimensional 1H
spectra (metabolic fingerprinting) and quantitative metabolite identification based on two
dimensional 1H, 13C HSQC spectra (metabolic profiling).
Staphylococcus aureus and Staphylococcus epidermidis are the leading pathogens
that contribute to a large portion of fatal infections in the USA because of their virulence
factors, abilities to survive and thrive on various hosts, and enhanced drug-resistance
through biofilm formation. The ability of pathogens to “sense” environmental conditions
and to mediate an adaptation of its metabolism to various conditions was studied using
NMR-based metabolomics. My research projects included: the correlation between TCA
cycle inactivation and biofilm formation related stressors in S. epidermidis; investigating

the metabolic details contributing to biofilm formation in S. epidermidis under conditions
that repress TCA cycle activity; establishing a correlations between iron depletion and
oxygen limitation in S. aureus metabolism; and evaluation of CcpE as a positive TCA
cycle regulator in S. aureus.
Ribose phosphate isomerase R (RpiR) is a transcriptional regulatory protein
involved in the pentose phosphate pathway. Inactivation of the TCA cycle increases
carbon flow into the pentose phosphate pathway where the RpiR protein family may be
involved. In S. aureus, mutations of intracellular ribose sensing regulators (members of
the RpiR family) resulted in changes in the synthesis of virulence factors. The inducer for
ribose phosphate isomerase A, B and the mechanism by which RpiRa regulates rpiA,
rpiB gene expression remain to be elucidated. The C-terminal domain of RpiRa was
predicted to be a sugar isomerase binding protein domain using homology modeling and
it was overexpressed and purified using an E. coli pET overrexpression system as a first
step towards the structural determination of this protein.
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CHAPTER 1
INTRODUCTION
1.1 A brief history of metabolomics
Metabolomics is a new member of the “omics” community and focuses on the
analysis of a collection of small molecules in a biological system.1 In the past decade, it
has gained great attention in fundamental science and has been applied in clinical practice
and in the pharmaceutical industry.2 The number of papers with the keyword
“metabolomics” has grown exponentially in the past decade (Figure 1). As a
methodology, metabolomics has made a fundamental impact on analytical techniques
such as NMR, mass spectroscopy and chromatography.3,4

Number of publications

PubMed search result
1800
1600
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1000
800
600
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Figure 1.1 PubMed search result of the number of publications with “metabolomics” as a
keyword.

2
Metabolites can be defined as all the small molecules with a molecular weight
less than 1 kDa subject to enzymatic transformation in all metabolic pathways.5 They can
be categorized into intracellular/intercellular metabolites based on the location of their
inception. The roles that metabolites play in a biological system vary greatly. First, they
are small molecules that can be used as building blocks by numerous metabolic pathways
to synthesize biological macromolecules. Second, they can be used by organismdependent respiration processes to provide energy in order to maintain regular cellular
functions. Furthermore, because of their high turnover rate, they are ideal molecules for
cells to produce and consume so as to counterbalance the environmental stimuli and keep
a homeostasis within the cells.6 A growing amount of evidence has shown that the
mediation of gene transcription and protein expression by metabolites is not rare, but
more likely to be a universal phenomenon.7,8 As metabolites participate in many cellular
activities, they can be used to evaluate the activity of proteins. Similarly, all of the
metabolites within a cell, a tissue, an organ, or even an organism can be used to represent
the biological state of the system.
The complete collection of metabolites is termed as the metabolome. The concept
of studying a large set of metabolites simultaneously under a certain set of conditions is
called “metabonomics” or “metabolomics”, representing two viewpoints of “how” to
interpret the metabolome.9 Professor Jeremy Nicholson, a pioneer of the field, suggested
the term “metabonomics” to be used during measurement of the multivariate metabolic
responses to various environmental and toxic stimuli.9 The metabolome can be therefore
used for biomarker identification10 and drug toxicity evaluation11 among other
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examples.12,13 NMR is mainly used for such applications in “metabonomics” and is ideal
for the detection of amino acids, organic acids, amines, carbohydrates and lipids. Another
camp uses the term “metabolomics”, which was first coined by Professor Oliver Fiehn.14
The information obtained using “metabolomics” places a greater emphasis on metabolic
profiling at a cellular or organ level and is primarily concerned with normal endogenous
metabolism. Genomics and proteomics data are routinely combined and used as a tool to
study functional genomics.15,16 Mass spectrometry (MS) has been heavily employed in
this camp to detect the metabolome.17 MS has to be coupled with gas chromatography,
liquid chromatography or capillary electrophoresis because of the low molecular-weight
dispersion of the metabolome and because biologically irrelevant information introduced
from ion suppression, matrix effect, and analyte fragmentation can otherwise prevent the
results from representing the true metabolome in vivo.18,19 Liquid Chromatography (LC)MS can be used to identify amino acids, amines, fatty acids, nucleosides, lipids,
carbohydrates. Gas Chromatography (GC)-MS can be used for organic acids, aldehydes,
ketones, volatiles, fatty acids, amino acids, and steroids. In practice, the difference
between “metabolomics” and “metabonomics” has become too obscure, so the terms are
used interchangeably in the literature, and as a matter of personal preference.
Different instruments have their own strengths and weaknesses and,
correspondingly, different coverage of the metabolome, so the correct choice of
instrumentation is critical to successfully address the specific metabolic question. The
selection of proper instrumentation is dependent on the availability of these platforms, as
well as the ability to combine different instruments to obtain a comprehensive metabolic
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profile. NMR is known for its simple sample preparation, high reproducibility and ease of
quantification so it is popular in detecting primary metabolites and metabolic fingerprints.
MS is well-established for detecting secondary or low abundant metabolites with its high
sensitivity in conjunction with a chromatography system. Currently, both instruments
have been widely used as standalone systems, or in combination, to analyze tissues,20
biofluids,21 mammalian cell culture,22 and plants.23 As an illustration, a recently
completed study identified a total of 445 metabolites in human urine samples using a
multi-platform analysis: 209 metabolites by NMR, 179 metabolites by GC-MS, 127
metabolites by DFI/LC-MS/MS, 40 metabolites by ICP-MS and 10 by HPLC.24 Thus,
platforms that combine multiple analytical techniques are likely to become a standard
approach in metabolomics. About 50 metabolites were regarded as the “cellular
metabolome” for E. coli in 1972. In 2013, a metabolomics database contains more than
2600 metabolites for the basic K-12 strain of E.coli.25 Thus, advancements in
instrumentation and the development of new methodologies are currently benefiting
metabolomics and are key factors to continued progress in the field.

1.2 Experimental protocols for NMR-based metabolomics
Metabolome samples can be generated from bacterial strains, human cell lines,
animal tissues, and various biofluids (urine, serum, etc.). The preparation protocols for
these different sources are rather diverse due to sample variability in pH, salt
concentration, and protein content, among numerous other factors. An efficient
metabolome sampling procedure also needs to consider the properties of the metabolites
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of interest: size, structure, solubility, concentration and stability. In addition, the response
of the metabolome to environmental or experimental changes can be extremely rapid.
Therefore, accurately analyzing the metabolome to obtain biologically relevant
information is technically very difficult and requires extensive methodology development.
In our efforts to establish a successful metabolomics sample preparation workflow, three
standards were considered.
The first standard considered was efficiency because of the relatively low
sensitivity of NMR. It is particularly challenging to completely extract the entire
metabolome from a cell, tissue, organ or organism. So a series of “trial and error”
experiments are required to optimize cell lysis, extraction buffer, and instrumental
parameters. A second critical criterion of metabolomics is the need to ensure that the
sample represents the “true” state of the cell or system being studied. The key is to
process all of the samples as quickly as possible while also stopping or slowing down all
cellular activities by quenching the sample. Achieving these goals makes it likely that an
accurate “snapshot” of the metabolome has been obtained. Consequently, quenching
cellular activities is a critical step of properly preparing metabolomics samples, where
evaluating different extraction and quenching procedures are discussed in Chapter 3.
Consistency was the third standard considered. The primary goal is to avoid the
introduction of biologically irrelevant variations in the metabolome by the investigator or
by any step of the protocol. While the introduction of irrelevant variations in
metabolomics samples is unavoidable, the goal is to optimize experimental protocols in
order to drastically reduce their occurrence and negative impact. An advantage of NMR
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is its easy sample preparation that does not require any chromatography or sample
separation step, which effectively removes variations attributed to sample handling and
preparation. Similarly, it is also critical to include proper experimental design in regards
to data collection and data process to reduce unwanted variation or bias and to ensure that
the variations detected are limited to the factors being modified (eg. untreated vs.
treatment). Besides these general standards, each research projects required further
optimization of sample preparation, metabolome extraction, data collection and data
analysis procedures. Improving the reproducibility and the quality of NMR-based
metabolomics data were important components of each project. Thus, additional
advancements in our metabolomics protocols and experimental details that led to
improved metabolomics datasets are described throughout the thesis.
The identification and quantification of metabolites is an important component of
metabolomics, where there are two general strategies – targeted and untargeted
metabolomics. In targeted metabolomics, the goal is to quantify changes to a specific set
of metabolites that have been previously associated with a particular biological process or
function.26 In untargeted metabolomics (also referred to as metabolic profiling, metabolic
fingerprinting (intracellular metabolites) or footprinting (intercellular metabolites), it is
not necessarily required to identify the metabolites. Instead, the goal is to identify global
similarities or differences in the metabolomes from two or more groups or classes (wildtype vs. mutant, untreated vs. drug treated, etc.) In untargeted metabolomics, the NMR
or MS spectra are often subjected to chemometric analysis, such as Principal Component
Analysis (PCA) and Orthogonal Projection Latent Structure for Discriminant Analysis
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(OPLS-DA).27,28 The resulting scores plot (Figure 3) identifies the relative class
differentiation based on the clustering pattern. Spectra that cluster together in the scores
plot have a similar metabolome. Conversely, the further two clusters are separated in the
scores plot indicates a relative difference in the metabolomes. Figure 3 illustrates
theoretical PCA scores plots demonstrating how cluster analysis can be used to determine
in vivo efficacy and selectivity of a drug candidate.29

Figure 1.2 Illustration of hypothetical PCA scores plot for the following scenarios a)
inactive compound, b) active and selective inhibitor, c) active, nonselective inhibition of
target and secondary protein, and d) active, nonselective preferential inhibition of
secondary protein. Reprinted with permission from reference. 29
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In the current application, the metabolome is perturbed by chemicals (i.e. drugs),
by biology (i.e. mutations), by phenotype (i.e. disease), or by the environment (i.e.
nutrients). The corresponding changes in the metabolome are used to investigate the
system’s response to the perturbation and identify the underlying molecular mechanisms.
For example, pathogenicity related stressors can reveal which normal metabolic
processes are connected with virulence biosynthesis. Alternatively, genes with unknown
function can be annotated by comparing changes in the metabolome between wild-type
and mutant cell lines. Specifically, I applied “differential metabolomics” or “comparable
metabolomics” to investigate biological process associated with the survivability and
adaptability of staphylococcus bacteria. The quantitative and qualitative analysis of
metabolites from intracellular extracts can be extremely valuable when investigating the
mechanism of drugs, diseases or environmental stimuli.30-32
NMR based metabolomics can also be used to study the gene functions besides
the global monitoring of metabolic perturbations under a stress. Enzymes are the driving
force of metabolic reactions and they make up to 25% of genes in microbes and 10% in
humans.33,34 An in silico genome-scale reconstruction of the metabolic network of
Staphylococcus aureus listed 774 reactions, representing 23% of its open reading frame.35
Unfortunately, our understanding of the metabolism on the system level is far from
complete because a large portion of genes encode proteins of unknown function (also
known as hypothetical proteins).36-39 There are two ways of studying gene functions in
terms of metabolomics data: forward genetics and reverse genetics.14 The forward
genetics approach has a defined biological state but unknown perturbation in genes,
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proteins and metabolites. The goal is to identify which genes, proteins or metabolites are
affected. Reversed genetics refers to the process where a target gene or protein is up- or
down-regulated, but its influence has not been explored.40 Nevertheless, there is no
consensus on how metabolomics data can be used to interpret how a biological systems
response to a perturbation. The challenge arises from the fact that individual metabolites
can be involved in many known or unknown metabolic pathways. Based on a single
concentration change, it is difficult to accurately distribution this change through multiple
pathways.
Another system-level approach to understand metabolomics data is computational
modeling.41 Flux analysis has been performed by using metabolic control analysis (MCA),
flux balance analysis (FBA) and other techniques.42-45 To date, all flux analysis studies
have concluded that it is not a trivial task to understand the “function” of individual
metabolite. In other words, there is no definite destination for a metabolite given a
complex array of highly-interrelated metabolic pathways. In effect, any solution is strictly
case-dependent. This is also a challenge in biomarker discovery.46 Thus, taking fulladvantage of the power of metabolomics is highly dependent on establishing a restricted
and determinant state, where genomics, transcriptomics, and proteomics data can provide
a biological context to the metabolomics data. In effect, the “omics” data complement
each other.

1.3 Optimization of NMR-based metabolomics methods
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Statistical methods, especially multivariate regression methods that include PCA
and OPLS, are routinely used in the analysis of one dimensional (1D) NMR spectra.
Therefore, a large portion of my research efforts were dedicated to the optimization of
PCA analysis of NMR datasets. In a PCA scores plot generated from NMR metabolomics
data, the analysis mainly lies in the determination of the relative distances between
multiple “clusters”. The presence of different class clusters is due to the fact that withingroup variability is smaller than the between-group variability. Multiple sample replicates
are required to statistically define a class cluster, which are dependent on the
reproducibility of the replicates. In practice, within-group variability is defined by a
combination of experimental conditions and the inherent variability of the biological
sample. Thus, a larger data set is always desirable because of the statistical power it
possesses in defining statistically relevant class separation.47 To address the need to
determine the statistical significance of class differentiation in a scores plot, a treediagram based on a matrix of center-averaged distances between each cluster was
generated. The significance of each node is based on traditional boot-strapping
approaches. The tree-diagram provides a quantitative alternative to the direct inspection
of a PCA scores plot.48
Heteroscedasticity is a commonly neglected property of chemometric data and it
has a negative impact on the multivariate classification. Simply, the variance of a variable
increases as the value of a correlated variable increases. This leads to biased standard
errors and biased inferences. Biological variability is one source of heteroscedasticity.
For example, more metabolic pathways are active during exponential growth when
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reproduction is taking place compared to post-exponential growth when metabolism is
focused on survival due to limited carbon sources. Therefore, the dynamics and
composition of the metabolome is completely different between the two phases. As a
result, metabolomes extracted from cells during the post-exponential phase resulted in
tighter clusters in a scores plot. Currently, there are few applications that explore such
information and Dr. Daniel Raftery is a leading researcher in this area. Ratio Analysis of
NMR Spectroscopy (RANSY) and Raito Analysis of Mass Spectrometry (RAMSY) have
been developed based on the assumption that individual peaks can be correlated by their
relative standard deviation.49,50 For each individual metabolite in a sample set, there can
only be one relative standard deviation in the metabolites concentration and, therefore, a
correlation between relative standard deviations can be used to assign all the NMR peaks
originating from the same metabolite. This assumes a small likelihood that peaks
originating from different metabolites having the same relative standard deviation. This
method is a complementary to their statistical total correlation spectroscopy (STOCSY)
method. STOCSY is based on a correlation of peak intensity that assumes coupling
patterns and peak overlap does not mask the correlated peaks.51 We have also taken
advantage of heteroscedasticity in our methodology development, albeit from a different
direction. The random, low intensity peaks in a 1D 1H NMR spectrum are considered
noise. It was previously shown that the inclusion of noise in a multivariate analysis can
negatively impact clustering in a scores plot and lead to erroneous interpretations.52 But,
the complete removal of noise regions, while leaving real signals intact, is particularly
challenging for complex NMR spectra of biological samples. To resolve this issue, a
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novel noise removal method was developed based on the relative standard deviation of
noise instead of the traditional cutoff based on arbitrary minimum signal intensity. A
region absent of peaks (spectral edge) is used to define the “noise” parameters, which is
then used to remove all noise from the remainder of the spectrum. The removal of noise
ensures that our PCA analysis does not unintentionally mask any biologically relevant
trends.
Two-dimension (2D) 1H, 13C Heteronuclear Single Quantum Coherence (HSQC)
correlates protons attached directly to a carbon, which is a very basic component of
organic structures. Thus, the 2D 1H, 13C HSQC experiment is a valuable approach to
improve the accuracy in metabolite identification. Although the analysis of 2D NMR
datasets takes considerable more time and effort, 2D NMR experiments are increasingly
being used by the metabolomics community because of several distinct advantages. The
two chemical shifts (1H and 13C) from a C-H pair must both match the chemical shift
values in a NMR metabolomics database to make a metabolite assignment. Also, peak
overlap and chemical shift ambiguity is significantly reduced by dispersing the chemical
shift information into two-dimensions. The 2D 1H, 13C HSQC experiment has been
recently improved and optimized for metabolomics to directly measure concentrations
(Figure 3).53,54 To enhance the detection of metabolites,55 the culture media is
supplemented with a 13C-labeled compound to boost the sensitivity of the 2D 1H, 13C
HSQC experiment due to the low natural abundance (1.1%) of 13C.56,57 More importantly,
only metabolites that are derived from the 13C-labeled compound are observable in the
2D 1H, 13C HSQC spectrum. It allows for monitoring carbon flow from the 13C-labeled
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compound throughout the metabolome. This also simplifies the analysis by restricting the
metabolome to a select sub-set of the metabolites. The judicious choice of the 13C-labeled
compound will only emphasizes the region of the metabolome that is particularly relevant
to the biological system under investigation. The application of 2D 1H, 13C HSQC
spectroscopy has been largely incorporated into our NMR-based metabolomics, which
includes a method to automate peak alignment, peak-picking, absolute concentration
determination, and multiple ways of representing metabolome changes.
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Figure 1.3 The principle of Time-0 HSQC experiment. A series of HSQC spectra
acquired with incremented repetition times (the time between the end of the first 1H
excitation pulse to the beginning of data acquisition) can be extrapolated back to zero
time to yield a time-zero 2D 1H, 13C HSQC spectrum (HSQC0) in which signal intensities
are proportional to concentrations of individual metabolites. Reprinted with permission
from reference 53,54

1.4 Metabolism-dependent biofilm formation in S. epidermidis and S. aureus
Biofilms are a ubiquitous microbial phenomenon that has been observed for
bacteria, fungi, algae, yeasts, protozoa, and other organisms.58-60 Biofilms were first
observed in 1923 during the fouling of ships’ hulls by marine microorganisms.61 In 1933,
Henrici wrote “it is quite evident that for the most part water bacteria are not free ﬂoating
organisms, but grow upon submerged surfaces”.62 In 1940, Heukelekian and Heller added
"development takes place either as bacterial slime or colonial growth attached to
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surfaces".63 It is worth noting that the extensive interest in biofilms are not merely a
result of scientific curiosity, but are also derived from practical concerns related to a
broad spectrum of areas such as medical science,64 material engineering,65 civil
engineering,66 and others.67 In particular, biofilm-related bacterial infections are a serious
health concern. A 2000 US government report identified infectious diseases as a leading
cause of death worldwide and the third leading cause of death in the United States.68 It
has been estimated that 60%-80% of human microbial infections are caused by bacteria
growing as a biofilm.69 Certain pathogenic biofilms are particularly concerning because
of the added issue of drug-resistance.70 As methicillin-resistant Staphylococcus aureus
(MRSA) and other resistant pathogens capable of biofilm formation continue to emerge
and propagate, understanding and circumventing biofilm resistance to antibiotics is a
paramount necessity.71
Bacteria can respond to a universal signal of nutrient exhaustion by 1) swimming
to new locations; 2) synthesizing enzymes that degrade macromolecules and use the
products; 3) secreting antibiotics that kill competitor bacteria in the local environment. A
biofilm is likely to form if these strategies are not successful in promoting normal culture
growth in a harsh environment.72 The biofilm phenotype is not exclusively caused by this
mechanism.73 In a biofilm, the metabolism of the bacteria is dramatically lowered so that
a minimal amount of nutrients are required for survival. Thus, a biofilm may provide
further protection against antibiotics that typically target cell growth-related processes.
Also, the biofilm matrix may provide a further layer of antibiotics resistance by acting as
a physical barrier and hindering drug delivery to the bacteria.74 Intercellular

16
communications within a biofilm and between planktonic cells is important to our
understanding of bacterial behavior.75 Quorum sensing,76 programed cell death or
population-wide drug resistance may be regulated by or are established examples of
intercellular communications.65,66 These observations raise some questions about the
validity of research into bacterial behavior that is based solely on highly homogenous
cultures. At a minimum, it suggests the need for studies that involve both planktonic and
biofilm forms in order to obtain a complete picture of bacterial cellular biology. In this
sense, the study of bacterial biofilms is still in its infancy.
As with most pathogens, the survival of staphylococcal bacteria is largely
dependent on host-pathogen interactions or on the environment. The host environment
provides the necessary nutrients and energy for the bacteria to grow and reproduce. These
cellular activities are accomplished through a series of metabolic pathways. In
staphylococci, the central metabolic pathways that include glycolysis, pentose phosphate
pathway and the tricarboxylic acid cycle (TCA cycle) can produce all the intermediate
building blocks for macromolecular production.77 To be more specific, the TCA cycle is
a major source of the metabolites and energy for the bacteria. Biofilm formation, as a
survival strategy, is also largely mediated by environmental stimuli and nutrient
availability (Figure 4). Thus, bacteria respond to a multitude of stressors to induce a
biofilm. Thus, based on its major role in central metabolism, the TCA could translate
environmental stressors into the metabolic signals and subsequently control the
metabolism and pathological activities of the cells.7 An accumulating amount of evidence
has demonstrated that cell sensoring and regulation, detoxification, repair and protection,
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and a variety of other important cellular activities are coordinated through
metabolites.78,79 An ultimate goal of our research is to examine global patterns of
metabolic control and the corresponding regulatory proteins and pathways under various
genetic model systems.

Figure 1.4 Summary of metabolic pathways that are associated with the TCA cycle’s
response to environmental stress.77

1.5 The RpiRa protein expression system and structural determination
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Studying metabolism is challenging because it is one of the most flexible and
complex systems of a living organisms in terms of regulation. Metabolism connects all of
the components (e.g., proteins, genes) of a cell with the external environment. As the
number of metabolites identified continues to increase, an obvious question arises - what
are the biological functions of these metabolites? Determining the structure of a protein
may be important to addressing these questions. The availability of a protein structure
may assist in our understanding of the protein’s biological function, which may include
interactions with small molecules like metabolites. Conversely, identifying metabolites
that interact with a protein may establish the biological importance of a specific
metabolite.
TCA cycle stress alters the intracellular ribose concentration in S. epidermidis and
also alters the temporal expression of virulence factors in S. epidermidis and S. aureus.
One metabolic change associated with TCA cycle repression is an increased
concentration of intracellular ribose. It indicates the presence of a pentose phosphate
pathway (PPP)-responsive regulator that can partially mediate TCA cycle-dependent
regulatory effects.77 In biofilm formation, the replication and production of nucleotides
requires overproduction of ribose. As a result, a PPP-responsive regulator may mediate
some of the TCA cycle-dependent regulatory effects.
Ribose Phosphate Isomerase (Rpi) is a family of protein hypothetically mediating
the regulation of PPP. A search of the S. aureus strain Mu50 genome returned three open
reading frames (ORFs) with significant amino acid homology to RpiR (21 to 23% amino
acid identity and 45 to 46% amino acid similarity): SAV0317, SAV0193, and SAV2315.
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For simplicity, these homologues were designated RpiRa (SAV0317), RpiRb (SAV0193),
and RpiRc (SAV2315).80 Two of these three homologues of Rpi (RpiRb and RpiRc) have
been found to positively influence the transcription of the PPP genes rpiA and zwf, while
the third homologue (RpiRa) is slightly antagonistic.80,81 In addition, inactivation of
RpiRc altered the temporal transcription of RNAIII, the effector molecule of the agr
quorum-sensing system.80 Thus, these data reveal the close linkage of central metabolism
and virulence determinant synthesis in terms of protein and metabolism regulation.
These observations led us to hypothesize that an RpiR homologue may link the
PPP to virulence factor regulation in staphylococci. The structure determination is a
direct way to understand protein functions in detail. Currently there is only one X-ray
crystal structure of RpiR C-terminal domain (CTD) from Sphaerobacter thermophilus
deposited in the Protein Data Bank (PDB) (unpublished data, PDB ID: 3SHO). It has a
sequence identity of 22% and similarity of 44% with RpiRa from S. aureus. A homology
model for the sugar isomerase-like CTD of S. aureus RpiRa was built up and examined
based on the Vibrio vulnificus NanR protein (PDB ID: 4IVN) using sequence alignment
tools of FASTA82 and BLAST®; domain prediction software packages of DomPred83 and
InterProScan84; secondary structure prediction tools of PredictProtein85 and PSIPRED86.
The CTD of RpiRa, a hypothetical sugar isomerase domain, was proposed to be a ligand
binding domain that can sense the perturbation of metabolites. Therefore, it can be used
as a metabolite regulatory mechanism in pathogenesis development. The purification of
various constructs of RpiRa CTD and analysis of NMR sample conditions to identify a
suitable sample for NMR structure determination.
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Figure 1.5 Predicted model of RpiRa structure. a) front, b) top, and c) side views of the
predicted model of the entire RpiRa structure. The RpiRa homology model was
determined using PSIPRED (http://bioinf.cs.ucl.ac.uk/psipred/) based on the Vibrio
vulnificus NanR protein (PDB ID: 4IVN).87

1.6 Overview of thesis
The study of metabolomics is making an increasingly beneficial impact on basic
and applied biology. The challenge of metabolomics is to combine well-established
instrumentation with novel biological experimental design. The desirable outcome of this
effort is to yield a meaningful and reliable dataset to support a hypothesis or to inspire a
new hypothesis.88,89 This dissertation describes my efforts to improve methodology
critical to the successful application of NMR-based metabolomics and the application of
these techniques to investigate the metabolome S. epidermidis and S. aureus.
In Chapter 2, a literature review summarizes the current progress in NMR-based
metabolomics methodologies as applied to biofilm formation. This review demonstrates
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the value and impact that NMR-metabolomics has had on the study of biofilms and
exemplifies how metabolomics can assist in solving real-world problems. This review
includes a detailed description of the history and current understanding of biofilm
formation, the mechanism of molecular regulations under harsh environmental stressors,
and many methods utilized to explore biofilms in a systems biology approach. In
summary, it provides a practical and broad view of how to incorporate metabolomics into
a biochemical research program.
The questions we asked ourselves everyday are how NMR spectroscopy is useful
in metabolomics and how can we modify the current 1D and 2D NMR spectroscopic
protocols so that they can provide more biologically relevant information. Thus, one
important focus of my dissertation, which has had a significant impact on the field, is the
establishment of protocols for NMR-based metabolomics. Dr. Steve Halouska made
significant contributions to this project. A detailed description of our NMR-based
metabolomics methodology is presented in Chapter 3. In Chapter 4, an in-house designed,
high-throughput NMR tube washer is discussed. The NMR tube washer is used on
routine and daily basis by a number of colleagues and undergraduate students.
Chapter 5-8 include two first- and two second-authored papers, showing the
contribution of our NMR metabolomics method to investigate the metabolome from
staphylococcal bacteria with our collaborator Dr. Somerville. The bacteria of S. aureus
may cause a multitude of serious and acute infections, while infections with S.
epidermidis are usually chronic and often involve the colonization and infection of
indwelling medical devices.90
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In Chapter 5, a series of conditions that induce biofilm formation are examined
and their effects on the TCA cycle are evaluated using NMR metabolomics. A
relationship between biofilm formation and TCA cycle metabolism is established and
well-characterized. Furthermore in Chapter 6, several environmental stressors are shown
to depress the TCA cycle activity in S. epidermidis and cause the up-regulation of
polysaccharide intracellular adhesion (PIA) biosynthesis. In Chapter 7, another
metabolomics study is focused on the redox status of S. aureus. Iron limitation and
aeration limitation are linked by oxidative stress and can lead to cell death. Fe or O2
limitation can also trigger biofilm formation. Therefore, the impact of Fe and O2
limitation on the S. aureus metabolome was investigated by NMR. A specific set of
metabolites and metabolic pathways were identified that explain the physiological
response of S. aureus to Fe and O2 limitation. In Chapter 8, an S. aureus carbon catabolite
repression (CcpE) deletion mutant, a postulated regulator of the TCA cycle, was
constructed, and its metabolome was analyzed by NMR. Taken together, these studies
strengthen our long-term hypothesis, originally postulated by Dr. Somerville, that the
TCA cycle functions as a global regulator of many pathological processes in S.
epidermidis and S. aureus. PIA, an important precursor of biofilm formation, is regulated
by the TCA cycle.
In Chapter 9, one of the hypothetical regulatory proteins in the pentose phosphate
pathway, the overexpression and multiple isotope labeling strategies for RpiRa is
performed. The domain structure of this protein was predicted by bioinformatics, and the
CTD is expected to be a ligand binding domain. The ligand-binding domain is predicted
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to sense, an as yet, undefined metabolite to regulated PPP. RpiRa has been shown to be a
PPP activator and can direct carbon flow away from the TCA cycle. Because of the size
of the protein and NMR size-limitations, only a CTD plasmid was constructed and overexpressed in E. coli. The optimal condition and procedures for protein expression and
purification is discussed. Preliminary studies in the structural determination are also
addressed. Chapter 10 is a concluding chapter containing the summary of the work and
future directions.
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CHAPTER 2
LITERATURE REVIEW
2.1 Introduction
Biofilms are a natural part of the ecology of the earth, and correspond to a “social
structure” of microorganisms compared to a planktonic state.1-3 Biofilms are a ubiquitous
microbial phenomenon that has been observed for bacteria, fungi, algae, yeasts, protozoa,
and other organisms. In a biofilm composed of multiple diverse organisms, the
interspecies interaction can range from neutral, to cooperative, to competitive, and finally
to antagonistic.4 The diversity of organisms able to self-organize and form biofilms is
quite astounding and may provide clues to the evolution of multicellular organisms.5 Are
biofilms a transitional state of evolution and the basis for multicellular organisms? Or are
biofilms simply a highly organized state of single cell organisms? The fact that biofilms
provide a significant survival advantage for adapting to the harsh and distinct
environmental conditions probably explains its broad adaptation.
Biofilms have been studied for almost a century. The fouling of ships’ hulls by
marine microorganisms was documented in 1923.6 In 1933, Henrici observed “it is quite
evident that for the most part water bacteria are not free ﬂoating organisms, but grow
upon submerged surfaces”.7 In 1940, Heukelekian and Heller added "development takes
place either as bacterial slime or colonial growth attached to surfaces".8 However, it was
not until the last decade of the last century that significant progress was made to
effectively study microbial communities. It was then that we began to appreciate the
significant implications of biofilms. Nevertheless, there are still many gaps in our
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understanding of the biological processes related to this phenomenon.1,9-11
The interest in biofilm is not merely a result of scientific curiosity, but is also
derived from practical concerns related to medical science,12 material engineering,13 civil
engineering,14 and others.15 In the area of medicine, research on biofilms has focused on
its relationship to bacterial infections and drug resistance. Bacterial infections are a
serious disease and major source of world-wide deaths. Especially concerning is the
growing resistance to antibiotics that has become a major medical issue in developing
countries. Between 1980 and 1992, infectious disease deaths increased by 58%; the major
contributors were HIV infections and AIDS, respiratory disease, and bloodstream
infection.16 A 2000 US government report identified infectious diseases as a leading
cause of death worldwide and the third leading cause of death in the United States.17 It
has been estimated that 60%-80% of human microbial infections are caused by bacteria
growing as a biofilm.18 Certain pathogenic biofilms are particularly concerning because
of the added issue of drug-resistance.19 Multidrug resistant pathogens, such as
Enterococcus faecium, Klebsiella pneumonia, Acinetobacter baumanii, Pseudomonas
aeruginosa, and Enterobacter species are infecting the majority of US hospitals.20 As
methicillin-resistant Staphylococcus aureus (MRSA) and other resistant pathogens
capable of biofilm formation continue to emerge and propagate, understanding and
circumventing biofilm resistance to antibiotics is a paramount necessity.21
Pathogens can be introduced into the human body through trauma, medical
operations, dental procedures, or by other means.22-24 Many surfaces of organs are
heavily colonized by microbes that have the potential to cause an infection, especially
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during any invasive medical procedure. In fact, the ratio of bacteria to mammalian cells
living within the human body is ten to one, providing ample opportunity for inducing a
bacterial infection from medical procedures or trauma.25 For example, there are over 500
species of microorganisms identified in typical dental plaque.26 Correspondingly, dental
cavities (caries) are commonly a result of bacterial biofilm infections.27 Biofilms are also
formed on our tongues, cheeks, in our intestines, nasal passages, sinuses, and on our
skin.26 These human microbial communities are largely unstudied and their role in
infections is largely unknown. But biofilms protect the organisms from both
antimicrobials and the host immune response, making infectious biofilms extremely
difficult to treat.28 For instance, staphylococcal biofilm infections have a 10 to 1000 fold
increase in antibiotic resistance.29-31
A serious source of biofilm infections is heart disease, which is also a major cause
of mortality in the US.32 Invasive surgical techniques are inevitably required to treat the
resulting symptoms of heart disease, which may lead to fatal staphylococcal infective
endocarditis (IE). S. aureus and S. epidermidis33 infections stemming from implantable
medical devices (e.g., pace makers,34,35 indwelling vascular catheters,36-38 grafts,39 and
left ventricular assist devices40-44) are common causes of IE. Biofilms have also been
identified on various other medical devices18,45 such as contact lenses, endotracheal tubes,
central venous catheters, pacemakers, and voice prostheses that account for over 80% of
microbial infections in the body. Catheter-associated urinary tract infection is also a
common source of biofilm infections. It has also been suggested that autoimmune
disorders like arthritis, chronic fatigue syndrome, fibromyalgia, Crohn's disease, and
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ulcerative colitis are caused by biofilm infections.46 In summary, bacterial biofilms pose a
serious threat to human health because of the added protection biofilms provide from an
immune response and antibiotic treatments, because of the ease of acquiring an infection
from trauma and medical procedures, and because of the rapid emergence of drug
resistance among bacteria that form biofilms.

2.2 Biofilm Structure
Initial scientific studies on bacterial biofilms have focused on understanding the
structure and composition of biofilms (Figure 2.1). Confocal scanning laser microscopy
(CSLM) combined with fluorescent molecular probes and antibody labeling has been
used to provide invaluable information on biofilm cell morphology, cellular metabolism,
and cell phylogeny.47,48 These studies revealed heterogeneous features for both purecultured and mix-cultured biofilms, and the adaptability of unicellular organisms to a
diverse range of physical, chemical and communal circumstances.49,50 Basically, a
biofilm is comprised of three parts: (1) a living or non-living substance that provides a
moist surface for attachment of the highly-organized microbial structure,51-53 (2) a slimlike matrix made of extracellular DNA, proteins, and polysaccharides (β (1-6)-linked Nacetylglucosamine polymer)54,55 that embeds the microorganism,56 and (3) an aggregate
of microorganisms in a community that exchange fluids, nutrients and chemical signals.57
Biofilms are viewed as layers of bacteria encapsulated within different
microenvironments due to variations in nutrient availability58 and differing cell
densities.50,59 Bacteria within the biofilm core exist in a stationary or dormant growth
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phase58 and are physiologically distinct from planktonic bacteria.60-63 Antibiotics that
target cellular mechanisms associated with growing bacteria have diminished activity
against biofilms.64,65 Presumably, the antibiotic is only affective against the fast growing
bacteria on the biofilm’s surface. The dormant bacteria in the interior can replenish a
biofilm’s outer layers after the antibiotic has been withdrawn. In order for these dormant
bacteria to enter a growth phase, it is necessary that they respond to a change in nutrient
and cell density resulting from the death of the fast growing bacteria on the surface.
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Figure 2.1 Horizontal optical thin sections (0 to 2.6 µm) of the P. aeruginosa biofilm
obtained by SCLM. The biofilm was negatively stained with 0.1% fluorescein. The
horizontal sections show the removal of out-of-focus information and reveal aspects of
the internal structure of the biofilm. Bar=5 µm. Reprinted with permission from
reference.50

Bacterial cells have also been shown to adopt various functions critical to the
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biofilm structure, such as forming the initial attachment point with the surface, producing
the slime matrix, forming water channels to deliver oxygen and other nutrients, or
comprising the simple building blocks of the biofilm.2 Bacterial cells within a microcolony can maintain homeostasis, achieve flexible spatial relationships with cooperative
organisms, and create an effective way of exchanging nutrients and metabolites with the
environment. The realization that biofilms consist of such a complex structure raised
intriguing scientific questions: how do bacteria create such an elaborate architecture and
what stimulates biofilm formation?
The life cycle of the biofilm turns out to be even more complicated and can be
divided into roughly three steps: attachment, growth and propagation (Figure 2.2). First, a
few colonies reversibly adhere to the surface via van der Waals forces to create an
initiation site. Attachment involves lipoteichoic acid anchored to the cell membrane.57
This is followed by an irreversible attachment of the cells through the production of the
exopolysaccaride (EPS) matrix and cell growth.52 The cell growth is not uniform and
results in the formation of channels.9 A combination of cell division and recruitment
occurs during the maturation stage and only biofilm shape and size are changed.9,53,66
Other organisms may be recruited to the biofilm depending on the microenvironments
created by on-going metabolic activity. Finally, detachment of individual cells and
dispersion enables the biofilm to spread and colonize new surfaces or to join another
biofilm.67,68 Biofilms form irregular spatial structures, which are affected by many
different ecological, biological, chemical, and physical factors. The effect of these factors
on biofilm formations have been investigated using a variety of computer simulations.69-
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Figure 2.2 a) The four-step process involved in the formation of bioﬁlms. b) The
lipoteichoic acid is anchored to the cell membrane and extends out past the edge of the
cell wall being the initial molecular contact between the bacterium and other materials. c)
The chemical structure of lipoteichoic acid. Reprinted with permission from reference.57

Biofilm models have been reported in the literature for different organisms and
biofilms composed of multispecies, for different nutritional conditions, and for different
environments. These mathematical models have been used to investigate the
interrelationship of various biofilm factors, especially for parameters that can be difficult
to vary experimentally.74 There are three primary biofilm mechanisms: (i) substrate
transport, (ii) growth, and (iii) necrosis and loss, which are applied to any computational
model.75,76 Biofilm models can be grouped into four different categories:77 (1) one-
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dimensional continuum models, (2) diffusion limited aggregation models, (3) cellular
automaton models, and (4) fully coupled biofilm-fluid models. One-dimensional
continuum models assume gradients are orders of magnitude higher in the direction
perpendicular to the attachment surface. Diffusion limited aggregation models have an
immobile seed located on a square lattice. One particle after another is released from a
random location from the seed and is allowed to diffuse through a random walk to form
an aggregate when it contacts the seed particle.78 Cellular automaton models consist of a
regular grid of cells where each cell is in one of a finite number of states. Rules determine
cell movement, replication, death, etc. as a function of micro-environmental changes. As
an example, different morphologies from dense layers to open, mushroom-like forms can
be simulated. Effectively, small changes in nutrient concentration can have a dramatic
effect on biofilm development.79 Fully coupled biofilm-fluid models are more complex
simulations and also take into account the hydrodynamics of the bulk fluid and the nonuniform distribution of cells and polymers.77

2.3 Biofilm formation at the molecular level
There are some general principals regarding biofilm formation that include the
need for metabolically active bacteria for surface adhesion, the need for an adequate
nutrient supply for cell replication and exopolysaccharide production, and the fact that
surfaces coated with organic nutrients stimulate biofilm formation.2,3 Correspondingly,
bacteria biofilms readily form on the surfaces of plastic or metal medical devices in body
fluids. Some common bacterial biofilm infections include Pseudomonas aeruginosa in
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the lung, Escherichia coli in the urinary tract, Vibrio cholera in the gastrointestinal tract,
S. epidermidis in the heart, S. aureus in arteries, Enterococcus species in the urinary tract,
and fungi such as Candida species in gastrointestinal tract.80 The identification of
biochemical pathways critical to biofilm formation is an important first-step to being able
to prevent these bacterial biofilm infections. Even with our general understanding of the
basic structure and development of bacterial biofilms, comprehending the underlying
processes responsible for inducing the transition from planktonic cells to a biofilm is still
unclear. Correspondingly, the planktonic to biofilm transition is a complex and highly
regulated process that results in a phenotypic change. Thus, the differential expression
and regulation of specific genes are associated with biofilm formation.
Genomics analysis of biofilm formation started in the 1990s by first screening for
biofilm-defective mutants.81,82 Such efforts identified a diverse number of genes required
for biofilm formation.83-89 More recently, DNA microarray technology has been used to
identify genes up- or down-regulated in bacterial biofilms.90 Unfortunately, there does
not appear to be a clear trend in biofilm related genes. Instead, multiple pathways to
biofilm formation that depend on media, growth conditions, and specific organism is
likely.91 Nevertheless, some broad, common features have been observed, such as the upregulation of genes for polysaccharide production, for various stress-induced pathways,
for stationary-phase induced genes, for a prevalence of genes of unknown function, and
new regulatory pathways.90 For example, Quoc et al. (2007) identified nineteen genes in
S. aureus associated with biofilm formation that were not previously observed.87 Again,
this highlights the difficulty encountered with identifying a uniform set of biofilm-related
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genes. Besides genes involved in polysaccharide intercellular adhesion (PIA) or unknown
function, the authors observe mutations in guanosine-dependent regulation and formation
of wall teichoic acid. The complexity of biofilm formation may be attributed to the fact
that the transition from planktonic cells to a biofilm is influenced by various and diverse
environmental factors such as ethanol,92 oleic acid,93 glucose,94 UDP-Nacetylglucosamine,95 sub-inhibitory concentrations of some antibiotics,96 anaerobic
conditions,97 Fe limitation,98-100 high osmolarity,101 and high temperature.101 The diversity
of these external stimuli suggests a versatile regulation system.
After two decades of research, multiple mechanisms of biofilm regulation have
been proposed: sigma factors, two-component systems, or quorum sensing. Sigma factors
control the expression of various genes including virulence factors and global regulators
that are related to biofilm formation.102-104 Sigma factors are activated when bacteria
sense environmental conditions that induce stress (heat shock, nitrogen-limitation,
starvation, high osmolarity, etc.).105 Two-component systems are an alternative stimulusresponse coupling mechanism that have been shown to regulate diverse metabolic
processes such as the bacterial cell cycle, cell-cell communication, and virulence factors
in biofilm formation.106 In a two-component system, a ligand or a signal molecule can
stimulate a histidine kinase sensor protein, which undergoes autophosphorylation at a
conserved histidine residue. The phosphoryl group is then transferred to the cognate
response regulator, which can activate or repress transcription of the target genes.106,107
Conversely, quorum sensing uses signal molecules for bacterial intercellular
communication. Quorum sensing enable bacteria to “sense” cell density and coordinate
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behavior in response to nutrient availability, toxic compounds, host-immune response,
and defense.108,109 In gram-negative bacteria, N-acyl homoserine lactones (autoinducer-1,
AI-1) have been identified as the signal molecules.110 AI-1 is synthesized and sensed by
analogous LuxI and LuxR regulatory proteins. The specific AI-1 molecule varies between
gram-negative organisms. For gram-positive bacteria, autoinducer peptides (with no
conserved sequence) have been identified as a signal molecule that involves a twocomponent signal transduction system.111 Furanosyl borate diester (AI-2) has been
identified as a universal interspecies signal molecule that regulates biofilm formation in
over 55 gram-positive and gram-negative species.112 Figure 2.3 illustrates some common
regulatory mechanisms of the planktonic to biofilm transition.
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Figure 2.3 Regulatory networks controlling transition between planktonic and biofilm
lifestyle. The external frames illustrate the bacterial envelope with one or two membranes
(OM: outer membrane, IM: inner membrane) according to Gram-positive (c) and Gramnegative bacteria (a, b, and d), respectively. a) Control of biofilm formation in P.
aeruginosa through the TCS GacS (HK)/GacA (RR) mediated by sRNA rsmY and rsmZ
gene transcription and modulated by RetS and LadS, two additional HK in P. aeruginosa.
b) Control of EPS alginate in P. aeruginosa, which further impacts biofilm architecture
by the system ECF sigma factor AlgU - anti-sigma MucA - AlgP (IM)-AlgW
(periplasmic) complex: 1) activation of AlgW/AlgP, 2) cleavage of MucA, 3) release of
AlgU, 4) activation of the alg UmucABCD operon. c) Control of S. aureus biofilm
formation through the Agr QS system: 1) AgrD autoinducer production, 2) AgrD
autoinducer accumulation in the extracellular medium where it reaches a threshold, 3)
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activation of the TCS AgrCA by AgrD at the threshold concentration, 4) AgrA-dependent
activation of the sRNA RNA III expression repressing expression of genes involved in
biofilm formation together with amplification loop of agrABCD. d) Control of P.
aeruginosa biofilm formation through the intracellular second messenger c-di-GMP level
controlled by the FimX protein having DGC and PDE domains, a RR domain, and a PAS
domain. Note that in FimX protein only PDE activity is detectable (continuous arrow),
whereas DGC activity is undetectable (dotted arrow). Reprinted with permission from
reference.113

Two-component systems (TCS) and autoinducers are promising drug targets for
biofilms because of the essential role in cell growth regulation and the unique
mechanisms of action compared to conventional antibiotics.114-117 Importantly, proteins
from TCS and quorum sensing are absent in humans, minimizing toxicity concerns. Also,
both biological processes are based on ligand-receptor interactions, which are typical
targets for drug discovery and have a reasonable likelihood of success. Histidine kinases
and response regulators, such as WalK/WalR, YhcS/YhcR81, HP165/HP166, and
MtrB/MtrA are potential drug targets for bacteria pathogens.117 Targeting the kinase
domain appears to suffer from poor selectivity, but targeting the sensor domain may
prove more successful. Also, targeting non-essential TCS proteins that regulate virulence
such as GacS/GacA, PhoQ/PhoP, and CorS/CorR, has demonstrated some initial positive
results.117
Alternatively, quorum sensing may be interrupted by targeting the LuxI, LuxR, or
LuxS transcriptional regulators,118,119 AIP receptors,116 or Lsr transporters.112 A common
approach is to use the three classes of autoinducers as chemical templates to design
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agonists or antagonists as a starting-point for drug design (Figure 2.4).120,121 For instance,
TCS proteins QseC/QseB from Escherichiacoli (EHEC) O157:H7 that responds to AI-3,
epinephrine, and norepinephrine, are inhibited by LED209 (N-phenyl-4[[(phenylamino)thioxomethyl]amino]-benzenesulfonamide).122 Additionally, the RNAIIIinhibiting peptide (RIP; YSPWTNF-NH2) is an inhibitor of the staphylococcal TRAP/agr
system, which is regulated by autoinducer RNAIII-activating protein.123 RIP was shown
to be active against methicillin-resistant Staphylococcus aureus graft infections. There
has also been significant effort in the design of AI-2 analogs as novel antibiotics because
of AI-2’s broad activity against multiple species.124,125 For instance Roy et al. (2010)
explored the activity C-1 alkyl analogs of AI-2 against multiple bacterial species. EthylDPD (DPD; 4,5-dihydroxy-2,3-pentanedione) was found to inhibit quorum-sensing in
both Escherichia coli and Salmonella typhimurium. In addition, Rui et al. (2012)
explored DPD analogs with a new stereocenter at C-5 (4S, 5R)-DHD.126 The compound
was also shown to be active against both E. coli and Vibrio harveyi. Conversely,
Tsuchikama et al. (2011) synthesized carbocyclic analogues of DPD that were inactive
against S. typhimurium and V. harveyi, suggesting the importance of the linear form of
DPD and the heterocyclic oxygen atom.127 Similarly, Lowery et al. (2005) explored a
variety of DPD analogs that resulted in a uniform lower activity that highlights the
general challenge in evolving a small chemical template into a drug.128 Nevertheless, the
unique mechanism of action for TCS and autoinducer targets holds the promise of a
valuable new class of drugs that may circumvent biofilm resistance to antibiotics (Figure
2.4).
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Figure 2.4 Structures of autoinducers and analogs. (top) AI-1 chemical structure and its
analogs a) homocysteine derivative 120; b) 3-oxopentanoyl HSL 121. (bottom) AI-2
chemical structure, its precursor DPD and its analogs c) ethyl-DPD 129; d) DHD (4S, 5R)4.130

2.4 An Overview of Metabolomics
Metabolomics is the study of metabolites, such as amino acids, carbohydrates and
lipids that are the end products of cellular regulatory processes, as well as intermediates
and other signaling molecules.131,132 The metabolome is the complete collection of all
metabolites within a biological cell compartment, cell, tissue, organ or organism
examined in the form of a cellular extract or biofluids.133,134 In general, a molecular
weight of 1 kDa is the typical limit that separates metabolites from macromolecules.135
There are many differences between conventional metabolite measurements and
metabolomics. First, metabolomics focuses on a global or broad-based analysis of
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metabolites through a high-throughput detection methodology compared to a limited and
directed analysis of a specific number of individual metabolites.132 In general,
metabolomics does not require the complete separation of individual metabolites. Instead,
it captures a “snap-shot” or “fingerprint” of the state of the metabolome. Thus,
metabolomics simplifies metabolite detection by using a single analytical technique to
characterize the state of the metabolome. In this manner, metabolomics also provides an
unbiased view of changes in metabolism by covering all major pathways. Thus, the
systematic analysis of the ultimate response of a biological system has a better chance of
describing pleiotropic effects.132 Second, metabolomics uses a combination of multiple
methodologies, such as cellular biology, instrumental analysis, chemometrics, and
bioinformatics to analyze the biological system. This combination of techniques provides
a better view of the global role that metabolism plays in cellular functions. Again the
analysis of a select set of metabolites does not provide this sort of global picture of
cellular activity. Yet in theory, it should be possible to correlate metabolic changes in a
biochemical pathway with the enzymes involved, and then to the underlying genetic
alterations or changes in gene expression or regulation.132 A computational simulation
could also integrate the experimental data to create a systematic view of the effected
biochemical pathways, and potentially, the relevant proteins. The identification of
specific proteins that are disease-related, or in this case related to biofilm formation, is a
fundamental and critical step of the drug discovery process.
Autoinducers are an excellent example of the significant roles that small
molecules can play in bacterial biofilms, where mimicking or inhibiting the mode of
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action of autoinducers is a potential drug discovery target. Other inter- or intracellular
small molecular-weight molecules may have similar roles in the initiation, progression
and survivability of bacterial biofilms. Specifically, biofilms are a spatial distribution of
heterogeneous cells, where cells exists in different metabolic states to maximize survival.
Thus, understanding biofilms requires a comprehensive characterization of the various
metabolic states within a complex cellular community. Correspondingly, metabolomics
provides a systematic approach to explain this complex system.136,137
Compared to genes and proteins, primary metabolites are highly conserved
between various cells and organisms.138 In a similar manner to gene expression, some of
the key metabolites, nutrients, and signal molecules (autoinducers) have been shown to
significantly influence biofilm formation.139 Thus, metabolite quantification and the
pathway modeling of complex biological systems is useful for exploring cell behavior in
establishing a biofilm community. Furthermore, metabolomics is an invaluable approach
for investigating antibiotic resistance in biofilms. By generating a network of metabolites
affected by the drug treatment, it is possible to predict the antibiotic’s mechanism of
action.140 Additionally, the phenotype of antibiotic resistance strains and biofilm strains
can be characterized through their relative metabolome differences. Similarly, monitoring
metabolic changes can be used to investigate the effects of other environmental stimuli
on biofilm formation.141 Metabolomics can also be used for detecting disease
biomarkers,142 and as a supplementary tool for proteomics and transcriptomics. The
linkage between metabolomics, mRNA and protein expression makes it possible to
visualize the biological state of an organism.143
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Metabolomics is the bridge between genotype and phenotype.132 Correspondingly,
metabolomics provides a better understanding of a disease since it links the pathology to
actual changes in the activity of biological processes. Metabolomics provides an
approach to diagnose a disease, monitor its progression, evaluate a response to therapy,
and identify potential novel drug targets. Thus, metabolomics has a wide range of
applications in drug discovery,144 including toxicology145 and functional genomics.143
The biofilm study can be categorized into either biological science or medical
engineering. However, so far, the main focus of our research is on the stage of
mechanism exploration. Therefore, metabolomics is mainly used for such purpose. A
series of examples addressed below demonstrated how metabolomics can be used to
answer fundamental science problems with some extension of future perspectives of how
metabolomics can be applied to engineering areas.
NMR metabolomics has been applied to identify biomarkers for cardiac disease,
146,147

liver disease,148 respiratory disease,149,150 cancer,151-154 and central nervous system

disorders,155-158 among others. Simply, NMR metabolomics provides a means to
differentiate between a disease and healthy state or between drug-treated and untreated.
Drug discovery or chemical-lead identification is then based on observing the
metabolome change from a disease-state to a healthy state or by simply observing that a
compound changes the metabolome. For example, Tizianni et al. (2011) describes using
NMR metabolomics in a high-throughput screening platform (96 well plates) to identify
kinase inhibitors.159 They demonstrate that changes in the lactate/pyruvate ratio in human
leukaemia cells (CCRF-CEM) and human ovarian cancer cells (SKOV-3) was successful
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in identifying inhibitors to eEF-2, NF-kB, MK2, PKA, PKC and PKG kinases. Similarly,
Halouska et al. (2012) demonstrate that the in vivo mechanism of action of a chemical
lead can be inferred by comparing the metabolome changes to a known drug.140 If two or
more drugs have a similar impact on the metabolome then the compounds share a similar
target. Additionally, NMR metabolomics is also widely-used for drug development and
personalized medicine.160-162 The consortium for metabonomic toxicology (COMET), an
organization of major pharmaceutical companies, was formed to share metabolomics data
from drug studies to characterize metabolites associated with kidney or liver toxicity. The
overall protocol for toxicity analysis is comparable to drug discovery and lead
identification. Specifically, biofluid (urine, serum, saliva, etc.) metabolites from animals
or patients undergoing drug treatment are analyzed by NMR to identify metabolites
known to be associated with drug toxicity or disease biomarkers. If the biofluid
metabolites reveal the presence of drug toxicity or the lack of drug efficacy, then an
alternative treatment can be prescribed.
Metabolomics is routinely combined with alternative strategies to resolve a
biological problem and to generate a comprehensive analysis. Although different
strategies may require alternative experiments and data analysis, targeted metabolite
analysis, metabolic profiling, and metabolic fingerprinting share the same general
workflow from sample preparation to data collection and analysis. Targeted metabolite
analysis is the exclusive study of the direct product of a corresponding enzyme or
protein.132 Metabolic profiling is the identification and quantification of a set of predefined metabolites in a biological sample.163 The metabolites may belong to a specific
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class of compounds or a particular metabolic pathway. As an illustration, metabolic
fingerprinting can be used to probe different metabolic phenotypes. Metabolic profiling
can then be used to provide a detailed analysis of specific metabolite changes between the
two phenotypes. Metabolomics can also be referred to as “metabolic fingerprinting”,164
and is generally meant to rapidly classify biological samples. The combination of
different strategies makes metabolomics a flexible and versatile technique for the analysis
of various biological systems, such as bacterial biofilms.165,166 The NMR metabolomics
methodologies described for drug discovery are equally applicable to investigating
bacterial biofilms, for identifying new drug targets and chemical leads, and evolving lead
candidates into new drugs. Again, characterizing and comparing the metabolomic
differences between planktonic cells and biofilms provides a means to identify active and
relevant biological processes associated with biofilm formation. Correspondingly,
proteins involved in these pathways are potential drug targets. Identifying and validating
drug leads can then be accomplished by observing chemical-induced changes in the
metabolome related to biofilm formation.
NMR-based metabolomics generally refers to a comprehensive approach to the
analysis of metabolomic samples that include specific NMR experiments, sample
preparation protocols, and multivariate statistical analysis.167-169 NMR spectroscopy is
used to characterize the metabolic samples by providing both qualitative and quantitative
data.134 NMR-based metabolomics of bacterial biofilms consist of the general procedures
outlined in figure 2.5: 1) prepare the metabolic samples by culturing the desired bacterial
strains under identical conditions, the only variable should be the specific environmental
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or genetic factor being investigated; 2) prepare the NMR samples by lysing the cells,
extracting the metabolites, and removing cell debris; 3) detecting the metabolites through
various NMR techniques; and 4) spectral processing, data normalization, statistical
analysis, and metabolite identification. The success of metabolomics largely depends on
accomplishing each step in a highly controlled and uniform manner. Variation in the
NMR metabolomics data should result from relevant biological differences between the
samples as opposed to artifacts introduced from sample or data handling. For example,
extracting the metabolites from the lysed cells should occur quickly and at low
temperatures to avoid changes to the metabolome that result from the process of
harvesting the cells. In effect, all potential variables such as: the number of cells, growth
phase, culture media, experimental conditions, bacterial strain, time, etc. need to remain
constant between all bacterial samples.170 Again, the only difference between the various
bacterial cultures should be the specific environmental or genetic factor being
investigated. Uniformity is the key to a successful metabolomics experiment. It is
impractical to investigate a heterogeneous sample composed of multiple bacterial
organisms since there is no mechanism to associate the majority of the commonly
observed metabolites to a specific organism. Alternatively, using flow cytometry or other
techniques to separate the cells prior to investigating the metabolome does not solve the
problem.171 The results would be invalid because the time required and the process of
separating the cells would perturb the state of the cells and, correspondingly, the
metabolome.
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Figure 2.5 A flowchart illustrating the general protocols for an NMR metabolomics
study.

Fundamental to a metabolomics study is the identification of the “classes” or
“groups” of bacterial cells that will be compared. A straightforward application is the
comparison between two groups, a bacterial strain in its planktonic state (class one) and
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its biofilm state (class two). Models of higher complexity include even more classes. For
example, Figure 2.6 illustrates the application of metabolomics to monitor in vivo drug
activity. The diagram illustrates the general analysis of clustering patterns in a principle
component analysis (PCA) scores plot. Simply, the metabolome of four different classes
are compared: 1) wild-type cells, 2) mutant cells where the drug-target has been
genetically knocked-out, 3) wild-type cells treated with the drug, and 4) mutant cells
treated with the drug. The activity and selectivity of the drug is determined by the relative
similarity of the four different metabolomes as described in Figure 2.6. As an illustration,
a drug is selective and active if the metabolome of the wild-type cells treated with the
drug clusters together with the metabolome obtained from the mutant cells with and
without drug treatment, where this cluster forms a separate cluster from the wild-type
cells without the drug treatment (Figure 2.6, top-right). Simply, these results indicate the
protein target in the wild-type cells was chemically inactivated since the metabolome is
identical to the mutant cells where the protein was genetically inactivated. It also differs
from the wild-type cells without the drug treatment where the protein is still active. The
drug is selective because there is no difference between the metabolomes for the mutant
cells with or without drug treatment. This analysis can be easily generalized. The “drug”
in this scenario can also be taken as any environmental condition, while the “mutant” can
be taken as the drug target or any knockout, repressed or over-expressed gene.
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Figure 2.6 Cartoon illustrations of hypothetical PCA scores plot for the following
scenarios: inactive compound, active and selective inhibitor, active, nonselective
inhibition of target and secondary protein, and active, nonselective preferential inhibition
of secondary protein. Reprinted with permission from reference.172

2.5 Metabolomics Sample Preparation
Metabolite sample preparation includes cell quenching, cell harvesting, cell
disruption and metabolite extraction. An important advantage of NMR-based
metabolomics is the minimal and relatively simple sample preparation protocol.
Nevertheless, the details of the procedure influence the accuracy, reliability, and
reproducibility of the metabolomics data.134 Different approaches to sample preparation
have various advantages in terms of speed, capability, consistency, efficiency and
metabolite recovery yield.173-175 Since biofilms can form on a wide range of surfaces or
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habitats, the experimental conditions for growing and harvesting cells can be highly
variable. Thus, this review will focus on a general discussion of sampling methods for
biofilm-related planktonic cells.
A very critical issue in sample preparation is the need to rapidly and efficiently
quench all enzymatic and biological activities in order to capture an accurate “snap-shot”
of the metabolome. This is because metabolites such as pyruvate, fumarate, oxoglutarate,
phosphoenolpyruvate, fructose-6-phosphate, and others have a rapid turnover rate.176
Also, it is important to avoid inducing a stress response or cell death that would
completely invalidate the study. Thus, a quick quenching step that involves reducing the
cell temperature has been shown to be a useful approach to slow down enzyme activity
within a cell.173 Methanol is commonly used because of its low melting point and
minimal toxicity relative to other organic solvents.174 However, methanol may only be
suitable for gram-positive bacteria or fungi due to the possibility of cell leakage and the
loss of metabolites during the quenching and washing steps.176 Choosing the proper
metabolite extraction protocol is extremely critical since it influences the efficiency and
accuracy of the entire metabolomics experiment.
Improperly removing the cell-growth medium and washing the cells is an easy
way to contaminate the metabolomic samples and generate unreliable data. Filtration and
centrifugation are the two main methods of removing the culture medium before
collecting the metabolome. Centrifugation takes longer so there are concerns regarding
induced stress and metabolome changes, but it has a higher consistency in sample
preparation. Conversely, filtration is significantly faster, and it is also easier to quench
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cells on a filter membrane. But, there are also practical concerns with uniformly and
consistently retrieving all the frozen cells from the filter paper. Nevertheless filtrationquenching was demonstrated to have the highest yield for an S. aureus metabolomics
study.177 Also, an NMR-based metabolomics study of P. pastoris applied a single
centrifugation step and demonstrated that there was no benefit to including an additional
washing step in the quenching process.178 Directly growing E. coli cells on filter paper
may provide an efficient and fast approach to quench cells and extract the metabolome.179
To date, the choice of technique to separate and wash cells is still very flexible, which
implies a necessary optimization step for any metabolomics study. An inability to
efficiently arrest all cell processes and purify the cells without inducing leakage or lysis
will inadvertently lead to undesirable changes in the state of the system and the
metabolome. Thus, choosing system appropriate washing, quenching and cell separation
protocols is the first and most critical step of a metabolomic project and will determine
the validity of the entire study.
Cell lysis and metabolite extraction can sometimes be done simultaneously. Both
mechanical disruptions, such as the Fast-Prep system or organic solvent-based methods
are widely used.175,180 Trichloroacetic acid (TCA) is a traditional approach for lysing cells
from filter paper, but TCA causes a significant background for metabolomics data
because it also degrades the filter paper.176 The optimal extraction buffer should: 1)
extract the largest number of metabolites, 2) be nonselective and not exclude molecules
with particular physical or chemical properties, and 3) be nondestructive and not modify
metabolites through chemical or physical means.181 Since metabolites are normally
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dissolved in a D2O buffer or CDCl3 for NMR, choosing alternative extraction solvents is
not particularly beneficial. A common extraction solvent is a (5:2:2) v/v mixture of
methanol, chloroform, and water.182 Others extraction mixtures include a (1:1) v/v
mixture of methanol and chloroform, or water and chloroform for metabolite extractions
that include lipids.183

2.6 NMR Experiments for Metabolomics
There are many practical challenges encountered when studying the bacterial
metabolome. A cellular metabolome can contain upwards of thousands of metabolites,
with a 7 to 9 order of magnitude range in concentrations (picomoles to millimoles).184
Therefore, it is generally not possible to analyze all cellular metabolites in a single
experiment. Also, cellular metabolism is very sensitive to environmental changes, where
the measurement and sampling process can influence the metabolome. Thus,
metabolomic measurements are also perturbed by including separation techniques.
Correspondingly, each biological system requires experimental optimization to accurately
study its metabolome.
Mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy
are the primary analytical techniques used for metabolite detection. Mass spectrometry
measures the mass-to-charge ratio of charged molecules that can be used to determine the
elemental composition and elucidate the chemical structure of molecules. While an exact
mass is determined by MS, the limited molecular-weight dispersion of the metabolome
generally requires using chromatography.185 Gas chromatography, high performance
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liquid chromatography (HPLC) and capillary electrophoresis are common separation
techniques used by MS-based metabolomics.186,187 Unfortunately, the use of
chromatography to separate metabolites inevitably leads to changes in the metabolome.
The amount that is recovered from the chromatography step will vary for each metabolite,
where some metabolites will be lost or chemically modified. MS also requires ionization
of the molecule for detection with the corresponding uncertainty that a specific
metabolite will ionize. Also, determining a concentration for each metabolite by MS is
particularly challenging.
Conversely, NMR determines a molecular structure by measuring nuclear
chemical shifts within a magnetic field.188 Three valuable pieces of information are
obtainable from a single peak in an NMR spectrum (Figure 2.7). The chemical shift is
related to the local chemical environment of that specific nucleus (1H, 13C, 15N, etc.), and
the peak-splitting (J-coupling) identifies chemically bonded nuclei, which are both used
to identify the chemical structure of the metabolite.188 Importantly, the peak intensity is
directly proportional to the metabolite’s concentration. Typically, multiple distinct NMR
resonances are observed per molecule that eliminates the need for chromatographic
separation and increases the accuracy of metabolite identification.
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Figure 2.7 1H NMR spectra of the intracellular metabolic profiles of aqueous extract of
MCF-7 cells. The sample used for spectrum contained ~6x105 cells. The inserted spectra
were also plotted using the same expanded x scale. Reprinted with permission from
reference.189

MS is significantly more sensitive than NMR and covers a wider diversity of the
metabolome, even though the use of cryogenic probes has significantly increased the
sensitivity of NMR by a factor of four.190 In effect, NMR only detects the most abundant
metabolites that are present at concentrations greater than 1 to 5 µM. 1H NMR is
typically used for metabolomics since 1H NMR is 64 times more sensitive than 13C NMR.
Nevertheless, NMR cryoprobes can still be used to detect metabolites using naturally
occurring 13C, which has an abundance of only 1.1% (12C is not detectable by
NMR).191,192 MS is a destructive technique, but it requires a significantly lower sample
amount (< 100 L) compared to NMR (600 L). Correspondingly, both approaches are
complementary to each other and contribute inherently distinct information to the
analysis of a metabolome.193 The complementary nature of MS and NMR has been
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demonstrated by a number of metabolomic studies using both techniques.194-198 In effect,
the MS and the NMR data can be combined to create a three-dimensional scores plot. The
added dimensionality from complementary data may provide the additional resolution
necessary to differentiate between multiple classes or groups.
The application of NMR spectroscopy for metabolomics can be categorized into
one of three groups, one dimensional (1D) NMR, two dimensional (2D) NMR
experiments and solid state NMR.188 1D and 2D solution-state 1H NMR experiments are
commonly used for global metabolomics analysis of bacterial cell extracts.199 Conversely,
solid state NMR can be used to analyze intact cells.200-202 In addition to 1H, other nuclei
are also used in 1D NMR-based metabolomics, such as the metabolic profiling of the
carbohydrate cycle using 1D 13C NMR,203,204 or tissue metabolism using 1D 31P NMR.205
A typical 1D 1H NMR spectrum of a bacterial cell lysate may contain thousands
of sharp lines from low molecular weight metabolites (Figure 2.7).134 The entire 1D 1H
NMR spectrum is used as a “fingerprint” to characterize the state of the bacterial cell. A
global investigation of the metabolome is simply based on a comparative analysis of the
features present or absent in each 1D 1H NMR spectrum. Effectively, a global
metabolomic analysis is based on how similar or how different the 1D 1H NMR spectra
are between each class or group. It is not necessary to assign each 1D 1H NMR spectrum
to identify and quantify all the metabolites present in each sample. Overlapping these
relevant NMR resonances and interfering with the analysis may be broad bands from
proteins or other biomolecules, which can be readily removed by using a Carr–Purcell–
Meiboom–Gill (CPMG) spin-echo sequence.206 The CPMG pulse sequence takes
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advantage of the large difference in T2 relaxation times between small molecular-weight
metabolites and large MW biomolecules. Effectively, the NMR resonances from the
biomolecules rapidly decay during the CPMG pulse. Alternatively, proteins and other
biomolecules can be removed by an appropriate choice of extraction solvents.207,208 The
large interfering signal from water or other buffer components is also eliminated by the
use of appropriate NMR solvent suppression methods and 100% deuterated buffer.209
Basically, the water NMR resonance is set in the center of the spectrum where selective
irradiation and gradient pulses suppress the solvent peak while leaving all other peaks
unaffected. In effect, any resonance in the 1D 1H NMR spectrum that does not originate
from the bacterial metabolome will generate a “false feature” that needs to be removed.
NMR resonances originating from proteins or solvents are likely to be variable and
dominate the spectra relative to metabolite signals. This will lead to an erroneous
interpretation of the 1D 1H NMR spectra and incorrect sample classification. For instance,
replicate samples may not cluster together because of a significant variation in the peak
height and peak shape of the water resonance despite the overall similarity in all the
metabolite NMR peaks.
High resolution magic angular spinning (HR-MAS) is used to generate in vivo 1D
1

H spectra of solids comparable to solution-state NMR.210 Thus, small, intact, and

untreated cells or tissues can be directly analyzed by HR-MAS by spinning samples at
speeds between 4 and 12 kHz at the “magic” angle of 54.7°relative to the external
magnetic field. Spinning the sample significantly reduces NMR line widths by averaging
out chemical shift anisotropy, magnetic susceptibility, and dipolar coupling that are
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prominent in solid samples.188
Assigning a 1D 1H NMR spectrum to identify the metabolites present in a
metabolomics sample is challenging because of the large number of peaks, the significant
overlap in peaks, the high chemical shift degeneracy (multiple metabolites have some
chemical shifts in common), and an incomplete database of NMR reference spectra for
metabolites. Again, assigning a 1D 1H NMR spectrum is not necessary for a global
analysis of the metabolome, but identifying the specific metabolites that are changing and
are the main contributors to class distinction is extremely valuable for understanding the
underlying biological differences. Statistical total correlation spectroscopy (STOCSY)
can be used to associate multiple NMR peaks from the same molecule in a complex
mixture.211 This significantly simplifies the assignment problem since most, if not all, of
the NMR resonances for a given metabolite can be used together in a database search. A
positive identification only occurs when all of the observed chemical shifts match the
metabolite’s known chemical shifts in a database. In STOCSY, a series of 1D 1H NMR
spectra is converted into a pseudo-2D spectrum that is based on a correlation of peak
intensities. NMR peaks from the same metabolite will change together as the metabolite’s
concentration varies across multiple distinct classes. The statistical heterospectroscopy
(SHY) is similar in concept to STOCSY.212 Instead of correlating NMR peak intensities,
SHY correlates chemical shifts from NMR with mass-charge (m/z) data from mass
spectroscopy. Thus, SHY can improve molecular identification by directly crosscorrelating NMR chemical shifts with molecular weight.
More commonly, 2D NMR spectroscopy improves the accuracy of metabolite
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assignments by significantly increasing spectral resolution by extending chemical shift
information into a second frequency dimension. Additionally, 2D NMR experiments can
identify the network of resonances associated with a specific metabolite through Jcoupling. Two-dimensional correlation spectroscopy (COSY) and total correlation
spectroscopy (TOCSY) experiments identify spin–spin coupling connectivities that
identify chemically bonded pairs of hydrogens, carbons or nitrogens.213,214 To a lesser
extent, 2D J-resolved NMR experiments are also used for metabolomics studies.215 In a
2D J-resolved NMR experiment, the data is dispersed into two-dimensions based on
chemical shifts and the J-coupling pattern.216 While it is possible to match coupling
patterns to identify bonded resonances, this is generally not practical for complex
metabolomics data set. So, a 2D J-resolved NMR experiment has significantly less
information then a 2D COSY or TOCSY experiment while requiring the same amount of
experimental time. Alternatively, a 1D projection of the 2D J-resolved NMR experiment
can be used to simplify the NMR spectra by removing peak multiplicity due to Jcoupling.217 This dramatically reduces the number of peaks and correspondingly reduces
peak overlap. Removing peak splitting improves the accuracy of metabolite identification
and quantification. Of course, a single 2D NMR experiment may require an hour or
longer to acquire compared to a few minutes for a 1D NMR experiment.
The 2D 1H, 13C HSQC (Heteronuclear Single-Quantum Correlation) experiment
correlates the 1H and 13C chemical shifts for each C-H pair in a molecule.218 This
provides unique information relative to the COSY, TOCSY or J-resolved experiments.
Also, metabolite assignments are easier with a 2D 1H, 13C HSQC experiment because of
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two correlated and distinct chemical shift assignments, the large 13C chemical shift
dispersion, and the simplified spectrum without splitting from J-coupling. However, due
to the low natural abundance (1.1%) of 13C, 13C-labeled compounds, such as 13Cmethanol, 13C-CO2219, 13C-glycerol220 and 13C-glucose221 are required as a bacterial
carbon source to enhanced the sensitivity of the NMR spectrum.222 This significantly
simplifies and focuses the analysis of the metabolome. Only metabolic intermediates and
products of the 13C-labeled materials will be partially or completely enriched with 13C.
Correspondingly, only these metabolites will be observed in a 2D 1H, 13C HSQC
spectrum, which provides a means to follow carbon-flow through the metabolome and
identify the perturbed metabolic pathways. Standard HSQC experiments are not
quantitative because of significant variability in coupling-constant and relaxation times
(T1 and T2) between metabolites. Nevertheless, the newly developed 2D extrapolated
time-zero 1H, 13C HSQC (HSQC0) experiment allows for the calculation of metabolite
concentrations.223 Basically, a series of 2D HSQC spectra are collected with an increasing
number of the core HSQC experiment. The peak intensity will decrease linearly with the
number of HSQC blocks, where a linear fit and extrapolation back to zero HSQC blocks
will determine the true peak intensity and metabolite concentration. Examples of 2D
NMR spectra used to identify metabolites from biological samples are shown in Figure
2.8.
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Figure 2.8 a) Overlay of 2D 1H, 13C HSQC spectra comparing wild-type S. epidermidis
strain 1457 (red) and aconitase mutant strain 1457-acnA::tetM (black) grown for 6 h in
standard TSB media augmented with 0.25% 13C-glucose. NMR resonances
corresponding to specific metabolites are labeled, where citrate is circled. b) Overlay of
2D 1H, 1H TOCSY spectra comparing wild-type S. epidermidis strain 1457 (red) and
aconitase mutant strain 1457-acnA::tetM (black) grown for 6 h in standard TSB media.
Reprinted with permission from reference.141
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For chemometrics (please see the Chemometrics and Bioinformatics Analysis of
Metabolomics Data section), the 1D 1H NMR spectra are transformed into a data matrix
of integrated peak intensities and corresponding chemical shift values. This data is used
to define the classes and to identify NMR spectral features that differentiate the classes.
Unfortunately, subtle instrument, temperature, and sample condition variability (pH,
ionic strength, etc.) can result in chemical shift differences between replicate samples.
Correspondingly, misalignments will occur in the NMR data matrix between these
replicate samples that will lead to clustering errors independent of any biological
differences. One approach to normalize NMR metabolomics samples is the inclusion of a
known concentration of chemical shift reference compound such as the sodium salt of 3trimethylsilylpropionic acid (TSP). The TSP peak intensity can also be used to calibrate
the concentrations of the metabolites in the biological sample. Unfortunately, an internal
reference only corrects for global differences. It does not correct for individual peak
position and shape variability due to subtle experimental differences. Instead, binning or
bucketing is commonly used to correct for peak variability between replicate
samples.224,225
In its simplest implementation, bucketing divides the NMR spectrum into equal
sized, non-overlapping sub-spectral regions with a width or bin size of 0.025 ppm. So, a
typical 1D 1H NMR spectrum with a width that ranges from 0 to 10 ppm will have 400
buckets. Bin sizes typically range from 0.01 to 0.04 ppm. The peak intensity within each
bucket is integrated, where these resulting integrals are then used as input to the
chemometrics analysis. In this manner, the buckets or bins smooth-out small peak
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variability with the expectation that the same peaks occur in the same bucket.
Unfortunately, bin edges create a second problem; the undesirable splitting of a peak
between buckets. Thus, “intelligent” or “adaptive” bucketing techniques have been
developed that vary the individual bin size to avoid dividing peaks between multiple
buckets.226-229 These methods use a Gaussian function, a recursive algorithm, optimize an
objective function using a dynamic programming strategy, or use underestimated wavelet
transforms to automatically identify bin edges. In all cases, intelligent bucketing performs
significantly better than uniform bucketing, where dynamic adaptive binning was
recently shown to perform the best.229 The use of intelligent bucketing results in a
significant improvement in replicate clustering in scores plots since it minimizes spectral
differences that are biologically irrelevant. Correspondingly, noise regions of the NMR
spectra are typically zeroed or removed from the bucketing.230 Similarly, buckets
resulting from solvent or buffer peaks that are unrelated to the bacterial metabolome are
also excluded. Again, this eliminates class distinction that results from biologically
irrelevant data. In essence, the variables used in the chemometrics analysis should be
relevant to real variations in the metabolome between the classes.170
Peak alignment is a more robust and complex alternative to NMR binning.231-234
The goal is to remove the chemical shift variability between the replicate 1D 1H NMR
spectra by individually aligning each NMR peak to a representative spectrum from each
class. The approaches used include fuzzy warping, genetic algorithms, a generalized
fuzzy Hough transform approach, a reduced set mapping (PARS) algorithm, or a
recursive segment-wise peak alignment. Each approach demonstrated acceptable results
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on test metabolomic samples and was shown to improve upon the results obtained from
bucketing.234 Nevertheless, intelligent bucketing is still the predominate methodology
used in NMR metabolomics.
An NMR spectrum is experimentally collected as a free induction decay (FID)
that requires further processing to convert the time-domain data into a frequency-domain
spectrum through a Fourier transform. This process can be accomplished using a variety
of software packages (Table 2.1). All of the software packages can import popular NMR
data formats such as: Bruker, Varian, Jeol Delta, JCAMP-DX, and others. Some NMR
software can process both 1D and 2D data, where others only focus on processing 1D
(most popular) or 2D data sets. In addition to the Fourier transform step, the processing
of NMR data may include zero-filling, phase correction, baseline correction, applying a
window function, and removal of solvent peaks. The inclusion of any of these steps
induces changes in the resulting NMR spectrum that is not biologically relevant. Thus,
uniformity in the NMR processing protocol is essential, where minimizing all spectral
manipulation is ideal. In general, phase correction is essential in order to obtain purely
absorption peak shapes. Uniform zero-filling of the NMR spectra is typically acceptable
since it provides a constant improvement in the digital resolution. Similarly, removing
residual solvent peaks by simply zeroing the corresponding region of the NMR spectrum
does not have any detrimental effect because these solvent regions are not included in the
binning process. Conversely, applying a window function or incorporating baseline
correction should be avoided, if possible, since these processes induce significant
variable changes in the NMR spectrum. The goal of a window function is to either
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increase the spectral resolution or the signal-to-noise by multiplying the FID with a
mathematical function. As a result, each NMR peak shape is artificially changed. Instead,
the signal-to-noise and spectral resolution should be improved experimentally. A baseline
correction is required if the baseline for the NMR spectrum is not flat. A flat baseline is
necessary for reliable chemometrics analysis. Distorted baselines may result from intense
solvent or buffer peaks, from phasing problems, errors in the first data points of the FID,
large range of T1 values (short recycle times), or short acquisition times. Again, baseline
problems should be experimentally minimized. Nevertheless, numerous computational
approaches to obtain a flat baseline are available and include a linear or polynomial (up
to 6 orders) fit of the baseline, FID reconstruction and spectrum averaging. The choice of
a baseline correction method depends on the specifics of the baseline distortion, which is
typically determined by trial-and-error. Importantly, a single baseline correction method
most be used for an entire metabolomics dataset in order to avoid inducing class
distinctions that are primarily a result of the NMR processing protocol.
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Table 2.1 NMR software packages.
Software

OS

Source

Reference

ACDLab

Win

Commercial

1D, 2D

Advanced Chemistry Development, Inc.

CCPNmr

Win/Mac/Unix

Academic

2D

235

Felix

Win/Unix

Commercial

2D

Felix NMR, Inc.

FERCH

Win

Commercial

1D

PERCH Solutions Ltd.

Gifa

Unix

Academic

1D, 2D

236

iNMR

Mac

Commercial

1D, 2D

Nucleomatica, Inc.

matNMR

Win/Mac/Unix

Academic

1D, 2D

237

MestreNova

Win/Mac/Unix

Commercial

1D, 2D

Mestrelab research

NMRPipe

Win/Mac/Unix

Academic

2D

238

NMRViewJ

Win/Mac/Unix

Commercial

2D

One Moon Scientific, Inc.

NUTS

Win

Commercial

1D, 2D

Acorn NMR Inc.

RMN

Mac

Academic

1D, 2D

P. J. Grandinetti, Ohio State University,
Columbus, OH, U.S.A.

rNMR

Win/Mac/Unix

Academic

2D

Sparky

Win/Mac/Unix

Academic

2D

SpinWorks

Win/Mac/Unix

Academic

1D, 2D

TARQUIN

Win/Mac/Unix

Academic

Solid state

240

WIN-NMR

Win

Commercial

1D

Bruker Instruments, Inc.

239

T. D. Goddard and D. G. Kneller, SPARKY 3,
University of California, San Francisco, CA,
U.S.A.
K.Marat, University of Manitoba, Winnipeg,
Manitoba, Canada

Ideally, the overall concentration of the metabolites and the corresponding signalto-noise of each replicate 1D 1H NMR spectrum will be essentially identical.
Unfortunately, in practice, there may be a significant variability in the signal-to-noise
between replicate NMR spectra due to random errors in cell lysing, metabolite extraction,
or the number of bacterial cells per sample. Correspondingly, the 1D 1H NMR spectra
needs to be normalized.241 Center averaging is a common normalization technique:
Z

Xi  X



(1)

where X is the average signal intensity, σ is the standard deviation in the signal intensity,
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and Xi is the signal intensity within a bin. Other normalization techniques include:
normalization to a constant sum, Pareto scaling, mean-centering, logarithmic scaling,
probabilistic quotient normalization, etc. A recent analysis of NMR processing
procedures by De Meyer et al. (2010), suggests that a combination of intelligent
bucketing with probabilistic quotient normalization yields the best results.242 Of course, it
was not practical to explore all the possible combinations of the various processing
techniques and, as a result, the analysis did not include center averaging. This highlights
a particular challenge with processing NMR metabolomics data; there is no clear
consensus of an optimal protocol because of all the possible combinations of parameters
that need to be evaluated.

2.7 Chemometrics and Bioinformatics Analysis of Metabolomics Data
For a detailed understanding of a complex biological system, it is essential to
follow the response of an organism to a conditional perturbation at the transcriptome,
proteome or metabolome level.143 Metabolic products are dependent on genotype,
environment, time, and location.243 Perturbations in any of these factors may lead to a
variety of biological changes that inadvertently effect the metabolome.143 The primary
goal of chemometrics is to reduce the complexity of the NMR-based metabolomics data
to understand these global correlations. In essence, chemometrics identifies the major
features within an NMR spectrum, the presence or absence of peaks, the change in peak
intensity, shape, or the change in chemical shifts that differ between the various classes.
A class definition can be based on any variable that affects or changes the bacterial cell
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culture, such as different bacterial strains (including wild-type and mutant cells) and
different experimental conditions (growth phase, drug dosage, media composition, pH,
etc.). Bioinformatics is used to uncover and characterize all the associated variables and
to reveal the underlying relationships. Essentially, bioinformatics is used to identify the
metabolites that correlate with the major changes in the NMR spectra and to associate
these metabolites with specific proteins and enzymes, with metabolic pathways, and other
biological processes.
For statistical modeling, principle component analysis (PCA) is the most common
multivariate technique for the comparison of metabolomic data.244 Basically, each
multivariable (chemical shift and intensity) NMR spectrum is converted into a singlepoint in multidimensional Cartesian space (Figure 2.9). Each axis (V1, V2, V3 … Vn)
corresponds to a specific chemical shift where the peak intensity is the value along each
axis. PCA determines the vector ( PC 1 ) corresponding to the largest variation in the data
and fits each NMR spectra to this vector. Each NMR spectrum is assigned a value (PC1principal component one) based on its distance to the vector ( PC 1 ). The process is
repeated for the next largest variation ( PC 2 ) orthogonal to the first vector. Plotting the
resulting principal components (PC1, PC2) corresponds to a scores plot, where similar
spectra (and metabolomes) cluster together in a scores plot. Spectra (and metabolomes)
obtained from different classes are expected to form separate clusters in the scores plot.
Figure 2.9 illustrates the hypothetical separation of class 1 (♦) from class 2 (●) and the
relatively tight clustering of the class replicates. The class separation is based on
differences in the 1D 1H NMR spectra.
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Figure 2.9 Conceptual illustration of the principal component analysis of NMR spectral
data. Each 1D 1H NMR spectrum is converted into a single point in multidimensional
space. Each axis (V1, V2, V3, etc.) corresponds to a chemical shift (ppm) and the value
along the axis is the peak intensity or bin integral. A vector (PC1) corresponds to the
largest variation in the data. The second vector (PC2) is orthogonal to the first vector and
corresponds to the second largest variation in the data. The scores corresponds to the fit
of each point (spectrum) to each principal component vector, where the resulting 2D
scores plot identifies the relative similarities and differences between the NMR spectra
based on the clustering pattern.

Orthogonal partial least squares discriminant analysis (OPLS-DA) is a related, but
alternative approach to PCA. Unlike PCA, OPLS-DA is a supervised method. This is an
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important and significant difference. In PCA, the different classes are not identified and
each 1D 1H NMR spectrum follows the protocol described above. Thus, the clustering of
each NMR spectrum in the scores plot is solely determined by the intrinsic differences
and similarities in the features of its NMR spectrum relative to all the other NMR spectra.
Conversely, in OPLS-DA each 1D 1H NMR spectrum is assigned to one of two classes,
(biofilm vs. planktonic, healthy vs. diseased, treated vs. untreated, wild-type vs. mutant,
etc.). More than two class definitions can be used, but it is generally not recommended.
As a result, OPLS-DA determines the clustering patterns in the scores plot based on the
NMR spectral features and the class definition. OPLS-DA tries to maximize the
separation between the classes based on these manual class assignments, while
minimizing the within class variation. This results in tighter class clustering in the OPLSDA scores plot relative to PCA. Fundamentally, if two classes are defined in OPLS-DA
then two clusters corresponding to the two assigned classes will be generated in the
resulting scores plot. OPLS-DA assesses a relationship between an X matrix (NMR data)
and Y matrix (the 0 or 1 class designation). Thus, OPLS-DA will only identify all the
spectral features that can be used to distinguish the two classes regardless of any real
significance (i.e., noise, small random variability in peak height, etc.). Conversely, the
class separation in a PCA scores plot depends on a combination of all principal
component variables. Since OPLS-DA is a supervised method or biased by the class
assignment, it is essential that the model is validated.170 Is the class separation due to
relevant changes in the 1D 1H NMR spectra resulting from changes in metabolite
concentrations?
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The quality of the OPLS-DA model can be evaluated by multiple statistical
factors and cross-validation, the goodness of fit (R2) and the quality assessment score
(Q2).245 A good OPLS-DA model has R2 values ≥ 0.5 (range of 0 to 1) that is
conceptually similar to simple linear regressions. Similarly, a typical value for Q2 for a
biological model is ≥ 0.4. The leave-one-out cross-correlation technique is commonly
used to calculate Q2, where a sub-set of the NMR spectra are left out to calculate a model
that is then used to predict the left out data.246,247 Q2 is the consistency between the
predicted and original data. Importantly, Q2 and R2 values should only be used as a figure
of merit and not validation of the model. A permutation tests is one approach to validate
the model.246,247 Simply, the NMR spectra classifications are randomly assigned creating,
in principal, a random data set that should have poor class separation and low Q2 scores.
The process is repeated numerous times (> 1000 permutations) until a Gaussian
distribution of Q2 scores are obtained for the random data set. The statistical significance
of the model with the correct NMR spectra classification can then be obtained by
comparing the model Q2 with the random Q2 scores and calculating a P-value. In addition
to Q2, a similar validation can be achieved by using the area under a receiver operating
characteristic (ROC) curve or the number of misclassifications.
Further validation of the OPLS-DA model can be assessed by determining if the
NMR features that determine the class separation are biologically relevant. S-plots and
loading plots are additional outcomes of an OPLS-DA model. An S-plot identifies the
relative contribution of each bin (chemical shift, metabolite) to the clustering in the
corresponding scores plot, each bin with a covariance of greater than 0.10 or less than -
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0.10 are identified as major contributors to the class separation.248 Similarly, a loadings
plot displays the relative contribution of each bin to the principal components. Thus, a
valid OPLS-DA model is supported by being able to assign metabolites to the bins that
are associated with the class separation. The model is further validated if multiple bins
assigned to the same metabolite are all major contributors to the class separation.
Additionally, the identification of multiple correlated metabolites, members of the same
metabolic pathway for instance, that are all major contributors to the class separation
would further strengthen the reliability of the OPLS-DA model. Again, the overall goal
of NMR-based metabolomics is to identify major changes in the NMR spectra that can be
associated to a specific set of metabolites with a relationship to a biological process, such
as bacterial biofilm formation.
A number of metabolomics software packages have been developed to automate
the chemometrics analysis by combining data normalization, data reduction, model
prediction and validation, and even metabolite identification, into a single work-flow.
These programs include: Automics,249 HiRes,250 MetaboAnalyst,251 and the R-package
Metabonomic.252 Among these, Automics is the most versatile and extensive package and
includes nine different statistical methods applicable to metabolomics data: feature
selection (Fisher's criterion), data reduction (PCA, LDA, ULDA), unsupervised
clustering (K-Mean) and supervised regression and classification (PLS/PLS-DA, KNN,
SIMCA, SVM). Automics also incorporates processing tools to generate a STOCSY
spectrum.
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Interpreting a PCA or OPLS-DA scores plot is fundamentally a cluster analysis. If
two or more classes cluster together in the scores plot, then the NMR spectra and the
corresponding metabolome are considered statistically similar. Conversely, two or more
classes that form distinct clusters indicate the samples are significantly different
metabolomes. For a simple metabolomics study that involves only two or three different
types of samples, the cluster analysis is generally straightforward. An ellipse that
corresponds to the 95% confidence limits from a normal distribution for each cluster can
be used to define each class in the 2D scores plot to visually determine class separation.
Alternatively, Werth et al. (2010) recently demonstrated the application of metabolomic
tree diagrams combined with standard boot-strapping techniques as a more robust
statistical analysis of clustering patterns in scores plots.253,254 Simply, each PC value (PC1,
PC2) is treated as an axis in a Cartesian coordinate system. An average position is
calculated for each class cluster, which is then used to calculate a Euclidean distance
between each class to create a distance matrix. The cluster centers and distances between
clusters are re-calculated by randomly selecting data points from each class. The process
is repeated until 100 different distance matrices are generated, which are then used to
generate 100 tree diagrams using Phylip 3.68b.255 A consensus tree is created, where the
bootstrap number is simply the number of times each node appears in all 100 trees.
Bootstrap values below 50% imply a statistically insignificant separation. Further
analysis to identify the metabolic processes that led to class separation may require
bioinformatics.256 An Example 2D OPLS-DA scores plot and associated metabolomics
tree diagram is shown in Figure 2.10.
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Figure 2.10 2D OPLS-DA comparing wild-type S. epidermidis 1457 cells grown 6 h in
standard TSB media ( ), with S. epidermidis 1457 cells grown 6 h in iron-depleted media
(DTSB) ( ), with the addition of 4% ethanol ( ),with the addition of 2% glucose ( ),
with the addition of 0.06 µg/mL tetracycline ( ), with the addition of 5% NaCl ( ), and 6
h growth of aconitase mutant strain 1457-acnA::tetM in standard TSB media ( ). The
ellipses correspond to the 95% confidence limits from a normal distribution for each
cluster. For the OPLS-DA scores plot, the 6 h growth of wild-type S. epidermidis 1457 (
) was designated the control class and the remainder of the cells were designated as
treated. The OPLS-DA used 1 predictive component and 4 orthogonal components to
yield a R2X of 0.637, R2Y of 0.966 and Q2 of 0.941. (b) Metabolomic tree diagram
generated from the the 2D OPLS-DA scores plot depicted in (a). The label colors match
the symbol colors from the 2D scores plot. Each node is labeled with the boot-strap
number, where a value above 50 indicates a statistically significant separation. Reprinted
with permission from reference.141

Metabolic pathway reconstructions has been widely employed with five major
goals: 1) contextualization of high-throughput data, 2) guidance of metabolic engineering,
3) directing hypothesis-driven discovery, 4) interrogation of multi-species relationships,
and 5) network property discovery.257 NMR-based metabolomics are routinely used to
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generate these metabolic networks for a particular biological system (Figure 2.11). The
first step of the process is to deconvolute and decode the NMR spectra. This is a difficult
and time-consuming process because the high-degeneracy of NMR chemical shifts makes
unambiguously assigning an NMR resonance to a specific metabolite extremely
challenging. This is further complicated by the incompleteness of metabolomics data and
by several technical problems that include proper peak assignment,199 peak
alignment,258,259 absolute concentration determination,223,260 and intensity
normalization.261 A number of metabolomics databases that contain NMR and MS
spectra with the associated assignments are available: Metabominer,262 Madison
Metabolomics Consortium Database (MMCD),263 BioMagResBank,264 and Human
Metabolome Database.265 Some efforts to automate the process have also been
made.199,249
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Figure 2.11 Cytoscape network depicting the metabolite concentration changes caused
by the inactivation of the TCA cycle. Nodes colored red correspond to metabolites with
an increase in concentration due to TCA inactivated. Nodes colored green correspond to
metabolites with a decrease in concentration due to TCA inactivated. Nodes colored grey
correspond to metabolites that are not observed in the NMR spectra, do not have a
reference NMR spectrum (or assignment), or did not exhibit a significant concentration
change. Metabolic pathways are labeled on the network. The metabolite names were
abbreviated as follows: ACA (Acetaldehyde), ACE (Acetate), ACP (Acetyl-P), AKG (αketoglutarate), ALAAc (Acetyl-alanine), AMI (4-Aminobutanoate), ARG (Arginine),

83
ASN (Asparagine), ASP (Aspartate), CIR (Citrulline), CIT (Citrate), ETH (Ethanol), F6P
(Fruc-6P), G1P (Gluc-1P), G6P (Gluc-6P), GAL (Galacturonic-acid), GAL1P (R-DGala-1P), GLN (Glutamine), GLR (Glucuronate), GLS (D-glucosamine), GLS6P
(Glucosamine-6P), GLSAc (N-Ac-D-glucosamine), GLSAc6P (Acetyl-glucosamine-6P),
GLU (Glutamate), GLUAc (Acetyl-glutamate), GLY (Glyceraldehyde), HIS (Histidine),
ICI (Isocitrate), INO (Ino, Ade, Xan), LAC (Lactate), ALA (alanine), LEU (Leucine),
LYS (Lysine), MANAc (N-acetyl-D-mannosamine), MET (Methionine), MIN (myo
inositol), MSE (selenomethionine), NEUAc (N-Ac-neuraminate), ORN (Ornithine),
ORNAc (Acetyl-ornithine), PEP (Phosphoenolpyruvic acid), PRO (Proline), RIB (Dribose), SAM (S-adenosyl-methionine), SER (Homoserine), SUCSER (O-Succinyl-Lhomoserine), UDPGLR (UDP-glucoronate), UDPGLSAc (UDP-NAc-D-glucosamine),
VAL (Valine). Reprinted with permission from reference.141

The next critical step is to analyze the identified metabolites and find all possible
correlations. The presence of metabolites and metabolic pathways in a particular
organism can be verified by the KEGG266 and MetaCyc databases.267 A metabolic
network map can then be generated using Cytoscape.268 Also, there are many
metabolome simulators that are useful for predicting the networks involving hundreds of
metabolites.269 Additionally, Cell Designer is a valuable diagram editor for drawing
biochemical networks.270

2.8 Analysis of Biofilms with NMR-based Metabolomics
An obvious application of NMR-based metabolomics has been used to
characterize the difference in the metabolome between planktonic and biofilm cells.
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Gjersing et al. (2007) applied 1H HRMAS to study the metabolome difference between
Pseudomonas aeruginosa chemostat planktonic and biofilm cells.166 There was no
apparent difference in the extracellular metabolite composition when planktonic and
biofilm cells were grown under continually feed chemostat mode. Conversely, the 2D
PCA scores plot of the intracellular metabolome indicated a clear distinction between the
batch and chemostat planktonic and biofilm cells (Figure 2.12 (top)). The corresponding
loadings plot suggests major and complex differences between the two metabolomes
(Figure 2.12 (bottom)). The metabolite differences were not analyzed in detail, but it was
noted that biofilm metabolites were generally lower in concentration, possibly due to the
cells closer to the substrate operating at a lower metabolic rate. Similarly, Workentine et
al. (2010) used 1H NMR to characterize the phenotype of different biofilm colonies of
Pseudomonas fluorescens.271 PCA of the 1D 1H NMR spectra yielded a 3D PCA scores
plot with distinct clustering for the four different P. fluorescens colonies (Figure 2.13
(left)). The class distinction was attributed to changes in amino acids (Asp, Glu, Gly, Met,
Phe, Pro, Trp, Val) and central metabolites (Acetate, Glutathione, Pyruvate). This is
suggestive of changes in exopolysaccharide production, response to oxidative stress, and
an impaired amino acid metabolism. Interestingly, the four different P. fluorescens
phenotypes exhibited distinctly different metal sensitivity (Figure 2.13 (right)).
Unfortunately, it was not possible to determine if the metabolome differences were a
result of the different metal sensitivity. Booth et al. (2011) also analyzed P. fluorescens
cells under metal stress, but compared planktonic to biofilms cells.165 1D 1H NMR was
combined with GC-MS to obtain a detailed analysis of metabolite changes caused by the
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addition of copper (Figure 2.14). Planktonic cells responded differently to copper stress
compared to biofilms. Planktonic cells experienced an oxidative stress response as
indicated by changes in the TCA cycle, glycolysis, pyruvate and nicotinate and
niacotinamide metabolism. Conversely, biofilms exhibited changes in exopolysaccharide
related metabolism suggestive of a protective response instead of the reactive changes
that occurred in planktonic cells.
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Figure 2.12 (top) PCA score plot for chemostat planktonic and biofilm cell samples for
Pseudomonas aeruginosa. (bottom) Loading plot of the first principal component.
Reprinted with permission from reference.166
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Figure 2.13 (above) Partial least squares discriminate analysis (PLS-DA) scores plot of
the metabolite concentrations of P. fluorescence CHA0 (black), CHA19 (red), SCV
(green) and WS (blue). Each data point represents a single extract and the position
determined as a linear combination of 32 metabolite concentrations obtained from the 1H
NMR spectra. The four strains could be separated along three components. (below)
Killing curves of P. fluorescens CHA0 (open squares), CHA19 (filled squares), SCV
(closed circles) and WS (open circles). Biofilms of each of the strains were exposed to a
series of metal concentrations for 4 h followed by viable cell counting. Shown are the
log-killing values, which are the number of cells killed following the exposure to metal.
Error bars represent standard deviation calculated from four replicates. Average cell
counts for the initial unexposed controls were 5.38 ±0.47, 4.89 ±0.45, 5.23 ±0.39, 5.17
±0.47 log10 cfu peg-1 for CHA0, CHA19, SCV and WS respectively. Reprinted with
permission from reference.271
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Figure 2.14 Hierarchical clustering analysis of control and copper exposed biofilm and
planktonic culture metabolite concentrations. Identified metabolites were analyzed for
any apparent patterns. Clustering was performed using Pearson correlation as the distance
metric. The cluster tree shows how the samples and metabolites divide. Across the top are
the samples, labeled by their class and along the side are the metabolites. These were
colored according to the grouping pattern that they showed: green metabolites were only
changing in the planktonic cultures, red only in biofilms and blue were changing in both
cultures in response to copper exposure. Reprinted with permission from reference.165
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Demonstrating a difference between planktonic cells and biofilms by NMR is an
important step towards an application in drug discovery. Does a chemical lead inhibit
metabolic pathways associated with biofilm formation? Does drug treatment result in a
metabolome more similar to planktonic cells despite conditions that induce biofilm
formation? Comparing the metabolome of planktonic cells with and without drug
treatment may provide an answer to these key questions. Furthermore, the comparative
analysis of planktonic cells and biofilms has already identified changes in the activity of
specific cellular process correlated with biofilm formation. Thus, proteins essential to
exopolysaccharide production and the response to oxidative stress may be novel targets
for disrupting biofilm formation. Additionally, the metabolome differences between
planktonic cells and biofilms can be used as a diagnostic tool and to design treatments.
As an illustration, Hall-Stoodley et al. (2006) describe the application of microbiological
culture, polymerase chain reaction (PCR)-based diagnostics, direct microscopic
examination, fluorescence in situ hybridization, and immunostaining to characterize
middle-ear mucosa biopsy specimens for biofilm morphology.272 The authors concluded
that chronic otitis media in children that require tympanostomy tube placement is biofilm
related. NMR metabolomics could provide a similar analysis of biopsy samples. The
treatment of biofilm infections that have colonized on medical implants often requires the
removal of the infected device.166 Investigating changes in bacterial metabolomes in
response to the different surfaces (metals, polymers, etc.) may contribute to the
development of novel materials resistant to biofilm formation.273,274 Coating or
embedding medical devices with antibiotics is a common approach to prevent biofilm
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infections, but the over-use of antibiotics incurs the risk of inducing the rapid
development of resistance.275,276
Besides characterizing cellular differences through metabolomics, NMR can also
be used to explore the overall structure and function of biofilms. Vogt et al. (2000) used
NMR to describe differences in metabolite diffusion within a biofilm.277 PFG-NMR was
used to measure diffusion coefficients for slowly moving water and other components in
a P. aeruginosa biofilm. Five groups of components including water, glycerol, and
polysaccharides, were observed with diffusion coefficients ranging from 1.8x10-9 to
5x10-13 (m2 s-1) that indicate locations in the biofilm pores or the extracellular polymeric
substance (EPS). Correspondingly, the complicated structure of a biofilm is a major
obstacle to a successful treatment with antibiotics. As the above NMR experiment infers,
a biofilm is a diffusion barrier that hinders the infusion and dispersion of antibiotics
within a biofilm.278 This also infers that the in vivo activity of a chemical lead is
determined by both its efficient dispersion throughout the biofilm in addition to its
intrinsic inhibitor activity.
A recent study by Rogers et al. (2010) analyzed the synergistic activity of 2aminoimidazole-derived compounds, a new class of anti-biofilm agents that disperse
biofilms.279 Combining a 2-aminoimidazole-derived compound with known antibiotics
resulted in a 2- to 8-fold reduction in MICs against biofilms of P. aeruginosa,
Acinetobacter baumannii, Bordetella bronchiseptica, and S. aureus. Importantly, the antibiofilm agent actually resensitized a multi-drug resistant strain of S. aureus (MRSA).
Similarly, Walencka et al. (2007) observed a synergy between salvipisone and
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aethiopinone from Salvia sclarea Hairy Roots with β-lactam antibiotics. An improved
activity was observed against MRSA and multi-resistant S. epidermis (MRSE).280
Salvipisone and aethiopinone are postulated to function by altering cell surface
hydrophobicity and cell wall/membrane permeability.
NMR metabolomics has also been used to investigate the mechanism by which
Staphylococcus epidermidis and S. aureus respond to a diverse set of environmental
signals to induce the planktonic to biofilm transition. Bacteria have been shown to form
biofilms in response to variations in ethanol, oleic acid, glucose, UDP-Nacetylglucosamine, sub-inhibitory concentrations of some antibiotics, anaerobic
conditions, Fe limitation, high osmolarity, and high temperature. Instead of numerous
distinct signaling pathways, a series of detailed NMR and molecular biology experiments
have demonstrated the presence of a single flexible metabolic signaling pathway centered
on the tricarboxylic acid (TCA) cycle.141,221,281 1D 1H NMR combined with OPLS-DA
was used to compare the metabolome of wild-type S. epidermidis 1457 and an aconitase
mutant strain 1457-acnA::tetM under various environmental stressors known to induce
biofilm formation (Figure 2.10). The change in the metabolome of wild-type S.
epidermidis 1457 in the presence of 4% ethanol, 2% glucose, Fe-limitation and 0.06
of tetracycline was shown to be essentially identical to the aconitase mutant with
an inactive TCA cycle. No change in the metabolome was observed for the aconitase
mutant with or without the addition of environmental stress factors. 2D 1H, 13C HSQC
experiments combined with bacteria grown in the presence of 13C-glucose were used to
generate a detailed analysis of the changes in the S. epidermidis metabolome (Figure
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2.11). Consistent with the global changes in the metabolome, wild-type S. epidermidis in
the presence of the environmental stressors induced the down-regulation of metabolites
associated with the TCA cycle and the up-regulation of metabolites related to PIA
production. These results suggest that biofilm formation is regulated by the activity of the
TCA cycle. Inactivating the TCA cycle allows the shuttling of key metabolites into PIA
production, which is generally necessary for biofilm formation. Similarly, White et al.
(2011) compared the metabolome of wild-type Salmonella and a CsgD deletion mutant
that prevents production of an extracellular matrix.282 GC-MS and NMR were used to
analyze the metabolome along with an analysis of gene expression. Metabolites
associated with glucogenesis and major osmoprotectants were up-regulated in wild-type
Salmonella, whereas; metabolites associated with the TCA cycle were up-regulated in the
mutant. Again, this is consistent with the TCA cycle activity regulating biofilm formation.
These results suggest that agonists of the TCA cycle would interfere with biofilm
formation. Diets or drugs that modulate the nutrient environment may be an approach to
prevent bacterial biofilm. As an example, iron-limitation down-regulates the TCA cycle
and induces biofilm formation.283 The major source of morbidity and mortality in cystic
fibrosis patients is P. aeruginosa biofilms formed in the lung. High iron concentrations
inhibit P. aeruginosa biofilms, where chelated sources of iron combined with antibiotics
hold promise as a treatment for cystic fibrosis.284,285
Metabolomics can also be used to construct metabolic pathways, with
contributions from proteomics and genomics information. Liebeke et al. (2011) provided
a time-resolved analysis of S. aureus during the transition from exponential growth to
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glucose starvation. The activity of more than 500 proteins and the concentration of 94
metabolites were followed. 1H NMR was used for the quantification of compounds in the
media before inoculation, and at defined time points during cell growth. Intracellular
metabolites were measured by gas/liquid chromatography–mass spectrometry. In general,
changes in the metabolome correlated with changes in the proteome, where the
metabolome displayed a larger dynamic range. The most dramatic changes were observed
for amino acids. During initial cell growth, glycolysis and protein-synthesis were highly
active, but as glucose was exhausted gluconeogenesis and the TCA cycle were activated.
Again, this is consistent with the TCA cycle activity regulating biofilm formation due to
variations in glucose concentrations.94 Metabolomics is a valuable approach to
characterize the state of a system. Nevertheless, incorporating additional complementary
data, such as proteomics, significantly enhances the reliability of the information.
Observing a correlation between a metabolite’s concentration and a protein’s expression
level further substantiates the importance and relevance of the protein to the system, such
as biofilm formation. From a drug discovery perspective, this provides substantial
corroboration of a potentially new drug discovery target.

2.9 Conclusion and future perspective
NMR metabolomics can be used to characterize different cell phenotypes, to
investigate the underlying biology of biofilm formation, to explore the impact of various
environmental stress factors on cell biology, to analyze the effect of gene mutations, to
the investigate the spatial and temporal structure of a biofilm, and even generate a three-
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dimensional image. Notably, the NMR metabolomics methodologies used to study the
biochemistry of bacterial biofilms are directly applicable to a drug discovery effort. NMR
metabolomics has been used to identify disease biomarkers and diagnose a disease, to
screen for drugs, to evaluate drug activity and toxicity, to identify new therapeutic targets
and design new treatments. While the application of NMR for the analysis of changes in
the metabolomics is a relatively new endeavor, the technique has already made some
significant contributions to our understanding of bacterial biofilms. More importantly,
NMR metabolomics holds great promise to significantly contribute to the diagnosis and
treatment of biofilm related diseases, where it may play an important role in personalized
medicine.
NMR-based metabolomics is a relatively new technology for systems biology and,
correspondingly, has only had a limited use in the investigation of bacterial biofilms. This
review summarized the majority of these studies. Nevertheless, the application of NMRbased metabolomics to the investigation of bacterial biofilms is only limited by the
creativity of the scientific community. For the near future, the further development of the
technology will be a primary focus. While NMR-based metabolomics is straight-forward
in concept, there are numerous practical considerations that can severely complicate the
routine application of the technique. A primary issue is our incomplete knowledge of the
metabolome; extensive effort is still required to characterize the metabolome from all
organisms and populate databases with reference NMR and MS spectra. Similarly, while
some progress has been made, a metabolomics software package is still needed that
automates and standardizes the processing of metabolomics data, chemometric analysis
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and model validation, and metabolite identification. Also, the efficient and accurate
extraction of metabolites from cell lysates requires continued optimization, and varies
depending on the organism under investigation. Developing these protocols is extremely
critical to the future success of metabolomics. Additional methodology advancements
that will benefit metabolomics include the routine integration of MS and NMR data, and
the efficient quantitation of metabolite concentrations from MS and 2D NMR
experiments.
Our understanding of bacteria cell biology is far from complete, where NMRbased metabolomics will be an invaluable addition to the study of biofilms and related
processes such as programed cell death, inter-/intra-species communication, and
pathogenesis. The systematic analysis of the bacterial genome, transcriptome, proteome
and metabolome will enable the construction of a detailed network to describe the
regulatory and metabolic pathways associated with biofilm formation, progression,
evolution and survivability. In addition to enhancing our basic understanding of bacterial
biofilms, NMR-based metabolomics will be an invaluable tool for drug discovery,
disease diagnosis and personalized medicine. NMR-based metabolomics can be used as
part of a drug discovery screening protocol. Observing an induced change in the bacterial
metabolome due to a drug treatment would further validate a chemical lead identified
from standard high-throughput screens.286,287 In fact, Halouska et al. (2012) recently
demonstrated how NMR-based metabolomics can be used to identify the in vivo
mechanism of action of a chemical lead.140 This addresses a major challenge with drug
discovery, identifying new drugs with activity against novel therapeutic targets that also
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avoid common mechanisms of resistance or toxicity. Similarly, characterizing the
metabolome of various pathogenic bacterial strains with a correlation to drug
susceptibility provides a means to personalize patient treatments. In essence, the
identification of characteristic metabolites from the biofluids of infected patients would
identify the bacterial strain and preferred form of treatment.
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CHAPTER 3
REVISITING PROTOCOLS FOR THE NMR ANALYSIS OF BACTERIAL
CENTRAL METABOLOMES
3.1 Introduction
Metabolomics is the study of small molecules in a biological system that
participates in the metabolic reactions responsible for cell growth, survival, and other
normal cellular functions.1-3 Additionally, the metabolome responds to transcriptional and
translational alterations associated with genotypical, epigenetic, or environmental
perturbations.4-7 Thus, metabolomics provides an assessment of global perturbations with
respect to an altered genome, proteome, or environment.2,8,9 The simultaneous integration
of genomic, transcriptomic and proteomic data has enabled an in-depth analysis of the
interplay, interaction, and regulation of DNA, RNA and proteins.10-12 Along this line,
monitoring the bacterial metabolome and integrating the results with other “omics” data
has provided valuable insights into bacterial adaptability,13 biofilms,14 evolution,15
pathogenesis,16 and drug resistance.17
Depending on the organism and growth state, the total number of metabolites
within a cell varies between several hundred to a few thousand, with a corresponding
diversity in physical and chemical properties, such as size, stability, and concentration.18
In addition to the challenge of the simultaneous study of all the metabolites within a
given biological system,19 the selection of an analytical technique will influence which
metabolites are observed. NMR and MS are commonly employed for metabolomics,
where both instruments can be interfaced with LC, GC, and CE systems to select and
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emphasize specific components of the metabolome.20-24 NMR has a number of
advantages in analyzing the metabolome that includes minimal sample handling and that
it is not reliant on chromatography to purify or separate metabolites. In addition, multiple
resonances from a single molecule increase the accuracy of metabolite identification and
quantitation. This accuracy can be further enhanced by the application of 13C- and 15Nisotope labeling to enhance specific regions of the metabolome.25,26 Importantly, the
choice of 13C- or 15N-labeled metabolite determines the region of the metabolome
observed by NMR, providing significant flexibility in experimental design. In contrast to
MS, NMR is a relatively insensitive technique and only observes the most abundant (≥ 1
to 5 µM) metabolites. In addition, MS has the advantage of detecting a wider-range of the
metabolome. However, because of the relatively low molecular-weight range of the
metabolome, MS methods generally require chromatography to separate metabolites
before analysis.27 Additionally, variations in ionization and the occurrence of ion
suppression in a complex mixture add uncertainty in detecting specific metabolites by
MS.28 Finally, quantitation by MS is typically more challenging than NMR. Taken
together, NMR and MS each have strengths and weaknesses but should be viewed as
complementary techniques.29
NMR-based metabolomics have been used to study a wide range of biological
systems such as tissues,30 biofluids,31 mammalian cell cultures,32 plants33 and bacteria.3436

The overall procedure for an NMR-based metabolomics study includes the following

general steps: cell growth and harvesting, metabolite extraction, NMR data collection and
analysis, multivariate statistical analysis, metabolite identification and quantification.37
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Typically, one-dimensional (1D) 1H NMR spectra are used for a multivariate analysis
such as principal component analysis (PCA) or orthogonal partial least squares
projections discriminant analysis (OPLS-DA).38,39 Both PCA and OPLS-DA provide
global profiles of metabolome changes.40,41 Two-dimensional (2D) 1H,13C Heteronuclear
Single Quantum Coherence (HSQC) or 1H,1H TOtal Correlated SpectroscopY (TOCSY)
NMR experiments are used for the quantitative assessment of metabolite changes
resulting from genetic modification or external stimuli.5,14 The ability to generate global
profiles and quantitative differences coupled with the ease of applying NMR-based
metabolomics has contributed to the rapid growth of the NMR metabolomics field. While
NMR data acquisition and analysis methods are improving, care must be taken to ensure
that the methods are appropriate to the task at hand and generate biologically relevant
information. As an example, protocols to efficiently extract metabolites without inducing
cellular changes are essential for success.32,42 In brief, the observed changes in the
metabolome should reflect a change in the state of the system instead of how the cells are
handled and processed. Similarly, variations in instrument performance, choice of
procedures for data collection and processing, and invalidated models from multivariate
analysis may induce unintended biases or incorrect interpretation of metabolomics
data.43-46
Since NMR-based metabolomics is a relatively new and still developing
technology, improving and enhancing the experimental protocols is necessary to advance
the field and ensure continued success. Toward this end, we describe our recently
developed and optimized protocols for the application of NMR metabolomics to
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microbial samples. We present our current methodology and also discuss the challenges
associated with each major step of the process: (i) sample preparation, (ii) NMR data
collection and processing, (iii) multivariate statistical analysis, (vi) metabolite
identification and network generation. Specifically, the overall methodology will be
discussed in detail, where a number of key features will also be highlighted, such as
automation, bioinformatics, experimental design, and harvesting the metabolome. The
focus of our efforts has been to identify and minimize procedural steps that negatively
influence the outcome of an NMR-based metabolomics experiment.

3.2 Experimental design
A general protocol for the analysis of bacterial metabolomes using NMR is shown
in Figure 3.1. The flow diagram illustrates procedures for both a global analysis of
metabolome changes (metabolomics fingerprinting); and the identification and
quantitation of specific metabolites correlated with the biological process (metabolomics
profiling). The overall process consists of the following key steps: bacterial cultivation
and harvesting, metabolite extraction, NMR data collection and analysis, multivariate
statistical analysis, metabolite identification and quantification. Successful metabolomics
sample preparation involves three steps: The first step is the simultaneous growth of all of
the bacterial cultures or as many as is practical at a time. The bacteria are grown in a
standard medium for fingerprint analysis, whereas the medium is supplemented with a
13

C-labeled metabolite for metabolomics profiling.47,48 After the bacteria are grown for a

defined time or they have achieved a specified cell density, bacteria are harvested and
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quenched to halt all enzymatic processes and washed to remove the medium. The third
sample preparation step involves lysing the cells and extracting the metabolome. A
variety of solvents are routinely employed depending on the solubility of the targeted
metabolites (cytosolic metabolites, lipids, etc.). The metabolomics samples are then used
to generate a series of NMR spectra, which are used for the multivariate statistical
analysis, metabolite identification and quantification. The individual steps of the NMRbased metabolomics protocol will be discussed in detail highlighting challenges
associated with each step.
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Figure 3.1 A flow chart of our protocol used for the NMR analysis of bacterial
metabolomes.

3.2.1 Identify the appropriate biological system for a metabolomics study
NMR-based metabolomics is an important tool in systems biology research. The
quantitative and qualitative measurement of metabolites from cytosolic extracts can be
extremely valuable for investigating cellular processes, pathogenesis, and the effects of
drugs or the environment on bacteria. Unfortunately, the bacterial metabolome is a
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complex mixture of metabolites and numerous interconnected metabolic and signaling
pathways. This high interconnectivity may result in significant metabolite concentrations
changes far from the origin of the perturbation (inhibited, inactivated or down-regulated
protein). Correspondingly, it is easier to observe changes to the metabolome than deduce
the primary source of the perturbation after its impact has rippled throughout the
metabolome. As an illustration, treating a bacterial culture with a particular drug would
be expected to lead to a global change in the metabolome, but interpreting these changes
to identify the therapeutic target is extremely challenging. To address this challenge, the
in vivo mechanism of action of a potential drug lead may be determined by comparing
these metabolome changes to other drugs with known biological targets49 or to a mutant
bacteria where a specific protein target is ablated or modified by genetic inactivation.50,51
This example illustrates that the comparative analysis between two or more metabolomes
is an effective application of metabolomics. In order to obtain reliable insights into the
physiology of bacteria or any other organism, it is essential to identify and establish at
least two reference metabolomes (wild-type vs. mutant, drug-resistant vs. drug
susceptible, nutrient-rich vs. nutrient-limited, etc.) for a comparative analysis. Once the
reference conditions are established, bacteria can be exposed to any range of
experimental variables such as a drug treatment, environmental stimuli (pH, temperature,
nutrient change), or gene knockout (mutants, RNAi, inhibitor) to determine if similarities
exists with the reference metabolome. The similarity between metabolomes infers an
overlap in the underlying physiological processes or responses that gave rise to the
metabolome changes. We have used this approach to demonstrate the similarity of
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Staphylococcus epidermidis metabolomes resulting from exposure to divergent
environmental stressors that are known to facilitate biofilm formation.5,14 Our results
suggested that the tricarboxylic acid (TCA) cycle acts as a metabolic signaling network to
transduce external stresses into internal metabolic signals. This conclusion was only
possible because the experimental design was based on comparing the metabolomes of
the S. epidermidis wild-type strain 1457 and an aconitase mutant strain 1457-acnA::tetM
with and without the treatment of biofilm stressors. In summary, the successful outcome
of a metabolomics study hinges on the experimental design and the proper choice of the
cellular metabolomes to be compared.

3.2.2 Minimize unintended bias and biologically irrelevant variations
In addition to the proper choice of bacterial strains to compare in a metabolomics
study, the experimental protocols must be optimized to reduce unwanted variation or bias
in the collection of cell-free lysates. It is essential to ensure that any metabolome changes
are limited to biologically relevant factors and are not caused by the handling or
processing of the samples. Thus, the key to metabolomics is establishing an efficient
methodology that closely captures the true state of the metabolome.52 Fundamental to a
successful metabolomics experiment is maximizing the uniformity of the preparation,
handling, processing, and analysis of each replicate sample.35,45,53-56 In instances where
cultivation and/or processing variation is unavoidable (e.g., if multiple incubators are
required to accommodate all the replicates), then the cultures should be randomly
distributed between the incubators to minimize bias. Ideally, all of the metabolomics
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samples should be handled by the same person because subtle differences in individual
techniques may influence the outcome. If multiple investigators are required to efficiently
handle the samples, each researcher should be assigned a specific set of tasks that are
consistently applied to each sample. For example, one investigator lyses all the bacterial
cells while another performs the metabolome extraction procedure on every sample.
As with sample cultivation and preparation methods, the NMR spectra generated
from metabolomics samples need to accurately represent the state of the system. In other
words, the NMR spectra must reflect the actual concentrations and identity of the
metabolites present in the biological sample at the time of harvest. If the sample
preparation and data acquisition represent the metabolic status at the time of harvest, then
multivariate statistical techniques, such as PCA and OPLS-DA, will enhance the
identification of similarities or differences in the NMR spectra, and, correspondingly,
between the bacterial metabolomes.39 These multivariate statistical techniques typically
involve multiple replicates of 1D 1H NMR or 2D 1H, 13C HSQC spectra for each bacterial
class or group (e.g. wild-type, mutant, drug treated, etc.). The exact number of replicates
is dependent on a number of factors: (i) the variance within a group, (ii) the variance
between groups, (iii) the number of variables, and (iv) type of statistical analysis
performed.57,58
In most metabolomics experiments, the number of biological samples is
significantly smaller than the number of variables; in this case, the variables correspond
to peaks in the NMR spectra or the detectable metabolites.58 For this reason, a larger
number of replicates (≥ 6) per class are required to obtain a statistically significant PCA
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or OPLS-DA model. While greater numbers of replicates are desirable, there are practical
considerations to increasing the number of replicates, including increased experimental
time, availability of incubator space, and practical limits on the number of samples that
can be simultaneously prepared and processed within a reasonable time frame. The
increased time, larger number of samples, and added complexity may be detrimental to
maintaining consistency between samples, where metabolite stability may become more
of an issue.59 So the potential benefit in improving the reliability of the PCA or OPLSDA models may be negated by too large of a sample size if sample consistency is
sacrificed. In general, 6 to 10 replicates per class can be routinely handled while
providing a statistically significant PCA or OPLS-DA model. Lastly, to increase the
sample consistency, the application of an automated sample changer or flow-probe can
minimize variability by eliminating human involvement and providing a uniform and
consistent protocol for NMR data collection. Nevertheless, instrument drift may still
occur during the high-throughput experiment so it is also important to randomize the
samples during data collection.

3.3 Sample Preparation
3.3.1 Bacterial cultivation
Consistency is critical to metabolomics, where variations in a bacterial
metabolome may be introduced by cultivation protocols. To achieve the reproducible
cultivation of bacteria requires consideration of three variables: bacterial strain, culture
medium, and cultivation conditions. Strain selection is often driven by investigator
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preference, availability, or cultivability. The choice of culture medium will largely
depend on which, if any, isotopically-labeled metabolite is being followed. For example,
when using 15N-arginine, it is impractical to add labeled arginine to a complex medium
containing an unknown concentration of unlabeled arginine. In this example, to achieve
maximal labeling of the bacteria, it would be best to use a chemically defined medium
lacking arginine. Importantly, the culture medium has to be consistently employed
throughout the metabolomics study. A different culture medium cannot be used for
metabolomics fingerprinting and profiling, it cannot vary based on the requirements of
the bacterial strain or to accommodate an experimental variable. Different culture media
will induce changes in the metabolome that will mask or complicate any analysis.
Bacterial cultures also need to be properly handled in order to avoid inducing biologically
irrelevant changes. For example, pre-warming the culture medium prevents temperature
shock and minimizes variation between biological replicates. Similarly, randomizing the
samples from each group and class also minimizes bias that may occur if all the samples
are processed in a predefined order. Importantly, different cell types may require special
care or different handling protocols. Cultivation conditions will also vary depending upon
the experiment; however, consideration must be given to each of the following:
temperature, pH buffering (if used), % CO2 (if used), the flask-to-medium ratio, the
revolutions per minute of agitation (if used), the use of baffled or non-baffled flasks, and
the inoculum dose. In effect, one protocol does not necessarily “fit all” and a general
metabolomics protocol needs to be optimized for each experiment and cell type.
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Deciding on the number of bacterial cultures needed for a metabolomics study and
identifying the optimal culture size are important next steps. The volume of the bacterial
culture should be large enough to provide a sufficient number of cells to maximize the
NMR signal-to-noise, but small enough to simplify the handling of numerous replicate
samples. An appropriate cell density must be determined empirically for each species and
bacterial strain, which will also limit the culture size. Similarly, the growth phase chosen
for harvesting bacteria will also contribute to defining the optimal culture size since cell
density changes drastically between the lag, exponential and post-exponential phases. In
our experience with staphylococcal and mycobacteria cultures, media volumes between
15 to 50 mL are used to grow cells to an optical density at 600 nm (O.D.600) of 1-2 for
bacterial cultures collected during the exponential phase. Conversely, media volumes of
between 3 to 5 mL are used to grow cells to an O.D.600 of 3 to 7 for bacterial cultures
collected during the post-exponential phase (e.g., 6 to 7 for Staphylococcus epidermidis,
and 3 to 4 for Mycobacterium smegmatis). The overall goal is to have an O.D.600 of 10 to
20 after the bacterial cells have been concentrated to a final volume of 1 mL. This will
ensure metabolite concentrations sufficient for detection by NMR. These culture volumes
and O.D.600 values should be viewed as guidelines and targeted goals that may require
further optimization for different bacterial strains or species. As previously stated, the
number of bacterial cultures determines the statistical significance of class differentiation
or metabolite changes. In our experience, ten replicates are an optimal choice for
metabolomics fingerprinting and only three replicates are needed for metabolomics
profiling.
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Metabolomics profiling requires 13C- or 15N-labeled metabolites and defines the
choice of culture media. In our laboratories, we typically label staphylococci using 13Cglucose in the complex medium tryptic soy broth (TSB) that is devoid of unlabeled
glucose.6,7 This medium allows for maximal biomass generation, while assuring that
nearly all (~99%; 1.1% is due to naturally occurring 13C) of the 13C-labeled metabolites
in the metabolome were derived from glucose. Similarly, we have labeled mycobacteria
using 13C-glucose or 13C-glycerol in Middlebrook 7H9 Albumin Dextrose Complex
(MADC; Becton-Dickinson) media. We have also supplemented culture media with 13Calanine, 13C-aspartate, 13C-glutamate, 13C-proline and 13C-pyruvate as a more targeted
approach to the analysis of the metabolome. These metabolites are associated with a
limited number of metabolic pathways. The analysis of the metabolome can be further
focused by using a targeted metabolite where only one or a few specific carbons in the
metabolite are 13C labeled. Only the metabolic pathways involving the specific 13Clabeled carbon will be observable by NMR. The concentration of the 15N-, or 13C-labeled

experience with staphylococcal and mycobacterial cultures, the volumes range from 25
mL to 100 mL and the culture media should be supplemented with approximately 2.5 to 4
g/L of 13C6-glucose or ~10-15 mg/L of a targeted metabolite like 13C-D-alanine in order
to acquire a 2D 1H, 13C HSQC spectrum with acceptable signal-to-noise.
Ideally, each bacterial culture should contain the same number of cells and be at
the same growth phase when harvested. In reality, differences in cultivation conditions,
media, and/or bacterial strains may substantially affect growth rates and/or growth yields.
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The two more common approaches to compensate for different bacterial growth rates are:
collect the bacteria when they have reached the same cell density, but at different times to
account for the different growth rates; and harvest the bacteria at the same time but
harvest equivalent cell numbers. As examples, in staphylococci, the exponential and postexponential growth phases were typically analyzed at the 2 h and 6 h time points,
respectively.5 For our mycobacterial experiments, a consistent growth phase was
achieved by harvesting bacteria at a uniform O.D.600 of 1.2. In practice, it is extremely
difficult to harvest every bacterial culture with an identical O.D.600 value. To correct for
this variability, all the bacterial cultures are normalized to the same number of cells.
Simply, the cultures are suspended into a phosphate buffer until the O.D.600 values are
equal. Typically the cultures are concentrated to an O.D.600 of 10 to 20 into a final
volume of 1 mL prior to lysis. Alternatively, the bacterial cell cultures can be normalized
based on colony-forming units (CFU) or total protein concentration.
To ensure consistency, the experimental variable such as a drug treatment,
environmental stimuli, or gene knockout needs to be uniformly applied to the “treatment”
class. An additional consideration for treatment of cultures, is that the impact on the
metabolome should be strong enough to detect.49 In other words, a particular drug dosage
needs to be large enough to affect the cellular metabolome relative to untreated cells, but
should not induce cell death. In our experience, a drug concentration that inhibits
bacterial growth by 50% relative to untreated cultures is a desirable target.49,50 The
availability from the literature of a minimal inhibitory concentration for the strain (MIC),
or otherwise for the population isolates (MIC50), provides a good starting point for
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optimizing a drug dosage, but the actual dosage must be determined empirically for each
set of cultivation conditions. In our experience, literature MIC or MIC50 values tend to be
too low for cultivation conditions used for metabolomics. We typically test drug
concentration ranges at between 1 to 24 times the reported MIC or MIC50 values in order
to identify an optimal drug dosage. Importantly, this also implies that drugs with a range
of biological activity will require different drug concentrations in a metabolomics study;
hence, the use of the 50% inhibition of growth is used as a metric as opposed to drug
concentration. Typically, in our experiments the drug treatments are normally
administered during the exponential phase and the bacteria are allowed to grow for at
least one generation before harvesting. In our experience, this provides a sufficient
amount of time for the drug to affect cell physiology and induce a perturbation in the
metabolome. Administering a drug at an earlier time point can be problematic because of
the inability to harvest enough bacteria.

3.3.2 Quenching, washing and harvesting the bacterial cells
Speed is critical to harvesting bacteria without inducing a change to the
metabolome. Changes occur quickly because of different metabolite turnover-rates,
varying stabilities, and the induction of stress responses, among other factors.59-61 As
bacteria are being harvested, the environment is changing dramatically: (i) the bacteria
are either adhered to the surface of filter paper or at the bottom of a centrifuge tube under
anaerobic conditions, (ii) the temperature is changed from 37oC to ~ 0o C, and (iii) the
growth media is replaced with either double distilled water or a phosphate buffer. To
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prevent perturbations to the metabolome caused by handling of the cell samples, the
bacteria need to be rapidly quenched in order to stop all cellular processes from
responding to these changes. Quenching efficiency has been widely discussed in the
literature.42,62-64 Importantly, the quenching technique employed also defines the washing
protocol and the order that quenching, washing and cell separation takes place. Our
quenching techniques consist of a filtered cells being quickly submerged into liquid
nitrogen or the cells and media being directly added to -60oC cold ethanol or methanol
solution while being vortexed. The media and ethanol/methanol volumes are at an equal
1:1 ratio. After centrifugation, the supernatant is decanted and disposed of, and the cell
pellet is ready for washing. Unfortunately, there is a possibility of cell leakage and loss of
metabolites when the cells are directly added to the cold ethanol or methanol solution.
Before intracellular metabolites can be analyzed, the bacteria need to be rapidly
separated from the culture media. Filtration and centrifugation are both routinely used in
our laboratory to separate bacterial cells from the media. Filtration has a definitive
advantage because it is significantly faster than centrifugation, but challenges in
removing and collecting intact cells from filter paper may lead to sample variability.
Conversely, the variability between metabolome replicates is expected to be reduced with
centrifugation because of the ease in handling the cells. Nevertheless, our experience with
washing bacterial cells using either filtration or centrifugation has resulted in essentially
identical metabolomics fingerprints (Figure 3.2a); thus, any undesirable variation within a
group likely occurs during sample preparation. Metabolome differences between replicate
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bacterial cultures likely arises from a combination of subtle variations in the number of
cells, culture conditions, length of bacterial cultivation time, and sample handling.
The use of centrifugation or filtration also determines the quenching protocol.36
Harvesting bacteria using centrifugation requires quenching the bacteria using the direct
addition to -60oC cold ethanol or methanol. The bacteria, culture media, and quenching
solution are in a properly sized conical centrifuge tube that is centrifuged for 8 minutes at
4,284 g (bucket rotor). Following centrifugation, the culture media and quenching
solution are decanted and the bacteria are suspended in 30 mL of an ice cold wash. We
routinely wash bacteria with ice cold double distilled water, phosphate buffer (20 mM,
pH 7.2), or phosphate buffered saline (PBS; 6 mM phosphate buffer, pH 7.4, 137 mM
NaCl and 2.7 mM KCl) to remove residual media and avoid contamination of the
metabolome. The bacteria are centrifuged again, the wash is decanted off and the process
is repeated. After two washes, the cell pellet is suspended in 1 mL of the ice cold wash
and transferred to a 2 mL vial for cell lysing. Additional washings provide an
insignificant benefit in removing media contaminates, but results in an undesirable
increase in time. Also, the buffered wash eliminates any impact on the cells from a pH
change, but double distilled water eliminates the possibility of “salting-out” any
metabolites that may occur from concentrating the buffer in subsequent steps.65 The cells
are kept on ice throughout this entire process.
Harvesting bacteria by vacuum filtration collects the bacteria on sterile filter paper
(0.45 µm pore size; Millipore), while simultaneously removing the media. The number of
bacteria that can be harvested onto a filter must be empirically determined to prevent a
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filter blockage. Under proper conditions, removing the media should take less than a
minute, and should never exceed two minutes. If this cannot be achieved, then the
bacteria need to be harvested using centrifugation. After filtration, the filter paper
containing the cells is then quickly placed into a 50 mL conical centrifuge tube and
submerged into liquid nitrogen to freeze and quench the cells. The conical vial is then
warmed by placing it into a bucket of ice for ~1 to 2 minutes. This prevents freezing of
the 1 mL of wash that is added to the conical vial. The cells are gently removed from the
filter paper with the wash and then transferred to a 1.5 mL microcentrifuge tube. The
cells are centrifuged and washed twice (1 mL) as before.
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Figure 3.2 Illustrations of the impact of a) filtration and centrifugation, b) number of
extraction steps, c) type of wash buffer, and d) lyophilization on the composition of the
metabolome.

3.3.3 Cell lysing and metabolite extraction
The cells need to be lysed in order to extract the cellular metabolome. Cells can be
lysed by chemical or physical means, but the use of chemicals runs the added risk of
contaminating the metabolome. Thus, the FAST-Prep bead beating method of lysing cells
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is our preferred approach. Before lysing, the samples are normalized to an O.D.600 value
of between 10 to 20 units. This insures an equivalent number of cells, comparable
metabolite concentrations, and a detectable NMR spectrum. Each sample is placed into a
2 mL micro-centrifuge tube with small glass beads (Lysinf Matrix B; MP Biomedical)
and 1 mL of extraction buffer. The cells are crushed by bead beating for 40 to 60 seconds
in the FAST-Prep instrument at a speed of 6.0 m/s. The sample is then centrifuged for 2
minutes at 17,000 g to pellet the cell debris. The supernatant with the extracted
metabolites is collected. The cell debris is washed 1 to 3 times with 1 mL of the
extraction buffer to maximize the metabolome yield (Figure 3.2b). Also, double distilled
water or a phosphate buffer are routinely used as the extraction buffer, since both
approaches provide similar results (Figure 3.2c). All extracts per sample are combined for
lyophilization, where the sample is then dissolved in 700 L of a phosphate buffer in D2O
at pH 7.2 (uncorrected). Lyophilization may negatively impact some volatile metabolites,
but, in general, no effect is observed (Figure 3.2d). A major concern during the extraction
step is maximizing the overall yield while minimizing any perturbation to the
metabolome. In our experience, the cell lysing and metabolite extraction process will
require approximately 45 minutes for 30 cultures. The metabolomics samples can be
stored in a -80oC freezer or directly lyophilized over-night.

3.3.4 Isotopic labeling of metabolites
Uniform or selective isotopic labeling with 13C/15N has often been used to boost
the sensitivity of carbon or nitrogen due to their low natural abundance in protein
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structural determination by NMR.66,67 The use of stable isotope tracing in metabolic
pathway studies is dated back to 1935.68 And there is no evidence that 13C/15N isotopic
labelling has an observable effect on the physiology of bacteria.69 Hence, stable isotope
labeling combines the analytical development and biological requirement and
demonstrates large potentials in the metabolomic study by handful applications.70-73 The
uniform labeling by 13C glucose is a common strategy in NMR-based metabolomics.74 It
often employs chemical defined medium (CDM) in which glucose as the sole carbon
source is used to completely label the metabolome. CDM is not ideal for many
physiological studies in bacteria because it has the drawbacks of less reproducibility and
less association with the growth conditions in the host.75 Therefore random labeling of
13

C isotope using 13C glucose within a complex medium can also be performed with a

good signal-to-noise ratio (Figure 3.3a). 13C glucose should be added to the medium
which is free of dextrose. However, there is a concern that if the 13C glucose should be
used in the overnight culture, or in another word, if the labeling of overnight culture
makes a difference on the labeling efficiency. In Figure 3.3b and 3.3d, there was no
significant difference between the two overnight cultures. In Figure 3.3a and 3.3c, as a
negative control experiment, 12C glucose was used for the post-exponential growth using
the overnight cultures. And very little difference was found. In conclusion, the small
amount of overnight culture has no significant effect on the labeling efficiency.
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Figure 3.3 Illustrations of isotope carry-over effects in the overnight culture using 1H,
13

C HSQC experiments of the metabolomes from: (a) overnight culture using 12C glucose

medium, post-exponential phase growth using 12C glucose, (b) overnight culture using
12

C glucose medium, post-exponential phase growth using 13C glucose, (c) overnight

culture using 13C glucose medium, post-exponential phase growth using 12C glucose, and
(d) overnight culture using 13C glucose medium, post-exponential phase growth using 13C
glucose.

3.3.5 Storage of metabolite samples
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The metabolite samples should be lyophilized and kept in -80oC freezer for longterm storage. Once the sample is prepared in NMR tubes, only short term storage in 4oC
for 1-2 days is allowed, as a short term in the room temperature can lead to observable
changes (Figure 3.4). This is important to notice when running multiple samples for long
experiments such as 1H, 13C HSQC experiments. The samples still in the queue should be
kept in 4oC refrigerator. It is also advisable to add 0.5 mM NaN3 to inhibit trace bacterial
activities.76

Figure 3.4 Metabolic changes dependent on the time of storage. 1H, 13C HSQC spectra of
the same sample: S. aureus wild-type Newman strain metabolome in post-exponential
phase.77

3.4 NMR Spectroscopy
3.4.1 One-dimensional 1H NMR methodology
One-dimensional (1D) 1H (proton) NMR is an unbiased, nonselective, and
nondestructive approach that requires no modification of the samples, where the data can
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be collected in a high-throughput manner. A 1D 1H NMR spectrum contains numerous
proton signals generated from a complex metabolomics mixture, where the chemical shift
of each signal describes the structural characteristic of a specific metabolite. Moreover,
the peak intensities or volumes are directly proportional to the concentration of each
metabolite. Quantification of metabolites can be achieved by using an internal standard
with a known concentration, where we routinely use 50 µM 3-(trimethylsilyl) propionic
acid-2,2,3,3-d4 (TMSP-d4, Sigma). Thus, 1D 1H NMR experiments combined with
multivariate statistics are commonly used for the global analysis of the metabolome.
Collecting 1D 1H NMR data for metabolomics is fast and simple, and provides
highly reproducible and accurate results. Importantly, the NMR experimental parameters
need to be identical for each metabolomics sample in order to collect reliable
metabolomics data. Any per sample variation will erroneously bias the resulting
clustering patterns in the PCA and OPLS-DA scores plot. To avoid this and maintain
sample consistency, we use a BACS-120 sample changer, Bruker ICON-NMR, an
automatic tuning and matching (ATM) unit, and autoshim to automate the NMR data
collection. Nevertheless, instrument drift may still occur during the high-throughput
metabolomics screen, so it is also important to randomize the samples during NMR data
collection. If an NMR spectrum is collected first for all the control samples followed
subsequently by each treatment class, there is a significant potential of inducing a
biologically irrelevant bias into the analysis. The clustering pattern in the PCA and
OPLS-DA scores plot may be dominated by the order of data collection instead of the
expected biological differences.
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In our laboratory, a typical 1D 1H NMR spectrum is collected using 128 scans and
32k data points on a Bruker 500 MHz Avance DRX NMR spectrometer equipped with a
triple-resonance, Z-axis gradient cryoprobe. The acquisition time is approximately 10
minutes per sample. The goal is to obtain optimal signal to noise while minimizing the
total experimental time. We previously demonstrated that spectral noise is detrimental to
the resulting PCA and OPLS-DA scores plot.53 Random noise fluctuations results in large
and irrelevant variations in the scores clustering. To avoid this problem, spectral noise
needs to be removed prior to PCA and OPLS-DA. Correspondingly, the quality of the
within class clustering in PCA and OPLS-DA scores plot is directly dependent on the
spectral signal-to-noise (Figure 3.5). The within class variance decreases dramatically as
the number of scans (signal-to-noise) is increased from right to left in the scores plot.
Importantly, the spectral noise was still removed prior to PCA. Thus, the accuracy of
identifying similarities or differences between multiple classes is dramatically improved
by reducing within class variance, which is achieved by improving spectral sensitivity.
Also, correctly identifying class differences improves with the number of replicates
(Figure 3.6). The statistical significance of cluster separation as measured by p-values is
shown to decrease as both a function of group variance and the number of replicates.78 As
a result, we prefer to use ten replicates per class and strive to achieve an average signalto-noise ratio of > 100 to 200. This is achieved by simply increasing the number of scans
or the number of cells, whichever is more practical. While signal-to-noise has a dramatic
impact on scores clustering, PCA and OPLS-DA is indifferent to changes in spectral
resolution unless the number of data points is ≤ 2K.
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Figure 3.5 Illustration of the impact of the NMR signal-to-noise on within class variation
in a PCA scores plot. From right to left, the 1D 1H NMR spectra were collected with an
increasing number of scans (1, 2, 4, 8, 16, and 32) resulting in a proportional increase in
signal-to-noise. All other experimental parameters were kept constant.

Figure 3.6 Illustration of the impact of within group variation and the number of
replicates on the p values calculated between clusters in a simulated PCA scores plot.
From top to bottom, p values from the simulated PCA scores plot were calculated with an
increasing number of replicates (6, 8, 10) resulting in a proportional decrease in p values.
Similarly, increasing the group variation by increasing the standard deviation (σ) per
cluster resulted in a significant increase in p values.
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A D2O phosphate buffer is the typical solvent of choice for aqueous metabolomics
samples in order to efficiently remove residual water signals and avoid interference from
buffer signals. Water and buffer signals are problematic since they can distort the NMR
spectrum and may overlap and obscure important metabolite signals. Most NMR
processing software can automatically remove the residual water peak, but extra data
processing is required to correct for baseline distortions induced by the solvent.
Unfortunately, simply applying a baseline correction changes the PCA and OPLS-DA
clustering patterns.79 Furthermore, different baseline correction protocols will induce
variable changes into the scores plot. Also, removing the residual water peak may result
in a potential loss of information by also removing metabolite peaks near the water
signal. Instead, a water suppression technique that experimentally removes the water
peak without inducing baseline distortions is the preferred alternative.
There are a variety of NMR pulse sequences for water suppression that are
available to the metabolomics community, such as WATERGATE, water pre-saturation,
WET, and PURGE.80-84 Our preferred choice for a water suppression pulse sequence is
Solvent-Optimized Gradient-Gradient Spectroscopy (SOGGY). SOGGY does an
outstanding job in eliminating the water signal without inducing any base line distortions
(Figure 3.2).84 SOGGY is a variant of excitation sculpting that employs a pulsed field
gradient with a simple phase-alternating composite pulse. SOGGY offers the flexibility to
optimize the 180 degree hard pulse to achieve optimal excitation of the water signal, and
adjusting the 180 degree soft pulse to optimize the range of the water frequency to be
suppressed.84,85 As a result, SOGGY efficiently suppresses the water signal while
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removing any phase cycle artifacts. A flat baseline is obtained while also maintaining
metabolite signals near the water signal.84 SOGGY completely eliminates the need to
apply any baseline correction.

3.4.2 Two-dimensional 1H, 13C HSQC NMR methodology
The severe overlap of signals in a 1D 1H NMR spectrum is a challenge for
metabolite identification. The difficulty arises because hundreds to thousands of peaks
occupy a small chemical shift range (~10 ppm), where multiple metabolites share similar
chemical shifts. Thus, we typically do not use 1D 1H NMR spectra to assign metabolites.
Instead, we routinely use 2D 1H, 13C HSQC experiments for metabolite assignments. The
2D 1H, 13C HSQC experiment is a more reliable approach for metabolite identification
because of the significantly higher resolution and the correlation between 1H and 13C
chemical shifts for each C-H pair in a molecule.86,87 Also, the 2D 1H, 13C HSQC
experiment simplifies the analysis of the metabolome because only compounds
containing a 13C-carbon derived from the 13C-labeled metabolite added to the media will
be detected.
In our laboratory, we use a standard 2D 1H, 13C HSQC pulse sequence on Bruker
500 MHz Avance DRX NMR spectrometer equipped with a triple-resonance, Z-axis
gradient cryoprobe. An acceptable signal-to-noise is achievable using 64 scans. Similarly,
a reasonable digital resolution is achieved by collecting 2K and 128 data points in the
direct and indirect direction, respectively, with a corresponding spectral width of 10 ppm
and 140 ppm along the 1H and 13C axis, respectively. Since some aromatic C-H pairs
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have a 13C chemical shift greater than 140 ppm, the spectrum will contain folded peaks,
but the folded peaks will not interfere with or overlap with other metabolite peaks due to
their unique position along the 1H axis (~ 7.0 ppm). In general, the 2D 1H, 13C HSQC
experiment requires approximately 4 hours per sample on our system.
A conventional 2D 1H, 13C HSQC spectrum is useful for detecting metabolite
changes by overlaying multiple spectra to identify missing peaks or peaks with
significant intensity changes. Unlike 1D 1H NMR spectra, obtaining metabolite
concentrations is more difficult because peak intensities are dependent on J-couplings,
dynamics and relaxation, in addition to metabolite concentrations.88,89 To quantify
absolute metabolite concentrations, we use the Time-Zero HSQC (HSQC0) experiment.88
This approach requires collecting a series of three HSQCs spectra (HSQC1, HSQC2,
HSQC3) with an increased number of pulse sequence repetitions. A natural log plot of
peak areas or intensities versus the increment number (1,2,3) allows for an extrapolation
back to increment 0 or zero-time. The experimental parameters used in the HSQC0
experiment is similar to the conventional method, but with some minor variations. The
number of scans is increased to 128 due to the decrease in signal-to-noise in HSQC2 and
HSQC3. To partially compensate for the increase in experimental time, the number of
data points in the indirect dimension is reduced to 64. In general, the HSQC0 set of
experiment requires approximately 6 hours per sample on our system.

3.5 Data analysis
3.5.1 Preprocessing of 1D 1H NMR data
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The 1D 1H NMR spectra are minimally processed (Fourier transformed and phase
corrected) using ACD/1D NMR Manager (Advanced Chemistry Development). Each
NMR metabolomics sample contains 50 µM of TMSP-d4 as an internal standard, where
each NMR spectrum is referenced to the TMSP-d4 peak and uniformly aligned to 0.00
ppm. Also, all peak heights are normalized to the intensity of the TMSP-d4 peak.
Intelligent bucketing within the ACD/1D NMR Manager is then used to integrate each
spectral region with a bin size of 0.025 ppm. The spectra are normalized; noise regions
and residual solvent and buffer resonances are removed, and then the remaining bins are
scaled prior to PCA and OPLS-DA using SIMCA12.0+ (UMETRICS).
The need for data normalization and scaling prior to multivariate statistical
analysis has been extensively discussed in the literature.90,91 Normalization adjusts for
experimental variations between replicates, different number of cells, varying signal-tonoise, etc., and minimizes these contributions to the clustering patterns in PCA and
OPLS-DA scores plot. We have encountered significant success in using a Z-score or
center averaging the spectrum:
Z

Xi  X



(1)

where X is the average signal intensity in a given spectrum,  is the standard deviation in
the signal intensity, and X i is the signal intensity within bin i (Figure 3.7a). After
normalization, all the noise bins are uniformly removed. This was initially accomplished
by manually identifying a “reference” noise region above 10 ppm and below 0 ppm; and
calculating an average noise value. If a bin across all replicates had an integral value of
less than twice the average noise, it was also identified as noise and removed (Figure
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3.7b). The protocol for identifying noise regions has been recently improved upon and
results in smaller within class variations (Figure 3.7c). This also results in an improved
separation between truly distinct classes and removed erroneous separations. For
example, the statistical significance between clusters 6hwt and 6hacna improved from a
p-value of 3.1x10-13 to 8.1x10-15, while the small, but biologically irrelevant, separation
between clusters 2hwt and 2hacna (p-value 2.5x10-3) was removed (Figure 3.7). Instead
of using an average minimal signal intensity to define noise, we now define noise based
on a relative standard deviation. This is based on the expectation that real NMR peaks
from metabolites will have a higher intrinsic variability compared to the noise because of
biological variations that naturally occur even between within class replicates.
Conversely, the variability of the noise should be effectively constant for a given
spectrometer operating within normal parameters. Simply, the standard deviation and
average is calculated for each bin, where the standard deviation is normalized by the
average peak intensity. This avoids eliminating weak peaks with a relatively small
standard deviation. The same is done for the reference noise region, which is then used to
define noise:
σi’≤σ0’

(2)

Cutoff: σ0’=avg(σn’)+2* sd(σn’)

(3)

Noise:

where σi’,σn’ are the relative standard deviations (absolute standard deviation divided by
the mean) for the ith bin in the spectral region and nth bin in the reference noise region,
respectively, and avg(σn’) and sd(σn’) are the mean and standard deviation of σn’
respectively. In effect, any peak that falls within the normal distribution of the reference
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noise region is defined as a noise bin. This approach is better at defining noise peaks in
crowded and overlapping regions of the NMR spectra.
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Figure 3.7 Illustration of the impact of NMR preprocessing on within and between class
variations in a PCA scores plot. a) The 1D 1H NMR spectra was not properly
preprocessed. The spectra were not normalized and the noise was not removed. The
spectra were only Fourier transformed, phased corrected, and the residual H2O resonance
was removed. b) The 1D 1H NMR spectra were processed as in a) with the addition of
normalization using center averaging, but without noise removal. c) The 1D 1H NMR
spectra were processed as in b) with the addition of noise removal. Each spectrum was
binned using intelligent bucketing with a bin size of 0.025 ppm. The ellipses correspond
to the 95% confidence limits from a normal distribution for each cluster. The PCA scores
plots compare the metabolomes of S. aureus wild-type (wt) strain SA564 with an
aconitase mutant (acnA) strain SA564-acnA::tetM at either two hours (2h) or six hours
(6h) of cell growth. Below each PCA scores plot is a corresponding dendrogram
generated from the scores using Mahalanobis distances, with p values for the null
hypothesis reported at each branch.

In addition to normalization, each bin or column in the data matrix also needs to
be scaled to account for the large dynamic range in peak intensities. PCA and OPLS-DA
emphasizes the absolute variation in bins between classes. Correspondingly, the relative
variation of an intense peak may be insignificant compared to a weak peak, but the
absolute changes in its intensity may completely mask biologically relevant changes in a
small peak. Scaling increases the weight of the low intensity peaks so strong peaks do not
dominate in PCA and OPLS-DA.90,91 In our experience, unit variance scaling, also known
as auto-scaling or a Z-score (see eqn. 1), has been shown to be effective in generating
reliable clusters with the correct separation based on biologically relevant class
distinctions. Also, within class variance is reduced using auto-scaling, which is our
default scaling method.
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3.5.2 Multivariate statistical analysis of 1D 1H NMR data
We routinely apply PCA, a non-supervised technique, to determine if the 1D 1H
NMR data can easily distinguish between the various test classes. PCA provides an
unbiased view of group clustering in the resulting 2D scores plot. We only use a threedimensional (3D) scores plot if class separation in a 2D scores plot is insufficient and the
PC3 contribution is significant (> 5 to 10%). OPLS-DA is only used if class separation is
observed in the PCA scores plot. OPLS-DA is a supervised technique and assesses a
relationship between the NMR data class designations. We limit OPLS-DA to only two
class designations that differentiate between the single control group (0) and the entire
treatment group (1). As a supervised technique, OPLS-DA maximizes a separation
between these two classified groups, while minimizing within class variations.39 Thus,
OPLS-DA identifies the important spectral features (metabolites) that primarily
contribute to class separation. We routinely use an OPLS-DA S-plot or loading plot to
readily identify the key metabolites that contribute to class separation. Since OPLS-DA is
a supervised technique and can generate a class separation even for random data,92 it is
essential to verify the model.46 But this is also an advantage of OPLS-DA over PCA; the
statistical significance of the model is quantified. We cross-validate OPLS-DA models
using a modified leave-one-out method93,94 and CV-ANOVA.95 The modified leave-oneout method provides a quality assessment score (Q2) and R2 values, where CV-ANOVA
provides a standard p-value. The theoretical maximum for Q2 is 1, where a value of ≥ 0.4
is an empirically acceptable value for biological samples,96 but Q2 does not have a critical
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value for inferring significance. It is still possible for an invalid model to produce a large
Q2 value. Similarly, the R2 values only provide a measure of the fit of the data to the
model. But large differences between Q2 and R2 (R2 >> Q2) does suggest an over-fit
model. Conversely, a p-value << 0.05 from CV-ANOVA provides clear validation of the
OPLS-DA model.
In addition to validating the OPLS-DA model, it is also extremely important to
verify the statistical significance of the clustering patterns in the PCA and OPLS-DA
scores plot. Is the between group difference larger than the within group variations? One
key factor is the number of replicate samples. We have previously shown that increasing
the number of replicates improves the statistical significance of cluster separation.97 This
finding is also supported by the increase in p-values seen with an increase in within class
variations (Figure 3.6). Again, increasing the number of replicates improves the statistical
significance of the class separation (lower p-value) even when within class variation
increases. Correspondingly, we routinely use 10 replicates per group in our metabolomics
study to improve the likelihood of observing statistical significant class separations.
It is also important to visually define each group or class within the PCA and
OPLS-DA scores plot and to classify the statistical significance of the class separation.
We developed a PCA and OPLS-DA utilities software package78 that draws ellipses or
ellipsoids around each group cluster in a scores plot, where the ellipse corresponds to the
95% confidence limits from a normal distribution for each cluster. Visual separation of
the ellipses infers a class separation. The same software package is also used to generate
a metabolomics tree diagram based on the group clusters in the scores plot.78,97 Simply, a
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centroid from each cluster is used to calculate a Mahalanobis distance between clusters,
where dendrograms are then generated from the resulting distance metric. The
significance of each node (cluster separation) is determined by using standard
bootstrapping techniques and returning a bootstrap number,98 where a value above 50
infers a significant separation; or from Hotelling’s T2 and F-distributions that returns a pvalue, where a number << 0.05 infers a statistically significant separation.
Observing a statistically significant difference in the global metabolome between
two or more bacterial samples is typically the first objective of a metabolomics
investigation. While this difference may infer some biological significance, the ultimate
goal is to identify the underlying metabolites and associated pathways that are the
primary contributors to the observed class separation in the PCA and OPLS-DA scores
plot. One approach is to generate an S-plot (Figure 3.1) from the resulting OPLS-DA
analysis. The S-plot identifies the key bins or 1H chemical shifts that are correlated or
anti-correlated with the separation between the two classes in an OPLS-DA scores plot.
The 1H chemical shifts can then be compared against a number of online NMR
metabolomics databases to assign the metabolites.99-103 Unfortunately, an unambiguous
assignment is rarely possible because of the low chemical shift dispersion and the large
number of potential metabolites. Instead, 2D NMR experiments combined with the
biological knowledge of the system under investigation are required to improve the
accuracy of metabolite identification.

3.5.3 Metabolite Identification
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3.5.3.1 Automated peak picking of 2D NMR data
2D 1H, 13C HSQC and 1H, 1H TOCSY spectra are commonly used for metabolite
identification because of the increase in chemical shift resolution achieved by spreading
the information out into two-dimensions. Also, the correlation between 1H chemical
shifts for each J-coupled H pair; and the correlation between 1H and 13C chemical shifts
for each C-H pair significantly reduces the assignment ambiguity. This occurs because
now both chemical shifts have to match a single metabolite in the database to make an
assignment. Despite the advantages, peak picking and organizing a table of intensities
from a 2D NMR experiment is a time consuming process, especially when multiple
spectra are involved. Numerous software packages are available to automate the peak
picking of 2D NMR spectra, however; it is extremely difficult, if not impossible, to align
and match multiple sets of spectra with different peak patterns due to unique
metabolomes.
For example, three different sets of cell cultures (different cell types, treatments or
environmental conditions, etc.) will each exhibit a distinct set of peaks in the NMR
spectrum due to the presence of unique metabolites. These unique peaks will be mixed
with other peaks common to all three groups, but the relative peak intensities are likely to
vary due to different metabolite concentrations. Thus, if the control group is designated
as the reference spectrum for automated peak picking, a peak list will be generated that
only contains peaks observed in the control spectrum that are above the designated noise
threshold. Correspondingly, peaks unique to the other two groups will be missed when
this peak list is used to peak pick their spectrum. In addition, weak peaks may also be
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missed due to different noise levels between the spectra and a corresponding difference in
the threshold setting for peak picking. Instead, a composite reference spectrum for
automated peak picking needs to be generated that captures all the peaks present in the
three separate groups. We accomplish this task by using the addNMR function in the
NMRpipe software package.104 As the name implies, addNMR mathematically sums all
spectra together from the three groups to make a single spectrum. This resulting “master
spectrum” contains all the peaks observed throughout the set of 2D experiments and is
used to generate a peak list for automated peak picking of each individual spectrum.
Critically, the 2D NMR spectra need to be collected and processed using identical
experimental parameters (spectral width, data points, zero-filling, etc.) and needs to be
aligned to an internal reference (TMSP-d4). In our experience, all the peaks from the
complete set of NMR spectra are routinely matched to the reference list by using a
chemical shift error-tolerance of 0.04 ppm and 0.25 ppm in the 1H and 13C dimensions,
respectively. This approach has greatly simplified and increased the efficiency of a
previously laborious procedure. The addNMR command can also be used to generate a
difference spectrum that clearly highlights the major spectral changes between two
classes (Figure 3.8).
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Figure 3.8 (a-c) Illustration of the procedure to generate a “master spectrum” and
facilitate automated peak picking by creating a complete peak list. (a-b) Representative
2D 1H, 13C HSQC spectra obtained from two distinct bacterial cultures, where some
major spectral differences are highlighted. c) The two 2D 1H, 13C HSQC spectra from (ab) were added to yield a master spectrum that contains all the observed NMR peaks. (d-f)
Illustration of the procedure to generate a “difference spectrum” to facilitate metabolite
identification by creating a signed (+, -, null) peak list. (d-e) Representative 2D 1H, 13C
HSQC spectra obtained from two distinct bacterial cultures. f) The two 2D 1H, 13C HSQC
spectra from (d-e) were subtracted to yield a difference spectrum that identifies the NMR
peaks, and correspondingly metabolites, that differ between the two bacterial cell
cultures. Positive peaks, increased metabolite concentration, are colored green and
negative peaks, decreased metabolite concentration, are colored red.

3.5.3.2 Assignment of an NMR peak to a metabolite
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Metabolite identification is an extremely important component of the
metabolomics process because it enables the determination of the key metabolites
perturbed by the treatment or the metabolites primarily contributing to class distinction.
This includes the discovery of important biomarkers associated with drug efficacy or
drug resistance. Also, metabolite identification is important to the drug discovery process
by either identifying metabolic pathways affected by a drug to evaluate efficacy or
potential toxicity; or by identifying potentially new therapeutic targets. Nevertheless,
accurate metabolite identification is very difficult and labor-intensive. The success of
metabolite spectral assignment relies largely on the completeness of metabolomics
databases. We routinely use a combination of the following databases: Human
Metabolome Database,99 Madison Metabolomics Consortium Database,100 Platform for
RIKEN Metabolomics,101 BioMagResBank,102 and Metabominer,103 which provide both
redundant and complementary NMR spectral data. Importantly, the reference NMR
spectra in the various databases were obtained under different buffer condition and use
different internal standards. This results in a range of potential chemical shifts for a given
metabolite. Thus, the database with sample conditions that closely match our
experimental conditions are used for chemical shift matching. The overall goal is to
identify a complete set of metabolites as quickly and accurately as possible without any
bias, by matching the experimental chemical shifts from the 2D NMR spectra with the
values in the database.
For a 2D 1H, 13C HSQC experiment, it is important to realize that metabolites may
be heterogeneously labeled by the carbon-13 source present in the growth media.
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Correspondingly, all the peaks for a specific metabolite may not be detectable in the 2D
1

H, 13C HSQC experiment. Also, a reference spectrum for the metabolite may not be

present in any of the available databases. The assignment of a particular peak might still
be ambiguous because multiple metabolites may contain the same chemical shift or
contain an identical substructure (i.e., ATP, ADP, AMP or NAD, NADPH). Therefore, a
few automated filters are applied to overcome some of these ambiguities during the peak
assignment process.
The first filter is to verify that the bacteria can actually produce the proposed
metabolite. This is routinely accomplished by searching the Biocyc105 and KEGG106
database for metabolites known to exist in the bacteria under investigation. The second
filter is based on a differential peak list. All the NMR peaks potentially assigned to a
specific metabolite should have the same trend relative to the control. Obviously, the
metabolite can only have one concentration and all the NMR peaks need to be consistent
with this single concentration. Correspondingly, all the peaks have to be increased,
decreased or the same relative to the same peaks in the control spectrum. This is easily
and quickly visualized by subtracting the two sets of spectra and generating a signed (+, , null) peak list. Peaks assigned to the same metabolite have to have the same sign. The
third filter is based on a biological relationship with other metabolites. Simply, the
likelihood of a correct assignment increases if other metabolites in a specific metabolic
pathway have also been assigned. It is more likely to observe multiple metabolites from
the same pathway than various metabolites from unrelated pathways. Similarly, if there is
a direct metabolic path between two or more metabolites, then their assignments are more
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likely to be correct. The final filter is the application of our biological knowledge of the
bacterial system under investigation. The pathways or metabolites that are expected to be
perturbed by the treatment would be given precedent in the assignment process. As a
simple example, a comparison between wild-type and mutant bacterial strains where
aconitase has been inactivated would reasonably be expected to lead to changes in
metabolites associate with the TCA cycle. Likewise, a comparison between untreated and
drug-treated cells would be expected to lead to changes in metabolic pathways inhibited
by the drug.

3.5.3.3 Statistical analysis of the 2D 1H, 13C HSQC data.
After assigning the 2D 1H, 13C HSQC spectra to a set of metabolites, the next goal
is to determine metabolite concentration differences between the various bacterial culture
conditions under investigation. Unfortunately, peak intensities in a standard 2D 1H, 13C
HSQC experiment are dependent on metabolite concentrations and J-couplings,
dynamics, and relaxation properties.88 Therefore, only a relative percent change in a
metabolite concentration can be determined.5 Alternatively, an absolute concentration can
be determined using HSQC0, which requires a set of three HSQC experiments per
sample. We routinely employ both approaches.88
A relative difference in peak intensities is determined by using a triplicate set of a
conventional 2D 1H, 13C HSQC experiment for each bacterial culture condition. Prior to
calculating a relative percent change in peak intensities, a detailed normalization process
is required, which was previously described in detail.5 First, the peak intensities within
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each spectrum are normalized by dividing each peak by the internal standard, the
intensity of the TMSP-d4 peak. Each peak pertaining to a specific chemical shift across
each triplicate data set is then normalized by the most intense peak in the set of three
peaks. Specifically, the maximal intensity for each peak across all data sets would be set
to 100 and all other intensities are scaled relative to this peak intensity. Then all the
normalized intensity for a given metabolite for each triplicate set is averaged together,
and a relative percent error can be calculated between different cultures. A Student’s ttest or ANOVA is then used to determine if the relative change in peak intensities is
statistically significant at the 95% confidence limit. Calculating a relative difference in
metabolite concentrations can be beneficial to understanding broader changes to the
system, especially when a cluster of metabolites in a specific pathway exhibit a similar
trend in concentration changes inferring an important role for the metabolic pathway.
Nevertheless, this approach is rather cumbersome and does not allow for a direct
comparison between different metabolites.
Alternatively, we routinely use the HSQC0 experiment to determine absolute
metabolite concentrations. The overall protocol for the extrapolation of peak intensities to
time-zero and the determination of the associated concentration has been previously
described in detail.88,89 A distinct advantage of this method is that a single calibration
curve can be made using multiple compounds with known concentrations to correlate the
time-zero peak intensity with a concentration. Figure 3.9 illustrates such a calibration
curve using 5 different mixtures, each consisting of 9 different 13C-labeled metabolites
ranging in concentrations from 5 to 300 µM. Also, the concentration for each metabolite
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was randomized in each mixture. For example the concentration of 13C-D-alanine in the 5
mixtures is 300, 10, 25, 5, and 100 µM, respectively. The data was fitted using a
weighted linear least squares calculation. Notably, the best-fit line (R2 0.997) has a yintercept close to zero as expected for a concentration of zero. Also, the correlation
between peak volume and concentration is independent of the metabolite. Importantly,
the accurate application of the calibration curve requires collecting and processing
HSQC0 spectra identical to the parameters used to obtain the original calibration curve.
Critically, the receiver gain must be the same for all samples, because any change in the
receiver gain influences the slope of the calibration curve. Also, the addition of 500 µM
TMSP-d4 as an internal standard is crucial, because both the calibration samples and
experimental samples must both be similarly normalized to the TMSP-d4 peak. As an
example, if the TMSP-d4 peak volumes for the calibration mixtures are 1000, 500, and
250 for each HSQCi (i = 1,2,3) spectrum, respectively, then the experimental results for
all in vivo metabolite extracts must be normalized so that the internal standard (TMSP-d4)
peak volumes are also 1000, 500, and 250. The concentrations are measured in triplicate,
where a Student’s t-test or ANOVA is used to determine if the concentration changes are
statistically significant at the 95% confidence limit.
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Figure 3.9 A strong correlation between NMR peak volumes and metabolite
concentrations (R2 0.997) is demonstrated by linear regression plot generated from
HSQC0 data. HSQC0 NMR spectra were collected for five different metabolite mixtures
containing nine 13C-labeled compounds with concentrations ranging from 5 µM to 300
µM. The relationship between peak volume and metabolite concentration is independent
of the metabolite.

3.5.4 Metabolomics Network Map
Metabolites are highly interconnected through numerous metabolic pathways that
form an extremely complex network.107 Correspondingly, it is not uncommon to observe
correlated changes between distantly connected metabolites. In effect, metabolomics
depends on these complex interactions to understand the phenotype of a bacterial cell.
Thus, a metabolomics network map provides an efficient approach to visualize and
summarize the overall changes to the metabolome, to validate metabolite assignments
based on clear connections to other metabolites, and the identification of key metabolic
pathways.
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We have routinely used Cytoscape to easily and quickly generate metabolomics
network maps. Cytoscape is a user-friendly software package with plug-ins related to
metabolomics.108-111 Cytoscape simply requires a list of the metabolites and their
associated concentration changes as input. The connections between nodes (metabolites)
in the map are based on metabolic pathways from the MetaCyc database.112 An example
of a typical Cytoscape map summarizing the observed changes in the S. epidermidis
metabolome caused by environmental stimuli associated with biofilm formation is shown
in Figure 3.1. The metabolomics network map can be easily modified to highlight
specific features of the metabolome. Edges can be broadened to highlight specific
pathways; and the color and size of nodes can be adjusted to reflect the direction and
magnitude of the concentration changes, respectively.113 Cytoscape also provides a range
of map design choices. Unfortunately, the resulting network maps (Figure 3.1) do not
resemble standard metabolic pathways. Thus, Cytoscape maps are simply used as a
template to manually draw more traditional looking metabolic pathways. Since
Cytoscape maps are so easily generated, we also use the software to assist in metabolite
assignments. Potential lists of metabolite assignments are input into Cytoscape to identify
metabolites that are isolated nodes excluded from the main network map. These
metabolites are likely misassigned and are reevaluated. In addition to Cytoscape, we also
use the R statistics package to create heat maps from absolute metabolite concentrations
or percent relative concentration changes. The structure is made of nodes and edges.
Metabolites are small molecules that are involved in the metabolism which is the overall
chemical reactions in the biological system. Therefore, in terms of choosing metabolites,
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the intermediates from glycolysis pathways, TCA cycle and pentose phosphate pathways
were taken as the major contributions since they are essential to synthesis all the
macromolecules for S. aureus, although for pentose phosphate pathway, only a portion of
it was selected because there are many metabolites that are not detectable by our
technique so far. Other metabolites, especially the common amino acids that can be
derived from these three pathways directly were also included. The goal is to maximize
the efficiency of the usage of the network so that it should represent the status of the cells
and provide systematic information on the perturbed cellular metabolome. For each
project, it can be modified as needed. The connections between different nodes are based
on S. aureus pathway stored in the MetaCyc database. The direct and indirect reactions
were all represented by edges without discrimination because multiple pathways can
happen. Therefore only the shortest one was shown. If a metabolite increases its
concentration, red color is assigned. If a metabolite decreases its color, green color is
assigned. If there is no change between the comparison pair, then a grey color is assigned.
The size of the node representing the metabolite is increased or decreased in proportion to
the relative change. For example, if metabolite A is 2 times increased in its concentration,
the node is 2 times larger than the ones with no change and vice versa. The exact number
of times is normalized from 1 to 2 in order to keep the basic shape of the map, without
being perturbed by some huge nodes that may be made. A student’s t-test is used to
determine that if a concentration is significantly changed or not, only p value smaller than
0.05 are taken to be changed in concentration. Under other conditions, if a change has a p
value larger than 0.05 but smaller than 0.1, a pink or light green was coded. The layout
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was designed based on traditional flowchart. The glycolysis and TCA cycle are
highlighted by broadening the width of the edges.

3.6 Conclusion
NMR metabolomics is an invaluable tool for systems biology and its application
is rapidly expanding. Global changes in the metabolic state of bacterial cells occur as a
result of environmental stressors, genetic modifications, drug treatments, or numerous
other factors. A detailed analysis of the differences in the NMR spectra is commonly
used to identify the key metabolite changes that differentiate between these bacterial
classes (i.e., controls versus treated). In addition, metabolite identification by NMR
allows for the subsequent identification of the important metabolic pathways that are
affected by the treatment, providing further insight into the underlying biological process.
The appeal of NMR metabolomics is its simplicity, but unfortunately it is also easy to
obtain unreliable results. The observed changes in the metabolome should be biologically
relevant, but because the metabolome is so sensitive to any environmental change; it is
also easily perturbed by the experimental protocol. This is clearly an undesirable
outcome. To address this issue, we described in detail our optimized protocols for the
NMR analysis of bacterial metabolomes. We also highlighted common problems and
potential sources of mistakes. We discuss the entire process that includes growing and
harvesting bacterial cells, extracting the metabolome, NMR data collection, processing
and analysis, statistical analysis, metabolite and network identification. The protocols
described have been successfully applied to a number of systems biology projects.
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CHAPTER 4
AN INEXPENSIVE HIGH-THROUGHPUT NMR TUBE CLEANING
APPARATUS
4.1 Introduction
High-throughput screening (HTS) is widely used in the biotechnology and
pharmaceutical industries 1-3 with an expanding interest in academia.4,5 HTS is an
efficient approach for the experimental testing of large sample sets for the discovery of
new drugs. Multiple reviews on HTS automation have discussed robotic systems
employed to transport samples, add reagents, mix samples or detect signals. 6-8 These
steps are clearly essential components to a successful screen and are understandably a
focal-point of any assay design. Conversely, there is a complete lack of reports discussing
the automation of recycling devices. For the majority of high-throughput screens, a
reliance on disposable labware (assay plates, pipette tips, etc) simplifies the execution of
the assay while being reasonably cost-effective.
Fragment-based NMR screens complement traditional HTS and have evolved to
become an important and common component of drug discovery.9,10 Fragment-based
screens utilize a chemical library of low molecule-weight ligands (≤ 200 – 300 Da)11 that
correspond to fragments of known drugs or have drug-like characteristics.12 NMR is used
to identify binders, to identify the ligand binding site, and to assist in “growing” the
fragments to improve binding affinity. There are several advantages to fragment-based
NMR screens over HTS that include maximizing ligand efficiency, improving coverage
of chemical space, higher hit rates and higher quality of leads, direct observation of
biologically relevant interactions, and a universal assay design. Conversely, NMR ligand
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affinity screens are typically limited to assaying only hundreds to thousands of
compounds. Another practical disadvantage is the hundreds of NMR tubes that quickly
accumulate and require cleaning.
High quality NMR tubes are generally used for ligand affinity screens and
because of cost ($2 to $8 per tube) are typically not limited to a single use. A standard
NMR tube cleaner (Sigma-Aldrich, St. Louis, MO) can handle from one to five tubes.
The NMR tube sits inverted on a glass adapter for washing, which is very fragile since it
has a small diameter (<5 mm) and long length (8 in.). Thus, the routine cleaning of
thousands of NMR tubes rapidly results in broken NMR tube cleaners at a cost of $90 to
$420 per cleaner. Besides manually cleaning, there are commercial devices available
such as the Bruker BioSpin Autoclean system (Billerica, MA) that is capable of cleaning
60 tubes per hour, but generates a significant amount of waste and has a cost of $15K.
Alternatively, NMR tubes can be completely discarded from the NMR screen by using a
flow-probe.13 The NMR probe contains a fixed cell with active volumes ranging from 30

liquid handling system. After data acquisition, the sample is either transferred to waste or
collected. Challenges with flow probes may include cross-contamination between
samples, clogging of the system by solid particulates that may also result in lost samples,
and problems with properly positioning the sample in the probe. There is also the initial
cost of $75K for a flow-probe system.
A cost effective and efficient means of cleaning thousands of NMR tubes is an
annoying problem and a routine challenge currently faced by NMR screening groups. To
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solve this problem, an inexpensive (~$300) and highly effective apparatus for cleaning
NMR tubes has been designed and successfully employed in our laboratory. It is
extremely efficient compared to existing tube cleaners since 180 tubes are cleaned in an
hour. Obviously, the use of large amounts of solvent increases the cost of cleaning and
diminishes the value of recycling NMR tubes. There are also safety and health concerns.
As a result, the design of the NMR tube cleaner apparatus and the development of the
protocol focused on minimizing solvent usage. Only 200 to 300 mL of solvent is used to
clean the 180 NMR tubes. The amount of solvent waste will increase proportionally if
multiple solvents are used. Similarly, an apparatus that routinely cracks, chips or
scratches the NMR tubes defeats the cost-effectiveness of recycling. More concerning is
the possibility of unnoticed tube damage that may result in a broken tube in an NMR
probe. Unlike the manual cleaning of a large batch of NMR tubes where damage is
common, we have not observed any damage to the hundreds of NMR tubes cleaned using
our apparatus. This is primarily a result of minimal handling of the NMR tubes during
cleaning and the fact that the tubes are simply placed inverted into a glass vessel.

4.2 Methods and Materials
Diagrams and pictures of our NMR tube cleaning apparatus are shown in Figure
4.1. The apparatus can be easily constructed in any laboratory with access to a glass
blower. The cleaner consists of three major components: (i) a specially designed glass
valve assembly (switch), (ii) a 750 mL Labconco® vacuum bottle, cap and adaptor, (iii)
and a standard pump system (not shown). The NMR tubes are simply placed inverted into
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the 750 mL Labconco® vacuum bottle. The cap is placed onto the vacuum bottle, which
is then partially filled with solvent. Our glass switch is attached to the cap and the
apparatus is connected to a vacuum pump. A flexibly attached glass tube extends from
the glass switch to the base of the vacuum bottle. A pressure differential is used to push
solvent into and out of the NMR tubes or to completely remove the solvent from the
apparatus. This occurs by manipulating the two Teflon valves on our glass switch while
the apparatus is attached to a vacuum pump. Basically, with the left valve closed, slowly
and briefly opening the T-valve to the vacuum position evacuates the air from the
Labconco® vacuum bottle and places it under a slight vacuum without removing the
solvent. Turning the T-valve to the vent position opens the vacuum bottle to atmosphere
breaking the vacuum and forcing solvent into the NMR tubes. Switching the T-valve
back to the vacuum position places the NMR tubes back under vacuum and removes the
solvent from the NMR tubes. Repeating the process two or three times effectively washes
the NMR tubes with solvent. Switching the T-valve to the vent position and opening the
left valve rapidly removes the solvent from the NMR tube cleaner into the filter flask.
The process can be repeated with other solvents.
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Figure 4.1 Schematic drawing a) and picture b) of our NMR tube cleaning apparatus.
Schematic drawing c) and picture d) of an expanded view of the glass switch. Important
features and dimensions are labeled.
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The general protocol for cleaning NMR tubes (Figure 4.2) corresponds to the
following steps: (1) empty the NMR tubes that need to be cleaned and remove any labels,
(2) load tubes into the NMR tube cleaner along with solvent, (3) install the valve
assembly and hook up the filter flask and vacuum system, (4) rinse multiple times with
solvents of choice, (5) remove tubes and dry in an oven at 100 ºC for an hour. For heavily
soiled NMR tubes that contain solid films or stains, a simple solvent wash may not be
sufficient. Instead, the NMR tubes are typically soaked overnight in a concentrated
(<70%) nitric acid bath. The tubes are then quickly rinsed with tap water before placing
in the NMR tube washer. The wash solvent is a saturated sodium bicarbonate solution in
deionized water. Various solvents can be used in the NMR tube cleaner depending on
need and the chemical composition of the original NMR samples.
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Empty NMR tubes

Load tubes &
assemble the apparatus

D. I. water
Acetone
Methanol

add 300mL of each
solvent and rinse 3x
before decanting

Overnight nitric acid bath

NaHCO3
D.I. water

rinse until neutral

o

Dry in an oven at 100 C/1h

Figure 4.2 Flow diagram of the NMR tube cleaning process.
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4.3 Conclusion
For a typical fragment-based NMR screen, deionized water is the first wash
solvent since it will effectively remove a majority of the aqueous-based samples. A
second wash using a polar organic solvent such as methanol, tetrahydrofuran or
dichloromethane may also be used to remove any compound residue and promote tube
drying. If necessary, a third and final wash with a non-polar solvent such as chloroform
could be employed. To ensure the effectiveness of our NMR tube cleaner, there are a few
general rules that need to be followed. It is important to avoid having the wash solvent
sit in the NMR tubes for an extended period of time. The rapid insertion and removal of
the wash solvent provides efficient agitation that assists in the cleaning process.
Conversely, prolonged exposure to a wash solvent may result in compound precipitation
and the formation of a difficult to remove film. For a similar reason, it is highly
undesirable to allow an NMR sample to evaporate to dryness. Effectively, NMR tubes
should be cleaned immediately after use to obtain optimal performance from our NMR
tube cleaner.
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CHAPTER 5
NMR ANALYSIS OF A STRESS RESPONSE METABOLIC SIGNALING
NETWORK
5.1 Introduction
In eukaryotic organisms, signaling pathways are essential to the life-cycle of cells
and are ubiquitous processes that regulate a variety of functions in response to both
extracellular and intracellular environmental changes.1-4 These signaling systems are
spatially and temporarily organized, where the kinetic properties of these cycles depends
on the cellular distribution of the activator and deactivator proteins. Protein activity is
usually controlled through a variety of post-translational modifications (phosphorylation,
acetylation, ubiquitylation, etc.), through protein complex formation, through
transcription regulation, or any combination of these factors. A prototypical signaling
cascade includes a membrane-bound receptor that binds a signal molecule which in turn
activates a kinase proximal to the membrane. This activated kinase phosphorylates a
second kinase, where the cascade continues and perpetuates the signal away from the
membrane to the final target. Typically, the impact of a signaling network is the up- and
down-regulation of a set of genes or proteins associated with a specific response
(apoptosis, metabolic process, proliferation, stress responses, etc.). Correspondingly, the
cell commits a significant amount of energy and resources to undergo such a phenotype
change.
In prokaryotes, signal transduction frequently involves two-component regulatory
systems that consist of a membrane-bound sensor histidine protein kinase and a response
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regulator.5 These two-component signal transduction systems are activated when an
external signaling molecule, peptide, metal ion, etc., is bound by the sensor kinase, which
undergoes autophosphorylation at a conserved histidine. Transfer of the phosphoryl
group to the receiver domain of a response regulator in the cytoplasm of a bacterium
completes the activation and the response regulator is then competent to activate
transcription of a limited set of genes. In staphylococci, there are numerous twocomponent regulatory systems,6 with the best studied being the agr quorum sensing
system.7 In addition to two-component systems, bacteria use sigma factors as a means to
detect environmental conditions that induce heat stress, envelope stress, nitrogen stress,
etc.8 In staphylococci, σB is activated during stress conditions, growth phase transitions,
and morphological changes.9,10 Most recently, the hypothesis that central metabolism can
act as a signal transduction pathway to transduce external environmental signals (e.g.,
iron-limitation) into intracellular metabolic signals by altering the activity of the enzymes
of central metabolism has been proposed.11
The tricarboxylic acid (TCA) cycle is part of central metabolism and provides
reducing potential, energy and biosynthetic intermediates necessary for other
macromolecular synthesis.12 Several studies have also shown that the TCA cycle is
involved in regulating or affecting virulence or virulent determinant biosynthesis.13-15
One specific example is the production of the exopolysaccharide, polysaccharide
intercellular adhesion (PIA),16 which is associated with virulence and biofilm
formation.17-20 PIA synthesis is regulated by nutrient availability and external stress
conditions.21,22 Importantly, TCA cycle activity has also been shown to be affected by
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changes in environmental stress factors.16,22,23 A number of environmental stress factors
have also been shown to influence biofilm formation: ethanol,24 oleic acid,25 glucose,26
UDP-N-acetylglucosamine,27 sub-inhibitory concentrations of some antibiotics,28
anaerobic conditions,29 Fe limitation,30-32 high osmolarity,33 and high temperature.33 The
diversity of these external stimuli suggests a versatile regulation system. Recently, we
used NMR metabolomics to demonstrate that Fe limitation and ethanol decrease TCA
activity.23 These stressors cause a common metabolic change that can be sensed by
metabolite responsive-regulators (e.g., catabolite control protein A; CcpA) that affect PIA
production. We proposed that the TCA cycle plays a central role in a metabolic signaling
network that senses disparate environmental stress conditions and regulates PIA
biosynthesis, virulence determinants and biofilm formation (Figure 5.1). Herein, we
report a further NMR analysis of the impact on the metabolome of S. epidermidis
resulting from a diverse range of environmental stress factors associated with biofilm
formation that include 5% NaCl,33 2% glucose,26 0.06 µg/mL tetracycline,28 and 400 nM
autoinducer-2 (AI-2, furanosyl borate diester),34 in addition to our prior study23 with 4%
ethanol,24 and Fe limitation.30-32
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Figure 5.1 An illustration of the interrelationship of metabolic pathways associated with
the TCA cycle and biofilm formation.

Our differential NMR metabolomics methodology has been applied to the study
of in vivo drug activity in Aspergillus nidulans35 and Mycobacterium smegmatis36 and is
ideally suited to a systems biology analysis of the impact of environmental stress factors
on the S. epidermidis metabolome and the corresponding role of the TCA cycle.23 In the
latter study, NMR was used to detect metabolic perturbations by following changes to S.
epidermidis (strain 1457) cultured under environmental stress conditions that induce
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biofilm formation. These results were then compared to the metabolome of a S.
epidermidis mutant (aconitase mutant strain SE1457-acnA::tetM) with an inactivated
TCA cycle. If S. epidermidis senses environmental stress conditions by affecting TCA
cycle activity as previously observed, then the impact on the metabolome caused by the
aconitase mutant and the disparate external signals were expected to be equivalent. The
overlapping clusters in principal component analysis (PCA) and orthogonal partial least
squares discriminant analysis (OPLS-DA) two dimensional (2D) scores plot and the
branch similarity on a metabolic tree diagram37 indicate that external biofilm signals
inactivate the TCA cycle. Furthermore, a detailed analysis of the relative concentration
changes of 55 different metabolites from 2D 1H, 1H TOCSY and 2D 1H, 13C HSQC
spectra implies the TCA cycle plays a central role in a metabolic signaling
network.35,36,38,39 A metabolic network created with Cytoscape40 illustrates this metabolic
signaling network and the interrelationship of the TCA cycle activity with alanine
metabolism, amino sugar metabolism, glycolysis/gluconeogenesis and the urea cycle.

5.2 Methods and Materials
5.2.1 Bacterial growth and NMR sample preparation
Staphylococcus epidermidis wild-type strain 1457 and the isogenic aconitase
mutant strain 1457-acnA::tetM were grown in tryptic soy broth (TSB; BD Biosciences)
without dextrose and supplemented with 0.25% glucose (Sigma Chemical) or 0.25%
13

C6-glucose (Cambridge Isotope Laboratories).
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All bacterial cultures were inoculated to an optical density at 600 nm (O.D.600) of
0.06 and were grown for 2 hours or 6 hours at 37oC with 225 rpm aeration in TSB or TSB
supplemented with a stressor know to induce biofilm formation. Either 10 or 12 replicate
bacterial cultures were grown for each bacterial strain or environmental condition for the
one-dimensional (1D) 1H NMR experiments. 3 replicate bacterial cultures were grown for
each bacterial strain or environmental condition for both the two-dimensional (2D) 1H,
13

C HSQC and the 2D 1H, 1H TOCSY experiments.
In general, four different bacterial cultures were harvested per experiment: (1)

wild-type S. epidermidis in TSB media, (2) wild-type S. epidermidis in TSB media with
an environmental stress condition, (3) aconitase mutant of S. epidermidis in TSB, and (4)
aconitase mutant of S. epidermidis in TSB with an environmental stress condition. The
environmental stress conditions used in this study were 5% NaCl,33 2% glucose,26 0.06
µg/mL tetracycline,28 400 nM autoinducer-2 (AI-2, furanosyl borate diester)34 in TSB
media. To facilitate integrating this current work with our recent study,23 control cultures
containing 4% ethanol24 in TSB or TSB medium depleted of iron (DTSB, defferated
TSB)30-32 were included for comparison. DTSB was prepared as described.23 AI-2,
furanosyl borate diester, was synthesized as previously described.41,42
For the 1D 1H NMR experiments, 2.74 O.D.600 units were harvested for analysis
and for both the 2D 1H, 13C HSQC and 2D 1H, 1H TOCSY experiments 5.48 O.D.600 units
were harvested. Following harvest, the culture medium was removed and the bacteria
were suspended in 1 mL portions of 50 mM phosphate buffer (PBS) in 99.8% D2O
(Isotec) at pH 7.2 (uncorrected). The bacteria were lysed using a FAST-Prep instrument
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(MP Biomedicals) for 40 seconds, centrifuged for 5 min to remove the bacterial debris
and glass beads, and frozen in liquid nitrogen.

5.2.2 NMR Data Collection
The NMR spectra were collected on a Bruker 500 MHz Avance spectrometer
equipped with a triple-resonance, Z-axis gradient cryoprobe. A BACS-120 sample
changer with Bruker Icon software was used to automate the NMR data collection. 1D 1H
NMR spectra were collected using excitation sculpting43 to efficiently remove the solvent
and maintain a flat baseline, eliminating any need for baseline collection that may induce
artifacts in the PCA or OPLS-DA 2D or three-dimensional (3D) scores plot. 1D 1H NMR
spectra were collected at 298K with a spectrum width of 5482.5 Hz and 32K data points.
A total of 16 dummy scans and 64 scans were used to obtain each spectrum.
2D 1H, 13C HSQC spectra were collected with solvent pre-saturation and
relaxation delay of 0.5 seconds.44,45 A total of 1024 data points with a spectrum width of
4734.85 Hz, and 64 data points with a spectrum width of 13834.26 Hz were collected in
the 1H and 13C dimensions, respectively. A total of 8 dummy scans and 128 scans were
used to obtain each of the 2D 1H, 13C HSQC NMR spectra. 2D 1H, 1H TOCSY spectra
were collected with WATERGATE solvent pre-saturation, and a relaxation delay of 2
seconds.46, 47 A total of 1024 data points with a spectrum width of 5000 Hz, and 256 data
points with a spectrum width of 5001.324 Hz were collected in the direct and indirect 1H
dimensions, respectively. A total of 16 dummy scans and 8 acquisition scans were used to
obtain each of the 2D 1H, 1H TOCSY NMR spectra.
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5.2.3

NMR Data Analysis
1D 1H NMR spectra were processed in the ACD/1D NMR manager version 12.0

(Advanced Chemistry Development, Inc). The residual H2O NMR resonance was
removed. Intelligent bucketing was used to integrate each region with a bin size of 0.025
ppm. Each NMR spectrum was center averaged to minimize any experimental variations
between bacterial cultures as follows:
̅

(1)

where ̅ is the average signal intensity, σ is the standard deviation in the signal intensity,
and Xi is the signal intensity within a bin. Noise regions of the spectra were omitted from
the PCA analysis by setting the corresponding bins to zero.48 The table of integrals was
imported into SIMCA11.0+ (UMETRICS) for PCA and OPLS-DA analysis using the
program’s standard parameters. The identification of the control group and treated group
or groups for the OPLS-DA analysis was based on the PCA clustering pattern.
2D NMR Spectra were analyzed using NMRView49 and Sparky (T. D. Goddard
and D. G. Kneller, SPARKY 3, University of California, San Francisco) to identify
chemical shifts and assign peak intensities. Peak intensities were normalized for each 2D
NMR spectrum by dividing by the average peak intensity for a given spectrum. Each
peak for each metabolite from each specific triplicate data set was averaged and the
intensity for each peak was further normalized across all data sets (i.e., wild-type,
aconitase mutant, and each bacterial growth condition). Specifically, the maximal
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intensity for each peak across all data sets was set to 100. The peak intensities in the
remaining data sets were all scaled relative to this peak intensity. Then, a normalized
intensity for the metabolite within each data set was calculated by averaging the
normalized intensity for each of the metabolite’s assigned peaks. In this manner, the
relative percent difference in metabolite intensity (concentration) can be reported
between different bacterial strains or bacterial growth conditions. As an illustrative
example, consider a metabolite with thee assigned peaks (A, B, C) in a 2D 1H, 13C HSQC
spectrum. The 2D 1H, 13C HSQC spectrum is collected in triplicate under three different
bacterial growth conditions for a total of 9 spectra and 27 peak intensities, 3 peaks in
each spectrum for the metabolite. Peak A has average intensities of 0.05, 0.10, and 0.20 in
the three different bacterial growth conditions, respectively. The values would be
normalized to 25, 50, and 100. Similarly, peaks B and C are normalized against their
maximal peak intensities for values of 20, 60, 100 and 30, 65, 100, respectively. Thus, the
average relative concentrations of the metabolite under the three bacterial growth
conditions would be the average of the three normalized peaks, yielding values of 25,
58.3 and 100, respectively. The bacterial growth condition with the highest relative
metabolite concentration (100) would have a corresponding concentration increase of 75
and 41.7 relative to the two other bacterial growth conditions.
The observed NMR peaks in the 2D 1H, 13C HSQC and 2D 1H, 1H TOCSY
spectra were assigned to specific metabolites using 1H and 13C chemical shift tolerances
of 0.05 ppm and 0.50 ppm, respectively. Metabominer,50 Madison Metabolomics
Consortium Database (MMCD)51, the BioMagResBank,52 and Human Metabolome
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Database53 were used to identify metabolites. The presence of metabolites and metabolic
pathways were verified with the KEGG54 and Metacyc55 databases. A metabolic network
map was generated using Cytoscape using a force directed layout.40 Metabolites
identified with a percent concentration difference of ≥ ±10% relative to wild-type S.
epidermidis were manually color-coded to indicate either an up- or down-regulated
concentration change.

5.3 Results and Discussion
5.3.1

NMR metabolomics and principal component analysis
The elimination of experimental factors that may inadvertently influence PCA or

OPLS-DA metabolomic data interpretation is essential. The observed variability in the
PCA or OPLS-DA data should result from differences in the biological samples as
opposed to changes in sample preparation, sample handling, data acquisitions, data
processing or any number of experimental parameters (temperature, pH, time,
concentration, etc.). In order to obtain accurate and reproducible metabolomic data, the
following general protocols were employed: (i) bacterial cultures of wild-type S.
epidermidis were used as a reference metabolome and were prepared with all sets of
bacterial cultures, (ii) equivalent bacterial numbers were used, so metabolite
concentrations were independent of any bacterial growth variability, (iii) all NMR spectra
were normalized using center averaging,56 so variability in sample concentration was
minimized, (iv) noise regions48 and solvents were removed from NMR spectra prior to
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PCA or OPLS-DA, and (v) minimal processing (no baseline correction or apodization
functions) of the NMR spectra.

5.3.2 Harvesting of S. epidermidis cultures
Bacteria grown in vitro undergo four different growth phases: (i) lag, (ii),
exponential, (iii) stationary, and (iv) death. Throughout a typical growth cycle, the state
of the bacteria and the environment are constantly changing. Clearly, there is a
fundamental difference between the exponential phase, when cell density is relatively
low, cells are rapidly dividing and the required nutrients are abundant; and the stationary
phase when these characteristics are effectively reversed. Correspondingly, the
metabolome is expected to reflect these differences. Therefore, exploring a biological
system by monitoring changes in the metabolome necessitates the appropriate choice of
the state of the system. In the case of S. epidermidis biofilm formation and the proposed
role of the TCA cycle in a metabolic signaling network, the proper choice of the state of
the system requires endogenous TCA cycle activity.
The TCA cycle is minimally active during the exponential phase (2 h growth)
when nutrients (i.e., glucose or other rapidly catabolizable carbohydrates) are sufficient
for bacteria to grow quickly.16,57 Overflow metabolism results in an incomplete oxidation
of glucose, leading to the accumulation of acetate, lactate, and other incompletely
oxidized metabolites in the culture medium (Figure 5.1.2a). During the transition to the
post-exponential growth phase (6 hours), the TCA cycle is de-repressed as the
carbohydrate(s) are depleted from the culture medium. Concomitantly, the incompletely
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oxidized metabolites that accumulated in the medium are catabolized through the TCA
cycle resulting in the depletion of secondary metabolites from the culture medium.

Figure 5.2 a) Typical S. epidermidis growth curve superimposed on the cellular
production of acetic acid. b) 2D PCA scores plot and c) 2D OPLS-DA scores plot
comparing 2 h growth of wild-type S. epidermidis 1457 (grey ●), 2 h growth of aconitase
mutant strain 1457-acnA::tetM (grey ▲), 6 h growth of wild-type S. epidermidis 1457
(black ●), and 6 h growth of aconitase mutant strain 1457-acnA::tetM (black ▲). The
ellipses correspond to the 95% confidence limits from a normal distribution for each
cluster. For the OPLS-DA scores plot, the 6 h growth of wild-type S. epidermidis 1457
(black ●) was designated the control class and the remainder of the cells were designated
as treated. The OPLS-DA used 1 predictive component and 3 orthogonal components to
yield a R2X of 0.788, R2Y of 0.992 and Q2 of 0.992.

The growth phase-dependent activity of the TCA cycle in S. epidermidis is also
apparent from the PCA 2D scores plot generated from 1D 1H NMR spectra of S.
epidermidis cell lysate (Figure 5.2b). The 2D PCA scores plot indicates that PC1 and PC2
account for 20.6% and 10.7% of the variations in the NMR spectra, respectively. A 3D
PCA scores plot (Figure 5.3) did not improve cluster separations. Each 1D 1H NMR
spectrum obtained for each cell lysate is represented as a single point in the PCA 2D
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scores plot, where the 10 replicates form four distinct clusters for the wild-type and
aconitase mutant strains grown for 2 hours and 6 hours, respectively. As expected and
consistent with our prior study,23 the metabolomes of the S. epidermidis wild-type and
aconitase mutant cells from the exponential growth phase (2 hours) were more similar to
each other than the 6 hour cultures. This is apparent from the close clustering in the 2D
scores plot for the 2 hour wild-type and aconitase mutant. This is consistent with the
minimal activity of the TCA cycle at 2 hours and the loss of TCA cycle activity for the
aconitase mutant. Conversely, there is a large separation in the 2D scores plot along the
PC1 axis between the 6 hour wild-type and aconitase mutant. In fact, the 6 hour aconitase
mutant cluster is closer to the 2 hour wild-type cluster. Again, this is consistent with an
increase in TCA activity at 6 hours and the loss of TCA activity in the aconitase mutant.
Correspondingly, the separation along PC1 reflects TCA cycle activity. Since the TCA
cycle is minimally active during the exponential phase, the 2 hour wild-type cluster is
slightly closer to the 6 hour wild-type cluster along PC1, compared to the aconitase
mutants.
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Figure 5.3. Three dimensional versions of the 2D PCA scores presented in Figure 5.2b,
Figure 5.5b, and Figure 5.7b, respectively. a) 3D PCA scores plot comparing S.
epidermis 1457 strain (circles) and aconitase mutant (triangles) grown for 2 hours (grey)
and 6 hours (black). The PCA model consists of 3 significant components where the
contribution (R2) for each successive component is 20.6%, 10.7%, and 6.8%. The overall
cross validation (Q2) is 15.9%, 7.58%, and 2.7%, respectively. b) 3D PCA scores plot
comparing wild-type S. epidermidis 1457 cells grown 6 h in standard TSB media ( ),
with S. epidermidis 1457 cells grown 6 h in iron-depleted media (DTSB) ( ), with the
addition of 4% ethanol ( ),with the addition of 2% glucose ( ), with the addition of 0.06
µg/mL tetracycline ( ), with the addition of 5% NaCl ( ), and 6 h growth of aconitase
mutant strain 1457-acnA::tetM in standard TSB media ( ). The PCA model consists of 5
significant components where the contribution (R2) for each successive component is
12.5%, 7.5%, 6.0%, 3.8%, and 3.3%. The overall cross validation (Q2) is 15.9%, 7.58%,
and 2.7%, respectively. c) 3D PCA scores plot comparing wild-type S. epidermidis 1457
cells grown 6 h in standard TSB media ( ), 6 h growth of aconitase mutant strain 1457acnA::tetM in standard TSB media ( ), aconitase mutant strain 1457-acnA::tetM in irondepleted media (DTSB) ( ), with the addition of 4% ethanol ( ), with the addition of
2% glucose ( ), with the addition of 0.06 µg/mL tetracycline ( ), and with the addition
of 5% NaCl ( ). The PCA model consists of 5 significant components where the
contribution (R2) for each successive component is 12.3%, 8.1%, 6.7%, 3.8%, and 3.4%.
The overall cross validation (Q2) is 10.1%, 6.8%, 6.0, 1.6%, and 2.3%, respectively.
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Alternatively, the separation along PC2 axis may reflect the variability in
nutrients available to the cells. Glucose is still present after 2 hours of bacterial growth,
but is being depleted while acetate is being accumulated. After 6 hours of growth, the
depletion of acetate is dependent on TCA cycle activity, resulting in the largest separation
along PC2 between the 6 hour aconitase mutant and the 2 hour wild-type samples. These
two samples correspond to the largest expected variation in glucose and acetate
concentrations. From the detailed 2D NMR analysis (please see below), acetate is
approximately twice as concentrated in the 6 hour wild-type sample compared to the 2
hour aconitase mutant. The glucose concentration is effectively reversed. Glucose is
twice as concentrated in the 2 hour aconitase mutant compared to the 6 hour wild type
sample.
The PCA results were used to guide a subsequent analysis using OPLS-DA
(Figure 5.2c). The OPLS-DA yielded a reliable model (R2X 0.788, R2Y 0.992, Q2 0.992).
The R2 and Q2 values represent the goodness of fit and predictability of the model,
respectively. The OPLS-DA scores plot is similar to the PCA scores plot, except for the
limited separation between the 2 hour wild-type and aconitase mutant clusters. Again,
this is consistent with the minimal TCA activity expected for the 2 hour wild-type and
aconitase mutant. Also, OPLS-DA emphasizes the difference between the control group
(6 hour wild-type) and the treated classes, while minimizing contributions from within
group variations. Thus, OPLS-DA generates significantly tighter clusters than PCA.
More importantly, the S-plot (Figure 5.4) generated from the OPLS-DA provides
unambiguous identification of the major contributors to the class separation (i.e., 1H
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NMR bins and associated metabolites). Specifically, comparing the 6 hour aconitase
mutant and the 6 hour wild-type samples, which had the largest separation along PC1 in
the PCA 2D scores plot, identified citrate, isocitrate, and other TCA related metabolites.
Similarly, comparing the 2 hour aconitase mutant and the 2 hour wild-type samples,
which had the largest separation along PC2 in the PCA 2D scores plot, identified glucose,
acetate and other nutrients required for cell growth. These results provide strong support
for our subjective analysis of the trends in the 2D PCA scores plot and demonstrate that
not only does PCA and OPLS-DA differentiate between metabolic profiles, but they also
provide information about specific enzymatic activity and environmental conditions.
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Figure 5.4 a) OPLS-DA S-plots comparing the S. epidermidis 1457 and aconitase mutant
strain 1457-acnA::tetM where both cell cultures were grown for 6 hours. The two cell
cultures were shown be separated along the PC1 axis in Figure 5.2a. Each point in the Splot represents a specific bin containing a chemical shift range of 0.025 ppm, where the
points at the extreme ends of the S-plot are the major contributors to the class distinction.
Each point was identified to a specific metabolite using the Human Metabolomics
Database and Madison Metabolomics Database. All the identified metabolites are
associated with TCA cycle inactivation. b) OPLS-DA S-plot comparing the mutant strain
1457-acnA::tetM grown for 2 hours and 6 hours. The two conditions are shown to be
separated along the PC2 axis in Figure 5.2a. The metabolites identified are associated
with variations in the utilization of glucose for cell growth. c) OPLS-DA loading plot
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comparing S. epidermidis 1457 and aconitase mutant strain 1457-acnA::tetM where both
cell cultures were grown for 6 hours. Negative values indicate a decrease in peak
intensity when comparing the wild type to the mutant, while positive values indicate an
increase in peak intensity. These results are comparable to the bar graphs depicted in
Figure 5.10 from the analysis of 2D NMR data. d) OPLS-DA loading plot comparing the
mutant strain 1457-acnA::tetM grown for 2 hours and 6 hours.

5.3.3 Impact of environmental stress conditions on the S. epidermidis metabolome
Numerous genes and protein complexes are involved in the transformation of
planktonic cells to a biofilm.58 This process requires that S. epidermidis “sense” changes
in its environment and the availability of nutrients, such as changes in temperature, O2
levels, osmorality, ethanol, glucose and iron.29,31,33,59-63 It is reasonable to expect that
different external factors would trigger distinct signaling pathways and mechanisms of
biofilm regulation. Correspondingly, different biofilm formation pathways would
presumably induce dissimilar metabolomic profiles. Alternatively, a versatile regulation
system responsive to disparate signals would be significantly more efficient. A metabolic
signaling pathway is one potential mechanism of rapidly responding to changing
environmental stress conditions. Conceptually, the environmental flux of essential
nutrients and metabolites would direct the up- or down- regulation of specific metabolic
pathways in response to concentration changes (Le Chatelier’s principle) to initially
reestablish equilibrium without affecting protein activity. Effectively, a limited or
abundant metabolite would direct the metabolic flow through a specific pathway causing
a cascade affect due to the high interrelationship of the metabolome. Eventually, gene
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and protein regulation processes would respond to the perturbed metabolic activity
leading to the up- or down- regulation of specific genes and proteins.
We have previously demonstrated that both Fe limitation and 4% ethanol decrease
TCA cycle activity.23 These environmental stress factors are known to induce S.
epidermidis biofilm formation.24,30-32 We have also demonstrated that Fe limitation and
4% ethanol had a similar impact on the S. epidermidis metabolome and altered the
activity of CcpA, a metabolite-responsive regulator. An important role for the TCA cycle
in a staphylococcal biofilm metabolic signaling pathway seems apparent, especially since
the TCA cycle is a central metabolic pathway that interacts with numerous other
pathways (Figure 5.1). Thus, we proposed that the TCA cycle senses environmental
stressors and transduces this signal through the metabolome to activate or repress the
activity of metabolite-responsive regulators, which, in turn, modulates PIA production,
virulence factor synthesis, and biofilm formation.23 To further support our hypothesis that
the TCA cycle senses disparate environmental signals to regulate PIA synthesis and
biofilm formation, we analyzed changes in the S. epidermidis metabolome caused by
additional environmental stress factors also known to induce an S. epidermidis biofilm.26
28,33,64

S. epidermidis cultures were treated with 5% NaCl, 2% glucose, 0.06 µg/mL
tetracycline, and 400 nM of autoinducer-2 (AI-2, furanosyl borate diester). Glucose and
NaCl were reported to induce biofilm formation by the regulation of the rbf gene,65 which
has been shown to be a regulator of icaR,66 a negative regulator of the icaADBC operon
that is required for PIA synthesis and biofilm formation.67 Subinhibitory concentrations
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of antibiotics enhance icaADBC gene expression28,68 by potentially inhibiting TcaR, a
weak negative regulator of icaADBC gene expression.69 AI-2 is an intercellular signaling
molecule that has a modest effect on staphylococcal biofilms.64 Conversely, if these
additional environmental stress factors impact the S. epidermidis metabolome in a
manner similar to Fe limitation and 4% ethanol, which is also correlated with TCA cycle
inactivation, then these results would further support the hypothesis that the TCA cycle
acts as a signal transducer as a part of a metabolic signaling network.
The PCA 2D scores plot (Figure 5.5a) and the associated metabolic tree (Figure
5.5c) indicates that S. epidermidis wild-type cultures grown with the addition of the
environmental stressors 4% ethanol, 0.06 µg/mL tetracycline or iron-limitation exhibited
essentially identical metabolomes as the aconitase mutant. Both the aconitase mutant and
wild-type cultures under these stress conditions formed a large cluster distinct from the
cluster of wild-type cells in standard growth media. These results further support our
hypothesis that environmental stress factors influence biofilm formation by inactivating
the TCA cycle and re-directing key metabolites into PIA synthesis. Conversely, growing
S. epidermidis wild-type cells in the presence of 5% NaCl showed no significant effect on
the metabolome since the wild-type cells in the presence and absence of 5% NaCl cluster
together. Similarly, AI-2 did not affect the S. epidermidis metabolome since both the
wild-type and aconitase mutant cells in the presence and absence of 400 nM AI-2 cluster
together (Figure 5.12). Interestingly, S. epidermidis cells treated with 2% glucose were
separated from both the wild-type and aconitase mutant clusters, implying a different
impact on the metabolome and a unique mechanism of regulating biofilm formation.
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Alternatively, the addition of 2% glucose may be viewed as an intermediary effect, where
the metabolome of the S. epidermidis cells grown with 2% glucose is moving toward the
aconitase mutant cells. Effectively, the amount of glucose added to the bacterial culture
was insufficient to completely inactivate the TCA cycle. It has been previously shown
that different strains have different glucose uptake rates and different sensitivities to
glucose-induced biofilm formation.70,71

211

Figure 5.5 (a) 2D PCA scores plot and (b) 2D OPLS-DA comparing wild-type S.
epidermidis 1457 cells grown 6 h in standard TSB media (black ●), with S. epidermidis
1457 cells grown 6 h in iron-depleted media (DTSB) (red ●), with the addition of 4%
ethanol (green ●),with the addition of 2% glucose (blue ●), with the addition of 0.06
μg/mL tetracycline (pink ●), with the addition of 5% NaCl (orange ●), and 6 h growth of
aconitase mutant strain 1457-acnA::tetM in standard TSB media (black ▲). The ellipses
correspond to the 95% confidence limits from a normal distribution for each cluster. For
the OPLS-DA scores plot, the 6 h growth of wild-type S. epidermidis 1457 (black ●) was
designated the control class and the remainder of the cells were designated as treated. The
OPLS-DA used 1 predictive component and 4 orthogonal components to yield a R2X of
0.637, R2Y of 0.966 and Q2 of 0.941. Metabolomic tree diagram generated from the (c)
2D PCA scores plot depicted in (a) and (d) 2D OPLS-DA scores plot depicted in (b). The
label colors match the symbol colors from the 2D scores plot. Each node is labeled with
the boot-strap number, where a value above 50 indicates a statistically significant
separation.
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The PCA results were used to guide a subsequent analysis using OPLS-DA
(Figure 5.5b) and the corresponding metabolomics tree diagram (Figure 5.5d). The
OPLS-DA analysis yielded a reliable model (R2X 0.637, R2Y 0.966, Q2 0.941), and
results identical to PCA. The wild-type cells in the presence and absence of 5% NaCl
were defined as the controls and, as expected, formed a single cluster in the 2D scores
plot. S. epidermidis wild-type cultures grown with the addition of the environmental
stressors 4% ethanol, 0.06 µg/mL tetracycline or iron-limitation again formed a single
cluster with the aconitase mutant in the 2D OPLS-DA scores plot. Also similar to the
PCA results, the S. epidermidis cells grown with 2% glucose formed a unique cluster.
Thus, the corresponding metabolomics tree diagram identified three distinct clusters with
bootstrap values of 100. The OPLS-DA results further support our hypothesis that
environmental stress factors influence biofilm formation by inactivating the TCA cycle
and re-directing key metabolites into PIA synthesis.
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Figure 5.6 a) OPLS-DA S-plots comparing wild-type S. epidermidis 1457 and S.
epidermidis cultured under the different stress conditions described in Figure 5.5. b)
OPLS-DA loading plot showing the contribution of the identified metabolites from the Splot. These results are comparable to the bar graphs depicted in Figure 5.10 from the
analysis of 2D NMR data.

To verify the observed effect on the S. epidermidis metabolome is due to
inactivating the TCA cycle as opposed to other potential factors, the S. epidermidis
aconitase mutant strain was also grown with the addition of 4% ethanol, 0.06 µg/mL
tetracycline, 2% glucose, 5% NaCl or under iron-limitation conditions. If the impact of
these stress conditions is primarily through the inactivation of the TCA cycle, then the
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metabolome of the aconitase mutant strain should be unperturbed. Otherwise, if the stress
conditions induce additional or alternative responses, then changes in the metabolome
should be observed. The 2D PCA scores plot (Figure 5.7a) and metabolomic tree (Figure
5.7c) indicate the stress conditions did not affect the metabolome of the aconitase mutant.
The aconitase mutant with and without the stress conditions forms a large cluster distinct
from the wild-type cluster. Importantly, this includes the addition of 2% glucose. This
implies the addition of 2% glucose to wild-type S. epidermidis resulted in an incomplete
inactivation of the TCA cycle instead of a novel mechanism of biofilm regulation. Again,
the PCA results were used to guide a subsequent analysis using OPLS-DA (Figure 5.7b)
and the corresponding metabolomics tree diagram (Figure 5.7d). The OPLS-DA analysis
yielded an acceptable model (R2X 0.488, R2Y 0.976, Q2 0.961), and results very similar
to PCA. The lower R2X is consistent with the larger spread observed within the two
primary clusters. The wild-type cells were defined as the controls and, as expected, the
aconitase mutant with and without the stress conditions formed a single large cluster.
Consistent with the PCA analysis, the single cluster also contained the addition of 2%
glucose. The OPLS-DA scores plot, along with the metabolomics tree diagram, suggests
sub-clusters are present within the large aconitase mutant cluster. But, the aconitase
mutant data is spread throughout this cluster, such that an ellipse that corresponds to the
95% confidence limit for the aconitase mutant data encompasses the two other apparent
sub-clusters. This result indicates that within the resolution of the PCA and OPLS-DA
model, no statistical difference is observed between the metabolomes of the aconitase
mutant with and without the stress conditions. Critically, the S-plot obtained from the
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comparison between the wild-type cells and the aconitase mutant treated with the stress
conditions was identical to the S-plot generated from the comparison between the wildtype cells and the untreated aconitase mutant cells. Again, this supports the conclusion
that the addition of the stressors did not perturb the metabolome of the aconitase mutant
cells.

Figure 5.7 (a) 2D PCA scores plot and (b) 2D OPLS-DA comparing wild-type S.
epidermidis 1457 cells grown 6 h in standard TSB media (black ●), 6 h growth of
aconitase mutant strain 1457-acnA::tetM in standard TSB media (black ▲), aconitase
mutant strain 1457-acnA::tetM in iron-depleted media (DTSB) (red ▲), with the addition
of 4% ethanol (green ▲), with the addition of 2% glucose (blue ▲), with the addition of
0.06 μg/mL tetracycline (pink ▲), and with the addition of 5% NaCl (orange ▲). The
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ellipses correspond to the 95% confidence limits from a normal distribution for each
cluster. The four ellipses correspond to clusters formed by (i) wild-type S. epidermidis
1457 cells, (ii) aconitase mutant strain 1457-acnA::tetM in standard TSB media, (iii)
aconitase mutant strain 1457-acnA::tetM in DTSB or with the addition of 4% ethanol,
and (iv), aconitase mutant strain 1457-acnA::tetM with the addition of 2% glucose, 0.06
μg/mL tetracycline, or 5% NaCl. For the OPLS-DA scores plot, the 6 h growth of wildtype S. epidermidis 1457 (black ●) was designated the control class and the remainder of
the cells were designated as treated. The OPLS-DA used 1 predictive component and 2
orthogonal components to yield a R2X of 0.488, R2Y of 0.976 and Q2 of 0.961.
Metabolomic tree diagram generated from the (c) 2D PCA scores plot depicted in (a) and
(d) 2D OPLS-DA scores plot depicted in (b). The label colors match the symbol colors
from the 2D scores plot. Each node is labeled with the boot-strap number, where a value
above 50 indicates a statistically significant separation.
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Figure 5.8 a) OPLS-DA S-plots comparing the S.epidermidis 1457 and the aconitase
mutant 1457-acnA::tetM under the different stress conditions described in Figure 5.7b. b)
OPLS-DA loading plot showing the contribution of the identified metabolites from the Splot. These results are comparable to the bar graphs depicted in Figure 5.10 from the
analysis of 2D NMR data.

5.3.4 Detailed analysis of changes to the S. epidermidis metabolome caused by
environmental stress
An overall correlation between the metabolomes of S. epidermidis under stress
and TCA cycle inactivation provides further support for our hypothesis that
environmental conditions induce biofilm formation though the regulation of the TCA
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cycle.23 Specifically, the disparate signals of 2% glucose, 4% ethanol, 0.06 µg/mL
tetracycline and iron-limitation are all sensed by the TCA cycle. To further support our
hypothesis, a detailed analysis of changes to the S. epidermidis metabolome caused by
these environmental stress factors was necessary. We previously reported an analysis of
changes in the metabolome of S. epidermidis caused by TCA cycle inactivation that
resulted in an increase in PIA production.16 Among other observed changes, amino-acids
derived from TCA cycle intermediates (Asn, Asp, Gln, and Glu) exhibited a decrease in
concentration. Correspondingly, an increase in concentrations was observed for the PIA
biosynthetic precursors UDP-N-acetyl-glucosamine and fructose-6-phosphate. A similar
approach using 2D 1H, 13C HSQC and 2D 1H, 1H TOCSY NMR spectra was applied to
quantitate metabolite changes in the S. epidermidis metabolome caused by Fe-limitation
and 4% ethanol (Figure 5.9).23

219

220
Figure 5.9 Overlay of (a) 2D 1H, 13C HSQC spectra and (b) 2D 1H, 1H TOCSY spectra
comparing wild-type S. epidermidis strain 1457 (red) and aconitase mutant strain 1457acnA::tetM (black) grown for 6 h in standard TSB media augmented with 0.25% 13Cglucose. NMR resonances corresponding to specific metabolites are labeled, where citrate
is circled.

2D NMR spectra improve metabolite identification by reducing the complexity
and congestion of 1D 1H NMR spectrum by spreading the information into twodimensions. Additionally, the 2D 1H, 13C HSQC experiment allows for monitoring the
flow of carbon-13 through the metabolome from a specifically 13C-labeled metabolite.
Alternatively, the 2D 1H, 1H TOCSY spectrum monitors all detectable metabolites with a
bias to metabolites with the highest concentration. This may include the carbon-13
labeled metabolites observed in the 2D 1H, 13C HSQC spectrum in addition to nonisotope labeled metabolites produced from other carbon sources. Therefore, the 2D 1H,
13

C HSQC and 2D 1H, 1H TOCSY NMR spectra are complementary experiments for

metabolomics and allow for a more complete analysis of metabolite concentration
changes. Specifically, S. epidermidis wild-type cells and the aconitase mutant cells were
grown with and without stress factors and harvested during either the exponential or postexponential phase with and without the addition of 13C-glucose. A total of 12 different
bacterial culture conditions were prepared in triplicate for both the 2D 1H, 13C HSQC and
2D 1H, 1H TOCSY NMR experiments for a minimum of 72 bacterial cultures or NMR
experiments. To maintain consistency, S. epidermidis wild-type cells were used as a
reference and prepared with each bacterial culture set.
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Differences in metabolite concentrations between the stresses, the bacterial
growth phases, the aconitase mutant cells, and the wild-type cells was based strictly on
detecting changes in peak intensities in the 2D 1H, 13C HSQC and 2D 1H, 1H TOCSY
NMR experiments. To minimize contributions from experimental variability, three levels
of normalization were used. First, metabolite concentrations were normalized based on
the total number of cells grown for each culture. Second, the peak intensities in each
NMR spectrum were normalized by the spectrum’s average peak intensity. Third, each
individual peak was normalized by scaling by the largest intensity observed for that peak
across the set of NMR spectra. The intensity of peaks assigned to each metabolite within
a spectrum were averaged and then averaged across the triplicate NMR data set. Relative
changes in peak intensities (metabolite concentrations) were compared to the S.
epidermidis wild type metabolome and are displayed as bar graphs in Figure 5.10.
Importantly, the metabolites identified from the 2D NMR experiments were also
consistent with the metabolites identified as the major contributors to class distinction in
the 2D OPLS-DA plots (Figures 3, 4). The OPLS-DA S-plots (Figure 5.8) identifies the
relative contribution of each bin (1H NMR chemical shift) to the clustering in the
corresponding 2D scores plot. Each NMR bin with a high reliability (p(corr)[1] ~ 1 or -1)
and a high magnitude (p[1] > 0.1 or < -0.1) was assigned to a metabolite that was also
found to be present in the Figure 5.10 bar graph.
An inactivated TCA cycle caused concentration changes for 55 metabolites
involved in the amino sugar pathway, glycolytic pathway, several amino acid pathways,
and the TCA cycle. The NMR data shows the amount of cellular glucose in the 6 hour
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post-exponential wild-type strain was reduced by 80% compared to the 2 hour
exponential phase. The amount of cellular acetate was increased by 25%. As expected,
the inactivation of the TCA cycle in the aconitase mutant resulted in the accumulation of
a large concentration of acetate. Acetate was the most intense peak in the 6 hour cultures
for the wild-type and aconitase mutant strains shown in Figure 5.9. There were also
noticeable differences in the aconitase mutant metabolome. Peaks corresponding to the
amino acids derived from the TCA cycle intermediates such as Asn, Asp, Gln, and Glu
were not present. Not surprisingly, a large amount of citrate was also seen, since the
inactivated aconitase prevents the conversion of citrate to isocitrate. Other metabolites
associated with the glycolytic pathway were up-regulated. Similarly, some amino sugar
and aromatic metabolites were up-regulated except for the significant down-regulation of
UDP-glucuronate.
As expected from the clustering pattern in the 2D PCA scores plot, the direction
of carbon flow in cells under stress were similar to the aconitase mutant cells, but
dramatically different from wild-type cells during post exponential growth. A decrease in
the concentration of amino acids derived from TCA cycle intermediates such as Asp,
Asn, Glu, and Gln shows that the TCA cycle is still repressed when the cells are under
stress. Instead the carbon flow is redirected back into the glycolytic pathway as indicated
by an increase in concentrations for phosphoenolpyruvate (PEP), acetaldehyde, and
fructose 6-phosphate. The carbon flow was also directed into the amino sugar pathway
with an increase in concentrations for UDP-N-acetylglucosamine, N-acetyl-neuraminate,
and N-acetyl-D-mannosamine. UDP-N-acetylglucosamine is an important precursor to
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PIA formation. Again, the detailed analysis of changes in the metabolome of S.
epidermidis provides additional support for the role of TCA cycle activity in a metabolic
signaling pathway that transduces disparate external stimuli into internal metabolic
signals that facilitate biofilm formation. Effectively, the observed changes in the
metabolome caused by disparate external stimuli are consistently suppressing TCA cycle
activity and inducing PIA synthesis required for biofilms.
Conversely, the change of the carbon flow in the 2 hour growth is minimal.
Again, this is consistent with the low TCA activity and the similar clustering in the 2D
PCA scores plot between the aconitase mutant and wild-type 2 hour growth (Figure
5.2b). Obviously, stress factors cannot suppress an already inactive TCA cycle. Instead,
the catabolic conversion of glucose into intermediates throughout the glycolytic pathway
proceeds as expected with a slight change since pyruvate is also produced. Much of the
carbon-13 from glucose was still directed to the production of acetate. The NMR data
indicates cellular acetate concentrations were similar across the 2 hour bacterial cultures,
but an increased amount of acetyl-phosphate was accumulated under stress conditions.
This confirms that when an abundant amount of glucose is present, it is processed by
glycolysis and pyruvate dehydrogenase into acetyl-CoA and converted into acetylphosphate for use in substrate level phosphorylation. The excretion of acetate into the
culture medium helps pH homeostasis due to the large flux of acetate.72 Aside from the
glycolytic pathway, the NMR data indicates that wild-type bacteria tend to utilize glucose
more efficiency based on small decreases in amino sugar and aromatic metabolites.
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Figure 5.10 Bar graphs showing the percent change in metabolite concentrations relative
to wild-type S. epidermidis strain 1457 grown in standard TSB media. Metabolite
concentration changes were measured after 2 and 6 h bacterial growths for the aconitase
mutant strain 1457-acnA::tetM in TSB media (light yellow), aconitase mutant strain
1457-acnA::tetM with iron-depletion (dark yellow), aconitase mutant strain 1457acnA::tetM with the addition of 4% ethanol (orange), wild-type S. epidermidis strain
1457 with iron-depletion (dark purple), and wild-type S. epidermidis strain 1457 with the
addition of 4% ethanol (light purple). Positive values represent increased concentrations
while negative values represent decreased concentrations with respect to S. epidermidis
strain 1457 grown in standard TSB media. The metabolite names were abbreviated as
follows: ACA (Acetaldehyde), ACE (Acetate), ACP (Acetyl-P), AKG (α-ketoglutarate),
ALAAc (Acetyl-alanine), AMI (4-Aminobutanoate), ARG (Arginine), ASN
(Asparagine), ASP (Aspartate), CIR (Citrulline), CIT (Citrate), ETH (Ethanol), F6P
(Fruc-6P), G1P (Gluc-1P), G6P (Gluc-6P), GAL (Galacturonic-acid), GAL1P (α-d-Gala1P), GLN (Glutamine), GLR (Glucuronate), GLS (d-glucosamine), GLS6P
(Glucosamine-6P), GLSAc (N-Ac-d-glucosamine), GLSAc6P (Acetyl-glucosamine-6P),
GLU (Glutamate), GLUAc (Acetyl-glutamate), GLY (Glyceraldehyde), HIS (Histidine),
ICI (Isocitrate), INO (Ino, Ade, Xan), LAC (Lactate), ALA (alanine), LEU (Leucine),
LYS (Lysine), MANAc (N-acetyl-d-mannosamine), MET (Methionine), MIN (myo
inositol), MSE (selenomethionine), NEUAc (N-Ac-neuraminate), ORN (Ornithine),
ORNAc (Acetyl-ornithine), PEP (Phosphoenolpyruvic acid), PRO (Proline), RIB (dribose), SAM (S-adenosyl-methionine), SER (Homoserine), SUCSER (O-Succinyl-lhomoserine), UDPGLR (UDP-glucoronate), UDPGLSAc (UDP-NAc-d-glucosamine),
VAL (Valine).
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5.3.5 Metabolic rearrangements during TCA cycle stress
The metabolome of S. epidermidis is not a series of independent isolated
metabolic pathways, but instead is a complex inter-connected network. Thus, metabolic
pathways connected to the TCA cycle are also affected by changes in TCA cycle activity.
In order to visualize the cascade effect of inactivating the TCA cycle, a metabolic
network was constructed using Cytoscape.40 The metabolic network (Figure 5.11) was
generated by manually associating each metabolite to its corresponding pathway from the
KEGG54 database and then using the automated biological network modules integrated
into Cytoscape.73,74 The network connects the 37 metabolites identified by NMR whose
concentrations are either increased (red) or decreased (green) by an inactivated TCA
cycle. Only metabolites affected by a minimally active TCA cycle under all
circumstances (aconitase mutant and stress factors) are highlighted on the network map.
It is important to note that NMR is not able to identify every metabolite affected by
perturbing the metabolome. The concentrations or stabilities of some metabolites are
simply below the NMR detection limit. These intervening and undetected metabolites are
colored grey in the metabolic network. The network shows the TCA cycle as the central
pathway where common metabolites connect the urea cycle, alanine metabolism, and
glycolysis/gluconeogenesis that then leads to amino sugar metabolism and other
metabolites associated with PIA synthesis.
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Figure 5.11 Cytoscape network depicting the metabolite concentration changes caused
by the inactivation of the TCA cycle. Nodes colored red correspond to metabolites with
an increase in concentration due to TCA inactivation. Nodes colored green correspond to
metabolites with a decrease in concentration due to TCA inactivation. Nodes colored
gray correspond to metabolites that are not observed in the NMR spectra, do not have a
reference NMR spectrum (or assignment), or did not exhibit a significant concentration
change. Metabolic pathways are labelled on the network. The metabolite names were
abbreviated as described in the legend to Figure 5.10.
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5.4 Conclusion
The systematic analysis of the S. epidermidis metabolome using NMR provides
further evidence for a metabolic signaling network for biofilm formation that involves the
TCA cycle. Inactivation of the TCA cycle enables metabolic precursors to flow into
pathways associated with PIA synthesis, an important component of S. epidermidis
biofilm formation. Disparate environmental stress conditions known to induce biofilm
formation were shown to perturb the metabolome of S. epidermidis in a manner similar to
an aconitase mutant. Effectively, iron-depletion, and the addition of ethanol, tetracycline,
and glucose resulted in the inactivation of the TCA cycle. Furthermore, a detailed
analysis of the specific changes to the S. epidermidis metabolome indicates that
essentially the same set of metabolites affected by TCA cycle inactivation are also
affected by environmental stress conditions. A network map identified the TCA cycle as
playing a central role in the proposed signaling pathway that also involves the urea cycle,
alanine metabolism, glycolysis/gluconeogenesis, amino sugar metabolism and other
metabolites associated with PIA synthesis. Interestingly, the addition of NaCl or
autoinducer-2 did not induce any effect on the S. epidermidis metabolome or effect TCA
cycle activity. Suggesting these factors must act through a distinct process from the other
environmental factors.
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APPENDIX A: EFFECT OF AUTOINDUCER-2 (AI-2) ON THE S. EPIDERMIDIS
METABOLOME
Autoinducer 2 (AI-2) is believed to be an intercellular signaling molecule used in
quorum sensing by both gram-negative and gram-positive bacteria.64 AI-2 minimally
represses biofilm formation in S. epidermidis where it has been reported that AI-2
indirectly effects the transcription of metabolic genes.75 This raises the possibility that
AI-2 may also function by affecting TCA cycle activity. To investigate the impact of AI2 on the TCA cycle, bacterial cultures of wild-type S. epidermidis and the corresponding
aconitase mutant strain were treated with AI-2. Zhao et al.34 recently demonstrated that S.
aureus cultures supplemented with 390 nM of 4,5-dihydroxy-2,3-pentanedione (DPD),
the AI-2 precursor molecule, restored a luxS deletion mutant. Thus, 400 nM of AI-2 was
used for our NMR metabolomics studies since this concentration of AI-2 was identified
as physiologically relevant. The 2D PCA and 2D OPLS-DA scores plots comparing AI-2
treated and untreated bacterial cultures indicates AI-2 did not change the typical
clustering pattern (Figure 5.12). In other words, the NMR metabolomics data suggests
AI-2 does not affect TCA activity or cause a corresponding perturbation in the S.
epidermidis metabolome. This observation is in contrast to the data reported by Li et al.,
where AI-2 was shown to effect the transcription of numerous metabolic genes.75 The
apparent discrepancy highlights the benefits of NMR metabolomics, where changes in the
metabolome reflect actual changes in protein activity. Conversely, a change in a
transcriptional profile does not necessarily correlate with a difference in protein
activity.76
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Figure 5.12 2D PCA scores plot comparing wild-type S. epidermidis strain 1457 and
aconitase mutant strain 1457-acnA::tetM with and without the addition of 400 nM of AI2. Cells were grown for 2 h or 6 h in standard TSB media, 2 h growth of wild-type S.
epidermidis strain 1457 with AI-2 ( ) and without AI-2 ( ); aconitase mutant strain
1457-acnA::tetM with AI-2 ( ) and without AI-2 ( ); 6 h growth of wild-type S.
epidermidis strain 1457 with AI-2 ( ) and without AI-2. ( ); and aconitase mutant strain
1457-acnA::tetM with AI-2 ( ) and without AI-2 ( ). b) Metabolomic tree diagram
generated from the 2D PCA scores plot depicted in (a). The label colors match the
symbol colors from the 2D PCA scores plot. Each node is labeled with the boot-strap
number, where a value above 50 indicates a statistically significant separation. c) 2D
OPLS-DA scores plot comparing wild-type S. epidermidis strain 1457 and aconitase
mutant strain 1457-acnA::tetM with and without the addition of 400 nM of AI-2. Each
pair of cell cultures treated with and without AI-2 were defined as a separate class for a
total of four separate classes. The model consists of 1 predictive component and 3
orthogonal components that yielded an R2X of 0.774, R2Y of 0.970, and a Q2 of 0.954
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CHAPTER 6
USING NMR METABOLOMICS TO INVESTIGATE TRICARBOXYLIC ACID
CYCLE DEPENDENT SIGNAL TRANSDUCTION IN STAPHYLOCOCCUS
EPIDERMIDIS
6.1 Introduction
Staphylococcus epidermidis is a skin-resident, opportunistic pathogen that is the
leading cause of hospital-associated infections.1 Although the type and severity of
diseases produced by this bacterium varies, its most common infectious manifestation is
associated with implanted biomaterials. The dramatic environmental changes that occur
during the transition from being skin-resident to residing on implanted biomaterials
necessitates the need for changes in the expression of genes coding for enzymes required
for growth in the new environment. This environmental adaptation often includes
activating transcription of virulence genes; hence, most virulence genes are regulated by
environmental and nutritional signals.2 Accordingly, a major area of interest in
microbiology is determining how bacteria “sense” and respond to environmental signals.
Given the tremendous diversity of microbial life it is not surprising that the mechanisms
bacteria employ are equally diverse. These mechanisms include two-component
regulatory systems, alternative sigma factors, mechanosensors, small RNAs,
riboswitches, and many others. Although remarkable advances have been made in
identifying the response regulators, our knowledge of signaling mechanisms has lagged
behind; the exception being cell-density signaling.
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The tricarboxylic acid (TCA) cycle has been implicated as regulating or affecting
staphylococcal virulence and/or virulence determinant biosynthesis.3-9 The TCA cycle
has three primary functions: i.) provide biosynthetic intermediates, ii.) generate reducing
potential, and iii.) directly produce a small amount of ATP. The availability of
biosynthetic intermediates affects the availability of amino acids and nucleic acids.
Increasing the reducing potential alters the bacterial redox balance, necessitating
oxidation reactions via the electron transfer chain. The small amount of ATP produced
directly by the TCA cycle is amplified many times when the ATP generated by oxidative
phosphorylation is considered. In short, the TCA cycle has a central function in
maintaining the bacterial metabolic status. Importantly, the activity of TCA cycle
enzymes is affected by the availability of nutrients and a variety of stress-inducing
stimuli;9-12 thus, the availability of biosynthetic intermediates, the redox status, and the
energy status can be altered by nutritional and environmental stimuli. These observations
led us to propose a fourth function for the TCA cycle, the transduction of external signals
into intracellular metabolic signals that can be “sensed” by metabolite-responsive
regulatory proteins.2 Fundamental to this hypothesis are the predictions that disparate
environmental stimuli will cause common metabolic changes and that these metabolic
changes will precede regulatory changes.
Two of the more extensively studied environmental stimuli that influence S.
epidermidis virulence determinant biosynthesis are iron-limitation13,14 and ethanol
stress.15,16 The effect of iron-limitation on bacterial growth is primarily through
preventing the activity of enzymes that require iron as a cofactor and altering
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transcription of iron-regulated genes.2 As S. epidermidis has many iron-requiring
enzymes (e.g., aconitase, serine dehydratase, peptide deformylase, iron-containing
alcohol dehydrogenase, nitrate reductase, etc.), it is reasonable to expect that the
metabolic effects of iron-limited growth are diverse and not restricted to the TCA cycle.
Ethanol denatures proteins in the cytoplasmic membrane causing changes in membrane
permeability, which can lead to the loss of membrane integrity.17 With the exception of
the succinate dehydrogenase complex, most TCA cycle enzymes are not membrane
associated; hence, it is reasonable to predict that the deleterious effects of ethanol stress
are largely independent of the TCA cycle. Taken together, these observations suggest that
disparate environmental conditions will cause divergent metabolomic changes. In
contrast to this suggestion, our central hypothesis predicts that different stresses will
cause common metabolomic changes that are dependent on the TCA cycle. To test our
central hypothesis, we chose to induce environmental stress by growing bacteria in an
iron-limited medium or in a medium containing ethanol and assessing the metabolic
changes using NMR metabolomics.

6.2 Methods and Materials
6.2.1 Bacterial strains, media, and growth conditions
S. epidermidis wild-type strain 145718 and the isogenic aconitase mutant strain
1457-acnA::tetM (tetM cassette inserted into position 856 of the 2,702-bp acnA gene) and
σB mutant strain 1457-sigB::dhfr 7,19 have been described. Strains 1457-codY, 1457-ccpA,
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1457-acnA-codY, and 1457-acnA-ccpA were constructed using the gene splicing by
overlap extension (gene SOEing) technique20 to replace the gene of interest with an
antibiotic resistance marker (i.e., ermB or tetM). Primers were designed to amplify
approximately 1 kb regions upstream and downstream of the gene of interest based on the
genome sequence of S. epidermidis strain RP62A. Gene knockouts were confirmed by
PCR and Southern blot hybridization. In addition, strains containing mutations in the
single S. epidermidis aconitase gene were assayed to ensure that no aconitase activity was
detected (data not shown). All strains were grown in tryptic soy broth without dextrose
(TSB; BD Biosciences) supplemented with 0.25% glucose (Sigma Chemical) or 0.25%
13

C6-glucose (Cambridge Isotope Laboratories). Defferated TSB (DTSB) was prepared

by adding 50 g of Chelex 100 (Sigma Chemical) to approximately 1 L of TSB and
stirring at 4°C for 20 h. After 20 h, the Chelex resin was removed, 1 mM MgSO4 was
added, the volume was adjusted to 1 L, and the medium was filter sterilized. To induce
ethanol stress and minimize growth defects, ethanol or deuterated ethanol (Isotec) was
added to the medium at a final concentration of 4% (v/v). All cultures were inoculated
1:200 from overnight cultures (normalized for growth) into glucose supplemented TSB,
incubated at 37°C, and aerated at 225 rpm with a flask-to-medium ratio of 7:1. Bacterial
growth was assessed by measuring the optical density at 600 nm (OD600). Antibiotics,
when used, were purchased from Fisher Scientific or Sigma Chemical and used at the
following concentrations: chloramphenicol (8 μg/mL), trimethoprim (10 g/mL), and
erythromycin (8 μg/mL).
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6.2.2 Aconitase activity assay
Cell-free lysates of S. epidermidis were prepared as follows. Aliquots (3 mL)
were harvested by centrifugation (1 min at 20,800 x g) at the indicated times, suspended
in 1.5 mL of lysis buffer containing 90 mM Tris (pH 8.0) and 100 M fluorocitrate. The
samples were lysed in 2 mL screw cap tubes containing lysing matrix B using a FastPrep
instrument (MP Biomedical). The lysate was centrifuged for 5 min at 20,800 x g at 4ºC.
Aconitase activity in the resulting cell-free lysate was assayed by the method described
by Kennedy et al.21 One unit of aconitase activity is defined as the amount of enzyme
necessary to give a A240 min-1 of 0.0033.22 Protein concentrations were determined by the
Lowry method.23

6.2.3 Northern blot analysis
Northern blot analysis of transcripts was performed as described.7
Oligonucleotide primers used in making DNA probes were designed using the S.
epidermidis RP62A genome sequence. Probes for northern blotting were generated by
PCR amplification of unique internal regions of RNAIII and glnA (femC) genes using
primers:
femC- forward, 5’-GATGTTTGATGGTTCATCTATTGAAGGTTTCG-3’;
femC-reverse, 5’-GCAGTATCAGTCAATTGTAAATCACCTTCAG-3’;
RNAIII-forward, 5’-TGAAAAATTTGCTTAATCTAGTCGAGTG-3’;
RNAIII-reverse, 5’- CATGATAAATTGAATGTTGTTTACGATAGC-3’.
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DNA probes were labeled using the North2South random prime labeling kit
(Pierce). Electrophoresis, transfer of the RNA to the Nytran SPC nylon membrane
(Whatman), and hybridization were done using the NorthernMax Kit (Ambion).
Detection was performed using the Chemiluminescent Nucleic Acid Detection Module
(Pierce).

6.2.4 PIA immunoblot assay
PIA accumulation was determined as described.24

6.2.5 NMR sample preparation
NMR samples for one-dimensional (1D) 1H spectra were prepared from 10
independent, 25 mL S. epidermidis cultures. Two-dimensional (2D) 1H, 13C HSQC25,26
and 2D 1H, 1H TOCSY27 spectra were prepared from 3 independent 50 mL cultures. The
TSB medium used in the 2D 1H, 13C HSQC analysis contained 0.25% 13C6-glucose
(Cambridge Isotope Laboratories). For 2D 1H, 13C HSQC and 2D 1H, 1H TOCSY
involving ethanol stress, deuterated ethanol (Isotec) was used to minimize the
contribution of exogenous ethanol to the NMR spectra. For 1D 1H NMR experiments,
2.74 OD600 units were harvested at each time point and for the 2D 1H, 13C HSQC and 2D
1

H, 1H TOCSY experiments, 5.48 OD600 units were collected. Bacteria were harvested by

centrifugation (4000 rpm for 5 min), suspended in 50 mM phosphate buffer in 100% D2O
at pH 7.2 (uncorrected), and lysed using lysing matrix B tubes and a FastPrep instrument.
The lysates were centrifuged to remove cell debris and glass beads and then frozen in
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liquid nitrogen. All samples were kept at -80°C until ready for analysis. At the time of
use, a 600 L aliquot of the cell-free lysate was transferred to each NMR tube.

6.2.6 NMR Analysis
The NMR spectra were collected on a Bruker 500 MHz Avance spectrometer
equipped with a triple-resonance, Z-axis gradient cryoprobe. A BACS-120 sample
changer with Bruker Icon software was used to automate the NMR data collection. The
1D 1H NMR spectra collection and principal component analysis (PCA) were performed
as described with minor modifications.28-30 Briefly, each multidimensional NMR
spectrum (chemical shifts and peak intensities) was converted to a single point in a
multidimensional Cartesian space. Conceptually, each axis corresponds to a specific
chemical shift, where the peak intensity is the value along the axis. PCA identifies a


principal component vector ( P1 ) corresponding to the largest variation in the data set


within this multidimensional space. The second vector ( P2 ) is orthogonal to the first and
represents the next largest variation in the data set. Each successive vector describes a
diminishing amount of the data set’s variability, where most of the variability is described
by the first two principal components. The PC1 and PC2 scores (unitless values) are




effectively the individual fit of each NMR spectrum to P1 and P2 . The PC1 and PC2
scores are usually presented in a 2D plot, where similar NMR spectra cluster together.
Solvent presaturation used excitation sculpting to efficiently remove the solvent
and maintain a flat baseline, eliminating any need for baseline collection that may induce
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artifacts in the 2D scores plot.31 Each NMR spectrum was center averaged for PCA
analysis to minimize any experimental variations between cultures.32
2D 1H, 13C HSQC spectra were collected and processed as previously described.7
2D 1H, 1H TOCSY spectra were collected with watergate solvent presaturation,33 and a
relaxation delay of 2 seconds. A total of 1024 data points with a sweep width of 5000
Hz, and 256 data points with a sweep width of 5001.324 Hz were collected in the direct
and indirect 1H dimensions, respectively. A total of 16 dummy scans and 8 acquisition
scans were used to obtain each of the 2D 1H, 1H TOCSY NMR spectra. The 2D 1H, 1H
TOCSY NMR spectra were processed similar to the 2D 1H, 13C HSQC spectra and both
spectra were analyzed using NMRView34(One Moon Scientific) and Sparky (T. D.
Goddard and D. G. Kneller, SPARKY 3, University of California, San Francisco) to
identify chemical shifts and assign peak intensities.
The observed NMR peaks in the 2D 1H, 13C HSQC and 1H, 1H TOCSY spectra
were assigned to specific metabolites using 1H and 13C chemical shift tolerances of 0.05
ppm and 0.50 ppm, respectively, and the Madison Metabolomics Consortium Database
(MMCD),35 the BioMagResBank,36 and the Human Metabolome Database.37 The
presence of metabolites and metabolic pathways were verified with the KEGG38 and
Metacyc39 databases.
Peak intensities were normalized for each 2D NMR spectrum by dividing by the
average peak intensity. The triplicate data sets were then used to calculate average
intensities for each peak observed in the 2D spectra for strain 1457, 1457-acnA, ethanol
stress and iron-limitation. A percent error was calculated for each peak by dividing the
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standard deviation by the average peak intensity. The average peak intensities were then
used to calculate a percent difference relative to the wild-type bacteria in TSB medium.
Peaks with calculated percent differences greater than 5 times the average percent error
were considered to have either decreased or increased concentrations relative to the wildtype strain 1457. Peaks with less than a 5-fold deviation were considered similar.
Secondary peaks assigned to the same metabolite were required to have the same relative
change in intensity in order to be classified as a metabolite with an increase or decrease in
concentration.

6.2.7 Metabolomic dendrogram
The relative clustering patterns in the PCA 2D scores plots were quantitatively
analyzed using a tree diagram and bootstrapping technique.40 The PC1 and PC2 scores
for each set of 10 duplicate NMR spectra representing a specific metabolic state (ironlimitation, ethanol treatment, etc.) are used to calculate an average PC score and standard
deviation. Any PC score outside 2 standard deviations were removed and a new average
was calculated. The average PC scores represent the center of a cluster of NMR spectra
(metabolic state) in the 2D scores plot. The process is repeated for each set of 10
duplicate NMR spectra. Distances between the average PC positions for each metabolic
state are then calculated using the standard equation for a Euclidean distance to create a
distance matrix.
To assess the significance of the similarity (overlap) or difference (separation)
observed between pairs of clusters in the 2D scores plot, standard bootstrapping methods
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were also applied.41,42 Briefly, the average PC scores are recalculated by randomly
selecting points from the data set. Distances are recalculated between the clusters using
the new average PC scores to create a new distance matrix. The process is repeated until
100 different distance matrices are created and transferred to version 3.68 of the
PHYLIP43 suite of software programs (http://www.phylip.com). PHYLIP calculates a tree
for each distance matrix and then determines a consensus tree. The program calculates a
bootstrap value for each node, which is simply the number of times the node appears in
all 100 trees. Bootstrap values below 50% imply a statistically insignificant separation.
Conversely, as the bootstrap number increases above 50% the confidence in the tree
branch or separation increases.

6.3 Results
6.3.1 Disparate environmental stresses create a metabolic block in the TCA cycle
To determine if ethanol stress and iron-limitation alter TCA cycle activity, the
specific activity of aconitase in S. epidermidis strain 1457 at 2 hours (exponential growth)
and 6 hours (post-exponential growth) post-inoculation was assessed (Figure 6.1). As
expected, iron-limited growth and ethanol stress prevented the post-exponential growth
phase increase in the specific activity of the iron-requiring enzyme aconitase, creating a
metabolic block in the TCA cycle (Figure 6.1). Although ethanol stressed bacteria are in
the post-exponential growth phase at 6 h post-inoculation, their growth is slower, which
slows the consumption of glucose and excess glucose can repress transcription of TCA
cycle genes. Irrespective of the mechanism by which ethanol repressed aconitase specific
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activity, the normal post-exponential growth phase increase in TCA cycle activity did not
occur. These data demonstrate that environmental stresses whose deleterious effects are
substantially different from one another have a similar effect on TCA cycle function.

Figure 6.1 The temporal induction of aconitase specific activity is inhibited by dissimilar
stressors. Aconitase activity was assessed during the exponential (2 and 4 h) and postexponential (6 h) growth phases during growth in DTSB or TSB containing 4% ethanol.
The data are presented as the mean and SEM of 2 independent experiments each
determined in triplicate.

6.3.2 Environmental stimuli elicit TCA cycle-dependent metabolic changes
The TCA cycle provides biosynthetic intermediates, ATP, and reducing potential;
therefore, alteration of TCA cycle activity will alter the metabolic status of a bacterium.
To determine the metabolic changes associated with iron-limitation, ethanol stress, and
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TCA cycle inactivation, NMR metabolomic analysis28,29 was used to assess the stressed
and non-stressed metabolomes of strains 1457 and the TCA cycle inactive strain 1457acnA. Specifically, S. epidermidis strains 1457 and 1457-acnA were grown for two or six
hours in TSB, TSB with 4% ethanol, or DTSB. Following acquisition of the NMR
spectra, the σ of integrals was used for PCA (Figure 6.3a). As expected, during the
exponential growth phase, PCA revealed that the effects of ethanol stress and ironlimitation on the metabolome were largely independent of the TCA cycle (Figure 6.2).
This was expected due to the normal repression of TCA cycle activity during nutrient rich
growth (Figure 6.18,44). Despite the TCA cycle being repressed during the exponential
growth phase, the different stresses induced common metabolomic changes (Table 6.1).
In contrast to the exponential growth phase, PCA of post-exponential growth phase
metabolomes revealed that ethanol stress and iron-limitation induced metabolomic
changes very similar to TCA cycle inactivation (Figure 6.3a and Table 6.2). In addition,
these data highlight the relative insensitivity of the metabolome of strain 1457-acnA to
ethanol stress and iron-limited growth, confirming that the major effect of these stressors
is dependent upon the TCA cycle. That being said, the more diffuse clustering of ethanol
stressed metabolomes of both the wild-type and aconitase mutant strains, suggest that
ethanol stress had TCA cycle-independent metabolomic effects (Figure 6.3a). The TCA
cycle-independent effects are likely due to the denaturation of membrane proteins not
related to electron transport or the TCA cycle. Taken together, these data demonstrate
that diverse environmental stimuli elicit common metabolic changes that require the TCA
cycle.
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Figure 6.2 PCA 2D scores plot comparing non-stressed, or iron-limited cultures of
strains 1457, 1457-acnA, and 1457-sigB::dhfr grown for 2h. Symbols and colors are
defined in the figure.
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Figure 6.3 Environmental stressors cause metabolomic perturbations similar to TCA
cycle inactivation. (A) PCA 2D scores plot comparing non-stressed, ethanol stressed, or
iron-limited cultures of strains 1457, 1457-acnA, and 1457-sigB::dhfr grown for 6 h.
Symbols and colors are defined in the figure. The ovals are manually drawn to identify
clusters of related samples and to guide the reader. They are not statistically relevant. The
relative contribution of each principal component is indicated in the parenthesis. (B)
Metabolic tree generated using the PCA scores plot data demonstrating the relationship
between stresses and strains. Bootstrap values are indicated on the dendrogram branches.
Bootstrap values below 50% imply a statistically insignificant separation; conversely, as
the bootstrap number increases above 50% the confidence in the tree branch or separation
increases.
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The common metabolomic response to environmental stimuli can be more easily
observed by a recently developed method to visualize PCA data.40 By calculating an
average position for each data set, such that each PC value (PC1, PC2, etc.) is treated as
an axis in a Cartesian coordinate system, a distance matrix can be generated.
Correspondingly, methods developed for representing genetic distances in phylogenetic
trees can be used to create a metabolomic dendrogram (Figure 6.3b).43 Using this
approach, it becomes clear that stress induced metabolomic responses are very similar to
the metabolome of the aconitase deficient strain 1457-acnA. As with the 2D scores plot
(Figure 6.3a), the higher bootstrap values in the dendrogram for ethanol stressed cultures
also indicate that ethanol has TCA cycle-independent effects on the metabolome.
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Table 6.1 Metabolites that have increased or decreased concentrations relative to the
wild-type strain 1457 at 2 h post-inoculation.
Strain 1457a
Strain 1457a
Strain 1457-acnAa
(DTSB)
(4% Ethanol)
(TSB)
Iron-limitation
Ethanol stress
TCA cycle inactivation
Metabolites whose concentration is increased relative to strain 1457 grown in TSB medium.
Acetaldehyde
Acetyl-phosphate
Acetyl-phosphate
Acetyl-phosphate
Citrate
Glyceraldehyde
Metabolites whose concentration is decreased relative to strain 1457 grown in TSB
medium.
Acetyl-glutamateb
Asparagine
Glutamate
Lactate
Lactate
Glutamine
Glutamine
Glutamine
Succinate
Succinate
Succinate
a

The intracellular concentration was considered to be increased or decreased when the
percent difference in the NMR peak intensities was 5-fold greater than the percent error
observed in the peak intensities between triplicate NMR spectra.
b
Due to peak overlap, we are unable to determine if the metabolite is acetyl-glutamine or
acetyl-glutamate; however, we note that acetyl-glutamine is uncommon in prokaryotes.
Metabolites whose concentrations were changed under all stress conditions relative to the
wild-type strain grown in TSB are shaded in grey.
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Table 6.2 Metabolites that have increased or decreased concentrations relative to the
wild-type strain 1457 at 6 h post-inoculation.
Strain 1457a
(DTSB)
Iron-limitation

Strain 1457a
(4% Ethanol)
Ethanol stress

Strain 1457-acnAa
(TSB)
TCA cycle inactivation

Metabolites whose concentration is increased relative to strain 1457 grown in TSB
medium.
Acetaldehyde
Acetaldehyde
Acetaldehyde
Acetate
Acetate
Acetate
Acetylalanine
N-Acetyl-glucosamine
N-Acetyl-glucosamine
Acetyl-glucosamine 6-phosphate
N-Acetyl-mannosamine
N-Acetyl-mannosamine
N-Acetyl-mannosamine
N-Acetyl-neuraminate
N-Acetyl-neuraminate
N-Acetyl-neuraminate
Acetyl-phosphate
Acetyl-phosphate
Acetyl-phosphate
Arginine
Citrate
Ethanol
Glucosamine
Glucosaminec
Glucosamine
Galactose-1-phosphate
GDP
GDP
Glucose
Glucose
Glucose
Glucose-1-phosphate
Glucose-6-phosphate
Glucose-6-phosphate
Glucose-6-phosphate
Glyceraldehyde
Glyceraldehyde
Glyceraldehyde
Lactate
Lactate
Lactate
myo-Inositol
Proline
Ribosec
Ribose
Ribose
UDP-N-acetyl-glucosamine
Metabolites whose concentration is decreased relative to strain 1457 grown in TSB
medium.
α -Ketoglutarate
α -Ketoglutarate
α-Ketoglutarate
ɣ -Aminobutyrate
ɣ -Aminobutyrate
ɣ-Aminobutyrate
Acetyl-glutamateb
Acetyl-glutamateb
Acetyl-glutamateb
Acetyl-ornithine
Alanine
Arginine
Asparagine
Asparagine
Asparagine
Aspartate
β-Alanine
β-Alanine
β-Alanine
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Citrulline
Fructose-6-Phosphate
Glutamate
Glutamine

Citrulline
Ethanol
Fructose-6-Phosphate
Glutamate
Glutamine

Citrulline
Ethanol
Fructose-6-phosphate
Glutamate
Glutamine

Isocitrate
Methionine
NAD+
Ornithine
O-Succinyl-L-homoserine

Isocitrate
Methionine
NAD+
Ornithine
O-Succinyl-L-homoserine

Isocitrate
Methionine

Proline
S-Adenosyl-L-methionine

Proline
S-Adenosyl-L-methionine

Sedheptulose
Selenomethionine
UDP-N-acetylglucosamine

Selenomethionine

Ornithine
O-Succinyl-Lhomoserine
S-Adenosyl-Lmethionine
Selenomethionine

a

The intracellular concentration was considered to be increased or decreased when the
percent difference in the NMR peak intensities was 5-fold greater than the percent
error observed in the peak intensities between triplicate NMR spectra.
b
Due to peak overlap, we are unable to determine if the metabolite is acetyl-glutamine or
acetyl-glutamate; however, we note that acetyl-glutamine is uncommon in prokaryotes.
c
The percentage difference in the NMR peak intensities of these metabolites fell just
below the 5-fold cutoff in the percent error observed in the peak intensities between
the triplicate NMR spectra.
Metabolites whose concentrations were changed under all stress conditions relative to the
wild-type strain grown in TSB are shaded in grey.

S. epidermidis grown in TSB under aerobic conditions have two distinct
metabolic states: the nutrient-rich exponential phase and the nutrient-limited postexponential phase. The transition from nutrient-rich conditions to nutrient-limited growth
coincides with the transition from generating ATP by substrate-level phosphorylation to
using oxidative phosphorylation. The reduced dinucleotides that drive oxidative
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phosphorylation are primarily derived from the TCA cycle; thus, inhibiting TCA cycle
activity (Figure 6.1) hinders the transition to oxidative phosphorylation and the postexponential growth phase.8,44 Iron-limited growth of strain 1457 or aconitase inactivation
did not significantly alter the growth rate; although, aconitase inactivation did increase
the lag phase (data not shown). Both aconitase inactivation and iron-limited growth
caused an early entry into the stationary phase; as such, the growth yield was decreased.
As stated, the addition of 4% ethanol decreased the growth rate; therefore, it slowed the
consumption of glucose. Based on these observations, it was reasonable to hypothesize
that post-exponential growth phase (6 h) stressed metabolomes will be more similar to an
un-stressed exponential growth phase (2 h) metabolome than to the unstressed
metabolome of post-exponential growth phase of cultures. As expected, PCA of
unstressed strain 1457 cultures, grown for 2 or 6 hours, form separate subsets in a 3D
scores plot (Figure 6.4). Consistent with our hypothesis, PCA of post-exponential growth
phase stressed and acnA mutant cultures were more closely associated with the unstressed
exponential growth phase metabolome of strain 1457 than with the strain 1457 postexponential growth phase metabolome (Figure 6.4). These data suggest that any stress
which interferes with TCA cycle function results in a metabolome similar to an
unstressed exponential phase culture.
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Figure 6.4 PCA 3D scores plot comparing non-stressed, ethanol stressed, or iron-limited
cultures of strains 1457 grown for 6 h to that of strain 1457 grown for 2 h. Symbols and
colors are defined in the figure. The ovals are manually drawn to identify clusters of
related samples and to guide the reader. They are not statistically relevant. The relative
contribution of each principal component is indicated within the parenthesis.

6.3.3 Metabolomic changes are largely independent of the σB-mediated general stress
response
In staphylococci, σB controls the general stress response and as such is activated
during stress conditions, growth phase transitions, and morphological changes.45,46 As
stated previously, the regulation of many virulence determinants is affected by
environmental stresses; therefore, the stress-dependent activation of σB has been an
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important area of research into the environmental regulation of staphylococcal virulence
determinants.47-49 Interestingly, σB does not directly respond to most environmental
signals, suggesting another path to transduce stress signals that is independent of σB. To
test this possibility, an S. epidermidis sigB mutant strain (1457-sigB::dhfr)19 was grown
for two or six hours in TSB, TSB with 4% ethanol, or DTSB and the metabolomes were
analyzed by NMR spectroscopy. The PCA scores plot demonstrates that the majority of
metabolomic changes associated with iron-limitation and ethanol stress occur largely
independent of σB (Figure 6.3a). Additionally, the metabolomic dendrogram confirms the
stressor induced metabolic changes observed in strain 1457-sigB::dhfr are most closely
associated with those in the TCA cycle mutant strain 1457-acnA (Figure 6.3b). Taken
together, these data demonstrate that environmental stresses can alter the staphylococcal
metabolome by a largely σB-independent mechanism that requires the TCA cycle.

6.3.4 Metabolomic changes precede genetic changes
Metabolomic data demonstrate that ethanol stress, iron-limitation, and TCA cycle
inactivation decrease the intracellular concentration of Gln relative to the wild-type strain
grown in TSB medium (Tables 6.1 and 6.2). The two more likely explanations for the
decreased intracellular concentration of Gln: i.) the stressors alter enzymatic activity
causing a decrease in the concentration of Gln; or ii.) the stressors decrease transcription
of genes involved in the biosynthesis of Gln, resulting in a decreased concentration of
Gln. If the first possibility is correct, then stressors will cause an increase in the
transcription of Gln biosynthetic genes, as bacteria attempt to compensate for the
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decreased availability of Gln. If the second possibility is correct, then stressors will cause
a decrease in the transcription of Gln biosynthetic genes. To determine which of these
two possibilities was correct, we performed northern blot analysis on glutamine
synthetase (femC; a.k.a. glnA) (Figure 6.5). The data suggest the first possibility is the
more correct one; specifically, bacteria are responding to metabolomic changes by
increasing transcription of genes necessary to counterbalance those changes.
Interestingly, in untreated wild-type cultures, the post-exponential growth phase
concentration of Glu and Gln increased between 2 and 5 times that of the exponential
growth phase concentration (data not shown) and this increase correlated with a postexponential growth phase decrease in glnA mRNA levels (Figure 6.5). Similarly, Gln and
Glu were not detected in the NMR spectra of the aconitase mutant strain and this
correlated with a high level of glnA mRNA in both the exponential and post-exponential
growth phases. The correlation between Gln and Glu concentrations and glnA mRNA
levels are consistent with a GlnR-dependent regulation of glnA transcription.2 This
correlation was maintained for Gln/Glu sufficient or insufficient conditions; however, the
intermediate concentrations of Gln and Glu found during ethanol stress and iron-limited
growth (data not shown) produce mixed glnA mRNA levels (Figure 6.5). These data
suggest that for the concentrations of Gln and Glu to affect glnA transcription, the stressinduced concentration change must be sufficiently large.
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Figure 6.5 Northern blot analysis of RNAIII and glnA mRNA levels in the exponential (2
h) and post-exponential (6 h) phases of growth. To ensure that equivalent quantities of
RNA were loaded in the gel, 23S and 16S rRNA were visualized by ethidium bromide
staining and used as loading controls (bottom panel). The results are representative of at
least two independent experiments.

6.3.5 CcpA responds to TCA cycle-associated metabolomic changes
Ethanol stress, iron-limitation, and TCA cycle inactivation increased the postexponential growth phase concentration of glucose-6-phosphate (Table 6.2). Glycolytic
intermediates such as glucose-6-phosphate and fructose-1,6-bisphosphate increase the
ATP-dependent phosphorylation of the histidine-containing protein (HPr) by enhancing
the activity of the HPr kinase.50 The increase in phosphorylated HPr enhances its
interaction with the catabolite control protein A (CcpA).51-53 CcpA primarily functions as
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a repressor; however, it also activates transcription of genes involved in fermentation and
overflow metabolism.52,54 In addition to the concentration of glucose-6-phosphate being
increased by TCA cycle stress, the concentration of several fermentation products or
intermediates (i.e., lactate, acetate, and acetaldehyde) and the small phosphodonor acetylphosphate (an indicator of overflow metabolism) were also increased (Table 6.1),
consistent with a change in CcpA-mediated regulation. The repressor CodY also
contributes to the regulation of overflow metabolism;54 however, CodY responds to the
intracellular concentrations of branched chain amino acids (BCAA).55 TCA cycle stress
did not alter the concentrations of BCAA beyond the 5-fold threshold (Table 6.1),
suggesting the increase in overflow metabolism was independent of CodY.
In S. aureus, CcpA enhances biofilm formation and PIA biosynthesis, while
CodY represses PIA synthesis.56,57 In S. epidermidis, ethanol stress, iron-limitation, and
TCA cycle inactivation enhance biofilm formation and PIA synthesis.7,13,14,16,24,58 Based
on the metabolomic data and published observations, it was reasonable to hypothesize
that PIA biosynthesis was regulated in response to TCA cycle-associated metabolomic
changes by a CcpA-dependent and CodY-independent mechanism. To test this
hypothesis, ccpA and codY deletion mutants were constructed in strains 1457 and 1457acnA and the amount of cell-associated PIA was determined after 6 hours of growth
(Figure 6.6). Consistent with previous observations,7 TCA cycle inactivation (strain
1457-acnA) dramatically increased the accumulation of PIA, while neither CodY nor
CcpA had a dramatic effect on the post-exponential growth phase amount of PIA. When
the codY mutation was introduced into an aconitase mutant background, PIA
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accumulation resembled the response in strain 1457-acnA, suggesting TCA cycleassociated changes in PIA biosynthesis are independent of CodY. In contrast to the codYacnA double mutant, the ccpA-acnA double mutant failed to produce PIA, strongly
suggesting that some TCA cycle-associated metabolomic changes (i.e., glucose-6phosphate) are “sensed” by CcpA, which in turn activates PIA biosynthesis.

Figure 6.6 CcpA is required for PIA synthesis during TCA cycle stress. PIA immunoblot
assay of strain 1457 and isogenic mutants of acnA, codY, ccpA, codY/acnA, and
ccpA/acnA grown for 6 h in TSB. The results are representative of 3 independent
experiments.

6.3.6 TCA cycle stress decreases RNAIII transcription
In S. aureus, inactivation of the TCA cycle increases the transcription or stability
of the accessory gene regulator (Agr) system’s riboregulator RNAIII.8,9 Conversely,
increasing TCA cycle activity decreases the transcription or stability of RNAIII.59 The
causal relationship between TCA cycle activity and RNAIII transcript levels in S. aureus
led us to examine if disparate environmental conditions would similarly affect RNAIII
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transcription or message stability in S. epidermidis. In contrast to S. aureus, TCA cycle
inactivation decreased RNAIII transcription or stability during the exponential and postexponential growth phases in S. epidermidis (Figure 6.5). Importantly, ethanol stress and
iron-limitation decreased RNAIII transcription or stability in a similar manner to TCA
cycle inactivation (Figure 6.5). In total, these data suggest that environmental stresses act
through the TCA cycle to elicit transcriptional changes to at least two of the major
staphylococcal virulence regulators (i.e., CcpA and RNAIII).

6.4 Discussion
In the life-cycle of S. epidermidis, the transition from a skin-resident, commensal
state to adhering on implanted biomaterials represents a dramatic environmental change.
In most pathogenic bacteria, environmental changes are accompanied by changes in the
transcription of virulence genes; thus, environmental signals (e.g., nutrient replete, ironlimiting, or oxygen-limiting growth conditions) commonly regulate virulence gene
transcription.2,60-64 Although S. epidermidis has relatively few virulence determinants,
one of its primary pathogenic effectors is the exopolysaccharide PIA.65-68 Previously, we
demonstrated that PIA biosynthesis is regulated by TCA cycle activity; specifically,
repression of TCA cycle activity dramatically enhances transcription of PIA biosynthetic
genes (icaADBC) and PIA accumulation.7,24,59 In this study, we demonstrate that
dissimilar environmental signals decrease TCA cycle activity (Figure 6.1) resulting in
common metabolomic changes (Figure 6.3 and Tables 6.1 and 6.2; summarized in Figure
6.7) that alter the activity of metabolite-responsive regulators such as CcpA (Figure 6.7).

265
These data lead us to propose that it is the TCA cycle itself that is “sensing” the
environmental transition and transducing this information into metabolic signals that
activate or repress the activity of metabolite-responsive regulators to modulate the
expression of PIA and other virulence determinants.

Figure 6.7 Summary of post-exponential growth phase metabolic changes associated
with TCA cycle stress. Metabolites in green represent an increased concentration relative
to the wild-type strain. Metabolites in red represent a decreased concentration relative to
the wild-type strain. Metabolites and pathways in black are inferred from the data but
they are inconclusive.

As S. epidermidis transitions from residing on the skin to being implanted in a
host, it enters into an environment where free iron is present at a concentration of 10-18 M
61

, a condition antagonistic to TCA cycle activity (Figure 6.1 & 9,11). Similarly, this
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transition dramatically decreases the availability of free oxygen (the partial pressure of
atmospheric O2 is 159 mmHg at sea level and this decreases to an estimated 3-5 mmHg at
the host cell level), a condition that is also antagonistic to TCA cycle activity. Taken
together, this type of environmental transition is accompanied by conditions that are
inhibitory to TCA cycle activity and stimulatory to PIA biosynthesis.7,24 In other words,
the transition from an external environment to an internal environment represses TCA
cycle activity and primes S. epidermidis for PIA synthesis, which enhances biofilm
formation and increases the likelihood of establishing a biomaterial-associated infection.
The significance of the data presented here is five-fold: First, it establishes a
mechanism by which well-established regulators (e.g., CcpA) participate in responding to
environmental stresses. Second, these data suggest how disparate environmental stimuli
can cause common phenotypic changes (e.g., iron-limitation and ethanol stress both
increase PIA synthesis and biofilm formation13,69). Third, these data suggest a difficulty
in attributing the effects of an environmental stimulus, such as iron-limitation, to a
specific regulator like the ferric uptake regulator (Fur),70 is that many of the effects are
due to metabolite-responsive regulators reacting to changes in the metabolome. Fourth, S.
epidermidis has a second general stress response system that is largely independent of the
σB-controlled general stress response (Figure 6.3). Finally, in bacteria, three metabolic
pathways (Embden-Meyerhof-Parnas, pentose phosphate, and TCA cycle) produce the
thirteen biosynthetic intermediates needed to synthesize all macromolecules in a bacterial
cell. Therefore, by linking virulence factor synthesis to the TCA cycle, bacteria are
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connecting virulence to the availability of biosynthetic intermediates needed to synthesize
virulence determinants.

6.5 Conclusion
TCA cycle stress alters the intracellular concentrations of metabolites (Tables 6.1
and 6.2) relative to those of the wild-type strain 1457. If the change in the concentration
of a metabolite is sufficiently large, then the activity of a regulator that can respond to
one of those metabolites may be altered. Therefore, these data present an exceptional
opportunity to identify regulators that coordinate metabolism and virulence in S.
epidermidis. Although a considerable amount of research needs to be done to determine
which metabolite-responsive regulators are involved in responding to TCA cycle
associated metabolomic changes, the work presented here sheds light on how
environmental signals alter the bacterial metabolic status to regulate adaptation to a new
environment.

6.6 References
(1)

von Eiff, C.; Peters, G.; Heilmann, C. Lancet Infect Dis 2002, 2, 677.

(2)

Somerville, G. A.; Proctor, R. A. Microbiol Mol Biol Rev 2009, 73, 233.

(3)
Begun, J.; Sifri, C. D.; Goldman, S.; Calderwood, S. B.; Ausubel, F. M.
Infect Immun 2005, 73, 872.

268
(4)
Coulter, S. N.; Schwan, W. R.; Ng, E. Y.; Langhorne, M. H.; Ritchie, H.
D.; Westbrock-Wadman, S.; Hufnagle, W. O.; Folger, K. R.; Bayer, A. S.; Stover, C. K.
Mol Microbiol 1998, 30, 393.
(5)
Mei, J. M.; Nourbakhsh, F.; Ford, C. W.; Holden, D. W. Mol Microbiol
1997, 26, 399.
(6)
Bae, T.; Banger, A. K.; Wallace, A.; Glass, E. M.; Aslund, F.;
Schneewind, O.; Missiakas, D. M. Proc Natl Acad Sci U S A 2004, 101, 12312.
(7)
Sadykov, M. R.; Olson, M. E.; Halouska, S.; Zhu, Y.; Fey, P. D.; Powers,
R.; Somerville, G. A. J Bacteriol 2008, 190, 7621.
(8)
Somerville, G. A.; Chaussee, M. S.; Morgan, C. I.; Fitzgerald, J. R.;
Dorward, D. W.; Reitzer, L. J.; Musser, J. M. Infect Immun 2002, 70, 6373.
(9)
Somerville, G. A.; Cockayne, A.; Dürr, M.; Peschel, A.; Otto, M.; Musser,
J. M. J Bacteriol 2003, 185, 6686.
(10)

Collins, F. M.; Lascelles, J. J. Gen. Microbiol. 1962, 29, 531.

(11)

Somerville, G.; Mikoryak, C. A.; Reitzer, L. J Bacteriol 1999, 181, 1072.

(12)

Varghese, S.; Tang, Y.; Imlay, J. A. J Bacteriol 2003, 185, 221.

(13) Knobloch, J. K.; Bartscht, K.; Sabottke, A.; Rohde, H.; Feucht, H. H.;
Mack, D. J Bacteriol 2001, 183, 2624.
(14) Presterl, E.; Suchomel, M.; Eder, M.; Reichmann, S.; Lassnigg, A.;
Graninger, W.; Rotter, M. J Antimicrob Chemother 2007, 60, 417.
(15) Korem, M.; Gov, Y.; Shirron, N.; Shuster, A.; Rosenberg, M. FEMS
Microbiol Lett 2007, 269, 153.

269
(16) Lyte, M.; Freestone, P. P.; Neal, C. P.; Olson, B. A.; Haigh, R. D.;
Bayston, R.; Williams, P. H. Lancet 2003, 361, 130.
(17)

Otzen, D. E.; Sehgal, P.; Nesgaard, L. W. Biochemistry 2007, 46, 4348.

(18)

Mack, D.; Siemssen, N.; Laufs, R. Infect Immun 1992, 60, 2048.

(19) Handke, L. D.; Slater, S. R.; Conlon, K. M.; O'Donnell, S. T.; Olson, M.
E.; Bryant, K. A.; Rupp, M. E.; O'Gara, J. P.; Fey, P. D. Can J Microbiol 2007, 53, 82.
(20)

Horton, R. M.; Cai, Z. L.; Ho, S. N.; Pease, L. R. Biotechniques 1990, 8,

528.
(21) Kennedy, M. C.; Emptage, M. H.; Dreyer, J. L.; Beinert, H. J Biol Chem
1983, 258, 11098.
(22)

Baughn, A. D.; Malamy, M. H. Proc Natl Acad Sci U S A 2002, 99, 4662.

(23) Lowry, O. H.; Rosebrough, N. J.; Farr, L.; Randall, R. J. J Biol Chem
1951, 193, 267.
(24) Vuong, C.; Kidder, J. B.; Jacobson, E. R.; Otto, M.; Proctor, R. A.;
Somerville, G. A. J Bacteriol 2005, 187, 2967.
(25)

Kay, L. E.; Keifer, P.; Saarinen, T. J. Am. Chem. Soc. 1992, 114, 10663.

(26) Palmer III, A. G.; Cavanagh, J.; Wright, P. E.; Rance, M. J. Magn. Reson.
1991, 93, 151.
(27)

Bax, A.; Davis, D. G. J. Magn. Reson. 1985, 65, 355.

(28) Forgue, P.; Halouska, S.; Werth, M.; Xu, K.; Harris, S.; Powers, R. J
Proteome Res 2006, 5, 1916.

270
(29) Halouska, S.; Chacon, O.; Fenton, R. J.; Zinniel, D. K.; Barletta, R. G.;
Powers, R. J Proteome Res 2007, 6, 4608.
(30)

Halouska, S.; Powers, R. J Magn Reson 2006, 178, 88.

(31) Nguyen, B. D.; Meng, X.; Donovan, K. J.; Shaka, A. J. J Magn Reson
2007, 184, 263.
(32) Craig, A.; Cloarec, O.; Holmes, E.; Nicholson, J. K.; Lindon, J. C. Anal
Chem 2006, 78, 2262.
(33)

Piotto, M.; Saudek, V.; Sklenar, V. J Biomol NMR 1992, 2, 661.

(34)

Johnson, B. A. Methods Mol Biol 2004, 278, 313.

(35) Cui, Q.; Lewis, I. A.; Hegeman, A. D.; Anderson, M. E.; Li, J.; Schulte, C.
F.; Westler, W. M.; Eghbalnia, H. R.; Sussman, M. R.; Markley, J. L. Nat Biotechnol
2008, 26, 162.
(36) Ulrich, E. L.; Akutsu, H.; Doreleijers, J. F.; Harano, Y.; Ioannidis, Y. E.;
Lin, J.; Livny, M.; Mading, S.; Maziuk, D.; Miller, Z.; Nakatani, E.; Schulte, C. F.;
Tolmie, D. E.; Kent Wenger, R.; Yao, H.; Markley, J. L. Nucleic Acids Res 2008, 36,
D402.
(37) Wishart, D. S.; Tzur, D.; Knox, C.; Eisner, R.; Guo, A. C.; Young, N.;
Cheng, D.; Jewell, K.; Arndt, D.; Sawhney, S.; Fung, C.; Nikolai, L.; Lewis, M.;
Coutouly, M. A.; Forsythe, I.; Tang, P.; Shrivastava, S.; Jeroncic, K.; Stothard, P.;
Amegbey, G.; Block, D.; Hau, D. D.; Wagner, J.; Miniaci, J.; Clements, M.;
Gebremedhin, M.; Guo, N.; Zhang, Y.; Duggan, G. E.; Macinnis, G. D.; Weljie, A. M.;
Dowlatabadi, R.; Bamforth, F.; Clive, D.; Greiner, R.; Li, L.; Marrie, T.; Sykes, B. D.;
Vogel, H. J.; Querengesser, L. Nucleic Acids Res 2007, 35, D521.
(38) Kanehisa, M.; Araki, M.; Goto, S.; Hattori, M.; Hirakawa, M.; Itoh, M.;
Katayama, T.; Kawashima, S.; Okuda, S.; Tokimatsu, T.; Yamanishi, Y. Nucleic Acids
Res 2008, 36, D480.

271
(39) Karp, P. D.; Ouzounis, C. A.; Moore-Kochlacs, C.; Goldovsky, L.; Kaipa,
P.; Ahren, D.; Tsoka, S.; Darzentas, N.; Kunin, V.; Lopez-Bigas, N. Nucleic Acids Res
2005, 33, 6083.
(40) Werth, M. T.; Halouska, S.; Shortridge, M. D.; Zhang, B.; Powers, R. Anal
Biochem 2009.
(41)

Efron, B.; Halloran, E.; Holmes, S. Proc Natl Acad Sci U S A 1996, 93,

(42)

Felsenstein, J. Evolution 1985, 39, 783.

(43)

Retief, J. D. Methods Mol Biol 2000, 132, 243.

13429.

(44) Somerville, G. A.; Saïd-Salim, B.; Wickman, J. M.; Raffel, S. J.;
Kreiswirth, B. N.; Musser, J. M. Infect Immun 2003, 71, 4724.
(45)

Wu, S.; de Lencastre, H.; Tomasz, A. J Bacteriol 1996, 178, 6036.

(46) Bischoff, M.; Dunman, P.; Kormanec, J.; Macapagal, D.; Murphy, E.;
Mounts, W.; Berger-Bachi, B.; Projan, S. J Bacteriol 2004, 186, 4085.
(47)

Bischoff, M.; Entenza, J. M.; Giachino, P. J Bacteriol 2001, 183, 5171.

(48) Meier, S.; Goerke, C.; Wolz, C.; Seidl, K.; Homerova, D.; Schulthess, B.;
Kormanec, J.; Berger-Bachi, B.; Bischoff, M. Infect Immun 2007, 75, 4562.
(49) Pane-Farre, J.; Jonas, B.; Forstner, K.; Engelmann, S.; Hecker, M. Int J
Med Microbiol 2006, 296, 237.
(50)

Deutscher, J.; Saier, M. H., Jr. Proc Natl Acad Sci U S A 1983, 80, 6790.

(51)

Bruckner, R.; Titgemeyer, F. FEMS Microbiol Lett 2002, 209, 141.

272
(52)

Sonenshein, A. L. Nat Rev Microbiol 2007, 5, 917.

(53)

Warner, J. B.; Lolkema, J. S. Microbiol Mol Biol Rev 2003, 67, 475.

(54)

Shivers, R. P.; Dineen, S. S.; Sonenshein, A. L. Mol Microbiol 2006, 62,

(55)

Shivers, R. P.; Sonenshein, A. L. Mol Microbiol 2004, 53, 599.

811.

(56) Seidl, K.; Goerke, C.; Wolz, C.; Mack, D.; Berger-Bachi, B.; Bischoff, M.
Infect Immun 2008, 76, 2044.
(57) Majerczyk, C. D.; Sadykov, M. R.; Luong, T. T.; Lee, C.; Somerville, G.
A.; Sonenshein, A. L. J Bacteriol 2008, 190, 2257.
(58) Matinaho, S.; von Bonsdorff, L.; Rouhiainen, A.; Lonnroth, M.;
Parkkinen, J. FEMS Microbiol Lett 2001, 196, 177.
(59) Zhu, Y.; Xiong, Y. Q.; Sadykov, M. R.; Fey, P. D.; Lei, M. G.; Lee, C. Y.;
Bayer, A. S.; Somerville, G. A. Infect Immun 2009, 77, 4256.
(60)
1978, 80, 1.

Bullen, J. J.; Rogers, H. J.; Griffiths, E. Curr Top Microbiol Immunol

(61)

Litwin, C. M.; Calderwood, S. B. Clin Microbiol Rev 1993, 6, 137.

(62)

Mekalanos, J. J. J Bacteriol 1992, 174, 1.

(63)

Park, M. K.; Myers, R. A.; Marzella, L. Clin Infect Dis 1992, 14, 720.

(64) Milenbachs, A. A.; Brown, D. P.; Moors, M.; Youngman, P. Mol
Microbiol 1997, 23, 1075.

273
(65) Vuong, C.; Kocianova, S.; Voyich, J. M.; Yao, Y.; Fischer, E. R.; Deleo,
F. R.; Otto, M. J Biol Chem 2004, 24, 54881.
(66) Vuong, C.; Voyich, J. M.; Fischer, E. R.; Braughton, K. R.; Whitney, A.
R.; DeLeo, F. R.; Otto, M. Cell Microbiol 2004, 6, 269.
(67)

Rupp, M. E.; Ulphani, J. S.; Fey, P. D.; Mack, D. Infect Immun 1999, 67,

2656.
(68) Rupp, M. E. In The Staphylococci in Human Disease; K, C., G, A., Eds.;
Churchill-Livingstone: New York, 1997, p 379.
(69)

Deighton, M.; Borland, R. Infect Immun 1993, 61, 4473.

(70) Torres, V. J.; Attia, A. S.; Mason, W. J.; Hood, M. I.; Corbin, B. D.;
Beasley, F. C.; Anderson, K. L.; Stauff, D. L.; McDonald, W. H.; Zimmerman, L. J.;
Friedman, D. B.; Heinrichs, D. E.; Dunman, P. M.; Skaar, E. P. Infect Immun 2010, 78,
1618.

274
CHAPTER 7
THE INFLUENCE OF IRON AND AERATION ON STAPHYLOCOCCUS
AUREUS GROWTH, METABOLISM, AND TRANSCRIPTION
7.1 Introduction
Staphylococcus aureus is a versatile pathogen capable of infecting almost any
niche within a human or animal host. As with most bacterial pathogens, successful
pathogenesis requires that S. aureus gain entry into a host (e.g., through a breach in the
skin), adhere to a suitable surface, avoid being killed by host’s immune system, acquire
nutrients, and proliferate. Notably, every step in this pathogenic process involves
metabolic changes and/or metabolic regulation. Entry into a host is an environmental
change that dramatically alters the availability of nutrients and co-factors. Similarly, the
transition from synthesizing adhesins to producing tissue-damaging secreted virulence
determinants is preceded by changes in the bacterial nutritional status.1 To avoid being
killed by the host’s immune system, S. aureus alters its metabolism to limit damage by
oxidative and nitrosative stress.2 The act of acquiring nutrients is regulated by metaboliteresponsive regulators that respond to changes in the bacterial metabolic status.3 Finally,
proliferation is a carbon and energy intensive undertaking. In short, S. aureus success as a
pathogen depends on its ability to meet the rapidly changing nutritional and energy
requirements necessary for survival and proliferation within a host. The ability to meet
the changing nutritional and energy requirements is complicated by the host, which limits
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access to enzymatic co-factors such as oxygen and iron by sequestering these in host
proteins and molecules (e.g., hemoglobin, heme, and transferrin). The limited availability
of these co-factors creates metabolic blocks that hinder virulence factor synthesis,4,5
which leaves S. aureus vulnerable to the host’s immune system.
The potential consequences of a metabolic block(s) (i.e., decreased fecundity,
fitness, and/or death) create selective pressure to maintain a functional metabolic state.
Over time, this selective pressure has led to the evolution/acquisition of metaboliteresponsive regulators (e.g., CodY, CcpA, RpiRc) that maintain metabolic homeostasis
when nutritional and environmental conditions are favorable, and that facilitate metabolic
adaptations when nutritional and environmental conditions change.6-8 Specifically, CodY
responds to changes in branched chain amino acids and GTP concentrations,9,10 while
CcpA indirectly responds to glucose-6-phosphate and fructose-1,6-bisphosphate.11 While
the RpiR regulators all have sugar isomerases binding domains, the metabolites that
modulate their activities have yet to be determined.8 These metabolite-responsive
regulators, i.e. CodY, CcpA, and RpiRc, coordinate both virulence determinant
biosynthesis and metabolism in staphylococci.8,9,12 In general, the activity of metaboliteresponsive regulators is controlled by intracellular concentrations of numerous
compounds, such as biosynthetic intermediates,13 amino acids,14 nucleic acids,15 and cofactors (e.g., iron).16 In Staphylococcus epidermidis, the intracellular concentrations of
metabolites can be altered by environmental stressors, such as antibiotics, ethanol, metal
ion-limitation, or nutrient-depletion.3,17,18 This creates a mechanism by which
extracellular stress can be transduced into intracellular metabolic signals that elicit
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regulatory changes via metabolite-responsive regulators. While the transduction of
external factors into internal metabolic signals has been demonstrated in S. epidermidis, it
has not been shown in S. aureus.
Two important enzymatic co-factors that influence S. aureus fitness and that are
controlled by the host are oxygen and iron. Numerous studies have shown that oxygenand iron-availability can influence growth, antibiotic tolerance, and synthesis of virulence
factors;19-23 however, little regard has been given to the metabolic changes that
accompany iron- and oxygen-limitation.24-26 Where the metabolic effects of iron- or
oxygen-limitation have been examined, those studies only addressed the metabolic
effects of a single stress and in a single growth phase/state. The analysis of a single
growth phase/state overlooks the fact that staphylococci have two very distinct metabolic
states that correlate with the exponential and post-exponential growth phases.27 Because
pathogenic bacteria rarely encounter a single stress, we chose to examine the combined
stresses of iron- and oxygen-limitation on the exponential and post-exponential
metabolomes. In addition, we also assessed the contributions of the single stresses (i.e.,
iron- or oxygen-limitation) to the overall effects of combined stresses (i.e., iron- and
oxygen-limitation). Lastly, by analyzing the metabolic effects of single stresses, we can
identify common metabolic signals, similar to what was done in S. epidermidis.17,18 In the
current study, the effects of oxygen- and iron-limitation on the metabolome of S. aureus
strain SA564 were examined using NMR metabolomics. In addition, a select set of genes
were examined for transcriptional changes that might be associated with the altered
growth conditions.
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7.2 Experimental procedures
7.2.1 Bacterial strains, media, and cultivation conditions
S. aureus strain SA564 was grown in tryptic soy broth (TSB; BD Biosciences) or
on tryptic soy agar (TSA). For iron-limitation cultivation conditions, deferrated TSB
(DTSB) medium was used.17 In this study, iron-limited medium was preferred to “ironfree” medium because iron-free medium requires the addition of adulterants, such as
deferoxamine mesylate. These adulterants are added to chelate iron; however, they also
chelate other cations,28 which makes comparison between cultivation conditions
impractical because more than one variable would be changed. To prevent pyrolysis of
labile metabolites, DTSB and TSB were prepared by filter sterilization. For iron-limiting
conditions, bacterial cultures were grown overnight in 10 mL of DTSB, harvested by
centrifugation at 3,795 x g, washed once in 10 mL of DTSB, and suspended in fresh
DTSB. This culture was used to inoculate (1:100) the starter cultures, which were
cultivated in 100 mL of DTSB or TSB for 2 h. After 2 h of growth, these cultures were
used to inoculate the primary cultures to an optical density at 600 nm (O.D.600) of 0.06.
Each primary culture was cultivated in pre-warmed DTSB or TSB with defined flask-tomedia ratios. All cultures were grown at 37°C with constant aeration (225 rpm) and
growth (O.D.600) and pH were measured at hourly intervals for 12 h. For the purpose of
varying culture aeration during growth, flask-to-media ratios (v/v) of 10:8, 10:4, 10:2.5,
10:1 were used. This approach takes advantage of the poor diffusion coefficient for
oxygen into water to alter the amount of oxygen available to the bacteria.29
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7.2.2 Sample preparation for NMR metabolomic analysis
Bacterial cultures were harvested during the exponential (2 h) and postexponential (6 h) growth phases. For one-dimensional (1D) 1H NMR experiments, eight
biological replicates (10 O.D.600 units each) were harvested for each cultivation condition
and growth phase. For two-dimensional (2D) 1H, 13C Heteronuclear Single Quantum
Coherence (HSQC) experiments, four biological replicates (20 O.D.600 units each) were
harvested for each cultivation condition and growth phase. Bacteria were harvested using
a sterile 0.45 µm Microfil V filtration system (EMD Millipore Corporation) that had been
pre-washed with 5 mL of sterile phosphate buffered saline (PBS, pH 7.4). Following
filtration, bacteria were washed twice with 5 mL of ice-cold PBS, each membrane was
transferred to a 50 mL conical tube, and quenched in liquid nitrogen. After quenching,
the conical tubes were placed in ice and bacteria were collected from the filter using icecold 20 mM phosphate buffer (1 mL). The bacterial suspensions were normalized to
equal O.D.600 units (10 for 1D NMR and 20 for 2D NMR) in a 1 mL total volume,
transferred to Lysing matrix B tubes, and lysed twice (Speed 6 and 40 s) using a FastPrep
FP120 instrument (MP Biomedicals). The samples were rested on ice for 5 min between
lysings. To remove cell debris and glass beads, samples were centrifuged at 17,000 x g
for 2 min at -9°C and 700 µL of supernatant from each tube was transferred into a new 2
mL microfuge tube (pre-cooled to -20oC). To the residual sample in the lysing matrix B
tubes, 1 mL of ice-cold phosphate buffer was added, mixed, and centrifuged. After the
second centrifugation, 900 µL of the supernatant from each tube were pooled with the
samples from the first centrifugation. Of the 1.6 mL volume for each sample, 100 µL was
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removed and the protein concentration was determined using a modified Lowry assay kit
(Thermo Fisher Scientific). The remaining 1.5 mL of each sample was lyophilized and
600 µL of D2O was added prior to analysis. 50 µM 3-(trimethylsilyl) propionic acid2,2,3,3-d4 (TMSP-d4) or 500 µM TMSP-d4 (Sigma-Aldrich) was added to each sample
as internal standards for 1D 1H NMR or 2D 1H, 13C HSQC experiments, respectively.

7.2.3 Data Collection
1D data collection was performed as described,30 while 2D time zero extrapolated
1

H, 13C HSQC (HSQC0) NMR spectra were processed as described.31 For each sample, a

total of 1024 data points with a spectrum width of 10.00 ppm in the 1H dimension, and 64
data points with a spectrum width of 140.00 ppm in the 13C dimension were collected. A
total of 16 dummy scans and 64 scans with a receiver gain of 9195.2 and a relaxation
delay of 1.5 seconds were applied for each sample.

7.2.4 Data analysis
1D 1H NMR spectra were processed as described.18 2D 1H, 13C HSQC spectra
were processed using the NMRPipe software package.32 Peak picking and peak matching
were done using NMRViewJ Version 8.33 A table of peaks along with respective
intensities were recorded and the concentrations of metabolites were calculated using a
standard curve generated using nine metabolites with known concentrations: [D-glucose13

C6, D-fructose-13C6, glycine-13C2, DL-alanine-3-13C, sodium pyruvate-13C3, succinic

acid-13C4, sodium acetate-13C2, 2-keto-3-(methyl-13C)-butyric acid-4-13C, sodium salt,
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and 2-ketobutyric acid-4-13C sodium salt hydrate (Sigma-Aldrich)].31 A Student’s T-test
was used to determine the statistical significance (p < 0.05) of metabolite concentration
changes.
The principal component analysis (PCA) and Orthogonal Projections to Latent
Structures-discriminant analysis (OPLS-DA) scores plots and shared and unique structure
(SUS)-plots were generated using the SIMCA 12.0+ (UMETRICS) statistical package
(http://www.umetrics.com/). The OPLS-DA models were validated using a modified
leave-one-out method34,35 and CV-ANOVA.36 The metabolomics tree diagrams
(dendrograms) and the ellipses corresponding to the 95% confidence limits from a normal
distribution for each cluster within the PCA scores plots were generated using our
PCA/PLS-DA utilities (http://bionmr.unl.edu/pca-utils.php).37,38

7.2.5 Data interpretation
The peaks were assigned to metabolites using chemical shift references from the
Human Metabolomics Database (HMDB),39 Platform for RIKEN Metabolomics
(PRIMe)40 Biological Magnetic Resonance Data Bank (BMRB)41 and Chenomx NMR
Suite 7.6 (Chenomx. Inc., Edmonton, Canada) software. Heat maps were generated in R
with a gplots package.42

7.2.6 ICP-MS analysis of DTSB
Cultivation of S. aureus strain SA564 was performed as described. For the
determination of iron concentrations in the culture supernatants, 1 mL of each culture was
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harvested during the exponential (2 h) or post-exponential (6 h) growth phases by
centrifugation at 3,795 x g for 5 min at room temperature. To remove any residual
bacteria, samples were passed through Nalgene 0.2 µm polyethersulfone membrane
syringe filters (Thermo Fisher Scientific). All samples were diluted 1:20 with a solution
containing 52.6 ppb 71Ga in 0.1% HNO3, which resulted in a 71Ga concentration of 50
ppb that was used as an internal standard. ICP-MS analyses were performed at the
University of Nebraska-Lincoln Spectroscopy Core Facility using an Agilent
Technologies ICP-MS 7500cs with an ESI SC-4 high-throughput autosampler (Elemental
Scientific Inc.). The concentration of metals was calculated using ChemStation for ICP
software with a calibration curve for 18 elements from serial dilutions of a standard stock
from Inorganic Ventures. The instrument was operated with an octopole collision
reaction cell filled with He at a flow rate of 5.0 mL/min and the following Ar plasma
conditions: plasma power, 1500W, plasma gas, 17 L/min, auxiliary gas, 1 L/min., sample
gas, 0.9-1.1 L/min and makeup gas 0.1-0.2 L/min, sample flow rate, 0.1 mL/min. For
each sample, three replicates from three independent cultures were analyzed. Statistical
significance was determined by one-way ANOVA using SigmaPlot 11.2 software (Systat
Software Inc).

7.2.7 Aconitase activity assay
Aconitase enzymatic activity was measured as described.17 Protein concentrations
were determined using a Modified Lowry Protein Assay Kit (Thermo Fisher Scientific).
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7.2.8 Real-time RT-PCR
Total RNA was isolated from 10 O.D.600 units of bacteria harvested in the
exponential (2 h) and post-exponential (6 h) growth phases using the FastRNA Pro Blue
kit (MP Biomedical) and the RNeasy kit (Qiagen) as described.43 For mRNA analysis, a
two-step real-time RT-PCR was performed with a cDNA synthesis from total RNA
followed by PCR. Ten µg of TURBO DNase (Bio-Rad) treated total RNA for each
sample was used to prepare cDNA by reverse transcriptase reaction using an iScript
master mix (Bio-Rad) according to manufacturer’s protocol. The reaction mixtures for
Real-time PCR contained 10 µL of 2×SsoAdvanced SybrGreen Supermix (Bio-Rad), 7
pmoles of each primer (Table 1), and 5 μl of 10-fold diluted cDNA, in a total volume of
20 μl. As an internal reference, primers for 16s rRNA were used in the same reaction
volume containing 1000-fold diluted cDNA as a template. The RT-PCR cycling
conditions were: Initial denaturation at 94°C for 3 min, followed by 40 cycles at 94°C for
15 sec, 60°C for 25 sec, and 72°C for 20 sec. Relative transcript levels were determined
by the comparative threshold (∆∆CT) method (Bio-Rad). Experimental set-up and data
analysis were carried out using CFX96 Real-Time PCR Detection System and Bio-rad
CFX Manager Software version 3.0 (Bio-Rad).
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Table 7.1 Real-time RT-PCR primers used in this study.
Primer

Mu50 orf*

Sequence

16SrRNA RTF
16SrRNA RTF
citB RTF
citB RTR
feoB RTF
feoB RTR
sbnA RTF

SAVrRNA16
SAVrRNA16
SAV1350
SAV1350
SAV2584
SAV2584
SAV0116

CGTGCTACAATGGACAATACAAA
ATCTACGATTACTAGCGATTCCA
GCGCAACAGCAACTGATTTA
GTTGTACACCTGGACCAAAGA
GGAATGACAGCAACACAGTTAC
GTGCTGACTGACCACCTAAA
TTCTGTAGGGCAAACACCTATG

sbnA RTR
sstC RTF
sstC RTR

SAV0116
SAV0735
SAV0735

GCTGCCTCCAGGATTCATATAC
GACCTAATGGTGCGGGTAAG
CAGACATGAGCTGTCCATCTATT

*Gene designations based on the Staphylococcus aureus strain Mu50 genomic DNA
sequence44

7.2.9 Acetate, glucose and lactate level determination of the media supernatant
Metabolite concentrations in the culture media were determined using kits
purchased from R-biopharm, Inc.

7.3 Results
7.3.1 Growth of S. aureus under iron- and oxygen-limitation
The transition from an oxygen- and iron-replete environment (e.g., the skin, the
nares) to an oxygen- and iron-limited environment (e.g., blood) constrains metabolic
possibilities because many enzymatic reactions require iron and oxygen as co-factors.
These constraints have fitness consequences; specifically, the ability to place progeny
into the next generation.45-47 To assess the extent of the fitness cost of iron- and oxygenlimitation on the growth yield, S. aureus strain SA564 was cultivated under iron- and/or
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oxygen-limited conditions and the growth was monitored (Figure 7.1a & 1b). As
expected, the growth rates were largely independent of iron- and/or oxygen-limited
conditions. Consistent with the Pasteur Effect, oxygen-limited growth conditions
dramatically decreased biomass generation, whereas, iron-limitation did not significantly
alter the biomass generated per mmol of glucose (Figure 7.1c).48 Importantly, these data
demonstrate the ease with which a batch culture can become microaerobic/anaerobic at
an atmospheric oxygen concentration of 20.946% and with vigorous agitation at 225
rpm.29 This transition to a microaerobic/anaerobic status is due to two factors: First, the
poor diffusion coefficient for oxygen into water; and second, the relatively small surface
area that is exposed to atmospheric oxygen as the volume of medium in a culture flask is
increased. In contrast to oxygen-limitation, iron-limitation only decreased the growth
yield of strain SA564 by ~25% relative to growth in iron-replete culture medium (Figure
7.1a). In S. aureus, the demand for iron is greatest in the post-exponential growth phase
when the TCA cycle and the electron transport chain are most active; hence, the small
amount of iron in the culture medium (Figure 7.1b) is sufficient to maintain the
exponential growth rate but not the growth yield (Figure 7.1a).5
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Figure 7.1 Cultivation of S. aureus strain SA564 under aeration- and/or iron-limitation
conditions. (a) Growth curves. (b) Iron concentrations of un-inoculated media and from
cultivation media harvested in the exponential and post-exponential growth phases. (c)
Glucose utilization as a function of growth. (d) pH profiles. (e) Acetate accumulation and

286
depletion in culture media. (f) Lactate accumulation and depletion in the culture media.
Data are presented as representative of experiments performed at least twice. The data in
panel B are presented as the mean of 3 independent experiments done in triplicate with
error bars representing standard deviations. Figure insets: Culture medium: TSB = tryptic
soy broth, DTSB = deferrated TSB; Flask-to-medium ratio: 10:1 (aerobic), 10:8
(microaerobic/anaerobic).

S. aureus is a facultative anaerobe and is well-adapted for growth in low-oxygen
environments when nutrients are abundant. As nutrients become scarce, S. aureus
catabolize incompletely oxidized carbon compounds (e.g., lactic acid or acetic acid) that
accumulate in the medium during the exponential growth phase;27 hence, the pH of the
culture medium will alkalinize. As expected, strain SA564 grown under oxygen- and
iron-replete conditions began to alkalinize the culture medium during the transition from
the exponential growth phase to the post-exponential growth phase (Figure 7.1d). Ironlimited growth slightly delayed and decreased the alkalinization of the culture medium,
while oxygen-limitation severely restricted alkalinization of the medium.
In contrast to previous speculation, iron-limitation does not lead to the
acidification of the culture medium.26 As stated above, the acidification of the culture
medium is the result of the inefficient use of carbohydrates during growth in nutrient-rich
conditions, which occurs irrespective of the availability of iron or oxygen (Figure 7.1c1f). The decreased ability of oxygen-limited cultures, and to a lesser extent iron-limited
cultures, to alkalinize the medium was most likely due to a diminished capacity to
catabolize organic acids and amino acids. To address this possibility, the concentrations
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of acetic acid and lactic acid in the culture media were measured throughout the growth
cycle (Figure 7.1e and 1f). During microaerobic/anaerobic growth (i.e., when the flaskto-medium ratio is 10:8), pyruvate is largely reduced to lactic acid (Figure 7.1f).49,50 In
contrast, when the flask-to-medium ratio was altered to 10:1, pyruvate was oxidized to
acetyl-CoA and CO2 by the pyruvate dehydrogenase complex (Figure 7.1e).51 In the
exponential growth phase, acetyl-CoA is used to generate the small phospho-donor
acetyl-phosphate, which serves as a substrate for acetate kinase in substrate-level
phosphorylation to generate ATP and acetic acid (Figure 7.1e). During the postexponential growth phase, this acetic acid can be used in the synthesis of acetyl-CoA to
fuel the TCA cycle. When iron was limiting, the catabolism of acetate and the biomass
generated from that catabolism were reduced (Figure 7.1e). As expected, oxygenlimitation inhibited the catabolism of acetate; however, it had only a slight effect on
lactate catabolism (Figure 7.1e and 1f). The latter data were surprising because acetate
catabolism through the TCA cycle27 and lactate catabolism through L-lactate-quinone
oxidoreductase (Lqo)52 both require electron acceptors to balance the redox status.

7.3.2 Iron- and oxygen-limitation create metabolic blocks
Staphylococci lack a glyoxylate shunt and catabolize acetate through the
tricarboxylic acid (TCA) cycle;27,53 hence, a diminished ability to catabolize acetate
(Figure 7.1e) suggests the TCA cycle had reduced activity under iron- and oxygenlimited growth. To test this suggestion, the TCA cycle enzyme aconitase was assayed for
activity under iron- and oxygen-limited growth conditions (Figure 7.2a & 2b). Since
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aconitase is an iron-sulfur cluster containing enzyme, iron-limitation would be expected
to decrease its activity. As expected, growth of S. aureus strain SA564 in iron-limited
culture medium dramatically decreased post-exponential growth phase aconitase activity
(Figure 7.2a). As stated earlier, one function of iron is to facilitate electron transfer
reactions, a process that requires an electron donor (e.g., NADH, NADPH) and acceptor
(e.g., oxygen). In the presence of iron but the absence of an electron acceptor, reduced
dinucleotides will accumulate, which should inhibit enzyme activity through a feedback
mechanism. To test this hypothesis, we limited oxygen availability by varying the flaskto-medium ratio and assayed for aconitase activity (Figure 7.2b).29 As the medium
volume was increased the surface area available for oxygen diffusion decreased, resulting
in a post-exponential growth phase decrease in aconitase activity. While aconitase is an
excellent metabolic sentinel, iron- and oxygen-limitation will affect the activity of many
enzymes in bacteria.
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Figure 7.2 Temporal and stress related aconitase activity differences in S. aureus strain
SA564 in the exponential (2h) and post-exponential (6h) growth phases. (a) Aconitase
activity during iron-limited growth. (b) Aconitase activity with decreasing aeration flaskto-medium ratios of 10:8, 10:5, 10:2.5, 10:1. (c) Addition of iron to DTSB medium
restores aconitase activity.

7.3.3 Iron and/or oxygen limitation alters the S. aureus metabolome
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Iron- and oxygen-limited growth created a metabolic block at aconitase in the TCA cycle
(Figure 7.2a & 2b); however, these stresses will also inhibit the activity of many different
metabolic enzymes and pathways. It is impractical to assay for all enzymes that might be
affected by iron- and/or oxygen-limited growth, so metabolic changes were assessed
using NMR metabolomics (Figure 7.3). As expected, principal component analysis (PCA)
of exponential growth phase metabolomes revealed they were minimally affected by
iron-limitation; whereas, oxygen-limitation caused modest changes in the metabolomes
(Figure 7.3a & 3c). The heterogeneity of the exponential growth phase metabolomes is
easily demonstrated in a PCA shared and unique structure (SUS)-plot, where very few
shared or inversely shared metabolites were identified (Figure 7.3e). In contrast to the
exponential growth phase, iron-limitation significantly altered the post-exponential
growth phase metabolome PCA scores plot (Figure 7.3b, 3d & 3f). Similarly, oxygenlimitation had a very pronounced effect on the metabolome. Interestingly, strain SA564
metabolomes from cultures grown in iron-limited medium and with reduced aeration
clustered nearer to the aeration-limited cultures than they did with the iron-limited
cultures in a PCA scores plot (Figure 7.3b). In other words, the effect of iron-limitation
was masked by growth under conditions that limit the diffusion of oxygen into the culture
medium. This can also be easily seen in the metabolic heat map where the metabolic
changes in post-exponential growth phase (6 h) cultures grown under aeration-limitation
are very similar, irrespective of iron-limitation (Figure 7.4). Taken together, these data
demonstrate the significance of iron-limitation on S. aureus metabolism is largely
determined by the growth phase and the availability of oxygen.
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Figure 7.3 Exponential and post-exponential growth phase metabolomic changes
associated with iron- and/or oxygen-limited cultivation. PCA scores plot of the (a)
exponential and (b) post-exponential growth phases of iron- and/or oxygen-limited
cultures of S. aureus strain SA564. The ellipses in the PCA scores plot correspond to the
95% confidence limits from a normal distribution for each cluster. Metabolic tree
generated using the PCA scores plot data demonstrating the relationship of iron- and/or
oxygen-limited cultures in the (c) exponential growth phase and (d) post-exponential
growth phase. The statistical significance of each node in the metabolic tree is indicated
by a p-value. Shared and unique structure (SUS)-plots generated from the PCA model of
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the (e) exponential and (f) post-exponential growth phases that compares the DTSB, 10:1
and TSB, 10:8 classes to a common reference (TSB, 10:1). The red boxes highlight the
chemical shift bins with intensity changes that are shared by both models. The blue boxes
highlight the chemical shift bins with intensity changes that are negatively-shared by both
models (relative intensity changes are in the opposite direction). The brown boxes
highlight the chemical shift bins with intensity changes unique to model 1 (TSB, 10:8 vs.
TSB, 10:1). The green boxes highlight the chemical shift bins with intensity changes
unique to model 2 (DTSB, 10:1 vs. TSB, 10:1). In the post-exponential growth phase, 73
bins were found to be present in the shared/inversely shared region of the plot, compared
to 29 bins to be found in the same regions of the exponential phase. Culture medium:
TSB = tryptic soy broth, DTSB = deferrated TSB; Flask-to-medium ratio: 10:1 (aerobic),
10:8 (microaerobic/anaerobic).

To identify metabolites that contributed to the separation of the sample clusters,
OPLS-DA was employed (Figure 7.4 & 1.5). In contrast to PCA, OPLS-DA is a
supervised classification analysis where all the variation leading to separation between
the two groups is aligned in the X-axis (Pp) and all other variation is aligned in the Yaxis (Po).54 To achieve separation based on aeration in an OPLS-DA scoring plot,
clusters TSB, 10:1 and DTSB, 10:1 were assigned a value of 0 and the clusters of TSB,
10:8 and DTSB, 10:8 were assigned a value of 1 (Figure 7.4). This model resulted in one
predictive and two orthogonal (1+2) components with a cross-validated predictive ability
of Q2(Y)=0.883, which indicated the data fit well within the model. The model was
validated with CV-ANOVA producing a statistically significant p-value of 8.27x10-12.
Based on this model, the perturbations caused by iron-limitation were largely suppressed
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when aeration was also limiting. As expected, the majority of the metabolic differences
between aerobic growth and oxygen-limited growth include fermentation products,
metabolites of pyruvate homeostasis, and amino acids (Figure 7.4). To achieve separation
based on iron availability in an OPLS-DA scores plot, clusters TSB, 10:1 and TSB, 10:8
were assigned a value of 0 and the clusters of DTSB, 10:1 and DTSB, 10:8 were assigned
a value of 1 (Figure 7.5). This model also produced an excellent fit that resulted in one
predictive and three orthogonal (1+3) components with a cross-validated predictive
ability of Q2(Y)=0.969 (Figure 7.5). This model was also validated with CV-ANOVA
producing a statistically significant p-value of 1.33x10-17. In this model, the four
metabolomic clusters are largely separated from each other, suggesting that oxygenlimitation as a stressor cannot be overwhelmed by iron-limitation. Altogether, the
clustering of metabolomes in both models suggested that the effects of iron-limitation
were suppressed by oxygen-limitation.
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Figure 7.4 (a) OPLS-DA scores plot generated from 1D 1H NMR spectra of iron- and/or
aeration-limited cultures of S. aureus strain SA564 in the exponential (2 h) growth phase.
The ellipses in the PCA scores plot correspond to the 95% confidence limits from a
normal distribution for each cluster. TSB, 10:1 (▲); DTSB, 10:1 (▲); TSB, 10:8 (▲);
DTSB, 10:8 (▲). (b) Metabolic tree generated using the OPLS-DA data demonstrating
the relationship of iron- and/or oxygen-limited cultures in the post-exponential growth
phase. (c) S-plot identifies the chemical shift bins that significantly contribute to class
separation in the OPLS-DA scores plot. (d) OPLS-DA loading plot comparing two
aeration conditions 10:1 and 10:8 for S. aureus strain SA564 grown on either TSB or
DTSB media. Negative values indicate a decrease in peak intensity when comparing 10:8
to 10:1, while positive values indicate an increase in peak intensity. The color scale on
the right indicates the relative correlation these data to the OPLS-DA model and class
separation.
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Figure 7.5 (a) OPLS-DA scores plot generated from 1D 1H NMR spectra of iron- and/or
aeration-limited cultures of S. aureus strain SA564 in the post-exponential (6 h) growth
phase. The ellipses in the PCA scores plot correspond to the 95% confidence limits from
a normal distribution for each cluster. TSB, 10:1 (▲); DTSB, 10:1 (▲); TSB, 10:8 (▲);
DTSB, 10:8 (▲). (b) Metabolic tree generated using the OPLS-DA data demonstrating
the relationship of iron- and/or oxygen-limited cultures in the post-exponential growth
phase. (c) S-plot identifies the chemical shift bins that significantly contribute to class
separation in the OPLS-DA scores plot. (d) OPLS-DA loading plot comparing two
aeration conditions 10:1 and 10:8 for S. aureus strain SA564 grown on either TSB or
DTSB media. Negative values indicate a decrease in peak intensity when comparing
DTSB media to TSB media, while positive values indicate an increase in peak intensity.
The color scale on the right indicates the relative correlation these data to the OPLS-DA
model and class separation.
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7.3.4 Iron-regulated gene transcription varies with oxygen availability
If oxygen-limitation can mask metabolic changes associated with iron-limitation,
then it raises the question as to whether iron-dependent transcriptional changes can be
obscured by oxygen-limitation. To address this question, bacteria were grown under ironand/or oxygen-limited culture conditions and transcriptional changes in genes regulated
by iron were assessed using qRT-PCR (Figure 7.7). As a positive control, transcription of
the aconitase gene acnA/citB was assessed and compared to the enzyme activity data
(Figure 7.2a). Overall, the acnA/citB mRNA levels correlated well (r = 0.83) with the
enzymatic activity data. Similar to the metabolomics data, oxygen-limitation was able to
mask the effect of iron-limited growth on some genes. Specifically, oxygen-limitation
dramatically decreased the exponential (2 h) and post-exponential (6 h) growth phase
transcription of the ferrous iron transporter, feoB, and the first gene (i.e., sbnA) of the
staphyloferrin B biosynthetic locus.55 This reduction in transcript levels occurred despite
the fact that the culture medium was iron-limited (Figure 7.1b). In contrast to feoB and
sbnA, some genes [e.g., sstC, which codes for an ATP binding cassette in a siderophore
transporter]56 had only minimal changes in mRNA levels under iron- and/or oxygenlimited growth. These data demonstrate that iron-dependent regulation of transcription in
S. aureus can be suppressed under conditions of low oxygen-availability. In addition,
these data highlight the necessity of carefully considering, and reporting, bacterial
cultivation conditions.29
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7.4 Discussion
When cultures of Staphylococcus epidermidis are challenged with ethanol,
antibiotics, iron-limitation, or high glucose concentrations, these stresses cause common
phenotypic changes; namely, they favor biofilm formation and/or biosynthesis of
polysaccharide intercellular adhesin.57-60 These same stresses cause the post-exponential
growth phase metabolomic profiles to resemble that of an S. epidermidis TCA cycle
mutant.17,18 The fact that divergent environmental challenges produce similar metabolic
and phenotypic alterations suggests that common regulatory changes are occurring to
produce the similar phenotypic outcomes.3 This suggestion was confirmed when it was
observed that an S. epidermidis ccpA mutant failed to respond to metabolic changes
associated with TCA cycle stress.7 Similar to S. epidermidis, we hypothesize that
divergent environmental stresses cause common metabolic changes in S. aureus that alter
the activity of metabolite-responsive regulators. The first step in identifying metaboliteresponsive regulators is to define the common metabolic changes associated with
environmental stresses (Figure 7.4 & 1.8). The metabolic effects of many of the
environmental stresses S. aureus encounters have been studied in detail; however, with
little, or no, deference to the temporal nature and the interconnectedness of metabolic
changes.26,61-63 The intent of the current study was to identify common metabolic changes
associated with iron- and/or oxygen-limitation that could alter the activity of metaboliteresponsive regulators; the identification of these regulators is an active area of research in

298
our laboratories. As a side benefit, this study reinforces the necessity of carefully
considering and reporting cultivation conditions.64
While the most prominent metabolomic differences are in the post-exponential
growth phase, the exponential growth phase changes are greatest under combined ironand oxygen-limited growth (Figure 7.3, 1.4 & 7.8). As an example, both iron- and
oxygen-limitation redirect carbon into amino sugar biosynthesis (e.g., UDP-N-acetylglucosamine, glucosamine-6-phosphate, acetyl-glucosamine). This redirection of carbon
appears to be at the expense of the exponential growth phase basal level TCA cycle
carbon flow because the concentration of succinate is decreased relative to the iron- and
oxygen-replete growth conditions (Figure 7.4 & 7.8). We observed a similar redirection
of carbon into amino sugar biosynthesis in S. epidermidis, where TCA cycle stress
induces the formation of an N-acetyl-glucosamine polymer known as polysaccharide
intercellular adhesin.43,65 Together these data suggest that TCA cycle dependent
regulation of polysaccharide intercellular adhesin synthesis is common to the
staphylococci and not just S. epidermidis. While amino sugar biosynthesis was increased
during oxygen- and iron-limited growth, S. aureus acidified the culture medium
irrespective of iron or oxygen availability (Figure 7.1d). This latter observation is
consistent with previous observations on staphylococcal carbohydrate catabolism,27,66,67
yet inconsistent with more recent speculation.26
As stated above, the metabolic perturbations during iron- and/or oxygen-limited
cultivation are greatest in the post-exponential growth phase (Figure 7.3a & 3b). These
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differences are primarily a consequence of three factors: 1.) the TCA cycle is catabolite
repressed during the exponential growth phase;27 2.) de-repression of the TCA cycle
creates a large demand for iron in the post-exponential growth phase [Fig 1F and 5]; and
3.) TCA cycle activity generates reducing potential, which creates a need for an electron
acceptor, most commonly, oxygen. Once glucose is depleted from the culture medium
during growth in iron- and oxygen-replete conditions (Figure 7.1b), catabolite repression
of the TCA cycle genes is relieved and enzymatic activities increase (Figure 7.2a, 2b &
1.7). In contrast, when S. aureus are cultivated under iron- and/or oxygen-limited
conditions, transcription of TCA cycle genes and enzymatic activity remain low despite
the depletion of glucose (Figure 7.1, 2a & 1.7). Though oxygen and iron are both
important for post-exponential phase growth (Figure 7.1), the availability of oxygen is the
major determinant of the metabolome (Figure 7.3b & 1.4). The absence of oxygen
prevents carbon flow through the TCA cycle, decreasing the concentrations of
biosynthetic intermediates and the amino acids derived from those intermediates (Figure
7.2a, 2b & 7.3); specifically, citric acid, succinate, and α-ketoglutarate, glutamate,
glutamine, aspartate, and asparagine are decreased (Figure 7.4 & 7.8). In other words, the
decreased carbon flow through the TCA cycle results in multiple amino acid auxotrophies.
In addition, decreased carbon flow through the TCA cycle likely decreased the
availability of oxaloacetate/PEP for gluconeogenesis, which is essential for growth when
glucose has been depleted from the medium. When combined, the amino acid
auxotrophies, a lack of gluconeogenesis, and inhibition of the electron transport chain
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(i.e., due to the lack of an electron acceptor) result in a decreased growth yield (Figure
7.1a).
Inhibition of electron transport forces bacteria to use alternative pathways to
oxidize dinucleotides; however, these alternatives are strongly dependent upon carbon
availability. When carbon sources that can generate pyruvate (e.g., glucose and serine)
are abundant in the medium, bacteria can maintain redox balance by using enzymes like
lactate dehydrogenase, which leads to the accumulation of lactic acid in the medium
(Figure 7.1f & 7.4). In addition to lactate dehydrogenase, S. aureus can oxidize
dinucleotides through alanine dehydrogenase, a result consistent with the postexponential growth phase accumulation of D-alanyl-D-alanine and alanine. These data
suggest that as readily catabolizable carbon sources were being depleted from the
medium several pathways are used to oxidize dinucleotides, resulting in an accumulation
of NAD+ (Figure 7.4). While oxidation of dinucloetides is important, it is only one part of
redox homeostasis, the other being reduction.
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Figure 7.6 Heat maps showing the changes in metabolites as a function of cultivation
conditions and growth phase. Culture medium: TSB = tryptic soy broth, DTSB =
deferrated TSB; Flask-to-medium ratio: 10:1 (aerobic), 10:8 (microaerobic/anaerobic).
Statistical significance (p < 0.05): ** = both oxygen- and iron-limitation; * = only
oxygen-limitation; + = only iron-limitation.
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Table 7.2. Summary of metabolite changes.a
Culture
conditions
Growth phase
Xanthosine
Uracil
UDPAcGlcN

TSB,
10:8
Ex PE
p
↓
↑
↑↑
↑↑

DTSB,
10:8
Ex PE
p
↓
↓

↑↑
↑

↑

↑↑
↑

Succinate
Ribose
Proline
NADH
NAD+
Lysine

DTSB,
10:1
Ex PE
p
↓

↑↑

Lactate
GPC
Glyceraldehyde
Glutamine

↑↑
↓
↑↑
↑↑
↑
↑↑
↑
↓
↑↑

↓

↑

Dihydroxyaceto
ne
Betaine
Aspartate

↑↑

Asparagine

↑↑
↑

Alanyl-alanine
Alanine
Acetylphosphate
Acetylglucosamine
Acetate
4Aminobutyrate
2Hydroxyglutara
te

↓↓
↑↑

Metabolic Pathway

↑↑↑
↑↑↑

C00042

↓
↑↑↑
↓
↑
↑

C00121
C00148
C00004
C00003
C00047

00020,00190,00250,00350,00360 ,00630,00650
,02020
00030,02010
00330,00970 ,01230,02010
00190, 01100, 04020
00190
00300,00310,00780, 00970,01210,01230,02010

C00186

00010,00620,00640

KEGG ID
00230, 01065
00240,00410,00770
00520, 00540,00550

↓↓

↓↓

↑↑
↑
↑↑
↑

↑↑↑

C00670
C00577
C00064

↑↑↑

C00025

↑↑↑

C00352

00564,00565
00030,00051,00561
00230,00240,00250,00330,00471,00970,01230,
02010,02020
00250,00330,00340,00430,00471,00480,00650,
00660,00970,01210,01230,02010,02020
00250,00520,02060

↑↑↑

C00184

00561,00680

↓↓

↓
↑↑↑

C00719
C00049

↓↓
↓
↓
↓↓
↓

↑↑↑

C00152

00260,02010
00250,00260,00270,00300,00330,00340,00410,
00770,00970,01210,01230,02010,02020
00250,00970,01230

↑↑↑
↑↑↑
↓↓

C00993
C00041
C00227

00473,00550
00250,00270,00430 ,00473,00970,01230,02010
00430,00620,00680

↓

↓

C00140

00520, 01110,02010,02060

↑↑

↓
↑

↑↑↑
↑

C00033
C00334

00010,00430,00440,00534,00620,00660,00680
00250,00330,00410,00650

↑↑
↑

↑↑
↑

↑↑

C00026

00020,00040,00053,00250,00300,00340,00430,
00471,00650,00660,01210,01230

Glutamate
Glc6P

↑↑
↑
↑↑
↑
↓
↑
↓

Metabol
ite
KEGG
ID
C01762
C00106
C00043

↑↑
↑
↑↑
↑
↓↓
↑↑
↑
↑

↓

↑

↓
↓

↑↑

↓↓
↓
↑↑
↓↓

↓↓

↓

a

“↑” indicates an increase; “↓” indicates a decrease. One arrow represents a p≤0.05
(Student’s T-test), two arrows represents a p≤0.01, three 3 arrows represents a p≤0.001.
b

Metabolites altered in the exponential (Exp) growth phase in TSB, 10:8, DTSB,10:1 and
DTSB10:8 relative to the cultures grown in TSB with a 10:1 flask-to-medium ratio.
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c

Metabolites altered in the post-exponential phase (PE) of growth in TSB, 10:8,
DTSB,10:1 and DTSB10:8 relative to the cultures grown in TSB with a 10:1 flask-tomedium ratio.
d

KEGG (Kyoto Encyclopedia of Genes and Genomes) database identification number for
the metabolite and the associate metabolic pathways.

When the TCA cycle is inhibited by iron- and/or oxygen-limitation, the ability to
reduce dinucleotides and restore redox balance is also greatly impaired. This inability to
reduce dinucleotides is reflected in the decreased concentrations of TCA cycle associated
αketoglutarate, glutamate, and glutamine. In addition to the TCA cycle, glycerol-3phosphate can be used in an electron transfer reaction to reduce NAD+ to NADH and
generate dihydroxyacetone phosphate. This reduction reaction is consistent with the
oxygen-limited accumulation of dihydroxyacetone (the phosphate is labile and can be lost
during harvest and sample preparation to generate the more stable dihydroxyacetone)
(Figure 7.4). When carbon flow through the TCA cycle and pentose phosphate pathway
is decreased, the ability to generate reducing potential via the NAD(P)H-dependent
glycerol-3-phosphate dehydrogenase (Figure 7.4) can be important for redox homeostasis
and biosynthesis. That being said, this metabolic rearrangement is insufficient to offset
the accumulation of NAD+. In summary, the necessity of maintaining redox homeostasis
explains why the availability of oxygen (i.e., its function as an electron acceptor) has a
greater influence on the post-exponential growth phase metabolome than does the
availability of iron (Figure 7.3b). In the absence of an electron acceptor, iron is not
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needed for electron transport; hence, the demand for iron will be lower. This also
explains why oxygen availability alters transcription of genes involved in iron-acquisition
(Figure 7.7). In essence, decreased oxygen availability suppresses the iron-sparing
response, a phenomenon similar to that seen in Saccharomyces cerevisiae.68
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Figure 7.7 Oxygen-limitation influences transcription of iron-regulated genes in the
exponential (2 h) and post-exponential (6 h) growth phases. Relative mRNA levels for
acnA/citB, sbnA, feoB, and sstC as determined by qRT-PCR. The data are the mean and
SEM of at least 2 biological replicates each determined in duplicate. Culture medium:
TSB = tryptic soy broth, DTSB = deferrated TSB; Flask-to-medium ratio: 10:1 (aerobic),
10:8 (microaerobic/anaerobic).
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Figure 7.8 Schematic representation of the central metabolic changes associated with
iron- or oxygen-limitation. The black/blue arrows indicate exponential/post-exponential
growth phase increased or decreased intracellular concentrations of metabolites in strain
SA564 cultivated in TSB with a 10:8 flask-to-medium ratio relative to a control culture
grown in TSB with a flask-to-medium ratio of 10:1. The red/orange arrows indicate
exponential/post-exponential growth phase increased or decreased intracellular
concentrations of metabolites in strain SA564 grown in DTSB with a flask-to-medium
ratio of 10:1 relative to a control culture of S. aureus strain SA564 grown in TSB with a
flask-to-medium ratio of 10:1. Statistical significance at the 95% confidence level (p<
0.05) is denoted by asterisks above the arrows.
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CHAPTER 8
CCPE IS A LYSR-TYPE REGULATOR CONTROLLING TCA CYCLE
ACTIVITY IN STAPHYLOCOCCUS AUREUS
8.1 Introduction
Carbon catabolite repression (CCR) in bacteria is a widespread, regulatory
phenomenon that represses transcription of genes and operons involved in the catabolism
of non-preferred carbon sources when the preferred carbon source(s) are present. CCR
has been studied extensively in Bacillus subtilis and serves as the prototype of CCRregulated gene expression in Gram-positive bacteria (reviewed in references 1).1,2 In B.
subtilis, the catabolite control protein A (CcpA) acts in concert with the small
phosphocarrier proteins histidine-containing protein (HPr) and catabolite repression HPr
(Crh) to regulate transcription in response to carbohydrate availability. In addition, the
metabolite-activated bifunctional HPr kinase/phosphorylase is involved in CCR through
its action of phosphorylating and dephosphorylating Hpr.3,4 There are several other
proteins in B. subtilis that contribute to CCR either in cooperation with, or independently
of CcpA, including CcpC,5,6 CcpN,7 CitR,8 Crh,9 CodY,10 and GlcU11 (reviewed in
reference 1a).1 In Staphylococcus aureus, homologs of CcpA and CodY regulate the
transcription of numerous metabolic and biosynthetic genes and virulence determinants;
thereby, linking staphylococcal carbon metabolism with pathogenicity.12
To identify additional CCR elements in S. aureus, we compared the genomes of S.
aureus strain Newman with that of B. subtilis strain 168 and found that S. aureus had
uncharacterized homologs of B. subtilis genes that are known to affect the regulation of
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carbon catabolism. Here we report about the identification of a putative carbon catabolite
responsive regulator, CcpE (NWMN_0641) that affects central metabolism by regulating
tricarboxylic acid (TCA) cycle activity via transcriptional control of the aconitaseencoding gene citB.

8.2 Methods and materials
8.2.1 Bacterial strains and culture conditions
The bacterial strains and plasmids used in this study are listed in Table 8.1. S.
aureus strains were grown in Luria-Bertani Lennox (LB-L) medium (BD, Heidelberg,
Germany) and B. subtilis strains were grown in TSS minimal medium supplemented with
0.2 % (w/v) glutamine and 0.5 % (w/v) glucose (6). All strains were grown at 37°C and
aerated at 230 rpm with a flask-to-medium volume ratio of 10:1. Antibiotics, when used,
were added to the medium at the following concentrations (per milliliter): 10 µg
chloramphenicol, 50 µg kanamycin, and 8 µg tetracycline.
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Table 8.1 Strains and plasmids used in this study.

Strain or plasmid
S. aureus
RN4220
Newman
THa
TH01
TH01c
B. subtilis
AF21
CJB9
E. coli

SCS110
Plasmids
pBT
pBT2-arcA
pBT lox-aph
pBus1

pRAB1
pT7HMT
pT7HMT-ccpE
pTH2

pTH2c
pTH3
pTH4
a

Relevant genotype or characteristic(s)a

Reference or source

NCTC 8325-4 r- m+ (restriction-negative, modification-positive)
Clinical isolate (ATCC 25904); CP-5 producer
RN4220 ∆ccpE::lox66-aphAIII-lox71, Kanr
Newman ∆ccpE::lox72
TH01 harboring plasmid pTH2c cis-integrated at the NWMN_0640
locus, leading to a duplication of the NWMN_0640 gene, ccpE+, Tcr

(34) 13
(35)14
This study
This study
This study

ΔamyE::Φ(citBp21-lacZ cat), Cmr
ΔamyE::Φ(citBp21-lacZ cat) ccpC::spc, Cmr, Spcr

(43)15
(3b)6

hsdR17(rk– mk+) deoR endA1 gyrA96 recA1 relA1
supE44 thi-1 F– λ–- Δ(lacZYA-argF) U169 φ80 lacZΔM15
dam dcm rpsL (Strr) thr leu endA thi-1 lacY galK galT ara tonA tsx
supE
lac-proAB) [F' traD36 proAB lacIqZ

Invitrogen

1.6-kb PCR fragment of the tet(L) gene of pHY300PLK into Alw26Idigested pBC SK(+) (Stratagene); Tcr
Allelic replacement vector for S. aureus arcA, harboring the lox66aphAIII-lox71 cassette; Kanr
pBT with a 1.6 kb lox66-aphAIII-lox71 fragment obtained from pBT2arcA cloned into the PstI site of pBT; Kanr, Tcr
E. coli-S. aureus shuttle plasmid with multicloning site from
pBluescript II SK (Stratagene) and the rrnT14 terminator sequence
from pLL2443; Tcr
cat, bla, PpagA-cre; pBT2 derivative; expression of Cre in
staphylococci; Cmr
pET28-based expression vector, allowing a T7 polymerase-driven
expression of hexahistidine-tagged fusion proteins, Kanr
pT7HMT derivative harboring the ccpE ORF cloned into the SalI and
NotI sites of the vector, Kanr
pBT with a 3 kb fragment covering the NWMN_0641 flanking regions
and the lox66-aphAIII-lox71 resistance cassette fully replacing the
ccpE ORF, Tcr
pBT with a 2 kb fragment covering the ccpE ORF and 1 kb of the
upstream region including the NWMN_0640 ORF, Tcr
pBus1 with a 1.7-kb fragment covering the B. subtilis ccpC promoters
P1/P2 and the ccpC ORF, Tcr
pBus1 with a 1.7-kb fragment covering the B. subtilis ccpC promoters
P1/P2 and the ccpE ORF, Tcr

(37)16

Stratagene

(10)17
This study
(11)18
(10)17
(38)19
This study
This study

This study
This study
This study

Abbreviations: Cmr, chloramphenicol resistant; Kanr, kanamycin resistant; Spcr,
spectinomycin resistant; Tcr, tetracycline resistant; ORF, open reading frame

316
Table 8.2 Primers used in this study.
Primer

Sequence (5’-3’)

Construction primer
MBH152
forward
MBH153
reverse
MBH154
forward
MBH155
reverse
MBH225
forward
MBH226
reverse
MBH239
forward
MBH255
reverse
MBH338
forward
MBH341
reverse
5’-RACE primer
5’ RACE-Adapter
NWMN_0640-RT
citB-RT
RACE_PCR_5’
NWMN_0640-PCR
Cit-PCR
Northern probe primer
MBH279
forward
MBH280
reverse
MBH281
forward
MBH282
reverse
Real-time RT PCR primer
Bs ccpC
forward
Bs ccpC
reverse
ccpE
forward
ccpE
reverse
citB
forward
citB
reverse
Bs citB
forward
Bs citB
reverse
citZ
forward
citZ
reverse
gyrB
forward
gyrB
reverse
Bs gyrB
forward
Bs gyrB
reverse
EMSA primer
ccpE
forward
ccpE
reverse
citBp
forward
citBp
reverse
citZp
forward
citZp
reverse
NWMNforward
0640P
NWMN0640P

reverse

GCAAATTGAGCTCTATCTTTAGAGC
gtcgGATCCGAGCATGTTGCAATTGCC
gtcggtacCTGGCGTCGCCTAATTGATAGG
gtcctcgaGTATGGCTGCAGCTTGAATTAC
gtcggatcCAGAATAGATTTGATGCTTCAGC
gtcggtACCAACTACGTTCAATTTAACCG
ggggtcgacACCAACTACGTTCAATTTAACCG
gtcggtaccTGATTTTCAATATCATATGTATCAC
GCATGTCFACCTCCTTTTTGTTATCAATAAG
ctgtctAGATCAACGATATAGAGACAGGG
GAUAUGCGCGAAUUCCUGUAGAACGAACACUAGAAGAAA
TCTACTGTACACGCATTACC
ACGTCATCCATTGCTTTACG
GATATGCGCGAATTCCTGTAGAACG
CGTGACTAAGCCTATAATACCC
GTAATACCTTGCTCTTCTACAGC
GGTATTATAGGCTTAGTCACG
GCAGTACATGATTTTCTTTTGG
AGACGAAACGAAAACGTTACG
GTAACTTTGTAACATCATCTCG
TGTGGAAAAGTATCCGAATGCA
CTGCTCCACCCGGTTATGA
CCGCTGATTCGTTCGACAT
CAATTGCAACATGCTCGGAT
CAAGATCATCAAGTGCCTATTCGT
CGTGATTACCACGTCTTGAACC
TAATCGGCGCGCGAAACTTGTC
CAGTAGCTATTGTTCCGTTTGG
CCGTAGGTTCTCTGAAAGGGC
AACATCGTCATAACTTGTTCGTTTG
GACTGATGCCGATGTGGA
AACGGTGGCTGTGCAATA
CATTGGCGAAACGGATCATA
GGGTCCGGGACAAAATGTG
CAAATAAAGCCTAAGCAATAT
AGTAAACGATAGTCTTCAATC
ATCATTTCTGTCCCACTCCCATC
GTAAGTATAACTTTGGCCATTCAAGTC
ATTGTAAAATTCATGGATTATTCAC
CTAAACCTCTTTGTAATTCTGCCAT
GTGATCAATGAAGTGGTTTGAAGG

CTTTTACCTCTGTGTATTCCCTATC
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8.2.2 Construction of a S. aureus ∆ccpE mutant
1 kb fragments, containing the flanking regions of the ccpE (NWMN_0641) gene
were amplified by PCR from chromosomal DNA of S. aureus strain Newman using
primer-pairs MBH154/MBH155 and MBH152/MBH153, respectively (primer sequences
are listed in Table 8.1). The PCR products were digested with KpnI/XhoI and
BamHI/SacI, respectively, and cloned together with the XhoI/BamHI digested lox66aphAIII-lox71 resistance cassette (obtained from pBT2-arcA) into suicide vector pBT to
generate plasmid pTH2. Plasmid pTH2 was electroporated into S. aureus strain RN4220
to obtain strain THa, in which the ccpE gene was replaced by the lox66-aphAIII-lox71
cassette by allelic replacement. THa was then used as a donor for transducing the ccpE
deletion into other S. aureus strains. The marker-free ∆ccpE mutant TH01 of S. aureus
strain Newman was constructed by treatment with the Cre recombinase expressed from
the temperature-sensitive vector pRAB1,17 which was subsequently removed from TH01
by culturing the strain at 42°C. The deletion of ccpE in TH01 was confirmed by PCR,
pulsed-field gel electrophoresis (PFGE) of total genome SmaI digests, and DNA
sequencing.
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Figure 8.1 Schematic representation of the ccpE region of S. aureus and the strategies
used to obtain the ΔccpE mutant TH01 and the cis-complemented derivative TH01c. 1)
genetic organization of the S. aureus Newman ccpE region. Open reading frames
(arrowed boxes) and promoters (vertical arrows) are indicated. 2) a 3-kb fragment
containing the lox66-aphAIII-lox71 resistance cassette and the flanking regions of the
ccpE gene was cloned into the vector pBT to generate plasmid pTH2. 3) plasmid pTH2
was electroporated into S. aureus strain RN4220 to obtain THa (RN4220 ΔccpE::lox66aphAIII-lox71), which was used as a donor for transducing the aphAIII-tagged ccpE
deletion into other S. aureus strains. 4) a marker-free ΔccpE mutant of S. aureus strain
Newman was obtained by treating a ΔccpE::lox66-aphAIII-lox71 positive derivative of
strain Newman with a Cre recombinase. Dotted lines between 3 and 4 indicate the region
removed by Cre. 5) a 2-kb fragment covering the ccpE ORF and 1 kb of the upstream
region including the NWMN_0640 ORF was cloned into the vector pBT to generate
plasmid pTH2c. 6) a dam- and dcm-methylation free aliquot of plasmid pTH2c was
directly electroporated into TH01 to obtain Th01c.
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8.2.3 Construction of the S. aureus ccpE cis-complementation strain TH01c
For the cis-complementation of the ccpE mutation in strain TH01, a 2 kb fragment
containing the wild-type ccpE allele and 1 kb of the upstream region including the
NWMN_0640 open reading frame, was amplified by PCR from chromosomal DNA of S.
aureus strain Newman using the primer-pair MBH225/MBH226. The resulting PCR
product was digested with BamHI/KpnI, and subsequently cloned into BamHI/KpnIdigested vector pBT to generate the suicide plasmid pTH2c. The plasmid was
transformed into and purified out of the dam- and dcm-negative E. coli strain SCS110
(Stratagene), and electroporated into S. aureus strain TH01 to obtain the ciscomplementation strain TH01c (TH01∆ccpE::pTH2c). Restoration of the ccpE wild-type
gene was verified by sequencing of the respective DNA fragment.

8.2.4 Construction of the B. subtilis ccpC promoter - B. subtilis ccpC and B. subtilis ccpC
promoter - ccpE trans-complementation plasmids
Nucleotide sequences covering the B. subtilis ccpC promoter and gene were
amplified by PCR from B. subtilis strain AF21 using the primer pairs MBH341/MBH255
and cloned into XbaI/KpnI digested shuttle vector pBus1.18 Similarly, the ccpE gene from
S. aureus strain Newman was amplified by PCR using primers MBH239/MBH226 and
the ccpE fragment was digested with SalI/KpnI and cloned into pBus1 that was digested
with the same restriction enzymes. The ccpC promoters P1 and P2 were amplified by
PCR by using primer pair MBH341/MBH338 and B. subtilis strain AF21 DNA. The PCR
product was digested with XbaI/SalI and cloned into pre-digested pBus1 harboring the S.

320
aureus ccpE open reading frame. The resulting plasmids, pTH3 (Bs ccpC P1/2-ccpC) and
pTH4 (Bs ccpC P1/2-Sa ccpE fusion), were used to transform competent cells of CJB9 or
to electroporate RN4220. The resulting derivatives of RN4220 were then used as a donor
for transducing it into S. aureus strain TH01.

8.2.5 Aconitase activity assay
Aliquots (2 mL) of bacteria were harvested after 3, 6, 9 and 12 h of growth in LBL, and suspended in 850 µL lysis buffer (90 mM Tris pH 8.0 and 100 µM fluorocitrate).
Bacteria were mechanically disrupted in a Fast Prep instrument (Qbiogene, Heidelberg,
Germany) at a speed of 6.0 for 30 sec. The lysate was centrifuged for 1 min at 15,000 x g
and 4°C. Aconitase activity was assayed in the cell-free lysate as described previously.20
One unit of aconitase activity was defined as the amount of enzyme necessary for a ∆A240
min-1 of 0.0033.21 Total protein concentrations were determined according to the method
described by Bradford.22

8.2.6 Citrate synthase activity assay
Citrate synthase activity was determined with the Citrate Synthase Assay Kit
purchased from Sigma-Aldrich (Taufkirchen, Germany) with slight modifications.
Aliquots (2 mL) of bacteria were harvested after 3, 6, 9 and 12 h of growth in LB-L and
suspended in CelLytic M Cell Lysis Reagent. Bacteria were mechanically disrupted in a
Fast Prep instrument (Qbiogene) at a speed of 6.0 for 30 sec. The lysate was centrifuged
for 1 min at 15,000 x g at 4°C, and 10 µL of the cell free lysate was mixed at room
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temperature with 0.1 mM 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) and 0.3 mM
acetyl coenzyme A (CoA) in 1x Assay buffer (Sigma-Aldrich). The solution was mixed
gently, and the absorbance of the reaction mixture at 412 nm (A412) was followed for 1.5
min to obtain a background reading. After the addition of 0.5 mM oxaloacetate (OAA),
the absorbance of the reaction mixture at A412 was monitored for an additional 1.5 min to
detect the formation of 5-thio-2-nitrobenzoic acid (TNB). Citrate synthase activity units
were calculated as micromoles of TNB produced (i.e., CoA-SH released) per minute per
milligram of total protein (µmol/min/mg). Total protein concentrations were determined
according to the method described by Bradford.22

8.2.7 Determination of citrate by GC/MS
Lyophilized cell pellets (10 mg dry weight) of Newman, TH01, and TH01c (each
harvested after 8 h of growth in LB-L) were combined with 0.5 mL glass beads (Roth,
Karslruhe, Germany; 0.25 – 0.5 mm diameter) and 1 mL of deuterated methanol
(MeOD4) was added. This mixture was subjected to homogenizer lysis (FastPrep FP120,
QBiogene, USA; 3 cycles each of 20 s at 6.5 m/s). After cell disruption, the cell debris
and glass beads were separated by centrifugation (10 min at 5,000 rpm). The supernatant
(0.5 mL) was dried under a stream of nitrogen. The residue was dissolved in 50 µL of
methoxyamine hydrochloride (solution of 20 mg per mL pyridine) and reacted at 30°C
for 90 min. 50 µL of N-methyl-N-(trimethylsilyl) trifluoroacetamide with 1 %
trimethylclorosilane (Fluka, Germany) were added and the mixture was incubated at
37°C for 30 min. GC/MS analyses were performed on a GC/MS Shimadzu QP 2010 Plus
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(Shimadzu, Duisburg, Germany) equipped with a fused silica capillary column (Equity
TM-5; 30 m × 0.25 mm, 0.25 µm film thickness; SUPELCO, Bellafonte, PA) and a QP5000 mass selective detector (Shimadzu, Duisburg, Germany) working with electron
impact ionization at 70 eV. An aliquot (1 µL) of the solution was injected in 1:10 split
mode at an interface temperature of 250°C and a helium inlet pressure of 76 kPa. The
column was developed at 70°C for 5 min and then with a temperature gradient of
5°C/min to a final temperature of 310°C that was held for 1 min. Data were collected
using the LabSolutions software (Shimadzu, Duisburg, Germany). Compound peaks were
assigned by comparison of the resulting mass spectra with those of a spectral library
(NIST05, Shimadzu) and with data of injected reference samples under the same
conditions.

8.2.8 Transcriptional analyses
For Northern blot experiments, overnight cultures of S. aureus were diluted to an
A600 of 0.05 into fresh pre-warmed LB-L and grown at 37°C and 230 rpm. Samples were
removed from the culture at the indicated times and centrifuged at 9,000 × g and 4°C for
2 min, the culture supernatants were discarded, and the cell pellets were snap frozen in
liquid nitrogen. Total RNAs were isolated according to,23 and blotting, hybridization, and
labeling were performed as described previously.24 Primer pairs MBH279/MBH280 and
MBH281/MBH282 were used to generate digoxigenin-labeled NWMN_0640- and ccpEspecific probes by PCR labeling, respectively.
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For the quantification of transcripts by real-time RT-PCR, RNA isolations and
real-time RT-PCRs were carried out essentially as described in (17).25 The obtained
cDNA was used for real-time amplification with specific primers (Table 8.1) and 20 ng
of cDNA per reaction. mRNA levels were normalized against the mRNA level of gyrB,
which is constitutively expressed under the conditions analyzed.26 The amounts of
different transcripts were expressed as the n-fold difference relative to the control gene
(2-∆CT, where ∆CT represents the difference in threshold cycle between the target and
control genes).

8.2.9 Determination of transcriptional start sites of NMMN_0640 and citB
Strain Newman TF was grown for 3h as described and the bacteria were harvested
by centrifugation at 8,000 × g for 10 min. RNA isolation was carried out as described
above. The transcriptional start points of NMMN_0640 and citB were determined by
rapid amplification of cDNA ends essentially as described by (19).27 The reverse
transcription of 8.2 µL of the ligated RNA was carried out with NMWN_0640 or citB
specific primers (Table 8.1) with the High Capacity cDNA Reverse Transcription Kit
(Life Technologies) according to the manufacturer’s instructions. 2 µL of the cDNA was
ampliﬁed by PCR using a primer complementary to the RNA adapter sequence, and a
specific primer for NMWN_0640 or citB (Table 8.1) closer to the 5’-end than the primers
used for the reverse transcription. Finally, the PCR products were sequenced.

8.2.10 Antibody production and Immunoblotting
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Polyclonal anti-CcpE antibodies were raised by injecting 500 µg of the His-tagged
recombinant CcpE into rabbits (Eurogentec, Liege, Belgium). The resulting crude
antisera were purified against the immobilized CcpE antigen. For the determination of
CcpE, cytoplasmic protein extracts were isolated from S. aureus cell cultures grown for
3, 6, 9 and 12 h in LB-L at 37°C as described previously,28 and protein fractions (20
µg/lane) were separated using SDS-PAGE, blotted onto a nitrocellulose membrane, and
subjected to Western blot analysis using the antigen-purified polyclonal anti-CcpE
antiserum.

8.2.11 Electrophoretic Mobility Shift Assays
The DNA probes for electrophoretic mobility shift assays (EMSAs) were
generated by PCR using S. aureus strain Newman chromosomal DNA as a template, and
primer pairs (listed in Table 8.1) that amplified the DNA regions preceding the ccpE,
citB, citZ, and NWMN_0640 ORFs. The 5’-ends of the double-stranded PCR products
were labeled using [ɣ-32P] ATP and T4 polynucleotide kinase. A typical assay mixture
contained (in 20 µL) 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM DTT,
0.1 µg of nonspecific competitor (poly(dI-dC)), 5% (v/v) glycerol, radioactive DNA
probe (2000 cpm mL-1), and various amounts (0, 15, 65, 130, and 200 nM) of purified
CcpE. After 30 min of incubation at room temperature, 20 µL of this mixture was loaded
into a native 4% (w/v) polyacrylamide Tris borate-EDTA Ready Gel (Bio-Rad) and
electrophoresed in 1% Tris borate-EDTA (v/v) buffer for 1 h at 100 V cm-1. Radioactive
species were detected by autoradiography using direct exposure to films.
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8.2.12 NMR Sample preparation
S. aureus strains were grown in filter-sterilized Luria-Bertani Lennox (LB-L)
medium (BD, Heidelberg, Germany) supplemented with 0.1% glucose (Sigma-Aldrich).
Bacteria from overnight cultures were diluted into pre-warmed medium to an optical
density at 600 nm (OD600) of 0.05. All bacterial cultures were incubated at 37oC under
aerated conditions at 225 rpm with a flask-to-medium ratio of 10:1. For two-dimensional
(2D) 1H, 13C HSQC analysis LB-L medium containing 0.1% 13C6-glucose (Cambridge
Isotope Laboratories) was used for main cultures. NMR samples for intracellular
metabolite analysis were prepared from independent cultures in exponential (3 h) and
post-exponential (8 h) growth phase. The extraction of the metabolome from cell lysates
followed our previously published protocols.29,30

8.2.13 NMR data collection, analysis and interpretation
Followed as previously published.29,30

8.2.14 Statistical analyses
Statistical significance was assessed using Student’s t-test or Mann–Whitney U
test. P values < 0.05 were considered significant.

8.3 Results
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8.3.1 Identification of potential carbon metabolism-affecting factors in S. aureus strain
Newman
A bioinformatic comparison of the genomes of B. subtilis isolate 168 (Genbank
acc. no. AL009126.3) and S. aureus strain Newman (acc. no. AP009351.1) suggested the
strain Newman genome might have genes whose products have been associated with
carbon catabolite repression (CCR) in B. subtilis (reviewed in reference 1). One
uncharacterized gene was NWMN_0641 (renamed here as ccpE), which shared 61%
similarity and 35% identity to the B. subtilis citrate-responsive regulator CcpC, and like
CcpC it was predicted to encode for a putative transcriptional regulator of the LysR
family. These observations and the fact that CcpC is a regulator of tricarboxylic acid
(TCA) cycle genes citZ (encoding citrate synthase) and citB (encoding aconitase)6, led us
to examine the function of CcpE in S. aureus.

8.3.2 Transcriptional organization of the ccpE locus in S. aureus strain Newman
Our microarray analysis of σB-mediated transcriptional changes suggested that
ccpE might form a bi-cistronic operon with the open reading frame (ORF)
NWMN_0640.31 Further bioinformatic analysis of this region suggested that both genes
were likely controlled by a promoter located upstream of NWMN_0640. To test this
suggestion, we assessed the transcription of NWMN_0640 and ccpE by Northern blotting
(Figure 8.1a). This Northern blot analysis revealed ccpE-specific transcripts with sizes of
approximately 4.1-, 2.9-, 2.3-, and 1.5-kb. The 2.9- and 1.5-kb transcripts migrated on the
gel to the same extent as the 16S- and 23S rRNAs; hence, they might represent
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degradation products of higher molecular weight transcripts. That being said, all
transcripts were detectable throughout the growth cycle and the transcription profiles of
ccpE and NWMN_0640 were nearly identical. Based on these results, and on the genetic
organization of the ccpE locus (Figure 8.1b), we hypothesized that all transcripts
originate from a single promoter in front of NWMN_0640, which would give rise to a
NWMN_0640/ccpE encoding 2.3-kb transcript, and a larger NWMN_0640/ccpE
/NWMN_0642/3 encoding 4.1-kb transcript.
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Figure 8.2 Transcriptional organization of the ccpE locus of S. aureus Newman
A, Northern blot of NWMN_0640 and ccpE transcriptions in strains Newman, TH01
(ΔccpE), and the complemented TH01c during growth in LB-L. Approximate transcript
sizes are indicated on the left. Ethidium bromide-stained 16 S rRNA are presented to
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indicate equivalent RNA loading. B, schematic representation of the ccpE region of S.
aureus. Proposed ORFs, promoters, terminators, and transcripts identified by Northern
analyses are indicated. ORF notations and nucleotide (nt) numbers correspond to those of
the respective genomic regions of strain Newman (GenBank accession
number AP009351.1). C, nucleotide sequence of the region preceding the NWMN_0640
open reading frame. The transcriptional start point identified by RACE (bent arrow),
putative −35 and −10 boxes (boxes), terminator sequences (hatched lines), and primers
used to amplify the NWMN_0640-ccpE promoter fragment used in EMSA (horizontal
arrows) are indicated. D, binding activity of CcpE to the DNA regions preceding the
NWMN_0640 and ccpE ORFs. The PCR-amplified DNA fragments were radioactively
labeled and incubated with the amount of purified CcpE indicated. The results are
representative of at least two independent experiments. E, Western blot analysis of CcpE
in cytosolic extracts of strains Newman, TH01, and TH01c cells grown in LB-L to the
time points indicated. The results are representative of at least two independent
experiments.
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Figure 8.3 Growth characteristics of S. aureus strain Newman (black symbols), TH01
(white symbols), and TH01c (gray symbols). Culture media pH and A600values during
growth in LB-L medium (A) and LB-L supplemented with 0.1% glucose (B). Time points
of sampling for downstream applications (enzyme assays, qRT-PCRs) are indicated
byarrows. The data presented are mean ±S.D. of at least three independent experiments.
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Student's t test *, p < 0.05; **, p < 0.01. C, glucose, acetate, and ammonia concentrations
in the culture supernatants of Newman (black bars), TH01 (white bars), and TH01c (gray
bars) cell cultures grown in LB-L + 0.1% glucose. The data presented are mean ±S.D. of
at least three independent experiments done in duplicate. Mann-Whitney U test. **, p<
0.01.

To identify the transcriptional start point (TSP) of NWMN_0640, we performed a
5`RACE experiment which identified a TSP 14 bp upstream of the proposed start point of
the NWMN_0640 open reading frame, and immediately upstream of the putative
ribosomal binding site of this ORF (Figure 8.1c). The TSP is preceded by the nucleotide
sequence ATGACA-17-TATAAT that strongly matched with the -35 and -10 hexamers
identified in the promoters of genes shown to be transcribed by S. aureus σA containing
RNA-polymerase.32,33
Since many LysR-type of regulators display autocrine regulation of their own
transcription,34 we determined the capacity of CcpE to bind to its own promoter. To do
this, purified CcpE was used in electrophoretic mobility shift assays with a PCR probe
covering the genomic region preceding the NWMN_0640 ORF (Figure 8.1d). As
expected, a clear, dose-dependent shift with CcpE and the radioactive-labeled
NWMN_0640 promoter probe fragment was observed, suggesting that CcpE affects its
own transcription. This DNA binding activity was specific, as an EMSA using a DNA
probe covering the region preceding the ccpE ORF did not cause a mobility shift. Taken
together, our data suggest that ccpE is transcribed in a bi-cistronic message using a
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promoter upstream of NWMN_0640, and that this promoter is subjected to autocrine
regulation by CcpE.

8.3.3 Inactivation of ccpE in S. aureus strain Newman
Using the cre-lox based deletion system described by Leibig and colleagues,17 we
created a marker-less deletion of ccpE in S. aureus strain Newman, giving rise to strain
TH01. In addition, a cis-complemented derivative was created by integrating the
NWMN_0640/ccpE containing suicide plasmid, pTH2c, into the deletion site of strain
TH01, resulting in strain TH01c. Sequencing of the respective genome regions confirmed
the mutations occurred as expected. Further, Northern blot analysis qualitatively
confirmed that strain TH01 did not produce a ccpE-specific transcript, while strain
TH01c expressed ccpE at a level comparable to that of the wild-type strain (Figure 8.1a).
Probing total RNA from TH01 and TH01c with a NWMN_0640-specific probe also
confirmed the deletion of ccpE in TH01, as we detected in strain TH01 NWMN_0640specific transcripts of approximately 3.3- and 1.5-kb. These mRNA sizes are consistent
with the deletion of 800 bp of the ccpE locus in this mutant. Importantly,
complementation restored all NWMN_0640-specific transcripts found in the wild-type
strain and also transcripts that were identified in TH01. This latter result was expected
due to our complementation strategy that created a duplication of the NWMN_0640 gene
due to the insertion of the suicide plasmid pTH2c in the NWMN_0640 open reading
frame. Taken together, these data confirmed that the correct gene was inactivated and that
wild-type transcription profiles could be restored by complementation.
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To assess the production of CcpE in S. aureus, rabbit polyclonal antibodies were
generated against CcpE and used in Western blot analyses of cytosolic protein fractions
from strains Newman, TH01, and TH01c grown in LB-L (Figure 8.2). In these anti-CcpE
Western blots, 33 kDa bands in both the wild-type strain and complemented strain TH01c
were observed throughout the growth cycle and, as expected, this band was absent in the
ccpE mutant strain TH01. These data were consistent with the Northern data (Figure
8.1a) and indicated that CcpE accumulated in the cytosols of the wild-type and TH01c
strains during the later stages of growth.

8.3.4 CcpE affects the in vitro growth yield of S. aureus
To determine if ccpE inactivation affected the physiology of S. aureus, we
assessed the growth and the culture medium pH profiles of strains Newman, TH01, and
TH01c in LB-L medium in absence or presence of 0.1% supplemental glucose (Figure
8.3a). In LB-L medium lacking glucose, strain TH01 displayed a slight decrease in the
growth yield relative to the wild-type and TH01c strains (Figure 8.3a). Additionally, the
pH of the culture medium for strain TH01 was less alkaline than for the wild-type and
TH01c strains, indicating that the ccpE mutant was either impaired in amino acid
catabolism or that the accumulation or depletion of organic acids has changed.
Supplementation of LB-L with 0.1% glucose increased the overall growth yields of all
three strains relative to cultures grown in LB-L, but it did not alter the growth rate
(Figure 8.3b). The similarity of the growth rates but the differences in growth yields
suggested that exponential growth phase metabolism was similar but that post-
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exponential growth phase metabolism was altered. Consistent with this suggestion, the
pH profiles and glucose, acetate, and ammonia accumulation in the medium were nearly
identical up until the post-exponential growth phase (Figure 8.3). In the post-exponential
growth phase, the culture medium of strain Newman and TH01c began to alkalinize as
acetate was extracted from the medium for catabolism via the TCA cycle, and ammonia
accumulated due to the deamination of amino acids (Figure 8.3c). In contrast to strains
Newman and TH01c, alkalization of the culture medium from strain TH01 was very
slow, as both acetate catabolism and ammonia accumulation were repressed. This
reduced ability to catabolize acetate and amino acids was also reflected in the decreased
biomass generation and final growth yield. As acetate catabolism and amino acid
catabolism were repressed, these data suggested that ccpE inactivation
inhibited/decreased TCA cycle activity.

8.3.5 Deletion of ccpE alters the S. aureus metabolome
The deletion of ccpE changed the accumulation and depletion of organic acids in
the culture medium and the pH profile (Figure 8.3), suggesting that ccpE inactivation
caused significant metabolic changes. To test this hypothesis, strains Newman, TH01,
and TH01c were grown in LB-L medium containing 0.1% 13C-glucose and the
metabolomes were analyzed by NMR spectroscopy. The metabolomic analysis of strains
Newman, TH01, and TH01c grown in LB-L medium containing 0.1% 13C-glucose
provided a metabolic snapshot of the exponential (3 h) and post-exponential (8 h) growth
phases (Figure 8.4). Consistent with growth and pH profiles for the strains (Figure 8.3b),
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an exponential growth phase PCA plot (Figure 8.4a) revealed no significant differences
in the metabolomes of strains Newman, TH01, and TH01c. In contrast to the exponential
growth phase, ccpE inactivation had a major effect on post-exponential growth phase
metabolism (Figure 8.4b-e). In particular, carbon flow through the TCA cycle was
reduced as evidenced by the accumulation of citrate and the shunting of pyruvate into
fermentative pathways. The accumulation of citrate in strain TH01 was also confirmed in
bacteria cultivated in LB-L without glucose, using gas chromatography-mass
spectrometry (GC-MS) (Figure 8.5). The metabolic block in the TCA cycle created by
ccpE inactivation led to a reduction in the intracellular concentrations of glutamate and
glutamine, which affects the availability of nitrogen donors. The decreased ammonia
assimilation via glutamate to glutamine may be the cause for an increased concentration
of asparagine, which is generated by amination of aspartate via asparaginase. In
summary, we can conclude that CcpE is involved in regulating carbon flow through the
TCA cycle, independent of glucose or its catabolic products.
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Figure 8.4 Effect of the ccpE deletion on the metabolome of S. aureus strain
Newman. Aand B, two-dimensional PCA scores plots generated from the entire onedimensional 1H NMR spectra of the exponential growth phase (3 h) metabolomes (A),
and post-exponential growth phase (8 h) metabolomes (B) of strains Newman (black
triangles), TH01 (red triangles), and TH01c (gray triangles). C, two-dimensional1H, 13CHSQC difference spectrum showing the post-exponential growth phase differences
between strains Newman (green) and TH01 (red). D, a heat map of six independent
replicates showing the major differences in metabolites produced in post-exponential
growth phase by strain TH01 in relationship to strain Newman. Relative concentration
changes were plotted as outlined under “Experimental Procedures,” using a color-scale
from −1 (red) to 1 (green). The dendrogram depicts hierarchal clustering of the
metabolite concentration changes, where metabolites exhibiting the same relative trend
and magnitude changes across all replicates are clustered together (n = 6). A
Student's t test was used to determine the statistical significance of each metabolites
change between the TH01 and Newman strains (*, p < 0.05).
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Figure 8.5 CcpE-dependent changes in the metabolome of S. aureus. A, a cytoscape
map showing the changes in the central metabolism associated with ccpE inactivation. B,
overlays of representative GC/MS profiles of Newman, TH01, and TH01c whole cell
extracts of 8-h LB-L cultures. The elevated citrate peak observed with TH01 is indicated.

8.3.6 Inactivation of ccpE affects transcription of TCA cycle genes and its activity
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The CcpE open reading frame in S. aureus was identified based on its homology
to CcpC in B. subtilis. CcpC is involved in the regulation of the TCA cycle genes citZ
and citB;5,6,8 hence, we hypothesized that CcpE might regulate the same TCA cycle genes
in S. aureus. To test this assumption, transcription of the TCA cycle genes citZ and citB
was assessed by qRT-PCR in strains Newman, TH01, and TH01c grown in LB-L
medium (Figure 8.6). In the wild-type strain Newman, citZ and citB mRNAs were at the
highest levels just prior to the post-exponential growth phase (Figure 8.6a). Inactivation
of ccpE decreased transcription of both citB and citZ; however, the effect on citB was
more dramatic. Complementation of the ccpE mutation restored citZ and citB
transcription to levels similar to that in the wild-type strain. Thus, in order to determine if
the differences in citB and citZ transcription were reflected in enzymatic activity changes,
the activities of citrate synthase and aconitase were measured in the wild-type, TH01, and
TH01c strains as well (Figure 8.6b). Consistent with the transcriptional data, citrate
synthase activity was decreased in strain TH01 at 3 h of growth only, while aconitase
activity was significantly decreased in TH01 cells in all growth phases. Also consistent
with the transcriptional data, complementation of the ccpE mutation restored citrate
synthase and aconitase enzymatic activities to those in the wild-type strain, strongly
suggesting that CcpE is a major positive transcriptional regulator of citB in S. aureus.
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Figure 8.6 Transcription and activity of citZ and citB in strain Newman and its
derivatives. A, quantitative transcript analysis of citZ andcitB by qRT-PCR of strains
Newman (black bars), TH01 (white bars), and TH01c (gray bars) during growth in LBL. mRNA levels are expressed relative to gyrase B (in numbers of copies per copy
of gyrB). The data presented are mean ±S.D. of four independent experiments each
determined in duplicate. B, enzyme activities of citrate synthase, and aconitase of strains
Newman (black bars), TH01 (white bars), and TH01c (gray bars) during growth in LBL. The data are presented as the mean ±S.D. of three independent experiments done in
duplicate. Mann-Whitney U test *, p < 0.05; **, p < 0.01. C, EMSA using purified CcpE
and the DNA probes generated from the citB and citZ promoters. The PCR-amplified
DNA fragments were radioactively labeled and incubated with the amount of purified
CcpE indicated. The results are representative of at least two independent experiments.

340
8.3.7 CcpE binds to the citB promoter
To assess whether CcpE might directly regulate transcription of citB and citZ by
binding to the respective promoters, we performed EMSAs using the citZ and citB
promoters as probes (Figure 8.6c). The probe generated from the citB promoter shifted
with CcpE in a dose-dependent manner; however, the citZ promoter region was not
shifted by CcpE, suggesting that CcpE directly controls the expression of citB but not
citZ. The similarity of CcpE to CcpC and the fact that citrate accumulated when ccpE was
inactivated, led us to determine if citrate would influence CcpE DNA binding activity. In
contrast to B. subtilis CcpC, the binding activity of CcpE was independent of the
concentration of citrate in the binding buffer. Similarly, the CcpE binding was
independent of NAD+ and NADH. These data suggest that CcpE is not a functional
ortholog of CcpC, but a newly described TCA cycle regulator.

8.3.8 CcpE is not a functional homolog of CcpC
In B. subtilis, CcpC regulates transcription of TCA cycle genes in response to
changes in citric acid, and inactivation of ccpC increases the exponential growth phase
transcription of citB.6 Although ccpE inactivation decreases citB transcription and its
DNA binding properties are not altered by citric acid; out of an abundance of caution, we
assessed whether the S. aureus ccpE gene could complement a B. subtilis ccpC mutant
and whether the B. subtilis ccpC gene could complement our S. aureus ccpE mutant. To
do this, plasmids having ccpC under the control of its native promoter (pTH3) and a
fusion plasmid harboring the B. subtilis ccpC P1 and P2 promoters fused to the S. aureus
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ccpE ORF (pTH4) were constructed. These plasmids were transformed into TH01 and
the B. subtilis ccpC mutant CJB9,6 respectively, and the final transformants were tested
for CcpE by Western blotting and citB, ccpC, and ccpE transcription using qRT-PCR
(Figure 8.7). As expected, citB transcription was increased in the B. subtilis ccpC mutant
strain CJB9 when grown in TSS minimal medium supplemented with 0.2 % (w/v)
glutamine and 0.5 % (w/v) glucose. Complementation of strain CJB9 with ccpC under
the control of its native promoter, plasmid pTH3, restored citB transcription to wild-type
levels. In contrast, transforming strain CJB9 with plasmid pTH4, harboring the S. aureus
ccpE under the control of the B. subtilis ccpC P1 and P2 promoters, failed to revert citB
transcription to wild-type levels. To exclude that the inability of CcpE to restore wildtype citB mRNA levels was due to the fact that it was not transcribed or translated, we
assessed the ccpE transcription using qRT-PCR and CcpE translation by Western
blotting. In strain CJB9 containing plasmid pTH4, ccpE was strongly transcribed and
CcpE was produced in large quantities (Figure 8.7a), demonstrating that the inability of
ccpE to complement a ccpC mutation was neither due to a failure of transcription nor
translation. Similarly, transforming strain TH01 with plasmids pTH3 (containing ccpC)
or pTH4 (containing ccpE) increased citB transcription to wild-type levels with ccpE but
not ccpC (Figure 8.7b). Taken together, these data demonstrate that CcpE is not a
functional homolog of CcpC.
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Figure 8.7 Trans-complementation ofB. subtilis ccpC and S. aureus ccpE mutants. A,
Western blot analysis of CcpE in cytosolic extracts of B. subtilis strains AF21, CJB9
(AF21::ccpC), CJB9 + pTH3 (ccpC under the control of its native promoters), CJB9 +
pTH4 (ccpC P1/2-ccpE fusion), S. aureus strains Newman, TH01, TH01 + pTH3, and
TH01 + pTH4 after growth in LB-L for 6 h. The results are representative of at least two
independent experiments. B, quantitative transcript analyses of ccpC, ccpE, and citB by
qRT-PCR of B. subtilisderivatives grown in TSS minimal medium supplemented with
0.2% (w/v) glutamine and 0.5% (w/v) glucose, and S. aureus derivatives grown in LB-L
to the mid-exponential growth phase. The data presented are mean ±S.D. of four
independent experiments each determined in duplicate. #, transcripts below detection
limits.
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8.4 Discussion
Central metabolism provides S. aureus with the thirteen biosynthetic
intermediates from which it derives all macromolecules; hence, central metabolism is
critically important for growth and survival.35 The TCA cycle is one component of
central metabolism that provides the bacterium with energy, reducing potential and three
of the thirteen biosynthetic intermediates. When these 13 biosynthetic intermediates, or
the amino acids, nucleic acids, fatty acids, etc. that these intermediates produce, are
exogenously available, TCA cycle activity is largely repressed.36 In the presence of
readily catabolizable carbohydrates, such as glucose, transcription of TCA cycle genes is
repressed by CcpA.37 Similarly, transcription of TCA cycle genes is repressed by CodY,
a highly conserved Gram-positive repressor that responds to intracellular concentrations
of branched-chain amino acids (BCAA) and GTP.12 When nutrients become growth
limiting, transcription of TCA cycle genes is de-repressed and TCA cycle activity
dramatically increases, allowing for the utilization of incompletely oxidized organic acids
that accumulated in the culture medium.38 This utilization of organic acids through the
TCA cycle allows S. aureus to generate biosynthetic intermediates needed for precursor
and macromolecular synthesis by shunting carbon into gluconeogenesis via PEP. In other
words, the TCA cycle is an important metabolic pathway that facilitates S. aureus
adaption to a nutrient-limited environment. The importance of the TCA cycle to the
success of S. aureus as a pathogen is illustrated by mutagenesis studies that identified
TCA cycle mutants to be attenuated in different mouse models39,40 and a Caenorhabditis
elegans-killing model.41,42 More recently, the significance of TCA cycle activity during
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the course of infection was also suggested by a study from Chaffin and colleagues,43
where it was observed that citB transcription increased over time in a mouse pneumonia
model.
The importance of the TCA cycle in metabolism, survival, and virulence factor
synthesis, led us to search the S. aureus genomic DNA sequence for TCA cycle
regulators that are present in B. subtilis. One such regulator that is present in B. subtilis
but undescribed in S. aureus is CcpC. We identified a homologue of CcpC in the S.
aureus genome, which we named CcpE. At the amino acid level, CcpE is similar to the B.
subtilis CcpC; however, the similarities end there. Deletion of ccpE in S. aureus
dramatically decreased transcription of citB and to a lesser extent citZ. This decreased
transcription resulted in decreased TCA cycle activity, causing a metabolic block in the
TCA cycle that increased the intracellular citrate concentration. The increased citrate
accumulation and the inability to effectively fully oxidize carbohydrates likely caused the
decreased growth yield. These data are in stark contrast to that of CcpC where
inactivation of ccpC in B. subtilis de-represses citB and citZ transcription.6 Also unlike
CcpC, the DNA binding activity of CcpE is not dependent upon the concentration of
citrate. In summary, CcpE is a major positive regulator of TCA cycle activity that binds
DNA independent of the citrate concentration.
TCA cycle activity has been also associated with virulence in staphylococci. In S.
aureus, TCA cycle activity was found to be critical for the elaboration of a capsule.44 In
contrast, TCA cycle activity negatively affects synthesis of polysaccharide intercellular
adhesin and biofilm formation.45 Because CcpE increases TCA cycle activity in S.
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aureus, it is likely that CcpE activity will affect virulence determinant biosynthesis and
pathogenesis. Experiments are ongoing to address this question. Moreover, another
unresolved question is what metabolite/co-factors alter the DNA binding properties of
CcpE. We know some that do not affect CcpE binding to DNA; namely, citrate and
NAD+/NADH. Lastly, we are in the process of identifying the DNA binding site for
CcpE.
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CHAPTER 9
OVEREXPRESSION AND PURIFICATION OF ISOTOPICALLY LABELED CTERMINAL DOMAIN OF RPIRA FOR NMR STUDIES
9.1 Introduction
Staphylococcus aureus is a life-threatening human pathogen associated with
biofilm formation on implantable medical devices.1 Biosynthesis of virulence factors that
can determine the pathogenicity of staphylococci is found to be regulated by tricarboxylic
acid (TCA) cycle activity.2 An interesting observation in Chapter 6 is that the TCA cycle,
as a component of central metabolism, can interdependently influence the carbon flow of
glycolysis and the pentose phosphate pathway (PPP).3 The fact that intracellular ribose
concentration increases during TCA cycle suppression indicates the presence of a pentose
phosphate pathway (PPP)-responsive regulator that can partially mediate TCA cycledependent regulatory effects.4 This led us to hypothesize that the ribose phosphate
isomerase (Rpi) protein is a potential regulator of PPP and TCA cycle.5-7
Ribose can be phosphorylated and uptaken from the growth medium using an Rbs
transport system or generated from nucleotide degradation.8 Ribose 5-phosphate is
mainly involved in the non-oxidative branch of the pentose phosphate pathway (PPP):
ribose 5-phosphate, ribulose 5-phosphate and xylubose 5-phosphate are interconverted in
reactions catalyzed by ribose phosphate isomerase and ribulose-5-phosphate 3-epimerase
(Figure 9.1).9 The family of Rpi naturally occurs in two distinct classes, ribose phosphate
isomerase A (RpiA; EC 5.3.1.6) and ribose phosphate isomerase B (RpiB; EC 5.3.1.6),
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and structures of both has been resolved using X-ray crystallography in several
organisms.10-12 In Escherichia coli (E. coli), RpiA is a homodimeric enzyme with an
α/β/(α/β)/β/α fold where arabinose 5-phosphate was identified as an inhibitor and the
complex structure was previously determined.11 RpiB is unrelated to RpiA in terms of
protein sequence and structure. RpiB exhibits a Rossmann-type αβα-sandwich fold and
also forms a dimer in E. coli and Coccidioides immitis (C. immitis).10,13 Besides the same
catalytic function as RpiA, a secondary activity of RpiB is unknown.

Figure 9.1 RpiR family of proteins role in the central metabolism.
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Members of the RpiR protein family often act as transcriptional regulators of
sugar catabolism, and RpiR homologues have been identified as repressors and activators
in both Gram-negative and Gram-positive bacteria, including E. coli, Pseudomonas
putida, and Bacillus subtilis.9,14,15 As sugar-responsive regulators, members of the RpiR
family of proteins have N-terminal helix-turn-helix DNA binding motifs and C-terminal
sugar isomerase binding domain.16 However, detailed structural information has not been
reported. There are three known members of the RpiR family: RpiRa, -b, and -c. RpiRb
and -c positively influence the activity of RpiA while RpiRa works as a downstream
antagonist of RpiA by binding to a certain dinucleotide (Figure 9.1).4 It has also been
reported that the inactivation of RpiRc altered the temporal transcription of RNAIII, the
effector molecule of the agr quorum-sensing system.4 Thus, central metabolism is
potentially linked with virulence determinant synthesis through RpiR and PPP.4
Consequently, our initial research goal is the structural determination and functional
annotation of the S. aureus RpiRa protein (S. aureus subsp. aureus Mu50, UniProt ID:
Q99WQ9; Gene Symbol SAV0317; Gene ID: 1120275) by NMR.
NMR spectroscopy is one of the cornerstone techniques for structural studies of
biological macromolecules. It is the only current technique that can obtain atomic level
information about both the structure and dynamics of macromolecules such as proteins,
nucleic acids and their complexes in a solution. The limitations of NMR spectroscopy
result from the low inherent sensitivity and from the high complexity of NMR spectra. As
a specific example, a minimal of 10-20 mg/L expression yield is practically required for
sufficient sensitivity in three and four dimensional NMR experiments. NMR also has a
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molecular-weight limitation and a routine strategy is to focus the NMR analysis to the
smallest possible subdomain. Thus, only the ligand binding C-terminal domain (CTD) of
RpiRa will be studied by multi-dimensional NMR. Two-, three-, and four-dimensional
NMR experiments are required to disperse the hundreds of NMR resonances from RpiRa
CTD to avoid spectral overlap and simplify the analysis. Typically, the additional NMR
dimensions correspond to 13C and 15N chemical shifts that are correlated with 1H
chemical shifts through large single-bond coupling constants. Heteronuclei like 15N, 13C
and 2H can be incorporated into proteins by uniform or selective isotopic labelling. As a
result, the NMR spectra are drastically simplified and the sensitivity of the nitrogen and
carbon signals is largely increased. In summary, obtaining a well folded protein with a
minimal molecular-weight that can be overexpressed and purified at a high concentration
and with isotopic labeling is the first step of using NMR to study a protein structure.
Several challenging aspects of this process that include overproduction, purification,
storage and isotopic labeling are addressed in this chapter.
The optimization of protein expression in a heterogonous system is one of the
major challenges of structural biology. Many recombinant proteins are expressed in the
prokaryotic system of E. coli due to its simplicity and high efficiency, but not all proteins
are expressed equally well in E. coli.17 Thus, it is critical to optimize the experimental
conditions in order to maximize the protein yield. Many different strategies have been
developed to meet the needs of a variety of proteins, such as E. coli strains supplemented
with rare codons,18 strains with disabled thioredoxin reductase and glutathioine
reductase,19 plasmids with a tunable promoter,20 transport or periplasmic spaces,21 and
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co-expression with other proteins.22 Despite all these efforts that have successfully
addressed known mechanisms of low yield, “trial and error” is still a large component of
most protein expression efforts.
Another common challenge of a protein structural study is the requirement for a
highly purified protein sample. In general, a purity level of 90%-95% of the target protein
is needed. A fusion tag is often used to simplify the purification process.23 An affinity tag
is a recombinant hybrid containing a polypeptide fusion partner which facilitates the
purification of the target protein.24 There are many different types of tags and the choice
of tag depends on the property of the protein: poly-Arg, FLAG, poly-His, c-myc, S and
Strep II-tag.25 A poly-His tag utilizes an immobilized metal affinity chromatography
(IMAC) to purify a recombinant protein containing hexa-histidine residues as a short
affinity-tag. A His-tag has been carried out successfully using a number of expression
systems including bacteria, yeast, and mammalian cells. It is commercially incorporated
in the cloning vectors such as pET-28a-c (+), which we used to express RpiRa CTD.
A purified protein has to be stored in a buffer at an extremely high concentration
of 1-2 mM for NMR studies. Therefore, another challenge of NMR structural biology is
the identification of an optimal buffer condition that can stabilize a properly folded
protein at a high concentration. The buffer should exhibit little or no change in pH with
temperature, show insignificant penetration through biological membranes, and have
maximum buffer capacity at the pH where the protein exhibits optimal stability. The
isoelectric point, hydrophobicity, intermolecular interactions and many other protein
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properties and NMR requirements significantly impacts and limits buffer choices. There
is no reliable approach to predict an optimal buffer for a given protein. Some of the most
commonly used buffer systems include Tris-HCl, sodium/potassium phosphate saline,
MES, and acetate.26 There are other factors to consider that include salt concentration, pH,
reducing reagents, etc. In short, buffer composition and physical properties can perturb
protein conformational stability because of a complex interplay between various effects
rather than through a single mechanism. The goal is to identify an optimal buffer that is
beneficial to both the protein and the NMR analysis.
One of the most important techniques for NMR structural studies is isotopic
labeling. The introduction of uniform 15N and 13C labeling into a protein provides NMR
signals that can be sequentially assigned by “walking through” correlated peaks between
neighboring residues. A two dimensional (2D) 1H, 15N heteronuclear single quantum
coherence (HSQC) spectrum is used as a template in which each peak corresponds to the
amide H-N bond for each amino acid residue in the protein sequence.27 Thus, the 2D 1H,
15

N HSQC spectrum provides the “root” 1H and 15N chemical shifts for each amino acid

in the protein. Each root is then connected to additional 1H and 13C chemical shifts
through a series of three dimensional NMR spectra. This establishes a complete set of
peaks per residue (spin system) based on the 2D 1H, 15N HSQC spectrum.27 Sequential
assignments are then made by identifying spin systems (residues) that have two or more
chemical shifts in common. Therefore, the structural analysis of proteins using NMR
starts with a 2D 1H, 15N HSQC spectrum. A high quality, well dispersed 2D 1H, 15N
HSQC spectrum indicates a properly folded protein. It also identifies the likelihood that
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the NMR assignments can be completed. The availability of backbone sequential
assignments and a high-quality 2D 1H, 15N HSQC spectrum are also important for an
NMR ligand-affinity screen (FAST-NMR).28 So, a 2D 1H, 15N HSQC spectrum is the
primary means of evaluating the preparation of a protein sample for NMR.
Deuterium (2H) labeling can simplify an NMR spectrum and sharpen peaks by
removing pathways that contribution to transverse relaxations. This is critical for
studying proteins with a high molecular weight because larger molecules tend to have
broader peaks due to their relatively slower tumbling and complex dipole-dipole
relaxations. Incorporating 2H labeling into a protein sample is difficult and more
challenging compared to 15N or 13C isotope labeling protocols. 2H doubles the atomic
weight that leads to significant isotope effects and drastic changes in enzymatic activity.
As a result, the viability of E. coli is negatively impacted by growing cells in D2O.29 If
D2O is the sole deuterium source, 0–86% of the chemically nonexchangeable hydrogen
atoms can be deuterated. Higher levels of “perdeuteration” require using deuterated
glucose because cell growth in higher percentages of D2O is not practical. In addition to
these uniform labeling strategies, selective labeling methods have also been applied for
more challengeable systems to further simplify the NMR spectrum.30 These isotopic
approaches complement NMR techniques to explore protein structures. For example,
transverse relaxation optimized spectroscopy (TROSY) type experiments can be used
with a high-field magnet NMR to increase the sensitivity of an NMR spectrum by
selecting the component, from a decoupled spectrum, in which the relaxation
mechanisms have almost cancelled leading to a single, sharp peak.31 TROSY is often
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combined with the 2H labeling.32,33 The efforts to optimize the overexpression and
purification of 2H, 13C, 15N labeled RpiRa CTD, and the use of selective labeling schemes
along with the application of TROSY-based NMR experiments for the backbone
sequential assignments of RpiRa CTD are discussed in this chapter.

9.2 Materials and Methods
9.2.1 Materials
For the RpiRa CTD79-266 NMR analysis, purified and uniformly 15N labeled,
uniformly 13C, 15N double labeled, and uniformly 2H , 13C, 15N, triple labeled proteins
were expressed in a pET-28a-c(+) cloning plasmid with an N-terminal His-Tag sequence
in the E.coli BL21 (DE3) strain. N-terminal modification of RpiRa CTD79-266 included
the addition of the following amino acid sequence: MGSSHHHHHHSSG
LVPRGSHMAS.
Deuterium oxide (99.9% D), 15N-NH4Cl (98% 15N), 13C6-glucose (99% D),
imidazole, NH4OAc, yeast extract Hy-Yest® 444, kanamycin sulfate salt, DLdithiothreitol, sodium azide (99.5%), and glycerol were obtained from Sigma-Aldrich
(Milwaukee, WI). The 3-(trimethylsilyl) propionic-2, 2, 3, 3-d4 acid sodium salt (98% D)
was purchased from Cambridge Isotope (Andover, MA). The potassium phosphate
dibasic salt (anhydrous, 99.1% pure) and sodium chloride (ACS reagent) was purchased
from Mallinckrodt (Phillipsburg, NJ). The BactoTm Agar and BactoTm Typtone were
purchased from BD (Franklin Lakes, NJ). The prestained Protein Marker, Broad Range
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(7-175 kDa) was purchased from New England BioLabs (Ipswich, MA). The tris (2carboxyethyl) phosphine hydrochloride (TCEP) was purchased from Biosynth (Itasca, IL).
The isopropyl β-D-thiogalactoside (IPTG) was purchased from GOLDBIO®COM (St.
Louis, MO). All the recipes for the cell culture media and buffers are listed in the
Appendix B.

9.2.2 Plasmid construction, E coli. strains and glycerol starter
The three plasmids with three different RpiRa CTD amino acid sequences and the
corresponding E. coli BL21 (DE3) strains were prepared by Dr. Marat Sadykov, Dr.
Nagender Ledala and Mckenzie Steger in Dr. Somerville’s lab.
Selected E. coli BL21 (DE3) colonies from fresh agar plate were inoculated into 3
mL of Luria-Bertani (LB) media containing 30 µg/mL kanamycin. The cells were
incubated at 37oC overnight with shaking at 220 rpm in a GYROMAXTM incubator
shaker (Concord, CA). 0.5 mL of glycerol was added to 1 mL of the initial culture, and
the mixture as the glycerol stock was stored at -80oC.
Same protocol was used to generate D2O adapted cultures. A series of minimal
media containing 20%, 40%, 60% and 80% of D2O were used sequentially to adapt the
cell culture to 80% D2O concentration. No antibiotics were added to the minimal media.
DNA sequencing was performed after this culturing to validate the sequence.
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9.2.3 Protein expression in M9 medium and high cell density medium
Selected colonies from fresh agar plate were inoculated into 3 mL of LB media
containing 30 µg/mL kanamycin. The cells were incubated at 37oC overnight with
shaking at 220 rpm. 1 mL initial culture was diluted into 100 mL M9 minimal media
containing 30 µg/mL kanamycin. The culture was grown at 37oC and 220 rpm until an
optical density at 600 nm (O.D.600) reached 0.6-0.8 unit. Freshly prepared stock solution
of IPTG was added to make a final concentration of 0.8 mM. The cells were grown for
another 3 hours. The cells were harvested by centrifuging at 5000 X g for 20 minutes at
4°C in a Sorvall RC-5B Refrigerated Superspeed centrifuge (Du Pont Instruments,
Wilmington, DE) and the pellets were collected for protein extraction.
Same incubation and centrifugation settings were used for high-cell density
medium-based protein expression. Selected colonies from fresh agar plate were
inoculated into 3 mL of LB media containing 30 µg/mL kanamycin. The cells were
incubated at 37oC overnight with shaking at 220 rpm. 1 mL initial culture was diluted
into 100 mL LB medium containing 30 µg/mL kanamycin. The culture was grown at
37oC and 220 rpm until an O.D.600 reached 2.5-3.0 units. The cells were harvested by
centrifuging at 4000 X g for 8 minutes. The cell pellets were suspended in high cell
density medium and inoculated for another 0.5-1 hour until an O.D.600 was increased by 1
unit. IPTG was added with a final concentration of 1 mM and the cells were grown for
another 4 hours. The cells were harvested by centrifuging at 5000 X g for 20 minutes at
4°C and the pellets were collected for protein extraction.
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9.2.4 Protein extraction and purification
The cells were re-suspended in the protein extraction buffer (see recipe in the
Appendix B) of 15-25 mL. Sonication was performed to lyse the cells using a Fisher
Scientific sonicator probe, Sonic Dismembrator Model 100 (Waltham, MA). A burst
cycle of 15 seconds on and 45 second off were chosen with 60% power. Nine burst
cycles were completed before the lysates were spun down at 7,000 X g for 45 min at 4oC.
The sample was kept on ice during this process.
The extraction was followed by purification. A gravity-flow IMAC column
packed with HisPur Cobalt beads (Thermo scientific, Rockford, IL) was equilibrated with
25 mL wash buffer consisting of phosphate buffer saline pH 7.2 with 10 mM imidazole
(to prevent nonspecific binding of endogenous proteins that have histidine clusters). The
cell lysate was applied to the column and allowed to bind for 2-3 h during which the
lysate solution was thoroughly mixed with the beads. The column was repositioned
vertically and drained to collect the flow-through. The beads were then washed with two
wash buffers: first with ~200 mL of 10 mM imidazole and second with ~200 mL of 50
mM imidazole. The bound RpiRa CTD79-266 was eluted by applying ~300 mL elution
buffer with 150 mM imidazole. The flow rate was 1 mL/min and 1 mL fractions were
collected. The presence of RpiRa CTD79-266 in the eluted fractions was assayed by
Ultraviolet-visible (UV-Vis) spectroscopy at a wavelength of 280 nm. All purification
steps were performed at 4°C.
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9.2.5 Imidazole removal, protein concentration and NMR sample preparation
All eluted fractions were collected until UV-Vis absorptive spectral readings
reached baseline. These fractions were concentrated to 10 mL using 15 mL Amicon
ultrafiltration cells with a 10 kDa cutoff membrane (EMD Millipore, Billerica, MA). The
filtration was performed by centrifugation using a Thermo scientific CL10 bench-top
centrifuge (Rockford, IL) and a swinging bucket rotor at 4000 x g and 25°C. A 10 mL
Float-A-Lyzer G2 with 8-10 kDa cutoff membrane from Spectrum®Laboratories
(Rancho Dominguez, CA) was used for dialysis. A total of 2 L NMR buffer was prepared
and four rounds of dialysis with 200, 200, 600, 1000 mL volume of the buffer were
performed. The protein was concentrated to 8-10 mL and stored at room temperature.
The RpiRa CTD79-266 was concentrated to a final volume of 500 µL using a 0.5 mL
Amicon ultrafiltration cells. 50 µL of a D2O buffer was added to the concentrated RpiRa
CTD79-266 protein sample to yield an NMR sample consisting of 1.2 mM RpiRa CTD79266

in a 91% H2O/9% D2O solution containing 100 mM NaCl, 25 mM K2HPO4/KH2PO4

at pH 4.5 (uncorrected). An Eppendorf 5415D Micro Centrifuge (New York, NY) was
used at 4000 X g at 25oC to concentrate the sample. The sample was kept in 5 mm NMR
tubes (Norell ST500-7, Norell, Inc., Landisville, NJ).

9.2.6 Analytical Apparatus and data analysis
For the RpiRa CTD79-266 NMR analysis, one dimensional (1D) 1H NMR
experiments were collected at 298 K on a three channel 500 MHz Bruker Avance DRX
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spectrometer equipped with a triple resonance, Z-axis gradient 5 mm Cryoprobe. A total
of 8192 data points were collected with a total of 16 dummy scans and 128 acquisition
scans and a sweep width of 5482.5 Hz. 2D 1H, 15N HSQC NMR experiments used were
collected at 298 K on the same instrument. A total of 1024 data points were collected in
the 1H dimension and 128 data points were collected in the 15N dimension. The spectrum
was collected with a total of 256 dummy scans and 64 acquisition scans and a sweep
width of 7002.8 Hz in the 1H dimension and 2027.3 Hz in the 15N dimension. TROSY2D 1H, 15N HSQC was collected at 298 K on a three channel 700 MHz Bruker Avance
III-HD spectrometer equipped with a triple resonance, Z-axis gradient 5 mm Cryoprobe.
A total of 2048 data points were collected in the 1H dimension and 128 data points were
collected in the 15N dimension. The spectrum was collected with a total of 128 dummy
scans and 32 acquisition scans and a sweep width of 9803.9 Hz in the 1H dimension and
2838.4Hz in the 15N dimension. 1D 1H NMR spectra were processed in the ACD/1D
NMR manager version 12.0 (Advanced Chemistry Development, Inc). 2D 1H, 15N HSQC
spectra were processed using the NMRPipe software package.34
UV-Vis spectroscopy was used for protein concentration determination and
optical density of cells using a PerkinElmer Lambda Bio+ spectrometer (Waltham, MA).
Circular dichroism (CD) absorption spectra were recorded on a JASCO J-815
spectropolarimeter (Easton, MD). A wavelength range of 200–240 nm in far-UV region
was used for probing the secondary structure of RpiRa CTD79-266. Far-UV CD spectra
were collected with 1 mm path length cuvette on an RpiRa CTD79-266 sample with an
estimated concentration of 50 μM in 50 mM potassium phosphate buffer, pH 7.4. All CD
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spectra were acquired at a scan speed of 10 nm/ min. The spectrum was plotted in Excel
(Microsoft, Redmond, WA).
SDS–polyacrylamide gel electrophoresis of the proteins in all fractions was
performed using a 4%-12% PAGE with a Bio-Rad Mini-Protean® 3 Multi-Casting
Chamber (Hercules, CA). Protein bands were visualized by Coomassie brilliant blue
staining and photographed.

9.3 Results
9.3.1 Determination of CTD amino acid region
10
20
30
40
50
MKFENRVQRY QHLFTKTDKR IVNYIRQNGY SDAFSTINSL AHAIGTSPAT
60
70
80
90
100
MTRFSHKLDY ENFQDLKFNI QQEMTETVIE NSPIIQRIHK YHQQIIQQTG
110
120
130
140
150
EFIDNDIIQT FIDKLQSSRH ILFAGLGSSG LSATEFYYRM IRMGLKGNVT
160
170
180
190
200
TDSHLMKISA SLLSHSDMFI AMSNSGNTSE LISAAEVAKS HGAYVVAITN
210
220
230
240
250
FEGSKLTDCA DLVLLTTDQS RNTDHQFINT QIATLFLIDI VSYHLLENTN
260
LSQTYQHTKS IILDNK

Scheme 9.1 RpiRa sequence.
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S. aureus RpiRa has a single polypeptide chain containing 266 amino acid
residues. The complete protein primary sequence is shown in Scheme 1. A collection of
database including DomPred,35 InterProScan36 and DOMAC37 were performed and two
domains were predicted: an N-terminal domain (NTD) of helix-turn-helix-like domain
and a C-terminal domain (CTD) of sugar isomerase-like domain. The predicted
boundaries of the CTD were shown below (Table 9.1). The starting position of CTD was
predicted with a range of 78-113. A closer look at the secondary structure prediction
using PsiPred,35,38 SWISS-MODEL39 and PredictProtein40 suggested that the boundary of
CTD and NTD should be in loop regions of 75-82 or 112-123. So a series of constructs
were proposed and three were validated experimentally. It turned out that both PsiPred
provided the closest prediction that residue I79 is the starting amino acid of an α-helix in
CTD and therefore the secondary prediction based on the same database was used for
secondary structure prediction.41
Table 9.1 Summary of boundary prediction of RpiR CTD.

BLAST
FASTA
InterproScan
DomPred
PsiPred
SWISS-MODEL

Beginning
108
112
111
113
79
78

Ending
240
238
251
NA
266
264

E-value
6.11e-37
5.1e-105
6.8e-13
NA
2e-07
NA

Three forms of RpiRa were constructed to experimentally determine the CTD
boundaries by residue sequence numbers: 81-259, 79-249 and 79-266 and the
corresponding proteins were termed as RpiRa CTD81-259, CTD79-249, and CTD79-266. These
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constructs were amplified by polymerase chain reaction (PCR) and cloned separately into
plasmid pET-28a (+). The CTD79-266 strain was selected based on its relatively high
protein expression level. The CTD79-266 strain has the longest sequence of the three
constructs and contains the seven predicted α-helices, increasing the likelihood of
obtaining correctly folded protein. There are 188 amino acids in the predicted RpiRa
CTD79-266 with a molecular weight of 21009.7 kDa. RpiRa CTD79-266 is also predicted to
have an extension coefficient of 8940 M-1 cm-1 at 280 nm, assuming all Cys residues are
reduced. The theoretical isoelectric point (pI) is 5.95. These parameters were calculated
using ProtParam.42 The experimental CD spectrum of RpiRa CTD79-266 predicted that
RpiRa CTD79-266 is 50.4% α-helical and 15.5% β-stranded (Figure 9.2b). This is also
comparable with the RpiRa homology modeling results (α-helix%: 51.1; β strand%: 13.3)
using PsiPred (Figure 9.2a).38
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Figure 9.2 a) Secondary structure prediction using PSIPRED
(http://bioinf.cs.ucl.ac.uk/psipred/). Top matched structure is Vibrio vulnificus NanR
protein (PDB ID: 4IVN) with a percentage identity of 29%. b) CD spectrum prediction
using K2D2, a web server to estimate α helix and β strand content of a protein from its
CD spectrum. (http://k2d2.ogic.ca/). Red line represented the query spectrum, and green
line represented the target spectrum. The maximum total α and β error of the prediction
was 0.32.

9.3.2 Protein expression
The optimization of protein expression was focused on optimizing cell growth
conditions. M9 and LB media only yielded an O.D. 600 of 1.5-1.8 units. Since the protein
expression level was also low; the limited amount of cells became a bottleneck for
providing enough proteins in a standard 1 L culture. Therefore, a high cell density
medium was used (Appendix B).43 Cell mass was increased to four folds compared to
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normal M9 media. The procedure is outlined in Figure 9.3a. The growth curves (induced
vs. non-induced) based on medium switch are shown in Figure 9.3b. A large production
of cells was achieved without wasting unnecessary nutrients. The media switch was also
beneficial for the introduction of 13C glucose and/ or 15N ammonium chloride for isotope
labeling. Bacterial cells in their mid-exponential phase were induced by IPTG and grown
to a higher O.D.600 of 5-6 units. A comparison between the protein expressions indicates
that a high cell density growth provided a higher protein yield (Figure 9.3c).
The protein was also expressed under anaerobic growth and aerobic growth
conditions. A volume ratio of flask to medium at 2:1 was used to generate an anaerobic
condition, while the ratio at 8:1 was used for aerobic growth. As shown in Figure 9.2c,
the expression level was much better under aerobic growth using the high cell density
growth. These results also agree with previous reports that high cell density media for E.
coli are generally designed for aerobic cultivations.44 A room temperature overnight
expression and a prolonged time of expression were also tested. Neither approach was
shown to be beneficial (Figure 9.4) since no increase in expression levels were seen after
4 hours. Different IPTG concentrations of 0.4, 0.6, 0.8, 1.0 and 1.2 mM were also
investigated, but no significant changes were observed. An IPTG concentration of 1.0
mM was used for all subsequent protein sample preparations.
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Figure 9.3 The overexpression of RpiRa CTD79-266: a) flowchart illustrating the protocols
for the high-cell-density expression system; b) E. coli growth curve using the high-celldensity expression system; c) comparison of RpiRa CTD79-266 protein expression levels
under different growth conditions.
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Figure 9.4 Impact of pH changes on RpiRa CTD79-266 protein expression levels using
aerobic growth with high cell density media at 25oC.

9.3.3 Protein extraction
Cell lysis was accomplished using sonication. The cell sample was immersed in
an ice bath during sonication to prevent any overheating effects. 20-25 mL extraction
buffer was used and the choice of buffer was mainly dependent on the compatibility of
the following purification procedures. Therefore 50 mM potassium dihydrogen
phosphate/ dipotassium hydrogen phosphate buffer (KH2PO4/K2HPO4) was chosen with a
pH of 7.4. It is advisable to measure the pH during the cell lysis to maintain a neutral or
mild basic conditions.45 5% glycerol was also proved to be useful to prevent damage to
the protein during the sonication. A burst cycle of 15 seconds on and 45 second off was
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chosen and sonication powers from 40% to 80% were tested to maximize the efficiency
of cell lysing. A 60% sonication amplitude was chosen due to its high lysing efficiency
without generating the appearance of a foam for a 20-25 mL cell suspension. The
presence of foam indicates denatured or destroyed proteins. As shown in Figure 9.5,
extending the number of burst cycles increased the amount of RpiRa CTD79-266 being
released from the cells. Nine burst cycles were chosen because it corresponded to the
largest increase in RpiRa CTD79-266 with the smallest number of burst cycles.

Figure 9.5 The impact of the number of burst cycles on the efficiency of extracting of
RpiRa CTD79-266.

9.3.4 Protein purification
HisPur cobalt IMAC resin can bind more than 10 mg proteins per mL of resin and
can maximize protein purity compared to nickel resins. The exact protocol was followed.
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The only variable in regards to the standard protocol was the length of the binding time –
the time the cell lysate is simply incubated with the resin. Binding times of of 2, 4 and 8
hours were tested, but 2 hours was chosen since extending the binding time did not
improve either the relative protein purification or the amount of protein recovered. Figure
9.5 showed the purified protein band in a denatured SDS-PAGE. The flowthrough sample
in Lane 2 indicated almost all the target protein was captured and the target protein band
in Lane 7 showed that the purity of the protein and the correct molecular weight in the
non-native SDS-PAGE.
The protein band in the elution buffer as shown in Figure 9.6a was rather pure,
but an extremely concentrated and overloaded sample (Figure 9.6b) verified the purity of
RpiRa CTD79-266. After weeks of room-temperature storage, a small amount of
proteolytic degradation was observed. Therefore, it is advisable to include broadspectrum protease inhibitors in the extraction buffer and the NMR sample. Figure 9.6b
demonstrates that after IPTG induction, not only was RpiRa CTD79-266 overexpressed, but
the levels of other protein were decreased. So, it appears that under carbon limitation, the
induction of a protein overexpression also suppress other protein expression. All of these
results are consistent with our protocol being successful in inducing the expression of
soluble RpiRa CTD79-266 exclusively and efficiently.
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Figure 9.6 a) The Co-affinity chromatography purification of RpiRa. Lane 1 is the
protein ladder, Lane 2 is the flow-through of non-binding proteins, Lane 4 and 6 are two
concentrated wash buffers containing non-specific bound proteins, Lane 7 is the elution
buffer containing the target protein. b) The cell lysate, before purification, that compares
expression and non-expression conditions. An over-loaded gel of RpiRa CTD79-266 was
also performed to verify the purity of the protein.

9.3.5 Protein buffer conditions
The pH was chosen to be from 4.5-5.5 so that the pH was at least one unit lower
from the theoretical pI value of 5.95. A lower pH also benefits the quality of the 2D 1H,
15

N-HSQC spectrum by decreasing backbone amide exchange rates.27 A series of

standard NMR protein buffer were tested that included: Tris buffer, MES buffer,
NH4OAc, acetate and potassium phosphate buffers (Appendix B). NH4OAc and
phosphate buffers both yielded higher quality NMR spectra. However, a phosphate buffer
was chosen for the final NMR sample conditions because of slightly better protein
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stabilization at higher temperatures. NaCl concentrations of 100 mM, 200, 300, 400, 500
mM were also tested. The final NMR sample contained 100 mM of NaCl because higher
ion strengths (>300 mM NaCl) was shown to denature the protein or decrease the
performance of the cryoprobe without any added benefit to protein stability. Additives
such as imidazole and glycerol may also improve protein stability, but they can also
negatively impact the quality of the NMR spectrum.46 No obvious benefit was observed
for including any additive to the RpiRa CTD79-266 NMR sample (Figure 9.7).
Dithiothreitol (DTT) was also tested over a range of concentrations: 1, 5 and 10 mM. 10
mM DTT was proved to be necessary to the long-term stability of the RpiRa CTD79-266
NMR sample. An alternative reducing reagent, TECP-HCl, was shown to similarly
stabilize the RpiRa CTD79-266 NMR sample at a concentration of 2 mM. A typical 1D 1H
NMR spectrum for RpiRa CTD79-266 in the optimized NMR buffer is shown in Figure 9.8.
A flash frozen and a slow frozen approach were tested for possible approaches to
achieve a long-term storage of RpiRa CTD79-266. Unfortunately, RpiRa CTD79-266 was
shown to be denatured after thawing from either these long-term storage techniques. A
storage temperature of -20oC or -80oC was also tested. Again, the protein was denatured
when thawed from either temperature. Similarly, RpiRa CTD79-266 is not stable to high
temperature and denatures when exposed to temperatures above 30oC for overnight
(Figure 9.9). RpiRa CTD79-266 is also not stable to lyophilization. Lyophilization of the
protein from (NH4)2CO3 or a phosphate buffer results in a precipitated protein that will
not re-dissolve into the original buffer. In practice, RpiRa CTD79-266 was always kept in
room temperature in the optimized NMR buffer.
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There are two common methods to perform buffer exchange: dialysis and
ultrafiltration using a centrifuge. Both float-A-analyzer and traditional dialysis membrane
tubing were tested and show comparable results. Importantly, a dialysis approach to a
buffer exchange outperformed Amicon ultrafiltration. Amicon ultrafiltration caused a
significant amount of protein purification probably because it is a harsh method relative
to dialysis.

Figure 9.7 The impact of adding stability agents to the RpiRa CTD79-266 NMR buffer.
Two optimal NMR buffer systems were tested for adding these additives. No observable
changes in the RpiRa CTD79-266 samples were observed after weeks of storage.
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Figure 9.8 The 1D 1H NMR spectrum of RpiRa CTD79-266. The water peak in the region
of 4.6-5.2 ppm was removed.

9.3.6 Isotopic labeling of RpiRa CTD
Uniformly 15N and 13C labeled RpiRa CTD79-266 was produced using minimal
medium supplemented with 15N NH4Cl and 13C glucose. Deuteration of the aromatic and
aliphatic protons in the protein can be achieved by expressing the protein in D2O.47
Deuteration of the non-exchangeable proton was shown to improve the resolution and
sensitivity of NMR experiments by reducing the overall relaxation rates of NMR active
nuclei (Figure 9.10a and 9.10b).48, 29 The difficulty of deuterium incorporation was
demonstrated by the fact that increasing the percentage of D2O in the cell culture media
dramatically slowed cell growth. 80% D2O was shown to be the highest percentage of
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D2O that the E. coli strain could tolerate. Although, after adaptation to D2O, the E. coli
growth was comparable to cell growth in H2O.
The non-exchangeable and exchangeable protons are both labeled with deuterium
during the cell culture, so it takes additional effort to exchange deuterated amides back to
protons to be observable by NMR. It may be particularly challenging to exchange amides
buried in the core of the protein or involved in secondary structures. Therefore, it may
require an increase in the temperature to partially unfold the protein in order to expose all
the amides to the solvent and increase the HD exchange rate. Also, it may simply require
waiting days or weeks until all of the deuterated amides have effectively changed back to
protons. As shown in Figure 9.8, the peaks of the 2D 1H, 15N HSQC spectrum were
sharpened after an overnight incubation at 30oC in H2O. But a longer incubation time
leads to the denaturing of RpiRa CTD79-266. An alternative and safer approach was chosen
in which the protein was placed in a 50 mL buffer at pH 7.4 for 2-4 days at room
temperature. This was effective in back exchange all of the amides since the amide
exchange rate is higher at higher pH. After the amide exchange was completed, the 2D
1

H, 15N HSQC spectrum improved and more peaks were observable (Figure 9.10a and b).

An alternative approach is to increase the sample temperature during NMR data
collection. The 2D 1H, 15N HSQC spectrum was collected at 25oC, 27oC, 29oC, and 31oC.
Temperatures higher than 31oC caused significant protein precipitation. No improvement
in the 2D 1H, 15N HSQC spectrum was observed, so the sample temperature was kept at
25oC for all NMR experiments. Figures 9.10b-c illustrates an interesting phenomenon.
Over a month time frame, the RpiRa CTD79-266 NMR sample slowly precipitated and then
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eventually stabilized. This resulted in a higher quality 2D 1H, 15N HSQC spectrum,
suggesting that there might be a concentration dependent monomer-dimer transition.
RpiRa CTD79-266 is a relatively large protein for NMR, so using TROSY
experiment are expected to improve the spectral quality by generating sharper peaks. As
shown in Figure 9.10d, the collection of a 2D 1H, 15N TROSY-HSQC experiment on a
700 MHz NMR spectrometer resulted in a dramatic improvement in the quality of the
NMR spectrum compared to the other 2D 1H, 15N HSQC spectra.

377

Figure 9.9 The overnight incubation of an RpiRa NMR sample at a) 25oC; b) 30oC; c)
35oC; d) 40oC.
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Figure 9.10 a) 2D 1H, 15N HSQC spectrum of uniformly 15N labeled RpiRa CTD79-266 ; b)
2D 1H, 15N HSQC spectrum of uniformly 2H (80%), 15N labeled RpiRa CTD79-266; c) 2D
1

H, 15N HSQC spectrum of uniformly 2H (80%), 15N labeled RpiRa CTD79-266 sample

from (b), but after a month; d) 2D 1H, 15N TROSY-HSQC spectrum of uniformly 2H
(80%), 15N labeled RpiRa CTD79-266.

9.4 Discussion
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The optimization of experimental conditions for the overexpression, purification
and storage of RpiRa CTD79-266 was primarily based on “trial and error” due to the
unpredictable nature of proteins. This initial and essential work was done to achieve an
RpiRa CTD79-266 sample amenable for future NMR structural biology studies. This effort
has led to the identification of an appropriate expression system and purification
protocols, to an optimal buffer condition to maintain protein stability and obtain high
quality NMR spectra, and an effective isotope labeling strategy to enable the use of
TROSY-based experiments. Further work in the application of selective labeling and
non-uniform labeling are still required to improve the likelihood that the NMR backbone
assignments can be obtained for RpiRa CTD79-266.
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APPENDIX B: Medium and buffer recipes
Note: All the buffers and media were prepared in nanopure H2O and autoclaved.
1. LB media (1 L):
10.0 g Tryptone
5.0 g Yeast extract
10.0 g NaCl

2. LB media agar plate (1 L):
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10.0 g Tryptone
5.0 g Yeast extract
10.0 g NaCl
15.0 g Agar

3. M9 minimal medium (1 L):
A) M9 salt (1 L, 5X)
64 g Na2HPO4·7H2O
15.0 g KH2PO4
2.5g NaCl
5.0 g NH4Cl (or 15NH4Cl)
0.2 mL of 10 mM FeCl3 stock solution

B) M9 minmal medium (1L)
200 mL 5XM9 salt
2.0 mL 1M MgSO4 stock solution
2.0 mL 1M CaCl2 stock solution
2 g glucose (or 13C-glucose)

4. High-cell-density medium (1 L):
13.4 g Na2HPO4·7H2O
3.4 g KH2PO4
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0.58 g NaCl
5 mL 1 M MgSO4 stock solution
0.2 CaCl2 stock solution
1.0 g NH4Cl (or 15NH4Cl)
10 g glucose (or 13C-glucose)

5. Extraction buffer (1 L):
2.63 g KH2PO4
5.34 g K2HPO4
17.55 g NaCl
50 mL glycerol

6. Wash buffer (1 L):
2.63 g KH2PO4
5.34 g K2HPO4
680.8 g NaCl
680.8 mg imidazole

7. Elution buffer (1 L):
2.63 g KH2PO4
5.34 g K2HPO4
3.40 g NaCl
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3.40 g imidazole (for 50 mM) or 10.2 g imidazole (for 150 mM)

8. NMR sample buffer (1 L):
8.1 Potassium phosphate buffer saline*
2.72 g KH2PO4
5.85 g NaCl
1.54 g DTT (or 0.57 g TCEP-HCl)
0.20 g NaN3
*

adjust pH to 4.5

8.2 Ammonium acetate buffero
1.54 g NH4OAc
5.85 g NaCl
1.54 g DTT (or 0.57 g TCEP-HCl)
0.20 g NaN3
o

adjust pH to 4.5
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CHAPTER 10
SUMMARY AND FUTURE DIRECTIONS
10.1 Summary
Simplistically, metabolomics can be considered as a continuous array of
metabolite assays, but it is not feasible to optimize a single experimental condition to
accurately measure each metabolite in this hypothetical array of assays. Therefore subtle
differences in experimental procedures may lead to detectable changes in metabolite
concentrations. This is an inherent challenge of metabolomics, but this issue is also
significantly diminished by relying on a comparative (instead of an absolute) analysis
between two of more samples. As long as experimental consistency is maintained
between all samples, the underlying errors will be constant. Thus, these errors will be
irrelevant and will “subtract out” when two or more samples are compared to identify
“differences”. So the first aim of my thesis was to exhaustively evaluate all of the
experimental factors that may contribute to any sample inconsistency and negatively
impact the outcome of an NMR-based metabolomics study.
Maintaining consistency across a dataset of 1D 1H NMR spectra is critical for an
untargeted metabolomics study because multivariate statistical techniques such as PCA or
OPLS-DA are intrinsically sensitive to all variations in the data, regardless of the origin
of these differences. Thus, biologically irrelevant variations between classes that are
introduced by the investigator of by the experimental protocols need to be removed in
order to avoid misinterpretations and erroneous conclusions. Towards this end, we
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optimized sample preparation protocols for bacteria and mammalian cell lines to
maximize reproducibility between replicates, and to achieve complete and efficient
extraction of the cellular metabolome. These protocols are described in detail in Chapters
3 and 4. The entire process includes: 1) growing and harvesting bacterial cells, 2)
extracting the metabolome, 3) NMR data collection, processing and analysis, 4) statistical
analysis, 5) metabolite identification, and 6) metabolic network generation. Consider, for
example, the preparation of a metabolomics sample, we were able to identify and correct
for a number of variables that decrease consistency between replicates. We
simultaneously use three different normalization schemes to correct for variations in total
metabolite concentration: the number of cells per sample, protein concentration per
sample, and Standard Normal Variate (SNV) data preprocessing. We can harvest and
quench each metabolomics sample in less than 20 seconds using centrifugation or
filtration. The type of glass beads, the bead beating program, and the temperature used
for cell lysis were all optimized to obtain complete extraction of the cellular metabolome.
Similarly, the type of solvent and buffer to obtain complete extraction of the metabolome
was also optimized. NMR experimental parameters that include the number of scan,
number of data points, receiver gain settings, water suppression pulse program, spectral
width, and relaxation time were optimized for each project. These validated experimental
protocols were successfully applied to all metabolic projects. Based on this exhaustive
analysis, we have a thorough understanding of the experimental parameters and
conditions that significantly impact the quality and outcome of a metabolomics study.
Consequently, in future studies, we only need to focus on these specific steps to
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successfully optimize the preparation and analysis of metabolomics samples. In return,
this will help increase the efficiency and consistency of future metabolomics studies.
The second aim of my thesis was to understand the regulatory role that the TCA
cycle plays in S. aureus and S. epidermidis biofilm formation. Specifically, how due
bacteria respond to a disparate set of environmental stress conditions that are all known
to induce biofilm formation? Iron-depletion, the addition of ethanol, glucose or lowdosages of antibiotics, temperature, and anaerobic conditions are all known to induce
biofilm formation. We observed that iron-depletion, the addition of ethanol, glucose,
low-dose tetracycline, and anaerobic conditions perturbed the metabolome of S.
epidermidis in a manner similar to an aconitase mutant. A metabolomics network map
identified the TCA cycle as playing a central role in the proposed signaling pathway that
also involves the urea cycle, alanine metabolism, glycolysis/gluconeogenesis, amino
sugar metabolism and other metabolites associated with PIA, which is a major precursor
to biofilm formation. 13C glucose was used to trace carbon flow in S. aureus and S.
epidermidis under conditions that induce biofilm formation. The observed inactivation
of the TCA cycle was correlated with an increase in a number of precursors of PIA,
which indicates PIA biosynthesis is reversely regulated by TCA cycle.1 As a result of
these observations, the TCA cycle can be considered as a metabolic sensor of
environmental stressors. In summary, the metabolomics study of the role that TCA cycle
plays in mediating intracellular energy and homeostasis in response to environmental
stressors significantly enhanced our understanding of a metabolism-dependent
mechanism of biofilm formation.

390
NMR-based metabolomics was also employed to investigate the impact of TCA
cycle activity on the S. aureus metabolome with a specific emphasis on the role of CcpE,
a putative LysR-type of regulator and a predicted activator of the TCA cycle. The
construction of a metabolic network based on perturbations in CcpE activity indicated
that changes in the S. aureus metabolome was centered on the TCA cycle. This clearly
supported our hypothesis that CcpE functions as a positive regulator of the TCA cycle.
Additionally, our analysis suggested that citB is a target of CcpE. This study combined
with previous studies of AcnA, CcpA, RpiR and CodY as metabolic regulators, describe
a group of genes in staphylococci that control the function of TCA cycle. Another
metabolomic study in S. aureus was focused on the influence of oxygen and iron
limitation. By decreasing the flask-to-medium ratio, the S. aureus metabolome shifts
from oxidative to a heterofermentatative metabolism. Similarly, iron-limitation also
shifted the metabolic profile to a heterofermentative metabolism. Both stressors caused a
suppression of the TCA cycle, as further evident by the decreased transcription of
aconitase (citB/acnA). Importantly, the effects of iron-limitation were obscured by the
oxygen-limitation. Once again, different environmental stressors were shown to have a
similar effect on the central metabolism in staphylococci, but our results also demonstrate
that two specific environmental stressors are connected and interdependent.
The last aim of my thesis was the optimization of experimental conditions for the
overexpression, purification and storage of RpiRa CTD79-266. This initial and essential
work was done to achieve an RpiRa CTD79-266 sample amenable for future NMR
structural biology studies. This effort has led to the identification of an appropriate T7
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expression system and the selection of the correct sequence for the RpiRa CTD79-266. Four
different growth strategies were compared and the aerobic growth on high cell density
medium was chosen to maximize the protein yield. A protein purification protocol and
NMR sample conditon was also optimized. The optimal buffer condition consisted of a
phosphate buffer pH 4.5 with 2 mM TCEP-HCl, 100 mM NaCl and 0.02 % NaN3 was
chosen to maintain protein stability and obtain high quality NMR spectra. An effective 2H,
13

C, 15N triple-labeling strategy to enable the use of TROSY-based experiments was also

implemented.

10.2 Future directions
The protocol used to extract and prepare a metabolomics sample also influences
the choice of analytical method (MS vs. NMR) and the corresponding analysis strategy.
There is a growing consensus that using multiple analytical techniques is a preferred
approach to thoroughly characterize the metabolome. This, in turn, requires the
integration of different methods in terms of sample handling, instrumental analysis, and
data process. In regards to NMR-based metabolomics, additional experimental techniques
for selective detection and suppression should also be considered. For example, 31P NMR
and 15N NMR can be used to highlight groups of metabolite such as phosphorylated
sugars and amino acids.2 31P and 15N isotopic labeling coupled with monitoring the flow
of nitrogen and phosphorus throughout the metabolome may yield interesting insights
about metabolic pathways not observed using 13C-labeled metabolites. Analyzing a
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subset of metabolites based on prior knowledge of biological relevance is a unique
feature of NMR. Investigating a smaller set of metabolites would also simplify metabolite
identification since the corresponding NMR spectra are greatly simplified and peak
overlap is significantly diminished. This addresses a major bottleneck of NMR
metabolomics – the manual peak assignments. Currently, metabolite identification is
based on the manual analysis of NMR spectra that requires using the entirety of the
spectral information combined with cross-validation using multiple database, all available
biological information, the experience of the investigator, and an iterative analysis that
relies on informed and educated guesses. Ideally, this process should be automated by
using a combination of new software and a series of NMR experiments such as 2D
COSY, TOCSY, HSQC, HMBC, and HSQC-TOCSY.
Staphylococcus epidermidis and Staphylococcus aureus are the leading causes of
hospital-associated infections.3 The only remaining treatment for most staphylococci is
glycopeptide antibiotic vancomycin, although a vancomycin resistant strain has been
found.4 Poor antibiotic penetration, nutrient limitation, slow growth, adaptive stress
responses, and formation of persister cells are all hypothesized to constitute a defense
system.5 Many of these mechanisms are metabolism associated. A critical fact is that
although the type and severity of the virulence produced, or level of drug resistance by
these bacteria can vary, the metabolic pathways that they utilize are very similar.
Staphylococcal species can synthesize all their virulence factors based on 13 small
molecules derived from central metabolic pathways.6 A study showed that over 90% of
the enzymes, metabolic reactions and metabolites were common to all strains.7 A
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common mechanism of their drug-resistance is biofilm-related infectious manifestations
associated with implanted biomaterials and biofilm formation can be largely influenced
by central metabolism.8 It is appealing to study the common feature of the metabolism so
as to not only understand their pathogenesis development, but also to search for next
generation antibiotics.6,1
In the structural characterization of RpiRa CTD, the most important and long term
goal is to solve its three dimensional NMR structure. Other aspects of interests include: (i)
different labeling strategies that highlight selected residues to simplify the NMR
assignments, (ii) implementation of non-uniform sampling to increase spectrum quality to
enable determining the NMR structure, (iii) ligand screening (FAST-NMR) that identifies
small molecules potentially related to the function of RpiRa and the identification of the
functionally relevant ligand binding site, and (vi) additional molecular and cellular
biology experiments to understand the regulation mechanism of RpiRa and its role in the
pentose phosphate pathway.
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